"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand",378,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations. The accuracy of these statements are necessarily subject to risks and uncertainties. These statements are not historical in nature, and use words such as anticipate, estimate, expect, project, intend, forecast, plan, believe and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, income tax matters, the outcome of contingencies, such as legal proceedings, the uncertainty of loss revenue estimates, share repurchases, acquisitions, foreign exchange and other economic business competitive and regulatory factors. Please refer to the cautionary statement regarding forward-looking information in Bard's September 30, 2015, 10-Q and the other -- and the information under the caption Risk Factors in the company's 2014 10-K, including disclosure of factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual private categories. Reconciliations of non-GAAP measures to the most comparable GAAP measures with respect to the company's historical financial results are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of January 28, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year-end. 
At this time, I will turn the call over to Timothy M. Ring. Please go ahead."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Ernie. Good afternoon, everybody, and welcome to Bard's Fourth Quarter 2015 Earnings Call. I would like to thank all of you for taking the time to join us today. I'd expect the presentation portion of the call to last about 40 minutes. You may not",995,"Thanks, Ernie. Good afternoon, everybody, and welcome to Bard's Fourth Quarter 2015 Earnings Call. I would like to thank all of you for taking the time to join us today. I'd expect the presentation portion of the call to last about 40 minutes. You may note we have also placed a few slides on the Investor Relations page of our website to help you understand some of the moving pieces on our results and guidance to give you a little more clarity. Our discussions today will go as follows: I'll begin with an overview of the results for the fourth quarter; John Whalen, our President and COO, will cover fourth quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; and then Chris Holland, our SVP and CFO, will cover the fourth quarter income statement, balance sheet and provide our financial guidance for 2016, and then we'll close with Q&A.
Fourth quarter 2015 net sales totaled $878.8 million. That's essentially flat on an as-reported basis and up 3% on a constant-currency basis over the fourth quarter of last year. Currency impact for the quarter versus prior year was unfavorable by about 300 basis points. Other nonoperating adjustments also negatively impacted revenue growth by about 200 basis points in the fourth quarter. Adjusting for these items are organic growth rate for Q4 2015 was 5.5%, which exceeded our guidance from 3 months earlier. We've provided a summary reconciliation of these quarterly revenue results on Slide 3 of the deck provided on the website that I just referenced.
Net sales for the full year were $3.4 billion. That's up 3% as reported and up 6% on a constant-currency basis. That correlates to approximately 6.8% organic growth for the year compared with our original guidance for the year of 4% to 5%. 
The U.S. launch of the Lutonix drug-coated balloon exceeded our expectations, and we're also pleased to see the acceleration of the rest of the portfolio in 2015. It's notable that every business was at the top or above the revenue guidance ranges we provided a year ago. 
Net income for the fourth quarter was $136.3 million and diluted earnings per share were $1.79. That's up 2% and 4%, respectively. Excluding items that affect the comparability of results between periods, which Chris will cover later, fourth quarter 2015 net income and diluted cash earnings per share, which exclude amortization of intangibles, were $164.6 million and $2.43. That's up 4% and 6%, respectively. 
Full year 2015 net income was $135.4 million and diluted EPS was $1.77. Excluding items that affect comparability between periods, full year 2015 net income was $615.8 million, and diluted cash EPS was $9.08. That's up 5% and 8%, respectively. These results exceeded our original guidance for the year despite an estimated additional $0.15 of headwind during the year from a combination of additional FX headwinds and dilution from acquisitions during the year.
Looking at the fourth quarter revenue growth geographically compared to the prior year on a constant-currency basis, net sales in the U.S. grew 2%. Internationally, we grew 5%, with Europe up 7%, Japan down 22%, and our other international geographies up 16%. 
To refresh your memory, the decline in Japan is due to the work down of inventory that was recorded as revenue when we sold into our Japanese joint venture prior to the acquisition of the joint venture. This issue should be substantially behind us after the first quarter of this year. As anticipated in our strategic investment plan, our emerging market sales continued to increase nicely and represented about 10% of our total revenue in the fourth quarter. 
Looking at overall results with some historical context. 3 years ago, we announced our strategic investment plan to invest in advance of the receive of the Gore royalty. At that time, our organic revenue growth profile was essentially flat. We increased our annual spending in SG&A and R&D by combined $70 million. We designed the investment plan to return the revenue growth of our portfolio to above-market rates and to put the company in a better position for the longer term. We then said on this call a year ago that 2015 was a very important year of execution for us to begin to see the results from that investment plan. 
As we look at where we are today, our organic growth rate has accelerated again to the top tier of the sector. We're pleased with how our teams have executed the plan, and we believe we've built the business in a manner that's sustainable. We've been able to achieve our objectives while continuing to invest in future growth despite absorbing various headwinds along the way. So while we're pleased with the execution of the plan so far, our focus remains solidly on the future. We have many potential opportunities for strong growth in front of us. We believe we have significant room for growth in emerging markets. We also have several technology platforms that we believe provide us with billions of dollars of market opportunity to pursue through new indications and expanded market development and penetration. And the Japan joint venture and Liberator acquisitions provide us better access to customers with delivery platforms that we believe will position us well for the long term. So we remain in investment mode to pursue these opportunities. Our objective remains sustained above-market growth on the top line that we believe should provide an organic engine positioned for reliable and attractive profitability on the bottom line. Chris will give you more details when he lays out our financial guidance. 
We continue to believe that the effective execution of our strategic investment plan will allow us to continue to increase shareholder value over the long term on a sustainable basis. 
With that, let me turn you over now to John Weiland for a review of our fourth quarter product line revenue."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, as usual, I'll be giving all percentage growth data and comparison to the prior year period on a constant-currency basis, unless otherwise noted.So let's start with Vascular. Total net sales in this category for",893,"Good afternoon, everyone. Before I start, as usual, I'll be giving all percentage growth data and comparison to the prior year period on a constant-currency basis, unless otherwise noted.
So let's start with Vascular. Total net sales in this category for the quarter were $239.3 million, a decline of 2% on a reported basis and an increase of 1% on a constant-currency basis when compared to Q4 of 2014. Adjusting for the nonoperating items, global Vascular sales were up 5%, with the U.S. business down 3% for the quarter and international up 18%. Sales in our Vascular graft category were up 7% in Q4, which is above trend, driven by some timing issues within our OEM business. 
Excluding the Gore royalty, our Endovascular business grew 4% in the fourth quarter. Within Endovascular, our biopsy line was up 10%, driven by strength in emerging markets. Our peripheral PTA products were up 5% this quarter. As expected, the growth rate here was affected by the anniversary of the significant stocking event for Lutonix in Q4 of 2014 as well as the reduction in Japanese sales due to our inventory adjustment there. 
As Tim said, we are very pleased with the first year of our drug-coated balloon sales in the United States. Sales in Q4 were as expected, and we estimate that end customer use, which more than doubled the prior year. We look forward to expanded adoption of this technology longer term as the market continues to develop. 
Our stent business was up 4% in the fourth quarter, which is better than recent trends, driven by strength in this product family internationally. And to complete the category, sales in our vena cava filter line were down 28% in the fourth quarter. This was mostly due to a supplier component issue that we expect will be resolved in the next few months. 
Now let's move to Urology. Total net sales were $217.9 million, which is flat versus Q4 of last year on an as-reported basis and up 3% on a constant-currency basis. Excluding the Japanese inventory issue, global growth was 5%, with the United States up 5% and international up 4%. 
The Targeted Temperature Management product sold double-digit growth again this quarter, both domestically and internationally. Our basic drainage business was up 3% in Q4 globally and up 9% in the United States. PICCs were flat globally and up 7% in the United States. We believe the strong finish to the year in the United States is more related to our sales mix than overall volumes. We saw particular strength in our temperature-sensing products, which are nearly double the ASP of our base product. We continue to see a favorable shift in mix to higher-ASP products. 
Our continents business declined 1% in the prior year quarter. Sales in urological specialties were up 1%. Our brachytherapy product line up 7%. We do not hold significant brachytherapy inventory in Japan. So that product line benefited from moving to end customer pricing in the fourth quarter. And sales from our StatLock catheter stabilization line decreased 3% in Q4. 
Before we leave Urology, we're pleased to announce that we completed the acquisition of Liberator Medical last week. As Tim said, this adds a new delivery platform to a strong technology platform, and we're very excited about the possibilities here. 
Now for Oncology. Total net sales in this category were $237.8 million, which was flat compared to the fourth quarter last year on an as-reported basis and up 3% on a constant-currency basis. Adjusting for the Japan inventory issue, global sales were up 4%, with the United States up 2% and international sales up 10%. Our port line was down 8% versus the fourth quarter of last year. The Japanese inventory issue contributed to this decline as the timing issues of orders in emerging markets, which were lower than trend in the fourth quarter as we expect to register next-generation devices there in the first quarter of 2016.
PICC revenue growth was 9% in the fourth quarter. Contrary to ports, we saw very few PICCs in Japan currently. So the impact from the acquisition is minimal. Our Vascular Access ultrasound product line was up 1% this quarter, and our dialysis catheter business was up 9% in the fourth quarter. 
So let's then finish up with Surgical Specialties. Net sales in this category were $152.8 million in the fourth quarter, up 5% on an as-reported basis and 8% on a constant-currency basis. Adjusting for the Japan inventory issue, global sales were up 10%, with the United States up 11% and international sales up 7%. 
Our biosurgical product portfolio grew double digits again this quarter, and we're excited about the long-term potential here. 
Our soft tissue repair business grew 9% overall in the fourth quarter. Within that subtotal, our total synthetic products were up 9% this quarter, while our natural tissue products increased 7%. 
We're pleased with the execution and the momentum in our broad product portfolio of synthetic, natural tissue and hybrid products for the treatment of hernia repair. Our fixation business grew 15% in Q4 benefited -- benefiting from the initial launch of new products in this product category. 
Closing out the surgical category, our performance irrigation business was down 22%. This quarter consistent with expectations. This concludes our product line revenue discussion. 
I'll now turn you over to John DeFord."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. 2015 was a pretty busy year with about 40 product launches and several important developments and milestones reached. We expect 2016 to be another year with a robust pipeline and a similar number of launches pla",1094,"Thanks, John, and good afternoon, everyone. 2015 was a pretty busy year with about 40 product launches and several important developments and milestones reached. We expect 2016 to be another year with a robust pipeline and a similar number of launches planned. 
I'll start today with our drug-coated balloon pipeline. We're building inventory for the launch in Q1 of recently approved additional lengths and diameters in the U.S. SFA product line. We've also submitted to FDA seeking approval for the treatment of lung lesions based on clinical data we've gathered in Europe. 
During the Life Interventional Course, or LINK meeting this week, investigators are sharing data and updated results from several of our Bard-sponsored studies as well as results from independent studies of DCBs conducted by clinicians. Some highlights include yesterday's presentation by Dr. Christopher Med of updated Lutonix global registry results, including a 93% from TLR at 24 months now in 229 patients. He also presented results for subgroups, including a first look at freedom from reintervention from patients treated with in-stent restenosis. At 12 months, almost 92% of ISR patients were free from reintervention, and that result was durable with over 88% of patients free from intervention at 24 months. 
Also yesterday, Dr. Sabine Steiner from University Hospital presented results from their single-center comparative study of the impact in Lutonix DCBs. This real-world retrospective study included 12-month analysis of 456 patients with SFA popliteal disease. The retrospective the baseline patient and lesion characteristics were pretty well matched. These studies treated very difficult patients with an average treatment length in both groups of over 280 millimeters. No statistical difference between devices was seen with freedom from reintervention at 12 months in excess of 82%. Sustained clinical benefit define this freedom from an increase in Rutherford class was also found to exceed 80% in both groups at 12 months. 
In our Below the Knee IDE enrollment progresses, and we continue to work with FDA to expand patient inclusion and analysis in this important study. At projected recruitment rates, we anticipate we'll continue to enrollment patients through 2016, putting PMA submission late in 2017 or likely into 2018. 
On the other hand, our AV access DCB IDE study, which begun recruitment in Q2 of 2015, continues to enroll quickly. At current rates, we anticipate enrollment could be complete in late Q1 or Q2 of this year, putting PMA submission slightly ahead of schedule in the first half of 2017. 
The in-stent restenosis IDE study is also ongoing, and we're working toward a projected second half 2016 PMA submission, seeking this expanded indication. 
Around the world, we're also working to expand access to this important technology with submission for approval expected in the first half of the year in Japan. We also expect enrollment to begin to accelerate in our Levant China study. 
Also in Vascular, the Lifestream balloon expandable covered stent continues to perform well in Europe. The IDE is in follow-up after completing enrollment in Q3. These clinical studies evaluating the technology for the treatment of iliac artery disease. We remain on schedule for the projected submission of the final module of the PMA in the second half of the year. 
Our COVERA next-generation stent graft, designed for use in AV access, recently received CE Mark and the IDE was submitted in December. Our current plans have enrollment commencing in Q1. 
And our new venous stent also received CE Mark in Q4, and our first case was completed in December. In the U.S., we received approval to commence our IDE study a few weeks ago. 
Next, moving to Urology and home care, we're expanding the launch of the new Magic3 Go self-lubricated catheter for female patients as our manufacturing ramps up inventory. We're also building large quantities of our Magic3 Touch list, and we anticipate launching the product family this quarter. And in endourology, we expect to launch around the end of Q1 upon FDA clearance the new family for flexible roscopy. 
In temperature management, we've released software upgrades for enhanced EMR connectivity and additional user controls. 
Moving to Oncology. Than new Site-Rite 8 ultrasound system, which launched in Europe in Q3, has received clearance in the U.S. and we're launching the product this quarter with 3CG diamond and Pinpoint GT capabilities. We continue to believe the combination of ultrasound needle guidance and catheter tracking and tip confirmation in an integrated system will provide a user-friendly and intuitive solution for vascular catheter placement. 
In PICCs, we're waiting FDA clearance for the launch anticipated in the first half of this year of our new family of chemical-resistant catheters based on a new material designed to resist commonly used chemotherapy solutions as well as cleaning and disinfecting agents. We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis or DVT and remain on plan to begin launching in the back half of the year. 
For the difficult stick IV catheter patients, we're gearing up to launch around the end of the first quarter an improved family of AccuCath wire-guided assisted products. These new products are anticipated to launch alongside our new midline catheter, the PowerGlide Pro, also slated for launch this quarter. 
And lastly, for the acute hemodialysis patient, we're preparing for the launch of the new dual lumen power Xenesys catheter, which was cleared by FDA earlier this month. Xenesys is designed for superior flexibility and kink resistance and flow rates in excess of 400 ml per minute in an 11 [ph] French configuration. 
I'll close my portion of the discussion today with surgery. In 2016, we'll continue to expand our Phasix and XenMatrix AB families of products with launches planned throughout the year. In our BioSurgery product family, we're awaiting PMA approval for our new TRIDYNE vascular sealant and continue to anticipate approval and launch of the first in a series of indications in the back half of 2016. We're also working toward the launch of a new Progel sealant configuration designed to improve visibility during minimally invasive and robotic surgery. 
And finally, in mesh fixation, we're expanding on our recent permanent and resorbable product launches with 2 additional fixation devices slated for later this year. 
And now before I hand you over to Chris, I'd like to invite all of you to our analyst day to be held on Monday, May 23 at the New York Alice Hotel at 4:30 p.m. I look forward to seeing you there. 
I've stalled about as long as I can, so I guess, I'll hand it over to Chris now."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John, and good afternoon, everyone. Let me start by covering the items that affect the comparability of our results between periods. Net acquisition-related items of $33.9 million pretax, a $14.5 million pretax charge for restructuring and prod",1800,"Thank you, John, and good afternoon, everyone. Let me start by covering the items that affect the comparability of our results between periods. Net acquisition-related items of $33.9 million pretax, a $14.5 million pretax charge for restructuring and productivity initiatives and a $4.5 million pretax charge for asset impairments. These items are detailed in the notes to the financial statements and the reconciliation accompanying our Q4 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $550.8 million in Q4 or 63.3% of sales. On an adjusted basis, gross profit was $553.2 million or 63.5% of sales. That's up 40 basis points from the prior year. The headwinds to GP in Q4 included new amortization of about 30 basis points and FX at about 30 basis points. Pricing pressure, which was about 100 basis points of headwind on the revenue line, was 40 basis points of headwind in GP during the quarter. 
On the positive side for GP, mix was favorable by about 40 basis points, and cost improvements in other items drove about 100 basis points of favorability this quarter. For the full year 2015, that brings adjusted gross profit as a percentage of sales to 61.8%, which was at the very high end of our original guidance, down 30 basis points from 2014. FX was a headwind of 30 basis points. Price was negative by 40 basis points and new amortization was also 40 basis points. Mix was positive by 30 basis points and cost improvements and other items were about 50 basis points favorable. 
SG&A expenses were $279.3 million for the quarter or 32.1% of sales. On an adjusted basis, SG&A was $271.3 million or 31.2% of sales. That's up 110 basis points from the prior year, primarily as a result of the acquisition of our Japanese joint venture. 
For the full year 2015, adjusted SG&A as a percentage of sales was 29.3%. That's a decrease of 30 basis points from the prior year. SG&A was higher than we guided at the beginning of the year, primarily because of acquisitions as well as some additional investment spending in the back half of the year, reflective of our strong operating performance. 
R&D expenditures totaled $69.4 million for the fourth quarter or 8% of sales. On an adjusted basis, R&D expense was $64.8 million or 7.4% of sales, a decrease of 80 basis points from the prior year period. 
For the full year 2015, on an adjusted basis, R&D was also 7.4% of sales, which was consistent with our guidance and reflective of a very robust level of investment spent. Interest expense was $11.2 million for the fourth quarter and $44.9 million for the full year. Other income and expense was $32.9 million of expense for the fourth quarter. On an adjusted basis, it was $5 million of income for the quarter and $1.6 million of income for the year. The effective tax rate for the quarter was 13.7%. On an adjusted basis, it was 22%, taking us to 24.1% for the full year, right in the middle of the guidance range we provided at the beginning of the year. The quarter, of course, was lower than the full year average due to the renewal of the R&D tax credit in December, which as you now know, has been made permanent. That all adds up to cash EPS of $2.43 for Q4, excluding items affecting comparability, bringing us in at $9.08 for the full year on a same basis. That's $0.03 above the high end of our original guidance for the year despite having absorbed roughly $0.15 of additional FX headwind and dilution during the course of the year, which is indicative of a strong operating performance we saw in 2015. 
We repurchased about 600,000 shares of stock in Q4, taking total buybacks in 2015 to approximately 2.7 million shares. The balance sheet as of December 31 reflects cash, restricted cash and short-term investments of $1 billion versus $1.1 billion at September 30. For the full year, AR days were up 0.8 days and inventory days were up 6.9 days, driven by the acquisition of our Japanese JV. 
Capital expenditures totaled $23.6 million for the quarter and $102.9 million for the year. On the liability side, total debt was $1.4 billion as of December 31, no change from September 30. That's a total cap at the end of the fourth quarter was about 49% and total shareholder investment was $1.5 billion at December 31. 
So with a strong 2015 now in the books, let's turn to financial guidance for 2016, excluding the impact of items that affect comparability. For revenue, we project 2016 constant-currency organic revenue growth between 5% and 6%. Beyond organic growth, we'll benefit from incremental revenue in 2016 from the applications of our Japanese JV as well as Liberator Medical. We also expect to see nonoperating reduction to revenue from lower sales of EP products to Boston Scientific that were prepared for a range of levels for the Gore royalty. Therefore, our overall constant-currency revenue guidance is between 6% and 8%. Our expectations assume no change in the market growth rates from where they've been in the last couple of years, which we would characterize as being in the low single digits. Obviously, the strength of the U.S. dollar will continue to be a headwind for U.S. multinational companies in 2016. We estimate that at current rates we're looking at a revenue headwind related to currency of about 1.5%, which would put our reported revenue guidance for 2016 between 4.5% and 6.5%. 
As far as constant-currency revenue growth in our [indiscernible] disease categories, in 2016, we expect a Vascular revenue growth to be between 3% and 7%, Urology to be between 8% and 11%, Oncology to grow between 5% and 8% and our Surgical Specialties business to grow between 6% and 9%. To be clear, these are constant-currency growth rates, not organic. We're only providing organic revenue growth guidance at the corporate level. 
As we move down the P&L for financial guidance, we're making one important change in our presentation. As you know, when the sector moved to cash EPS, the vast majority of our peers excluded amortization of intangibles from their entire adjusted P&L. Up until now, we've been reporting amortization in the entire P&L and only excluding it from EPS number below the line. In order to make it easier for investors to understand our results in context with others in the sector, beginning with 2016, we'll exclude the amortization of intangibles from our entire adjusted P&L. We've provided a reconciliation of the key margin percentages on the Reg G section of our Investor Relations page on our website. And a summary of that reconciliation is provided on Slide 6 of the deck associated with this call. 
So the following guidance excludes items that may affect comparability and amortization of intangibles. We expect our overall gross margin percent to improve in 2016 between 50 and 100 basis points compared to 2015, which translates to a gross margin range between 65.8% and 66.3%. That reflects about 30 basis points of pressure from FX. Pricing pressure continues to be a challenge for us, and we estimate the impact on 2016 to be between 30 and 50 basis points of gross margin headwind. Our cost improvement programs are projected to contribute between 80 and 100 basis points of benefits to GP, and we expect mix to be favorable between 50 to 60 basis points, which includes the positive gross margin impact from our acquisition in Japan. 
We expect SG&A as a percentage of sales to be about the same as 2015 as we continue to increase our investment in emerging markets this year and work to integrate our recent acquisitions. And we expect R&D as a percentage of sales to be in the mid-7% range again this year. This would project our operating margin in 2016 to be between 29% and 29.5%, which is an improvement of 50 to 100 basis points compared to 2015 on the same basis. We expect interest expense in 2016 to be between $50 million and $55 million, reflecting higher projected activity rates and debt levels compared to 2015. Primarily as a result of jurisdictional mix, we expect a slight pause in the cadence of our improvement in the effective tax rate, which we project to be between 25.5% and 26% in 2016. The R&D tax credit is now permanent, so we will not have a sharp reduction in the Q4 effective rate that we have seen the last couple of years. So all of that adds up to adjusted cash EPS for 2016, excluding items that affect comparability, between $9.90 and $10.05, representing 9% to 11% reported growth over 2015. This guidance includes a projected negative currency impact of about $0.30 based on today's rates. The suspension of the medical device excise tax represents approximately $0.20 of benefit to us, essentially offsetting 2/3 of our overall estimated currency headwind in 2016 at today's rates. So we do exclude both the negative impact of currency and the benefit from the debt suspension, our operational EPS growth forecast would have been between 10% and 12%. 
As we enter 2016, we continue to be in investment mode with planned, targeted incremental spending in SG&A, particularly in emerging markets, and a continued robust level of investment in R&D. We're pleased that we're able to provide attractive 2016 guidance with strong reported earnings growth without having to reduce or delay investments and projects we believe will provide long-term value to our shareholders. 
In Q1, we expect constant-currency sales growth between 4.5% and 5.5% and reported revenue growth between 2.5% and 3.5%. As was the case in Q4, Q1 revenue guidance reflects the negative impact from the sell-through of existing inventory in Japan. We expect this factor to be behind us by Q2. On an organic basis, we expect Q1 sales growth to be in the 5.5% to 6% range. We expect adjusted cash EPS in Q1 2016 to be between $2.14 and $2.18, which reflects the initial dilution from recent acquisitions as well as a foreign exchange headwind. We expect the dilutive impact from acquisitions, in particular our joint venture buyout in Japan, to moderate as we move through 2016. Excluding the front-loaded dilution from acquisitions, Q1 adjusted EPS would have been about 10%. So operationally, I expect us to be off to a very solid start to the year as we move into Q1. 
As for capital expenditures, we expect 2016 to be in the $120 million range, and we expect operating cash flow to be in the $700 million range in 2016. 
Thank you for your attention, and with that, I'll turn you back over to Tim."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Chris. While we're pleased with our performance in 2015, as I mentioned earlier, we remain very focused on the growth opportunities in front of us and our execution against the plan for those. We look forward to updating you on our continued pr",71,"Thank you, Chris. While we're pleased with our performance in 2015, as I mentioned earlier, we remain very focused on the growth opportunities in front of us and our execution against the plan for those. We look forward to updating you on our continued progress in the coming quarters. 
With that, that concludes the formal part of the presentation. I'll now turn you back to the moderator to facilitate the Q&A."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We'll go to Bob Hopkins with Bank of America.",11,"[Operator Instructions] We'll go to Bob Hopkins with Bank of America."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Couple of things I wanted to ask about just in terms of the guidance that you provided. I was wondering, Chris or Tim, if you guys could talk a little bit about some of the assumptions that drive the 2016 guidance, specifically on buyback and share count",105,"Couple of things I wanted to ask about just in terms of the guidance that you provided. I was wondering, Chris or Tim, if you guys could talk a little bit about some of the assumptions that drive the 2016 guidance, specifically on buyback and share count for 2016. I'm wondering you're assuming. And then also on drug-coated balloons, could you give us a sense as to the contribution in growth in Q4? And in the contribution to growth in '16 that you're assuming. I assume it's probably between 1 and 1.5 points of contribution to top line growth, but just wanted to confirm that."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, thanks for the questions. I think on the buyback side, we're not going to give a specific guidance number. I think we've been pretty consistent as repurchaser of stock. I think having said that, we feel really good about the operational momentum in",234,"Sure, thanks for the questions. I think on the buyback side, we're not going to give a specific guidance number. I think we've been pretty consistent as repurchaser of stock. I think having said that, we feel really good about the operational momentum in the business. So I think we'll continue to have a latitude to maintain a lot of flexibility with the balance sheet. And while we'll certainly be active repurchaser, I think we've got a lot of flexibility as we move into '16 given what we see as really strong operating performance straight down the P&L. I think from a Lutonix standpoint, we're really happy about where we are. Q4 came in as we expected it to be. Obviously, overall, we're ahead of our guidance for the quarter. And I think as we move into '16, we're -- we like to talk about not being about one big thing. I think we're trying to really focus on the entire portfolio. We feel terrific about Lutonix as momentum going into '16. I think some of the data that John referenced, that's just hot off the press out of link. Continues to show a great clinical positioning of the product. That frankly continues to get better the more we see some of this real-world data coming out. So it's a component of what we think is really strong organic growth profile coming into '16."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Fair enough. And then Tim, just on emerging markets, we've heard a lot of discussion other companies on emerging markets today. And it sounds like for you guys, the growth continues to be strong. But I just wanted to ask your views on emerging marke",86,"Okay. Fair enough. And then Tim, just on emerging markets, we've heard a lot of discussion other companies on emerging markets today. And it sounds like for you guys, the growth continues to be strong. But I just wanted to ask your views on emerging markets you're exiting 2015 and beginning 2016. In Q4, did you see the same kind of growth trends of that you've seen in the last couple of quarters? And just any highlights in emerging markets or specific geographies would be helpful."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We haven't really seen a change from the trends that we've seen. Clearly, we pay attention to what others are seeing, feeling in emerging markets. I think it might be kind of the mix of the geographies where we're strong and have a sizable presence.",89,"Sure. We haven't really seen a change from the trends that we've seen. Clearly, we pay attention to what others are seeing, feeling in emerging markets. I think it might be kind of the mix of the geographies where we're strong and have a sizable presence. And some of the geography that seem to be others more of an issue, either it's the mix of our operating in those geographies that don't seem to be impacted and/or we're not very strong in some of those other geographies. So John..."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add is I think one of the unusual nature's of our business is we're really still rolling out the portfolio of products into a lot of these markets. In fact, we had 252 new product approvals in 2015. That was up from 114 in 2014. So we h",111,"The only thing I'd add is I think one of the unusual nature's of our business is we're really still rolling out the portfolio of products into a lot of these markets. In fact, we had 252 new product approvals in 2015. That was up from 114 in 2014. So we have a bolus of new products yet that are still in regulatory agencies around the world waiting for approvals. All those are a wave that are coming through our international businesses through 2016. I think that's a little unique to us, based on the investments of that we've made and the product mix that we're developing for these markets."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Let's go to the line of Larry Kush with Raymond James.",12,"Let's go to the line of Larry Kush with Raymond James."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So can we start off just, Tim, maybe I know that you said that you assume the environment is sort of where it's been. But I'm wondering as you kind of move through the fourth quarter and into 2016, was there anything notable that you might have been seein",55,"So can we start off just, Tim, maybe I know that you said that you assume the environment is sort of where it's been. But I'm wondering as you kind of move through the fourth quarter and into 2016, was there anything notable that you might have been seeing that was changing in the U.S.?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No. We didn't detect any notable difference really at all, John.",11,"No. We didn't detect any notable difference really at all, John."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think that we didn't see any trends that would cause us to believe it's different from what we experienced through the majority of 2015.",27,"And I think that we didn't see any trends that would cause us to believe it's different from what we experienced through the majority of 2015."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Terrific. And then Tim, look, you -- on the home side, you obviously the deliberate deal. You did Rochester a while back. Can you sort of help us think about just what the strategy now is for the home now? You've got some enhanced distribution. You",67,"Okay. Terrific. And then Tim, look, you -- on the home side, you obviously the deliberate deal. You did Rochester a while back. Can you sort of help us think about just what the strategy now is for the home now? You've got some enhanced distribution. You obviously have some new products flowing through, which John talked about. But where would we go with the home strategy?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So look, I think it's coming together. We're still figuring it out as we go here. And I do think we do know certain of the trends, right? So hospitals are trying to take care of more people outside of hospitals. And obviously, we pay attention to tha",320,"Yes. So look, I think it's coming together. We're still figuring it out as we go here. And I do think we do know certain of the trends, right? So hospitals are trying to take care of more people outside of hospitals. And obviously, we pay attention to that. We've done a lot of work relative to understanding that dynamic. We think we understand very much the difference between a good solid product model and a service model and a profitability and sustainable growth differences between those 2. So I like the way we're provisioned. I'd say we're still understanding it and trying to figure out where to plug and play in that kind of a environment. But we're optimistic about it, which is why we pulled the trigger on Liberator. We felt we needed that platform as a missing piece to solving that puzzle. So we're pleased with that, and I think you'll continue to hear more from us in the future about that, so I think just the one thing I got in I think it's important as you think about this strategy both Rochester and Liberator were movements into the home but based on the back of a strength in Urology. And I think as we said when we did Rochester and I'll repeat it again now that we've got this really interesting platform, it works just on the back of a Urology entry strategy into the home for us. What it's given us is clearly these other capabilities that we can begin think about how we can leverage into some other category areas. But we don't need to do that to make this both Rochester and Liberator now a combination very successful and really accretive to us for a long period of time. So I'd characterize that lower-risk build of a new capability into an adjacency on the back of some core strengths we already have."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Brooks West with Piper Jaffray.",12,"Next, we'll go to the line of Brooks West with Piper Jaffray."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Question on margins, may be more theoretical. Chris, you're getting back to the margin profile that you had in 2012, which I think was a big kind of milestone for investors, maybe a little bit ahead of gross margins, almost there operating margins. I'm ju",106,"Question on margins, may be more theoretical. Chris, you're getting back to the margin profile that you had in 2012, which I think was a big kind of milestone for investors, maybe a little bit ahead of gross margins, almost there operating margins. I'm just wondering, you've got leverage left in the business and specifically from the emerging markets investments that you made. How do you think about running the business going forward? You kind of get the 30% operating margin and reinvest from there? Is there significant upside to where you might see operating margins progressed from here? And just curious on your thoughts there."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think what we've been saying now for a number of years, Brooks, is we're focused on driving margins higher certainly back to the levels we were out we made. good progress in '15 and we've now committed to making additional significant progress in '",160,"Yes. I think what we've been saying now for a number of years, Brooks, is we're focused on driving margins higher certainly back to the levels we were out we made. good progress in '15 and we've now committed to making additional significant progress in '16. As we do that, we're continuing to balance that objective with longer-term investments that make all of this sustainable. So we're not giving a longer-term margin goal that we get to and then we think about running the business differently. We're making investments in China as we go into '16, and making investments in other areas in the business, but still committing to 50 to 100 basis points in operating margin performance. We'll continue to try to strike that balance. Obviously, there'll be headwinds that come our way along the way, but as Tim said, this is all about sustainability. And we like where we're at. We like the opportunities in front of us."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I add to what Chris said this when you look at our guidance for 2016, you'd note -- and in our 2015 results, you'd note the strength of the contributions of our operating manufacturing teams around the world. That's a core capability that we believe we'll",84,"I add to what Chris said this when you look at our guidance for 2016, you'd note -- and in our 2015 results, you'd note the strength of the contributions of our operating manufacturing teams around the world. That's a core capability that we believe we'll deliver every year for the corporation moving downstream. And it gives us a lot of, I think, a lot of strength and the ability to make a lot of move strategically, depending on where we see the opportunities."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just one on the acquisition environment, if I could. There's been a lot of speculation on consolidation perhaps this year and medtech. I'm just wondering it seems like there's still a disconnect between valuation expectations from sellers and buy",64,"And then just one on the acquisition environment, if I could. There's been a lot of speculation on consolidation perhaps this year and medtech. I'm just wondering it seems like there's still a disconnect between valuation expectations from sellers and buyers. I'm wondering if you're seeing that change at all or how your expectations might be for kind of the rest of the year."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think it's hard to comment specifically, Brooks. Obviously, there's been a lot of volatility in the market. Certain stocks have settled at much lower levels. Certainly, sellers always have a long memory in terms of recent highs. So I think all of that n",152,"I think it's hard to comment specifically, Brooks. Obviously, there's been a lot of volatility in the market. Certain stocks have settled at much lower levels. Certainly, sellers always have a long memory in terms of recent highs. So I think all of that noise doesn't really affect us, frankly. We're very focused on a number of key criteria. And transactions need to make sense from us from a whole other set of perspectives as well as obviously from a valuation perspective. So we're obviously in a world here with a lot of market volatility, but I don't think it changes the things we're focused on. And we looked at a lot of things in '15. We'll continue to be very active in looking. But we'll pull the trigger on things that need a whole bunch of criteria and we can get at a price that makes sense for our shareholders."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll gave Roman with Goldman Sachs.",7,"Next, we'll gave Roman with Goldman Sachs."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to start off with one clarification question around the EPS guidance. Can you just help us tease out what the deal-related dilution is in your guidance and if that $0.25 number you provided around Medicon still holds and how that tracks throughou",71,"I wanted to start off with one clarification question around the EPS guidance. Can you just help us tease out what the deal-related dilution is in your guidance and if that $0.25 number you provided around Medicon still holds and how that tracks throughout the course of the year. I think you said it was mostly Q1 weighted. But anymore you can provide around the dilution from deals would be helpful."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, so the medicon dilution in the year, David, is about $0.20. It's about half of that. Actually, it hits us in Q1 again because you've got obviously the full P&L with the reduction in sales as well. And the other acquisition, Vascular Pathways acquisit",128,"Yes, so the medicon dilution in the year, David, is about $0.20. It's about half of that. Actually, it hits us in Q1 again because you've got obviously the full P&L with the reduction in sales as well. And the other acquisition, Vascular Pathways acquisition as we're really ramping up some of the R&D spending around those the products that were acquired are also more heavily impacted in Q1 before we launch the new AccuCath. So the dilution from medicon still a good $0.20 number for the full year. The other acquisitions, Vascular Pathways, cost us $0.03 to $0.05 in 2015. It'll be a little bit less than that during the course of 2016. But obviously, all of that's fully loaded into the 990s [ph] and 10 05."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And then on -- maybe on Japan specifically, you can help us think about the opportunity that exists in front of you and the least way we thought about was 2 pieces. There's obviously the price recovery from shifting from distributor",113,"Okay. That's helpful. And then on -- maybe on Japan specifically, you can help us think about the opportunity that exists in front of you and the least way we thought about was 2 pieces. There's obviously the price recovery from shifting from distributor to direct. But then I think there's very significant marketeer opportunity across at least 3 of your 4 categories. So can you may be help us think about a cadence at which we might be able to recognize that benefit if it's sort of a similar playbook to what you've been able to execute in emerging markets and how we should think about the contribution to growth going forward."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. I'll start in the media John Weiland wants to jump in. I wouldn't compare it to an emerging market. And the models that we are running our different. It's more of a mature market model. Maybe it's a little bit of a high grade in the sense that becau",167,"Okay. I'll start in the media John Weiland wants to jump in. I wouldn't compare it to an emerging market. And the models that we are running our different. It's more of a mature market model. Maybe it's a little bit of a high grade in the sense that because we haven't had total control in management over all of these selling and marketing resources, some of the things that we do relative to training and some of the management generally that practices we have around the world haven't been fully implemented there. And we do think that implementing those in Japan will have a positive influence. But that underlying growth market isn't anywhere close to what the emerging markets are. So we see this as -- we continue to invest in getting some of the clinical trials and some of the market investment build-out of training, et cetera, clinical trials having control of that we felt was an important thing for the long term in Japan."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the only thing I'd add is we have 191 salespeople in Japan. They will now be fully integrated in the Bard's selling model, which I think will be a significant momentum builder for us. And I think that the product lines, which we expect to come out",90,"I think the only thing I'd add is we have 191 salespeople in Japan. They will now be fully integrated in the Bard's selling model, which I think will be a significant momentum builder for us. And I think that the product lines, which we expect to come out of our own internal R&D and clinical base, this has been largely a Urology business historically. As we move our competence into Oncology, Endovascular, into surgery. I think that's where we believe we're going to have the bigger payback from."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And maybe just one more and a longer-term basis. You look at the acquisition medicon as well as Liberator I think you've talked about both being accretive on a go-forward business. Do you think you're tangibly getting closer to havin",65,"Okay. That's helpful. And maybe just one more and a longer-term basis. You look at the acquisition medicon as well as Liberator I think you've talked about both being accretive on a go-forward business. Do you think you're tangibly getting closer to having a higher degree of confidence in being able to steal the ""borehole"" as we look toward a much more outer year period."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think these are just 2 more examples of all the things we're trying to do to grow the business in a way that we've got a really strong organic engine with lots of different growth platforms that are hopefully increasingly accretive as we approach the en",85,"I think these are just 2 more examples of all the things we're trying to do to grow the business in a way that we've got a really strong organic engine with lots of different growth platforms that are hopefully increasingly accretive as we approach the end of '19 and '20. So these are just consistent with, I think, everything we're trying to do to build a really strong sustainable organic engine that looks attractive when it's compared to other alternatives in the sector."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Let's go to the line of Mike Weinstein with the JPMorgan.",12,"Let's go to the line of Mike Weinstein with the JPMorgan."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, can you just walk me through the impact of Medicon buy-in on your organic growth, both this quarter and then as we -- more importantly as we roll through 2016?",31,"Chris, can you just walk me through the impact of Medicon buy-in on your organic growth, both this quarter and then as we -- more importantly as we roll through 2016?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It'll be -- it's about 2 points in Q1, Mike, in comparison to prior year. The thing about comparing it to last year is we were selling in dollars into Japan last year, right? And so the -- as the yen has weakened, and we're now consolidating the JV, the B",81,"It'll be -- it's about 2 points in Q1, Mike, in comparison to prior year. The thing about comparing it to last year is we were selling in dollars into Japan last year, right? And so the -- as the yen has weakened, and we're now consolidating the JV, the Bears in a negative impact to organic really over the course of the year. But it's somewhat muted compared to what we're seeing in Q1 because of the inventory sell-through."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","But when we look at your organic growth as you guys are characterizing it here. You're expecting a lower number, obviously, in the first quarter because of Medicon and then a much higher number over the back half -- back half of the year.",44,"But when we look at your organic growth as you guys are characterizing it here. You're expecting a lower number, obviously, in the first quarter because of Medicon and then a much higher number over the back half -- back half of the year."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's excluded from our organic growth, Mike, in the 5% to 6% guidance.",14,"It's excluded from our organic growth, Mike, in the 5% to 6% guidance."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So the Medicon impact is excluded from that?",8,"So the Medicon impact is excluded from that?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And that's in your nonoperational items?",7,"And that's in your nonoperational items?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, exactly.",2,"Yes, exactly."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So you're including that in that.",7,"So you're including that in that."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, so it's totally pulled out.",6,"Yes, so it's totally pulled out."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","and then Chris, when you get to that $0.30 impact from FX off of just 150 basis points on the top line, can you just -- could you bridge us on that, but it's just them up in 60% pretax drop but obviously it's tied to the Japanese distributor.",49,"and then Chris, when you get to that $0.30 impact from FX off of just 150 basis points on the top line, can you just -- could you bridge us on that, but it's just them up in 60% pretax drop but obviously it's tied to the Japanese distributor."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's driven by Japan, Mike. So again that we could think about this last year, the JV was hedged at the 1.02 on the yen. This year, we're naked on the yen. So it's really -- and we have 100% of exposure to the JV compared to 50% last year. So the $0.20 of",71,"It's driven by Japan, Mike. So again that we could think about this last year, the JV was hedged at the 1.02 on the yen. This year, we're naked on the yen. So it's really -- and we have 100% of exposure to the JV compared to 50% last year. So the $0.20 of dilution is really all from the impact of the yen when you compare '15 to '16."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","And let's go to the line of David Lewis with Morgan Stanley.",13,"And let's go to the line of David Lewis with Morgan Stanley."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe one for Chris and one for Tim. So Chris, you have 2 deals in '16, Medicon and Liberator. They have this muted effect on '16 both with the yen exposure of Medicon and the reinvestment in Liberator but there's this hopefully bigger effect in '17. We t",123,"Maybe one for Chris and one for Tim. So Chris, you have 2 deals in '16, Medicon and Liberator. They have this muted effect on '16 both with the yen exposure of Medicon and the reinvestment in Liberator but there's this hopefully bigger effect in '17. We think these deals could be at least $0.25, $0.30 accretive in '17. So I know you've been reluctant to provide the returns on Medicon, but is there anything you can tell us about the potential returns the Medicon or accretion Medicon relative to the '16 dilution? And give us a sense of the relative magnitude of the Liberator investment in '16 so we can start thinking about how this begin to hit the P&L in '17."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think join us about a year from now and I'll give you a lot more visibility to that. and I think seriously that they both become accretive going into '17. The Liberator platform is strategic to us, so we are making significant investments in '16. And we",158,"I think join us about a year from now and I'll give you a lot more visibility to that. and I think seriously that they both become accretive going into '17. The Liberator platform is strategic to us, so we are making significant investments in '16. And we've got a lot of work integrating Medicon into John's point turning that sales force into a Bard sales force engine. I think as we move into '17, between now and then, obviously lots of other things are going to happen. Those will be 2 nice tailwinds. But I'm not going to call out specific accretion from them in '17 and have you guys make assumptions before we wrap everything up and think about what kind of commitment we want to make for '17. But those are 2 nice tailwinds that we'll have, and then we'll reassess additional investments -- incremental investments as we get closer to '17 growing up."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think one of the things to think about in the Liberator and in our home strategy in general in Urology is that unlike most homecare segments, most homecare segments are episodic. A patient gets home from hospital. They're getting care at home for a give",113,"I think one of the things to think about in the Liberator and in our home strategy in general in Urology is that unlike most homecare segments, most homecare segments are episodic. A patient gets home from hospital. They're getting care at home for a given period of time. They get well and they move off the roads. That's not the case in the urological segment. Most of these patients are on catheterization for the rest of their life. So you build to naturally build the business year after year after year as you add more patients to your segments, Liberator and Rochester help us do that. And they're both hand in glove."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Very helpful. And then Tim just coming back to this notion of drop-through. I think it seems like the message you have for shareholders are moving towards the basement kind of 6% top, 10% bottom line model look at the presentation and the PowerPoint",110,"Okay. Very helpful. And then Tim just coming back to this notion of drop-through. I think it seems like the message you have for shareholders are moving towards the basement kind of 6% top, 10% bottom line model look at the presentation and the PowerPoint provided an obviously underlying growth rates are in excess of 10% earnings. So maybe just give us a sense of do you think you can deliver greater than 10% earnings growth? Or is this sort of 300 to 400 basis points of leverage on whatever top line you put up is that the sort of the model that we should continue to expire and expect?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, the guidance we just give for the earnings with the guidance. So I'm not going to change that during the course of the call here. But if you go back even historically and look at some of the leverage between our revenue and our earnings, it's been a",115,"Well, the guidance we just give for the earnings with the guidance. So I'm not going to change that during the course of the call here. But if you go back even historically and look at some of the leverage between our revenue and our earnings, it's been about that kind of a range. We were 8 and 12[ph],10 years ago. You can get that kind of rates which we think gives us a very fair return to shareholders, and also gives us the flexibility to invest in the business for future growth. And it's that balance between those 2 that we manage. And we think that's a good balance at least for this year."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Kristen Stewart with Deutsche Bank.",12,"Next, we'll go to the line of Kristen Stewart with Deutsche Bank."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess most my questions were taken, so I guess, just thinking about, I guess, just acquisitions and just kind of appetite now. Are you seeing any -- how do you expect kind of the rollout in 2016? Do you continue to think the pace of tuck-in acquisitions",62,"I guess most my questions were taken, so I guess, just thinking about, I guess, just acquisitions and just kind of appetite now. Are you seeing any -- how do you expect kind of the rollout in 2016? Do you continue to think the pace of tuck-in acquisitions will accelerate from here? Of that was kind of ask couple different ways but..."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","We haven't changed our strategy at all relative to acquisitions despite the commentary earlier about valuations perhaps changing around. And we have a very disciplined set of filters that we look at. And it starts with strategic first. And we don't see an",120,"We haven't changed our strategy at all relative to acquisitions despite the commentary earlier about valuations perhaps changing around. And we have a very disciplined set of filters that we look at. And it starts with strategic first. And we don't see any reason to change that. I would say our pipeline is extremely full. I do know, for example, just earlier this year, we've had meetings with the well over 50 different companies and technologies, et cetera, which is a very strong start for the year. So that cadence hasn't changed, really. The effort, momentum, the resources are all what they were. So we don't feel any differently about our profile in terms of doing acquisitions going forward."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Do you think the suspension of the medical device excise tax perhaps changes minds, especially on the small company level in terms of their desire to sell out over the near term.",32,"Do you think the suspension of the medical device excise tax perhaps changes minds, especially on the small company level in terms of their desire to sell out over the near term."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No I haven't had that or heard that portrayed by anybody yet.",13,"No I haven't had that or heard that portrayed by anybody yet."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then Chris, I guess, you had mentioned in terms of the guidance you'd mentioned seems a wide range of, I guess, scenarios with the Gore royalty. Just wondering if you could share what those wide range scenarios are or if you have any sense of change i",77,"And then Chris, I guess, you had mentioned in terms of the guidance you'd mentioned seems a wide range of, I guess, scenarios with the Gore royalty. Just wondering if you could share what those wide range scenarios are or if you have any sense of change in terms of the cadence of what that could be anything I don't know if you just said that to include just different possibilities or if there's something behind that."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","That's how we've been approaching it, Kristen, so there's not a change. Obviously, it's been flat to down. obviously, there's some FX component that we frankly don't have visibility into. And we're making commitments to you guys, and we take it really ser",116,"That's how we've been approaching it, Kristen, so there's not a change. Obviously, it's been flat to down. obviously, there's some FX component that we frankly don't have visibility into. And we're making commitments to you guys, and we take it really seriously. And we understand we may see some variability there, but we continue to not have visibility to the royalty until it comes in the door. And so I think the same dynamic that's been in play for a while continues to be in play. It's just we need to make sure that we've got business plans that can deliver on the commitments we're making to you without visibility to that one item."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's not unlike Kristen our other businesses. We give you a range for the businesses that we run and though something about. And there's say high and low end to those, too, when the Gore thing is not dissimilar as we don't have control over.",46,"It's not unlike Kristen our other businesses. We give you a range for the businesses that we run and though something about. And there's say high and low end to those, too, when the Gore thing is not dissimilar as we don't have control over."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go to the line of Dave Turkey with the GMP Securities.",13,"We'll go to the line of Dave Turkey with the GMP Securities."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just quickly on the Liberator deal, I'm going couple times sort of the I wonder if you could spend a moment on sort of why that was a buy decision sort of what the secrets that you gained?",39,"And just quickly on the Liberator deal, I'm going couple times sort of the I wonder if you could spend a moment on sort of why that was a buy decision sort of what the secrets that you gained?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, David. We -- on the back of Rochester, one of the things we spent the last couple of years is doing really smart in the DME space. And the obviously came to a strategic conclusion that we wanted to control our destiny and Liberator really in Urology",217,"Sure, David. We -- on the back of Rochester, one of the things we spent the last couple of years is doing really smart in the DME space. And the obviously came to a strategic conclusion that we wanted to control our destiny and Liberator really in Urology, is the market-leading, highest-quality provider of Urology-related products. There's no question. If you look at their metrics, the quality of their billing, the quality of their customer service and really the great partnerships they have with all the leading manufacturers, they were, frankly, the only platform that would have fit what we were looking for. And so the complexity of building a nationwide DME distribution, having all of the licenses and all the capability to build and ship to Medicare patients in virtually all the 50 states and to do that at the volume of transactions that they need to do it at is something that frankly would've not been economically viable for us to try to build. So we're really fortunate that, that team is now part of the Bard family, and welcome them. And really again, they were the only -- they're really the only company that was going to allow us to pursue the strategy so we really feel great about having them on board now."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just on the tip navigation or confirmation on the PICC side. We've seen some news from competition I guess, penetration today, where does that stand? And I guess, how big of an opportunity do you think that is for you guys moving forward?",45,"And then just on the tip navigation or confirmation on the PICC side. We've seen some news from competition I guess, penetration today, where does that stand? And I guess, how big of an opportunity do you think that is for you guys moving forward?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we're very well penetrated. We don't give that number out for competitive reasons, but we have a high degree of penetration in our base business. We continue to add segments to that, as you can see by the new product launches that we talk about year",125,"Well, we're very well penetrated. We don't give that number out for competitive reasons, but we have a high degree of penetration in our base business. We continue to add segments to that, as you can see by the new product launches that we talk about year in and year out within that segment. So we're not slowing down at all. And at the same time, if you look at some of the new product lines that we're bringing to the PICC area, John talked about them tonight. You add some of those important competitive differentiators to our already strong differentiated position. We think our position only gets stronger and stronger in the months and years to come versus any competitive offerings in the play."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","yes, and as John said, we've been trying to move the needle here and move the game is the gold post time after time. So as we've added Pinpoint GT, which is rolling out this quarter, it's a new technology to further improve and simplify the placement of o",143,"yes, and as John said, we've been trying to move the needle here and move the game is the gold post time after time. So as we've added Pinpoint GT, which is rolling out this quarter, it's a new technology to further improve and simplify the placement of our devices. And we already have, of course, the ultrasound capability, which is pretty unique to us on an integrated basis. And then our tip-tracking technology, the Sherlock. And then, of course, we also continue to improve upon our final tip confirmation technology. And so we continue to add new algorithms and new ways to make that better, like 3CG Diamond. So we think we're going to continue to do that. We've got a few other tricks up our sleeves, and we'll -- as we get further down the pathway here, we'll talk about them."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Matt Taylor with the Barclays.",12,"Next, we'll go to the line of Matt Taylor with the Barclays."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So I wanted to just ask one [ph] you are going through some new products in lines of the Lutonix balloon that you are coming out in the beginning of year. I'm just wondering if you thought that would make a material difference in the applicability and the",68,"So I wanted to just ask one [ph] you are going through some new products in lines of the Lutonix balloon that you are coming out in the beginning of year. I'm just wondering if you thought that would make a material difference in the applicability and the growth rate are there any catalyst you're looking for in '16 that you think of meaningfully reduce your DCB sales."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","So I think there's a few things that we've got in there. We talked about the longer lengths. So we submitted data, seeking approval for treatment of patients with lengths up to about 300 millimeters. So about twice the length that we have now. That could",175,"So I think there's a few things that we've got in there. We talked about the longer lengths. So we submitted data, seeking approval for treatment of patients with lengths up to about 300 millimeters. So about twice the length that we have now. That could potentially open up the market. In-stent restenosis, probably a lot of that is going on today, but I have ability to promote that. It's going to be helpful. And some of the other sizes we talked about. We've got some other launches that we hope will come in this year that we think will be helpful. And obviously expanding indications is going to be key Below the Knee AV access, which is a little more near term for the U.S. market and it's an area where we're particularly strong anyway with our stent graph technology as well as some of the other products we have for dialysis patients. I think give us what we think is a pretty good opportunity for DCB and our ability to leverage that."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then I was just curious on Liberator really 2 kind of minor questions. One is the kind of see their mix in the last in terms of what they distributed. Just wondering if you could help us understand how much of that revenue is going through your",86,"Great. And then I was just curious on Liberator really 2 kind of minor questions. One is the kind of see their mix in the last in terms of what they distributed. Just wondering if you could help us understand how much of that revenue is going through your different segments. And then also, I guess, what was your history with and you're working with them before? How much comments product was going through that channel? And what else can you bring out to the table?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So just to be clear, we're selling through them today and part of the acquisition just Urology products and we were a pretty small part of their volume. So probably less than 10% overall. They've been a good does a very high-quality partner up to us",91,"Sure. So just to be clear, we're selling through them today and part of the acquisition just Urology products and we were a pretty small part of their volume. So probably less than 10% overall. They've been a good does a very high-quality partner up to us. Again, they are the leading Urology DME. And so they have Urology, ostomy and some mastectomy products, but again, we're only selling Urology products to them today. And that's certainly a busy going to be continue to be the case for the foreseeable future."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. I guess, what else can you kind of bring into the channel right away? or maybe where you see that expanding down the road?",25,"Okay. I guess, what else can you kind of bring into the channel right away? or maybe where you see that expanding down the road?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","yes, I think that's -- that was the point I was trying to make. We're obviously, to John's commentary around the expansion of our ISE catheter portfolio that's continue to become much more robust, and that's really the first R&D products coming out of the",163,"yes, I think that's -- that was the point I was trying to make. We're obviously, to John's commentary around the expansion of our ISE catheter portfolio that's continue to become much more robust, and that's really the first R&D products coming out of the Rochester R&D engine. This acquisition and this strategy is a winner for us just within Urology. And that's what we're focused on integrating liberator, getting this off to a very strong start. We've talked about investing in the platform and expanding it, including the sales force that's supporting it. Those are the near-term milestones that we're focused on. What we're going to have now is just aperture into the home that's going to allow us to think more broadly beyond Urology. Again, we don't need to do that to make this successful, but that's something that I think you should look for really over the coming years as opposed to anything within the next 12 or 18 months."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","In our final question will come from the line of Rick Wise with Stifel.",14,"In our final question will come from the line of Rick Wise with Stifel."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","A little more on Lutonix. You highlighted, John, the AV Access, BTK and in-stent restenosis indications that are coming up. Just can you give us some color on the indication opportunity? Is it 50% bigger? Is it double the current opportunity you're tackli",53,"A little more on Lutonix. You highlighted, John, the AV Access, BTK and in-stent restenosis indications that are coming up. Just can you give us some color on the indication opportunity? Is it 50% bigger? Is it double the current opportunity you're tackling? What are we looking and what are you looking at?"
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think if we look -- the SFA if you kind of look in that broad category, I think the SFA is a big part of the overall market opportunity. I think Below the Knee is -- I'm not a marketing guy so I'm looking at John Weiland here. But I think it's 20%",93,"Well, I think if we look -- the SFA if you kind of look in that broad category, I think the SFA is a big part of the overall market opportunity. I think Below the Knee is -- I'm not a marketing guy so I'm looking at John Weiland here. But I think it's 20%, 30% of the SFA opportunity. AV Access kind of in that same ballpark. So certainly, significant incremental opportunities. But the SFA probably makes up about half of the overall may be more than half of the overall opportunity."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the other thing to think about, Rick, is that after a little bit over a year into this now, physicians now are getting to the point that have started using DCBs on some of their patients. They're not only looking at the data. They're looking at th",129,"I think the other thing to think about, Rick, is that after a little bit over a year into this now, physicians now are getting to the point that have started using DCBs on some of their patients. They're not only looking at the data. They're looking at the fact of the patients aren't coming back for intervention. And as patients don't come back for interventions, they get great confidence in using the device on more and more and more patients in the future. And I think we like that in combination with their real-life data that's coming out on our product and the fact that we're generating those kinds of results with 50% less drug on than other players in the space in the United States right now."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think just to add a little bit to that, I think physicians are still sort of figuring out what's the right treatment paradigm and how do they optimize the outcomes for their patients. And so we certainly here in our interaction with customers, that",97,"Yes, I think just to add a little bit to that, I think physicians are still sort of figuring out what's the right treatment paradigm and how do they optimize the outcomes for their patients. And so we certainly here in our interaction with customers, that the DCB gives them an important tool in a toolbox but exactly how they combine that with other therapies is still sort of under development. So as John said, there's a lot of work going on out there. In I think there's a lot of penetration opportunity still ahead of us."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes. And just one last one. Just the 100 basis point cost-reduction benefits that we saw, just remind me again where that came from. And how sustainable that is. Is there more to come of that magnitude in '16? I just wasn't clear on that point.",46,"Yes. And just one last one. Just the 100 basis point cost-reduction benefits that we saw, just remind me again where that came from. And how sustainable that is. Is there more to come of that magnitude in '16? I just wasn't clear on that point."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Rick. And John referenced that the core strength of the company and actually within our guidance for 2016, we're projecting 80 to 100 basis points of incremental benefit from all the initiatives that are manufacturing and sourcing teams will be unde",155,"Sure, Rick. And John referenced that the core strength of the company and actually within our guidance for 2016, we're projecting 80 to 100 basis points of incremental benefit from all the initiatives that are manufacturing and sourcing teams will be undertaking in the course of '16. So that is something that we believe does have a long runway. It's not easy, but our guys are superb at doing it. And they delivered in '15 and they're telling us and we're expecting them to deliver a similar magnitude in '16. I think the unfortunate thing is what FX has been doing and price as well. That's been mitigating a lot of that benefits. So if we can get some of those headwinds to shift or to be a little more benign, you'll really see I think the power of what our operating -- our operation and sourcing teams are delivering year in and year out."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I would think about it as almost half being operating efficiencies in terms of cost savings in our plants and production at about 50% on sourcing initiatives that are reducing raw material costs into our plants.",36,"I would think about it as almost half being operating efficiencies in terms of cost savings in our plants and production at about 50% on sourcing initiatives that are reducing raw material costs into our plants."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. This does conclude our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments.",25,"Thank you. This does conclude our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Great. Thank you. I'd like to thank all of you for joining us here today, and I'd also like to take this opportunity, as I always do, to thank Bard employees around the world for their dedication, commitment and very strong execution throughout 2015. Look",62,"Great. Thank you. I'd like to thank all of you for joining us here today, and I'd also like to take this opportunity, as I always do, to thank Bard employees around the world for their dedication, commitment and very strong execution throughout 2015. Look forward to catching up with all of you again after the first quarter. Have a good evening."
254131,321219429,923102,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And that does conclude our conference today. Thanks again for your participation and for using AT&T Executive TeleConference services. You may now disconnect.",25,"Thank you. And that does conclude our conference today. Thanks again for your participation and for using AT&T Executive TeleConference services. You may now disconnect."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand",378,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations. The accuracy of these statements are necessarily subject to risks and uncertainties. These statements are not historical in nature, and use words such as anticipate, estimate, expect, project, intend, forecast, plan, believe and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, income tax matters, the outcome of contingencies, such as legal proceedings, the uncertainty of loss revenue estimates, share repurchases, acquisitions, foreign exchange and other economic business competitive and regulatory factors. Please refer to the cautionary statement regarding forward-looking information in Bard's September 30, 2015, 10-Q and the other -- and the information under the caption Risk Factors in the company's 2014 10-K, including disclosure of factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual private categories. Reconciliations of non-GAAP measures to the most comparable GAAP measures with respect to the company's historical financial results are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of January 28, 2016, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to the prior year-end. 
At this time, I will turn the call over to Timothy M. Ring. Please go ahead."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Ernie. Good afternoon, everybody, and welcome to Bard's Fourth Quarter 2015 Earnings Call. I'd like to thank all of you for taking the time to join us today. I'd expect the presentation portion of the call to last about 40 minutes. You may note we",997,"Thanks, Ernie. Good afternoon, everybody, and welcome to Bard's Fourth Quarter 2015 Earnings Call. I'd like to thank all of you for taking the time to join us today. I'd expect the presentation portion of the call to last about 40 minutes. You may note we have also placed a few slides on the Investor Relations page of our website to help you understand some of the moving pieces on our results and guidance to give you a little more clarity. Our discussions today will go as follows: I'll begin with an overview of the results for the fourth quarter; John Weiland, our President and COO, will cover fourth quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; and then Chris Holland, our SVP and CFO, will cover the fourth quarter income statement, balance sheet and provide our financial guidance for 2016, and then we'll close with Q&A.
Fourth quarter 2015 net sales totaled $878.8 million. That's essentially flat on an as-reported basis and up 3% on a constant currency basis over the fourth quarter of last year. Currency impact for the quarter versus prior year was unfavorable by about 300 basis points. Other nonoperating adjustments also negatively affected revenue growth by about 200 basis points in the fourth quarter. Adjusting for these items, our organic growth rate for Q4 of 2015 was 5.5%, which exceeded our guidance from 3 months earlier. We've provided a summary reconciliation of these quarterly revenue results on Slide 3 of the deck provided on the website that I just referenced.
Net sales for the full year were $3.4 billion. That's up 3% as reported and up 6% on a constant currency basis. That correlates to approximately 6.8% organic growth for the year, compared with our original guidance for the year of 4% to 5%. 
The U.S. launch of the Lutonix drug-coated balloon exceeded our expectations, and we're also pleased to see the acceleration of the rest of the portfolio in 2015. It's notable that every business was at the top or above the revenue guidance ranges we provided a year ago. 
Net income for the fourth quarter was $136.3 million and diluted earnings per share were $1.79. That's up 2% and 4% respectively. Excluding items that affect the comparability of results between periods, which Chris will cover later, fourth quarter 2015 net income and diluted cash earnings per share, which exclude amortization of intangibles, were $164.6 million and $2.43. That's up 4% and 6%, respectively. 
Full year 2015 net income was $135.4 million and diluted EPS was $1.77. Excluding items that affect comparability between periods, full year 2015 net income was $615.8 million and diluted cash EPS was $9.08. That's up 5% and 8%, respectively. These results exceeded our original guidance for the year, despite an estimated additional $0.15 of headwind during the year from a combination of additional FX headwinds and dilution from acquisitions during the year.
Looking at the fourth quarter revenue growth geographically, compared to the prior year on a constant-currency basis, net sales in the U.S. grew 2%. Internationally we grew 5%, with Europe up 7%, Japan down 22%, and our other international geographies up 16%. 
To refresh your memory, the decline in Japan is due to the work down of inventory that was recorded as revenue when we sold into our Japanese joint venture prior to the acquisition of the joint venture. This issue should be substantially behind us after the first quarter of this year. As anticipated in our strategic investment plan, our emerging market sales continued to increase nicely and represented about 10% of our total revenue in the fourth quarter. 
Looking at overall results with some historical context. 3 years ago, we announced our strategic investment plan to invest in advance of the receipt of the Gore royalty. At that time, our organic revenue growth profile was essentially flat. We increased our annual spending in SG&A and R&D by combined $70 million. We designed the investment plan to return the revenue growth of our portfolio to above-market rates and to put the company in a better position for the longer term. We then said on this call a year ago that 2015 was a very important year of execution for us to begin to see the results from that investment plan. 
As we look at where we are today, our organic growth rate has accelerated, again, to the top tier of the sector. We're pleased with how our teams have executed the plan, and we believe we've built the business in a manner that's sustainable. We've been able to achieve our objectives while continuing to invest in future growth despite absorbing various headwinds along the way. So while we're pleased with the execution of the plan so far, our focus remains solidly on the future. We have many potential opportunities for strong growth in front of us. We believe we have significant room for growth in emerging markets. We also have several technology platforms that we believe provide us with billions of dollars of market opportunity to pursue through new indications and expanded market development and penetration. And the Japan joint venture and Liberator acquisitions provide us better access to customers with delivery platforms that we believe will position us well for the long term. So we remain in investment mode to pursue these opportunities. Our objective remains sustained above-market growth on the top line, that we believe should provide an organic engine positioned for reliable and attractive profitability on the bottom line. Chris will give you more details when he lays out our financial guidance.  
We continue to believe that the effective execution of our strategic investment plan will allow us to continue to increase shareholder value over the long term on a sustainable basis. 
With that, let me turn you over now to John Weiland for a review of our fourth quarter product line revenue."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, as usual, I'll be giving all percentage growth data and comparison to the prior year period on a constant currency basis, unless otherwise noted.So let's start with Vascular. Total net sales in this category for",900,"Good afternoon, everyone. Before I start, as usual, I'll be giving all percentage growth data and comparison to the prior year period on a constant currency basis, unless otherwise noted.
So let's start with Vascular. Total net sales in this category for the quarter were $239.3 million, a decline of 2% on a reported basis and an increase of 1% on a constant currency basis when compared to Q4 of 2014. Adjusting for the nonoperating items, global Vascular sales were up 5%, with the U.S. business down 3% for the quarter and international up 18%. Sales in our Vascular graft category were up 7% in Q4, which is above trend, driven by some timing issues within our OEM business. 
Excluding the Gore royalty, our Endovascular business grew 4% in the fourth quarter. Within Endovascular, our biopsy line was up 10%, driven by strength in emerging markets. Our peripheral PTA products were up 5% this quarter. As expected, the growth rate here was affected by the anniversary of the significant stocking event for Lutonix in Q4 of 2014 as well as the reduction in Japanese sales due to our inventory adjustment there. 
As Tim said, we are very pleased with the first year of our drug-coated balloon sales in the United States. Sales in Q4 were as expected, and we estimate that end customer use, which more than doubled the prior year. We look forward to expanded adoption of this technology longer term as the market continues to develop. 
Our stent business was up 4% in the fourth quarter, which is better than recent trends, driven by strength in its product family internationally. And to complete the category, sales in our vena cava filter line were down 28% in the fourth quarter. This was mostly due to a supplier component issue that we expect will be resolved in the next few months. 
Now let's move to Urology. Total net sales were $217.9 million, which is flat versus Q4 of last year on an as-reported basis and up 3% on a constant currency basis. Excluding the Japanese inventory issue, global growth was 5%, with the United States up 5% and international up 4%. 
The Targeted Temperature Management product sold double-digit growth again this quarter, both domestically and internationally. Our basic drainage business was up 3% in Q4 globally and up 9% in the United States. I.C. Foleys were flat globally and up 7% in the United States. We believe the strong finish to the year in the United States is more related to our sales mix than overall volumes. We saw particular strength in our temperature-sensing products, which are nearly double the ASP of our base product. We continue to see a favorable shift in mix to higher-ASP products. 
Our continence business declined 1% in the prior year quarter. Sales in urological specialties were up 1%, with our brachytherapy product line up 7%. We do not hold significant brachytherapy inventory in Japan. So that product line benefited from moving to end customer pricing in the fourth quarter. And sales from our StatLock catheter stabilization line decreased 3% in Q4. 
Before we leave Urology, we're pleased to announce that we completed the acquisition of Liberator Medical last week. As Tim said, this adds a new delivery platform to a strong technology platform, and we're very excited about the possibilities here. 
Now for Oncology. Total net sales in this category were $237.8 million, which was flat compared to the fourth quarter last year on an as-reported basis and up 3% on a constant currency basis. Adjusting for the Japan inventory issue, global sales were up 4%, with the United States up 2% and international sales up 10%. Our port line was down 8% versus the fourth quarter of last year. The Japanese inventory issue contributed to this decline as the timing issues of orders in emerging markets, which were lower than trend in the fourth quarter as we expect to register next-generation devices there in the first quarter of 2016.
PICC revenue growth was 9% in the fourth quarter. Contrary to ports, we saw very few PICCs in Japan currently. So the impact from the acquisition is minimal. Our vascular access ultrasound product line was up 1% this quarter, and our dialysis catheter business was up 9% in the fourth quarter. 
So let's then finish up with Surgical Specialties. Net sales in this category were $152.8 million in the fourth quarter, up 5% on an as-reported basis and 8% on a constant currency basis. Adjusting for the Japan inventory issue, global sales were up 10%, with United States up 11% and international sales up 7%. 
Our biosurgical product portfolio grew double digits, again, this quarter, and we're excited about the long-term potential here. 
Our soft tissue repair business grew 9% overall in the fourth quarter. Within that subtotal, our total synthetic hernia products were up 9% this quarter, while our natural tissue products increased 7%. 
We're pleased with the execution and the momentum in our broad product portfolio of synthetic, natural tissue and hybrid products for the treatment of hernia repair. Our fixation business grew 15% in Q4 benefited -- benefiting from the initial launch of new products in this product category. 
Closing out the surgical category, our performance irrigation business was down 22%. This quarter consistent with expectations. This concludes our product line revenue discussion. 
I'll now turn you over to John DeFord."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. 2015 was a pretty busy year with about 40 product launches and several important developments and milestones reached. We expect 2016 to be another year with a robust pipeline and a similar number of launches pla",1100,"Thanks, John, and good afternoon, everyone. 2015 was a pretty busy year with about 40 product launches and several important developments and milestones reached. We expect 2016 to be another year with a robust pipeline and a similar number of launches planned. 
I'll start today with our drug-coated balloon pipeline. We're building inventory for the launch in Q1 of recently approved additional lengths and diameters in the U.S. SFA product line. We've also submitted to FDA, seeking approval for the treatment of lung lesions based on clinical data we've gathered in Europe. 
During the Leipzig Interventional Course, or LINC meeting, this week, investigators are sharing data and updated results from several of our Bard-sponsored studies as well as results from independent studies of DCBs conducted by clinicians. Some highlights include yesterday's presentation by Dr. Christopher Metzger of updated Lutonix global registry results, including a 93% freedom from TLR at 24 months, now in 229 patients. He also presented results for subgroups, including a first look at freedom from reintervention for patients treated for in-stent restenosis. At 12 months, almost 92% of ISR patients were free from reintervention, and that result was durable with over 88% of patients free from intervention at 24 months. 
Also yesterday, Dr. Sabine Steiner from University Hospital Leipzig presented results from their single-center comparative study of the impact in Lutonix DCBs. This real-world retrospective study included 12-month analysis of 456 patients with SFA and popliteal disease. The retrospective the baseline patient and lesion characteristics were pretty well matched. This study treated very difficult patients with an average treated length in both groups of over 280 millimeters. No statistical difference between devices was seen with freedom from reintervention at 12 months in excess of 82%. Sustained clinical benefit defined as freedom from an increase in Rutherford Class was also found to exceed 80% in both groups at 12 months. 
In our Below the Knee IDE enrollment progresses, and we continue to work with FDA to expand patient inclusion and analysis in this important study. At projected recruitment rates, we anticipate we'll continue to enroll patients through 2016, putting PMA submission late in 2017 or likely into 2018. 
On the other hand, our AV access DCB IDE study, which begun recruitment in Q2 of 2015, continues to enroll quickly. At current rates, we anticipate enrollment could be complete in late Q1 or Q2 of this year, putting PMA submission slightly ahead of schedule in the first half of 2017. 
The in-stent restenosis IDE study is also ongoing, and we're working toward a projected second half 2016 PMA submission, seeking this expanded indication. 
Around the world, we're also working to expand access to this important technology, with submission for approval expected in the first half of the year in Japan. We also expect enrollment to begin to accelerate in our Levant China study. 
Also in Vascular, the LifeStream Balloon Expandable Covered Stent continues to perform well in Europe. The IDE is in follow-up after completing enrollment in Q3. These clinical studies evaluating the technology for the treatment of iliac artery disease. We remain on schedule for the projected submission of the final module of the PMA in the second half of the year. 
Our COVERA next-generation stent graft, designed for use in AV access, recently received CE Mark, and the IDE was submitted in December. Our current plans have enrollment commencing in Q1. 
And our new Venovo venous stent also received CE Mark in Q4, and our first case was completed in December. In the U.S., we received approval to commence our IDE study a few weeks ago. 
Next, moving to Urology and home care, we're expanding the launch of the new Magic3 Go self-lubricated catheter for female patients as our manufacturing ramps up inventory. We're also building launch quantities of our Magic3 Touchless, and we anticipate launching the product family this quarter. And in endourology, we expect to launch around the end of Q1 upon FDA clearance the new process [ph] sheath family for flexible ureteroscopy. 
In temperature management, we've released software upgrades for enhanced EMR connectivity and additional user controls. 
Moving to Oncology. The new Site-Rite 8 ultrasound system, which launched in Europe in Q3, has received clearance in the U.S., and we're launching the product this quarter with 3CG Diamond and Pinpoint GT capabilities. We continue to believe the combination of ultrasound needle guidance and catheter tracking and tip confirmation in an integrated system will provide a user-friendly and intuitive solution for vascular catheter replacement. 
In PICCs, we're waiting FDA clearance for the launch anticipated in the first half of this year of our new family of chemical-resistant catheters based on a new material designed to resist commonly used chemotherapy solutions as well as cleaning and disinfecting agents. We're also making steady progress on our new PICC family, designed to reduce the risk of thrombosis or DVT, and remain on plan to begin launching in the back half of the year. 
For the difficult stick IV catheter patients, we're gearing up to launch around the end of the first quarter an improved family of AccuCath wire-guided assisted products. These new products are anticipated to launch alongside our new midline catheter, the PowerGlide Pro, also slated for launch this quarter. 
And lastly, for the acute hemodialysis patient, we're preparing for the launch of the new dual-lumen Power Xenesys [ph] catheter, which was cleared by FDA earlier this month. Xenesys [ph] is designed for superior flexibility and kink resistance and flow rates in excess of 400 ml per minute in an 11 French configuration. 
I'll close my portion of the discussion today with surgery. In 2016, we'll continue to expand our Phasix and XenMatrix AB families of products with launches planned throughout the year. In our BioSurgery product family, we're awaiting PMA approval for our new TRIDYNE vascular sealant and continue to anticipate approval and launch of the first in a series of indications in the back half of 2016. We're also working toward the launch of a new Progel sealant configuration, designed to improve visibility during minimally invasive and robotic surgery. 
And finally, in mesh fixation, we're expanding on our recent permanent and resorbable product launches with 2 additional fixation devices slated for later this year. 
And now before I hand you over to Chris, I'd like to invite all of you to our Analyst Day to be held on Monday, May 23, at the New York Palace Hotel at 4:30 p.m. I look forward to seeing you there. 
I've stalled about as long as I can, so I guess, I'll hand it over to Chris now."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John, and good afternoon, everyone. Let me start by covering the items that affect the comparability of our results between periods. Net acquisition-related items of $33.9 million pretax, a $14.5 million pretax charge for restructuring and prod",1813,"Thank you, John, and good afternoon, everyone. Let me start by covering the items that affect the comparability of our results between periods. Net acquisition-related items of $33.9 million pretax, a $14.5 million pretax charge for restructuring and productivity initiatives and a $4.5 million pretax charge for asset impairments. These items are detailed in the notes to the financial statements and the reconciliation accompanying our Q4 earnings press release. 
Now let's go through the statement of income for the quarter. Gross profit was $550.8 million in Q4 or 63.3% of sales. On an adjusted basis, gross profit was $553.2 million or 63.5% of sales. That's up 40 basis points from the prior year. The headwinds to GP in Q4 included new amortization of about 30 basis points and FX at about 30 basis points. Pricing pressure, which was about 100 basis points of headwind on the revenue line, was 40 basis points of headwind in GP during the quarter. 
On the positive side for GP, mix was favorable by about 40 basis points, and cost improvements in other items drove about 100 basis points of favorability this quarter. For the full year 2015, that brings adjusted gross profit as a percentage of sales to 61.8%, which was at the very high end of our original guidance, down 30 basis points from 2014. FX was a headwind of 30 basis points. Price was negative by 40 basis points and new amortization was also 40 basis points. Mix was positive by 30 basis points and cost improvements and other items were about 50 basis points favorable. 
SG&A expenses were $279.3 million for the quarter or 32.1% of sales. On an adjusted basis, SG&A was $271.3 million or 31.2% of sales. That's up 110 basis points from the prior year, primarily as a result of the acquisition of our Japanese joint venture. 
For the full year 2015, adjusted SG&A as a percentage of sales was 29.3%. That's a decrease of 30 basis points from the prior year. SG&A was higher than we guided at the beginning of the year, primarily because of acquisitions as well as some additional investment spending in the back half of the year, reflective of our strong operating performance. 
R&D expenditures totaled $69.4 million for the fourth quarter or 8% of sales. On an adjusted basis, R&D expense was $64.8 million or 7.4% of sales, a decrease of 80 basis points from the prior year period. 
For the full year 2015, on an adjusted basis, R&D was also 7.4% of sales, which was consistent with our guidance and reflective of a very robust level of investment spent. Interest expense was $11.2 million for the fourth quarter and $44.9 million for the full year. Other income and expense was $32.9 million of expense for the fourth quarter. On an adjusted basis, it was $5 million of income for the quarter and $1.6 million of income for the year. The effective tax rate for the quarter was 13.7%. On an adjusted basis, it was 22%, taking us to 24.1% for the full year, right in the middle of the guidance range we provided at the beginning of the year. The quarter, of course, was lower than the full year average due to the renewal of the R&D tax credit in December, which as you now know, has been made permanent. That all adds up to cash EPS of $2.43 for Q4, excluding items affecting comparability, bringing us in at $9.08 for the full year on the same basis. That's $0.03 above the high end of our original guidance for the year despite having absorbed roughly $0.15 of additional FX headwind and dilution during the course of the year, which is indicative of the strong operating performance we saw in 2015. 
We repurchased about 600,000 shares of stock in Q4, taking total buybacks in 2015 to approximately 2.7 million shares. The balance sheet as of December 31 reflects cash, restricted cash and short-term investments of $1 billion versus $1.1 billion at September 30. For the full year, AR days were up 0.8 days and inventory days were up 6.9 days, driven by the acquisition of our Japanese JV. 
Capital expenditures totaled $23.6 million for the quarter and $102.9 million for the year. On the liability side, total debt was $1.4 billion as of December 31, no change from September 30. That's a total cap, at the end of the fourth quarter, was about 49% and total shareholder investment was $1.5 billion at December 31. 
So with a strong 2015 now in the books, let's turn to financial guidance for 2016, excluding the impact of items that affect comparability. For revenue, we project 2016 constant currency organic revenue growth between 5% and 6%. Beyond organic growth, we'll benefit from incremental revenue in 2016 from the acquisitions of our Japanese JV as well as Liberator Medical. We also expect to see a nonoperating reduction to revenue from lower sales of EP products to Boston Scientific and we're prepared for a range of levels for the Gore royalty. Therefore, our overall constant currency revenue guidance is between 6% and 8%. Our expectations assume no change in the market growth rates from where they have been in the last couple of years, which we would characterize as being in the low single digits. Obviously, the strength of the U.S. dollar will continue to be a headwind for U.S. multinational companies in 2016. We estimate that at current rates we're looking at a revenue headwind related to currency of about 1.5%, which would put our reported revenue guidance for 2016 between 4.5% and 6.5%. 
As far as constant currency revenue growth in our 4 disease state categories, in 2016, we expect Vascular revenue growth to be between 3% and 7%, Urology to be between 8% and 11%, Oncology to grow between 5% and 8% and our Surgical Specialties business to grow between 6% and 9%. To be clear, these are constant currency growth rates, not organic. We're only providing organic revenue growth guidance at the corporate level. 
As we move down the P&L for financial guidance, we're making one important change in our presentation. As you know, when the sector moved to cash EPS, the vast majority of our peers excluded amortization of intangibles from their entire adjusted P&L. Up until now, we have been reporting amortization in the entire P&L and only excluding it from the EPS number below the line. In order to make it easier for investors to understand our results in context with others in the sector, beginning with 2016, we'll exclude the amortization of intangibles from our entire adjusted P&L. We've provided a reconciliation of the key margin percentages on the Reg G section of our Investor Relations page on our website. And a summary of that reconciliation is provided on Slide 6 of the deck associated with this call. 
So the following guidance excludes items that may affect comparability and amortization of intangibles. We expect our overall gross margin percent to improve in 2016 between 50 and 100 basis points compared to 2015, which translates to a gross margin range between 65.8% and 66.3%. That reflects about 30 basis points of pressure from the FX. Pricing pressure continues to be a challenge for us, and we estimate the impact on 2016 to be between 30 and 50 basis points of gross margin headwind. Our cost improvement programs are projected to contribute between 80 and 100 basis points of benefits to GP, and we expect the mix to be favorable between 50 to 60 basis points, which includes the positive gross margin impact from our acquisition in Japan. 
We expect SG&A as a percentage of sales to be about the same as 2015 as we continue to increase our investments in emerging markets this year and work to integrate our recent acquisitions. And we expect R&D as a percentage of sales to be in the mid-7% range again this year. This would project our operating margin in 2016 to be between 29% and 29.5%, which is an improvement of 50 to 100 basis points compared to 2015 on the same basis. We expect interest expense in 2016 to be between $50 million and $55 million, reflecting higher projected average rates and debt levels compared to 2015. Primarily as a result of jurisdictional mix, we expect a slight pause in the cadence of our improvement in the effective tax rate, which we project to be between 25.5% and 26% in 2016. The R&D tax credit is now permanent, so we will not have the sharp reduction in the Q4 effective rate that we have seen in the last couple of years. So all of that adds up to adjusted cash EPS for 2016, excluding items that affect the comparability, between $9.90 and $10.05 representing 9% to 11% reported growth over 2015. This guidance includes a projected negative currency impact of about $0.30 based on today's rates. The suspension of the medical device excise tax represents approximately $0.20 of benefit to us, essentially offsetting 2/3 of our overall estimated currency headwind in 2016 at today's rates. So we do exclude both the negative impact of currency and the benefit from the end debt suspension, our operational EPS growth forecast would have been between 10% and 12%. 
As we enter 2016, we continue to be in investment mode, with planned, targeted incremental spending in SG&A, particularly in emerging markets, and a continued robust level of investment in R&D. We're pleased that we're able to provide attractive 2016 guidance with strong reported earnings growth without having to reduce or delay investments and projects, we believe will provide long-term value to our shareholders. 
In Q1, we expect constant currency sales growth between 4.5% and 5.5% and reported revenue growth between 2.5% and 3.5%. As was the case in Q4, Q1 revenue guidance reflects the negative impact from the sell-through of existing inventory in Japan. We expect this factor to be behind us by Q2. On an organic basis, we expect Q1 sales growth to be in the 5.5% to 6% range. We expect adjusted cash EPS in Q1 2016 to be between $2.14 and $2.18, which reflects the initial dilution from recent acquisitions as well as the foreign exchange headwind. We expect the dilutive impact from acquisitions, in particular, our joint venture buyout in Japan, to moderate as we move through 2016. Excluding the front-loaded dilution from acquisitions, Q1 adjusted EPS would have been about 10%. So operationally, I expect us to be off to a very solid start to the year as we move into Q1. 
As for capital expenditures, we expect 2016 to be in the $120 million range, and we expect operating cash flow to be in the $700 million range in 2016. 
Thank you for your attention. And with that, I'll turn you back to Tim."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Chris. While we're pleased with our performance in 2015, as I mentioned earlier, we remain very focused on the growth opportunities in front of us and our execution against the plan for those. We look forward to updating you on our continued pr",70,"Thank you, Chris. While we're pleased with our performance in 2015, as I mentioned earlier, we remain very focused on the growth opportunities in front of us and our execution against the plan for those. We look forward to updating you on our continued progress in the coming quarters. 
With that, that concludes the formal part of presentation. I'll now turn you back to the moderator to facilitate the Q&A."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We'll go to Bob Hopkins with Bank of America.",11,"[Operator Instructions] We'll go to Bob Hopkins with Bank of America."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Congrats on the strong finish to the year and the strong guidance. Couple of things I wanted to ask about just in terms of the guidance that you provided. I was wondering, Chris or Tim, if you guys could talk a little bit about some of the assumptions tha",117,"Congrats on the strong finish to the year and the strong guidance. Couple of things I wanted to ask about just in terms of the guidance that you provided. I was wondering, Chris or Tim, if you guys could talk a little bit about some of the assumptions that drive the 2016 guidance, specifically on buyback and share count for 2016. I'm wondering what you're assuming. And then also on drug-coated balloons, could you give us a sense as to the contribution in growth in Q4, and the contribution to growth in '16 that you're assuming? I assume it's probably between 1 and 1.5 points of contribution to top line growth, but just wanted to confirm that."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Bob. Thanks for the questions. I think on the buyback side, we're not going to give a specific guidance number. I think we've been pretty consistent as a repurchaser of our stock. I think having said that, we feel really good about the operational m",239,"Sure, Bob. Thanks for the questions. I think on the buyback side, we're not going to give a specific guidance number. I think we've been pretty consistent as a repurchaser of our stock. I think having said that, we feel really good about the operational momentum in the business. So I think we'll continue to have the latitude to maintain a lot of flexibility with the balance sheet. And while we'll certainly be an active repurchaser, I think we've got a lot of flexibility as we move into '16 given what we see as really strong operating performance straight down the P&L. I think from a Lutonix standpoint, we're really happy about where we are. Q4 came in as we expected it to be. Obviously, overall, we're ahead of our guidance for the quarter. And I think as we move into '16, we're -- we like to talk about not being about one big thing. I think we're trying to really focus on the entire portfolio. We feel terrific about Lutonix as momentum going into '16. I think some of the data that John referenced, that's just hot off the press, out of link. Continues to show a great clinical positioning of the product. That frankly continues to get better the more we see some of this real world data coming out. So it's a component of what we think is really strong organic growth profile coming into '16."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Fair enough. And then Tim, just on emerging markets, we've heard a lot of discussion out of other companies on emerging markets today. And it sounds like for you guys, the growth continues to be strong. But I just wanted to ask your views on emergin",87,"Okay. Fair enough. And then Tim, just on emerging markets, we've heard a lot of discussion out of other companies on emerging markets today. And it sounds like for you guys, the growth continues to be strong. But I just wanted to ask your views on emerging markets you're exiting 2015 and beginning 2016. In Q4, did you see the same kind of growth trends that you've seen in the last couple of quarters? And just any highlights on emerging markets or specific geographies would be helpful."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We haven't really seen a change from the trends that we've seen. Clearly, we pay attention to what others are seeing, feeling in emerging markets. I think it might be kind of the mix of the geographies where we're strong and have a sizable presence.",93,"Sure. We haven't really seen a change from the trends that we've seen. Clearly, we pay attention to what others are seeing, feeling in emerging markets. I think it might be kind of the mix of the geographies where we're strong and have a sizable presence. And some of the geography that seem to be causing others more of an issue, either it's the mix of our operating in those geographies that don't seem to be impacted, and/or we're not very strong in some of those other geographies. So John are you familiar?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add is that, I think one of the unusual natures of our business is, we're really still rolling out the portfolio of products into a lot of these markets. In fact, we had 252 new product approvals in 2015. That was up from 114 in 2014. S",113,"The only thing I'd add is that, I think one of the unusual natures of our business is, we're really still rolling out the portfolio of products into a lot of these markets. In fact, we had 252 new product approvals in 2015. That was up from 114 in 2014. So we have a bolus of new products yet, that are still in regulatory agencies around the world waiting for approvals. All those are a couple of wave that are coming through our international businesses through 2016. I think that's a little unique to us, based on the investments that we've made and the product mix that we're developing for these markets."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Let's go to the line of Larry Keusch with Raymond James.",12,"Let's go to the line of Larry Keusch with Raymond James."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So could we start off just, Tim, maybe I know you -- like you've said that you assume the environment is sort of where it's been. But I'm wondering as you kind of move through the fourth quarter and into 2016, was there anything notable that you might hav",57,"So could we start off just, Tim, maybe I know you -- like you've said that you assume the environment is sort of where it's been. But I'm wondering as you kind of move through the fourth quarter and into 2016, was there anything notable that you might have been seeing that was changing in the U.S.?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No. We didn't detect any notable difference really at all. John, I don't know if you know.",17,"No. We didn't detect any notable difference really at all. John, I don't know if you know."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I think that the -- we didn't see any trends that would cause us to believe it's different from what we experienced through the majority of 2015.",28,"No, I think that the -- we didn't see any trends that would cause us to believe it's different from what we experienced through the majority of 2015."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Terrific. And then Tim, you know look, you -- on the home side, you obviously did deliberate a deal. You did Rochester a while back. Can you sort of help us think about just what the strategy now is for the home now? You've got some enhanced distrib",69,"Okay. Terrific. And then Tim, you know look, you -- on the home side, you obviously did deliberate a deal. You did Rochester a while back. Can you sort of help us think about just what the strategy now is for the home now? You've got some enhanced distribution, you obviously have some new products flowing through, which John talked about. But where we go with the home strategy?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So look, I think it's coming together. We're still figuring it out as we go here. And I do think we do know, and I'm certain of the trends, right? So hospitals are trying to take care of more people outside of hospitals. And obviously, we've paid att",167,"Yes. So look, I think it's coming together. We're still figuring it out as we go here. And I do think we do know, and I'm certain of the trends, right? So hospitals are trying to take care of more people outside of hospitals. And obviously, we've paid attention to that. We've done a lot of work relative to understanding that dynamic. We think we understand very much the difference between a good solid product model and a service model, and a profitability and sustainable growth differences between those 2. So I like the way we're provisioned. I'd say we're still understanding it and trying to figure out where to plug and play in that kind of an environment. But we're optimistic about it, which is why we pulled the trigger on Liberator. We felt we needed that platform as a missing piece to solving that puzzle. So we're pleased with that, and I think you'll continue to hear more from us in the future about that."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Larry, I think just the one thing I'd add and I think it's important, as you think about this strategy, both Rochester and Liberator were movements into the home but based on the back of a strength in Urology. And I think as we said when we did Rochester,",161,"Larry, I think just the one thing I'd add and I think it's important, as you think about this strategy, both Rochester and Liberator were movements into the home but based on the back of a strength in Urology. And I think as we said when we did Rochester, and I'll repeat it again, now that we've got this really interesting platform, it works just on the back of a Urology-entry strategy into the home for us. What it's given us is clearly these other capabilities that we can then begin to really think about how we can leverage into some other category areas. But we don't need to do that to make this -- both the Rochester and the Liberator now a combination very successful and really accretive to us for a long period of time. So I'd characterize that a lower-risk build of a new capability into an adjacency on the back of some core strengths we already have."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Brooks West with Piper Jaffray.",12,"Next, we'll go to the line of Brooks West with Piper Jaffray."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just had a question on margins, may be more theoretical. Chris, you're getting back to the margin profile that you had in 2012, which I think was a big kind of milestone for investors, maybe a little bit ahead of gross margins, almost there operating ma",109,"I just had a question on margins, may be more theoretical. Chris, you're getting back to the margin profile that you had in 2012, which I think was a big kind of milestone for investors, maybe a little bit ahead of gross margins, almost there operating margins. I'm just wondering, you've got leverage left in the business and specifically, from the emerging markets investments that you made. How do you think about running the business going forward? You kind of get the 30% operating margin and reinvest from there? Is there significant upside to where you might see operating margins progress from here? Am just curious your thoughts there."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think what we've been saying now for a number of years, Brooks, is we're focused on driving margins higher, certainly back to the levels we were at. We made good progress in '15 and we've now committed to making additional significant progress in '",160,"Yes. I think what we've been saying now for a number of years, Brooks, is we're focused on driving margins higher, certainly back to the levels we were at. We made good progress in '15 and we've now committed to making additional significant progress in '16. As we do that, we're continuing to balance that objective with longer-term investments that make all of this sustainable. So we're not giving a longer-term margin goal that we get to and then we think about running the business differently. We're making investments in China as we go into '16, and making investments in other areas in the business, but still committing to 50 to 100 basis points on operating margin performance. We'll continue to try to strike that balance. Obviously, there'll be headwinds that come our way along the way, but as Tim said, this is all about sustainability. And we like where we're at, we like the opportunities in front of us."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","And I would want to add to what Chris said, is that when you look at our guidance for 2016, you'd note -- and in our 2015 results, you'd note the strength of the contributions of our operating manufacturing teams around the world. That's a core capability",89,"And I would want to add to what Chris said, is that when you look at our guidance for 2016, you'd note -- and in our 2015 results, you'd note the strength of the contributions of our operating manufacturing teams around the world. That's a core capability that we believe we'll deliver every year for the corporation moving downstream. And it gives us a lot of, I think, a lot of strength and the ability to make a lot of move strategically, depending on where we see the opportunities."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just one on the acquisition environment, if I could. There's been a lot of speculation on consolidation, perhaps this year in medtech. I'm just wondering, it seems like there's still a disconnect between valuation expectations from sellers and bu",65,"And then just one on the acquisition environment, if I could. There's been a lot of speculation on consolidation, perhaps this year in medtech. I'm just wondering, it seems like there's still a disconnect between valuation expectations from sellers and buyers. I'm wondering if you're seeing that change at all or how your expectations might be for, kind of the rest of the year here."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think it's hard to comment specifically, Brooks. Obviously, there's been a lot of volatility in the market. Certain stocks have settled at much lower levels. Certainly, sellers always have a long memory in terms of recent highs. So I think all of that n",152,"I think it's hard to comment specifically, Brooks. Obviously, there's been a lot of volatility in the market. Certain stocks have settled at much lower levels. Certainly, sellers always have a long memory in terms of recent highs. So I think all of that noise doesn't really affect us, frankly. We're very focused on a number of key criteria. And transactions need to make sense to us from a whole other set of perspectives as well as obviously from a valuation perspective. So we're obviously in a world here with a lot of market volatility, but I don't think it changes the things we're focused on. And we looked at a lot of things in '15. We'll continue to be very active in looking, but we'll pull the trigger on things that meet a whole bunch of criteria and we can get at a price that makes sense for our shareholders."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we go to the line of David Roman with Goldman Sachs.",12,"Next, we go to the line of David Roman with Goldman Sachs."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to start off with one clarification question around the EPS guidance. Can you just help us tease out what the deal-related dilution is in your guidance, and if that $0.25 number you provided around Medicon still holds and how that tracks througho",75,"I wanted to start off with one clarification question around the EPS guidance. Can you just help us tease out what the deal-related dilution is in your guidance, and if that $0.25 number you provided around Medicon still holds and how that tracks throughout the course of the year. I think you said it was mostly Q1 weighted. But if anymore do you see -- can provide around the dilution from deals would be helpful."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, so the Medicon dilution in the year, David, is about $0.20. It's about half of that. Actually, it hits us in Q1 again, because you've got obviously the full P&L with the reduction in sales as well. And the other acquisition, Vascular Pathways acquisi",128,"Yes, so the Medicon dilution in the year, David, is about $0.20. It's about half of that. Actually, it hits us in Q1 again, because you've got obviously the full P&L with the reduction in sales as well. And the other acquisition, Vascular Pathways acquisition, as we're really ramping up some of the R&D spending around those, the products that were acquired are also more heavily impacted in Q1 before we launch the new AccuCath. So the dilution from Medicon still a good $0.20 number for the full year. The other acquisitions, Vascular Pathways, cost us $0.03 to $0.05 in 2015. It'll be a little bit less than that during the course of 2016. But obviously, all of that's fully loaded into the $9.90s [ph] and $10.05 [ph]."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And then on -- maybe on Japan specifically, you could help us think about the opportunity that exists in front of you and at least the way we thought about was, 2 pieces there. There's obviously the price recovery from shifting from",118,"Okay. That's helpful. And then on -- maybe on Japan specifically, you could help us think about the opportunity that exists in front of you and at least the way we thought about was, 2 pieces there. There's obviously the price recovery from shifting from distributor to direct. But then I think there's also a fairly significant marketeer opportunity across, at least 3 of your 4 categories. So can you may be help us think about the cadence at which we might be able to recognize that benefit, or if it's sort of a similar playbook to what you've been able to execute in emerging markets? And how we should think about the contribution to growth going forward."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. I'll start and maybe John Weiland wants to jump in. I wouldn't compare it to an emerging market. And the models that we are running are different. It's more of a mature market model. Maybe it's a little bit of a high grade in the sense that because",170,"Okay. I'll start and maybe John Weiland wants to jump in. I wouldn't compare it to an emerging market. And the models that we are running are different. It's more of a mature market model. Maybe it's a little bit of a high grade in the sense that because we haven't had total control in management over all of these selling and marketing resources, some of the things that we do relative to training and some of the management, generally that practices we have around the world, haven't been fully implemented there. And we do think that implementing those in Japan will have a positive influence. But that underlying growth rate of that market isn't anywhere close to what the emerging markets are. So we see this as -- we continue to invest in getting some of the clinical trials and some of the market investment build-out of training, et cetera, clinical trials having control that of that, we felt was an important thing, for the long term in Japan."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the only thing I'd add is we have 191 salespeople in Japan. They will now be fully integrated in the Bard's selling model, which I think will be a significant momentum builder for us. And I think that the product lines which we expect to come out",90,"I think the only thing I'd add is we have 191 salespeople in Japan. They will now be fully integrated in the Bard's selling model, which I think will be a significant momentum builder for us. And I think that the product lines which we expect to come out of our own internal R&D and clinical base, this has been largely a Urology business historically. As we move our competence into Oncology, Endovascular, into surgery. I think that's where we believe we're going to have the bigger payback from."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And maybe just one more -- on a longer-term basis, as you look at the acquisition, Medicon as well as Liberator, I think you've talked about both being accretive on a go-forward business. Do you think you're tangibly getting closer t",66,"Okay. That's helpful. And maybe just one more -- on a longer-term basis, as you look at the acquisition, Medicon as well as Liberator, I think you've talked about both being accretive on a go-forward business. Do you think you're tangibly getting closer to having a higher degree of confidence in being able to steal the ""borehole"" as we look toward a much more outer-year period."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think these are just 2 more examples of all the thought things we're trying to do to grow the business in a way that we've got a really strong organic engine, with lots of different growth platforms that are hopefully increasingly accretive, as we appro",86,"I think these are just 2 more examples of all the thought things we're trying to do to grow the business in a way that we've got a really strong organic engine, with lots of different growth platforms that are hopefully increasingly accretive, as we approach the end of '19 and '20. So these are just consistent with, I think, everything we're trying to do to build a really strong sustainable organic engine that looks attractive when it's compared to other alternatives in this sector."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Let's go to the line of Mike Weinstein with JPMorgan.",11,"Let's go to the line of Mike Weinstein with JPMorgan."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, can you just walk me through the impact of Medicon buy-in on your organic growth, both this quarter and then as we -- more importantly as we roll through 2016?",31,"Chris, can you just walk me through the impact of Medicon buy-in on your organic growth, both this quarter and then as we -- more importantly as we roll through 2016?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It'll be -- it's about 2 points in Q1, Mike, in comparison to prior year. The thing about comparing it to last year is, we were selling in dollars into Japan last year, right? And so the -- as the yen has weakened, and we're now consolidating the JV, ther",79,"It'll be -- it's about 2 points in Q1, Mike, in comparison to prior year. The thing about comparing it to last year is, we were selling in dollars into Japan last year, right? And so the -- as the yen has weakened, and we're now consolidating the JV, there's a negative impact to organic, really over the course of the year. But it's somewhat muted compared to what we're seeing in Q1 because of the inventory sell-through."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","But when we look at your organic growth as you guys are characterizing it here. You're expecting a lower number, obviously, in the first quarter because of Medicon, and then a much higher number over the back half -- somewhere over the back half of the ye",47,"But when we look at your organic growth as you guys are characterizing it here. You're expecting a lower number, obviously, in the first quarter because of Medicon, and then a much higher number over the back half -- somewhere over the back half of the year."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's excluded from organic growth, Mike, in the 5% to 6% guidance.",13,"It's excluded from organic growth, Mike, in the 5% to 6% guidance."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So the Medicon impact is excluded from that?",8,"So the Medicon impact is excluded from that?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And that's in your nonoperational items?",7,"And that's in your nonoperational items?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, exactly.",2,"Yes, exactly."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So you're including that in that.",7,"So you're including that in that."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, so it's totally pulled out.",6,"Yes, so it's totally pulled out."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then Chris, when you get to that $0.30 impact from FX off of just 150 basis points on the top line, can you just -- could you bridge us on that, but it's just the math implies theres a 60% pretax drop there, but obviously it's tied to the Japanese dis",52,"And then Chris, when you get to that $0.30 impact from FX off of just 150 basis points on the top line, can you just -- could you bridge us on that, but it's just the math implies theres a 60% pretax drop there, but obviously it's tied to the Japanese distributor."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's driven by Japan, Mike. So again the way to think about is, that last year, the JV was hedged at the 1.02 on the yen. This year, we're naked on the yen. So it's really -- and we have 100% of the exposure to the JV compared to 50% last year. So the $0.",73,"It's driven by Japan, Mike. So again the way to think about is, that last year, the JV was hedged at the 1.02 on the yen. This year, we're naked on the yen. So it's really -- and we have 100% of the exposure to the JV compared to 50% last year. So the $0.20 of dilution is really all from the impact of the yen when you compare '15 to '16."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","And let's go to the line of David Lewis with Morgan Stanley.",13,"And let's go to the line of David Lewis with Morgan Stanley."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe one for Chris, and one for Tim. So Chris, you have 2 deals in '16, Medicon and Liberator. They have this muted effect on '16, both with the yen exposure of Medicon and the reinvestment in Liberator, but there's this, hopefully, bigger effect in '17.",124,"Maybe one for Chris, and one for Tim. So Chris, you have 2 deals in '16, Medicon and Liberator. They have this muted effect on '16, both with the yen exposure of Medicon and the reinvestment in Liberator, but there's this, hopefully, bigger effect in '17. We think these deals could be at least $0.25, $0.30 accretive in '17. So I know you've been reluctant to provide the returns on Medicon, but is there anything you can tell us about the potential returns of Medicon or accretion Medicon relative to the '16 dilution? I mean give us a sense of the relative magnitude of the Liberator investment in '16, so we can start thinking about how this begin to hit the P&L in '17."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that hopefully you'll join us about a year from now and I'll give you a lot more visibility to that. And I think, seriously, that they both become accretive going into '17. The Liberator platform is strategic to us, so we are making significant in",164,"I think that hopefully you'll join us about a year from now and I'll give you a lot more visibility to that. And I think, seriously, that they both become accretive going into '17. The Liberator platform is strategic to us, so we are making significant investments in '16. And we've got a lot of work integrating Medicon into John's point turning that sales force into a Bard sales force engine. I think as we move into '17, between now and then, obviously lots of other things are going to happen. Those will be 2 nice tailwinds. But I'm not going to call out specific accretion from them in '17 and have you guys make assumptions before we wrap everything up and think about what kind of commitment we want to make for '17. But those are 2 nice tailwinds that we'll have, and then we'll reassess additional investments -- incremental investments as we get closer to seeing how '17 is growing up."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think one of the things to think about in the Liberator and in our home strategy in general, and Urology, is that unlike most homecare segments -- most homecare segments are episodic. A patient gets home from the hospital. They're getting care at home f",115,"I think one of the things to think about in the Liberator and in our home strategy in general, and Urology, is that unlike most homecare segments -- most homecare segments are episodic. A patient gets home from the hospital. They're getting care at home for a given period of time. They get well and they move off the rolls. That's not the case in the urological segment. Most of these patients are on catheterization for the rest of their life. So you build to naturally build the business year after year after year, as you add more patients to your segments, Liberator and Rochester help us do that, and they're both hand in glove."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Very helpful. And then Tim just coming back to this notion of drop-through. I think it seems like the message you have for shareholders is, you're moving towards this durable, kind of, 6% top, 10% bottom line model. I look at the presentation -- the",114,"Okay. Very helpful. And then Tim just coming back to this notion of drop-through. I think it seems like the message you have for shareholders is, you're moving towards this durable, kind of, 6% top, 10% bottom line model. I look at the presentation -- the PowerPoint you provided and obviously, underlying growth rates are in excess of 10% earnings. So maybe just give us a sense of you know, do you think you can deliver greater than 10% earnings growth? Or is this sort of 300 to 400 basis points of leverage on whatever top line you put up? Is that sort of the model that we should continue to expire and expect?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, the guidance we just give for the earnings are with the guidance. So I'm not going to change that during the course of the call here. But if you go back even historically, and look at some of the leverage between our revenue and our earnings, it's b",121,"Well, the guidance we just give for the earnings are with the guidance. So I'm not going to change that during the course of the call here. But if you go back even historically, and look at some of the leverage between our revenue and our earnings, it's been about that kind of a range. We were 8 and 12, 10 years ago. You can get that kind of range which we think gives us a very fair return to shareholders, and also gives us the flexibility to invest in the business of -- for future growth. And it's that balance between those 2 that we manage, and we think that's a good balance, at least -- certainly for this year."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Kristen Stewart with Deutsche Bank.",12,"Next, we'll go to the line of Kristen Stewart with Deutsche Bank."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess most of my questions were taken, so I guess, just thinking about, I guess, just acquisitions and just kind of appetite now. Are you seeing any -- how do you expect kind of the rollout in 2016? Do you continue to think the pace of tuck-in acquisiti",66,"I guess most of my questions were taken, so I guess, just thinking about, I guess, just acquisitions and just kind of appetite now. Are you seeing any -- how do you expect kind of the rollout in 2016? Do you continue to think the pace of tuck-in acquisitions will accelerate from here? That has kind of been asked in a couple of different ways but..."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","We haven't changed our strategy at all relative to acquisitions despite the commentary earlier about valuations perhaps changed around. And we have a very disciplined set of filters that we look at, and it starts with strategic first. And we don't see any",124,"We haven't changed our strategy at all relative to acquisitions despite the commentary earlier about valuations perhaps changed around. And we have a very disciplined set of filters that we look at, and it starts with strategic first. And we don't see any reason to change that. I would say our pipeline is extremely full. I do know, for example, just already this year, we've had meetings with the -- well over 50 different companies and technologies, et cetera, which is a very strong start for this, certainly, in the year. So that cadence hasn't changed, really, the effort, momentum, the resources are all what they were. So we don't feel any differently about our profile in terms of doing acquisitions going forward."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Do you think the suspension of the medical device tax perhaps changes sellers' minds, and it's especially on the small company level, in terms of their desire to sell out over the near term.",34,"Do you think the suspension of the medical device tax perhaps changes sellers' minds, and it's especially on the small company level, in terms of their desire to sell out over the near term."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No I haven't had that or heard that portrayed by anybody yet.",13,"No I haven't had that or heard that portrayed by anybody yet."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then Chris, I guess, you had mentioned -- in terms of the guidance you'd mentioned that it seems a wide range of, I guess, scenarios with the Gore royalty. I was just wondering if you could share what those wide range scenarios are? Or if you had any",82,"And then Chris, I guess, you had mentioned -- in terms of the guidance you'd mentioned that it seems a wide range of, I guess, scenarios with the Gore royalty. I was just wondering if you could share what those wide range scenarios are? Or if you had any sense of change in terms of the cadence of what that could be? Anything, I don't know if you just said that to include just different possibilities or if there's something behind that?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","That's how we've been approaching it, Kristen, so there's not a change. Obviously, it's been flat to down. Obviously, there's some FX component to that, that we frankly don't have visibility into. And we're making commitments to you guys, and we take it r",118,"That's how we've been approaching it, Kristen, so there's not a change. Obviously, it's been flat to down. Obviously, there's some FX component to that, that we frankly don't have visibility into. And we're making commitments to you guys, and we take it really seriously. And we understand we may see some variability there, but we continue to not have visibility to the royalty until it comes in the door. And so I think the same dynamic that's been in play for a while continues to be in play. It's just we need to make sure that we've got business plans that can deliver on the commitments we're making to you, without visibility to that one item."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's not, unlike, Kristen, our other businesses. We give you a range for the businesses that we run and know something about. And there's a high and low end to those, too, and the Gore thing is not dissimilar, it's just we don't have any control over.",48,"It's not, unlike, Kristen, our other businesses. We give you a range for the businesses that we run and know something about. And there's a high and low end to those, too, and the Gore thing is not dissimilar, it's just we don't have any control over."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go to the line of Dave Turkaly with the JMP Securities.",13,"We'll go to the line of Dave Turkaly with the JMP Securities."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just quickly on the Liberator deal. You know, I was going to ask a couple of times sort of the buy versus build and I wonder if you could spend a moment on, sort of, why that was a buy decision, sort of what the secrets sauces there that you gained?",52,"And just quickly on the Liberator deal. You know, I was going to ask a couple of times sort of the buy versus build and I wonder if you could spend a moment on, sort of, why that was a buy decision, sort of what the secrets sauces there that you gained?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, David. We -- on the back of Rochester, one of the things we spent the last couple of years doing is getting really smart on the DME space. And we obviously came to a strategic conclusion that we wanted to control our destiny, and Liberator, really,",221,"Sure, David. We -- on the back of Rochester, one of the things we spent the last couple of years doing is getting really smart on the DME space. And we obviously came to a strategic conclusion that we wanted to control our destiny, and Liberator, really, in Urology, is the market-leading, highest-quality provider of Urology-related products. There's no question. If you look at their metrics, the quality of their billing, the quality of their customer service and in really the great partnerships they have with all the leading manufacturers, they were, frankly, the only platform that would would've fit what we were looking for. And so the complexity of building a nationwide DME distribution, having all of the licenses and all the capability to build -- bill and ship to Medicare patients, in virtually all the 50 states, and to do that at the volume of transactions that they need to do it at, is something that frankly would've not been economically viable for us to try to build. So we're really fortunate that, that team is now part of the Bard family, and welcome them. And really again, they were the only -- they're really the only company that was going to allow us to pursue this strategy, so we really feel great about having them on board now."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just on the tip navigation or confirmation on the PICC side. We've seen some news from competition, I guess -- penetration today, where does that stand? And I guess, how big of an opportunity do you think that is for you guys moving forward?",46,"And then just on the tip navigation or confirmation on the PICC side. We've seen some news from competition, I guess -- penetration today, where does that stand? And I guess, how big of an opportunity do you think that is for you guys moving forward?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we're very well penetrated. We don't give that number out for competitive reasons, but we have a high degree of penetration of our base business. We continue to add segments to that, as you can see by the new product launches that we've talked about",125,"Well, we're very well penetrated. We don't give that number out for competitive reasons, but we have a high degree of penetration of our base business. We continue to add segments to that, as you can see by the new product launches that we've talked about year in and year out within that segment. So we're not slowing down at all. And at the same time, if you look at some of the new product lines that we're bringing to the PICC area, John talked about them tonight. You add some of those important competitive differentiators to our already strong differentiated position. We think our position only gets stronger and stronger in the months and years to come versus any competitive offerings in the play."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, and as John said, we've been trying to move the needle here, and move the game and the goal post time after time. So as we've added Pinpoint GT, which is rolling out this quarter, it's a new technology to further improve and simplify the placement of",143,"Yes, and as John said, we've been trying to move the needle here, and move the game and the goal post time after time. So as we've added Pinpoint GT, which is rolling out this quarter, it's a new technology to further improve and simplify the placement of our devices. And we already have, of course, the ultrasound capability, which is pretty unique to us on an integrated basis. And then our tip-tracking technology, the Sherlock. And then, of course, we also continue to improve upon our final tip confirmation technology. And so we continue to add new algorithms and new ways to make that better, like 3CG Diamond. So we think we're going to continue to do that. We've got a few other tricks up our sleeves, and we'll -- as we get further down the pathway here, we'll talk about them."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Matt Taylor with Barclays.",11,"Next, we'll go to the line of Matt Taylor with Barclays."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So I wanted to just ask one. You were going through some of the new products in lines of the Lutonix balloon that you are coming out this year -- in the beginning of the year. I'm just wondering if you thought that would make a material difference in the",76,"So I wanted to just ask one. You were going through some of the new products in lines of the Lutonix balloon that you are coming out this year -- in the beginning of the year. I'm just wondering if you thought that would make a material difference in the applicability and the growth rate, or if there are any other catalyst that you're looking for in '16 that you think meaningfully reduce your DCB sales."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","So I think there's a few things that we've got in there. We talked about the longer lengths. So we've submitted data, seeking approval for treatment of patients with lengths up to about 300 millimeters. So about twice the length that we have now. That cou",177,"So I think there's a few things that we've got in there. We talked about the longer lengths. So we've submitted data, seeking approval for treatment of patients with lengths up to about 300 millimeters. So about twice the length that we have now. That could potentially open up the market. In-stent restenosis, probably a lot of that is going on today, but I have an ability to promote that, it's going to be helpful. And some of the other sizes we talked about. We've got some other launches that we hope will come in this year, that we think will be helpful. And then obviously, expanding indications is going to be key. Below the Knee AV access, which is a little more near term for the U.S. market, and it's an area where we're particularly strong anyway, with our stent graph technology as well as some of the other products we have for dialysis patients. I think give us what we think is a pretty good opportunity for DCB and our ability to leverage that."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then I was just curious on Liberator. Really 2, kind of minor questions. One is the kind of see their mix in the last 10K, in terms of what they distributed. Just wondering if you could help us understand how much of that revenue is going throu",87,"Great. And then I was just curious on Liberator. Really 2, kind of minor questions. One is the kind of see their mix in the last 10K, in terms of what they distributed. Just wondering if you could help us understand how much of that revenue is going through your different segments. And then also, I guess, what was your history with them? You're working with them before, how much product was yours going through that channel? And what else can you bring now to the table?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So just to be clear, we're selling through them today and part of the acquisition, just Urology products, and we were a pretty small part of their volume. So probably less than 10% overall. They've been a good does, a very high-quality partner to us",89,"Sure. So just to be clear, we're selling through them today and part of the acquisition, just Urology products, and we were a pretty small part of their volume. So probably less than 10% overall. They've been a good does, a very high-quality partner to us. Again, they are the leading independent Urology DME, and so they have Urology, Ostomy and some Mastectomy products, but again, we're only selling Urology products to them today. And that's certainly obviously going to continue to be the case for the foreseeable future."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. I guess, what else can you, kind of, bring into the channel right away? Or maybe where you see that expanding down the road?",25,"Okay. I guess, what else can you, kind of, bring into the channel right away? Or maybe where you see that expanding down the road?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think that's -- that was the point I was trying to make. We're obviously, to John's commentary, around the expansion of our ISE catheter portfolio. That's continued to become much more robust, and that's really the first R&D products coming out of",164,"Yes, I think that's -- that was the point I was trying to make. We're obviously, to John's commentary, around the expansion of our ISE catheter portfolio. That's continued to become much more robust, and that's really the first R&D products coming out of the Rochester R&D engine. This acquisition and this strategy is a winner for us just within Urology. And that's what we're focused on integrating liberator, getting this off to a very strong start. We've talked about investing in the platform and expanding it, including the sales force that's supporting it. Those are the near-term milestones that we're focused on. What we're going to have now is just aperture into the home that's going to allow us to think more broadly beyond Urology. Again, we don't need to do that to make this successful, but that's something that I think you should just look for, really, over the coming years as opposed to anything within the next 12 or 18 months."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","And our final question will come from the line of Rick Wise with Stifel.",14,"And our final question will come from the line of Rick Wise with Stifel."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","A little more on Lutonix. You highlighted, John, the AV Access, BTK, in-stent restenosis, indications that are coming up. Just can you give us some color on the indication opportunity? Is it 50% bigger? Is it double the current opportunity you're tackling",52,"A little more on Lutonix. You highlighted, John, the AV Access, BTK, in-stent restenosis, indications that are coming up. Just can you give us some color on the indication opportunity? Is it 50% bigger? Is it double the current opportunity you're tackling? What are we looking, and what are you looking at?"
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think if we look -- the SFA -- if you kind of look in that broad category, I think the SFA is a big part of the overall market opportunity. I think Below the Knee is -- I'm not the marketing guy so I'm looking at John Weiland here. But I think it'",96,"Well, I think if we look -- the SFA -- if you kind of look in that broad category, I think the SFA is a big part of the overall market opportunity. I think Below the Knee is -- I'm not the marketing guy so I'm looking at John Weiland here. But I think it's 20%, 30% of the SFA opportunity. AV Access, kind of in that same ballpark. So certainly, significant incremental opportunities. But the SFA probably makes up about half of the overall -- maybe a little more than half of the overall opportunity."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the other thing to think about, Rick, is that after, we're a little bit over a year into this now, physicians now are getting to the point that they've started using DCBs on some of their patients. They're not only looking at the data, they're loo",133,"I think the other thing to think about, Rick, is that after, we're a little bit over a year into this now, physicians now are getting to the point that they've started using DCBs on some of their patients. They're not only looking at the data, they're looking at the fact that the patients aren't coming back for reintervention. And if patients don't come back for reinterventions, they get great confidence in using the device on more and more and more patients in the future. And I think we like -- we'd like that in combination with the real-life data that's coming out on our product, and the fact that we're generating those kinds of results with 50% less drug on than other players in the space in the United States right now."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think just to add a little bit to that, I think physicians are still sort of figuring out what's the right treatment paradigm, and how do they optimize the outcomes for their patients. And so we certainly hear in our interaction with customers that",98,"Yes, I think just to add a little bit to that, I think physicians are still sort of figuring out what's the right treatment paradigm, and how do they optimize the outcomes for their patients. And so we certainly hear in our interaction with customers that, that the DCB gives them an important tool in the toolbox but exactly how they combine that with other therapies is still sort of under development. So as John said, there's a lot of work going on out there, and I think there's a lot of penetration opportunity still ahead of us."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes. And just one last one. Just the 100 basis point cost-reduction benefits that we saw. Just remind me again where that came from, and how sustainable that is? Is there more to come of that magnitude in '16? I just wasn't clear on that point.",46,"Yes. And just one last one. Just the 100 basis point cost-reduction benefits that we saw. Just remind me again where that came from, and how sustainable that is? Is there more to come of that magnitude in '16? I just wasn't clear on that point."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Rick. And then John referenced that the inner real core strength of the company and actually within our guidance for 2016, we're projecting 80 to 100 basis points of incremental benefit from all the initiatives that our manufacturing and sourcing te",160,"Sure, Rick. And then John referenced that the inner real core strength of the company and actually within our guidance for 2016, we're projecting 80 to 100 basis points of incremental benefit from all the initiatives that our manufacturing and sourcing teams will be undertaking in the course of '16. So that is something that we believe does have a long runway. It's not easy, but our guys are superb at doing it. And they've delivered in '15 and they're telling us and we're expecting them to deliver a similar magnitude in '16. I think the unfortunate thing is with, what FX has been doing and iron price as well, that's been mitigating a lot of that benefit. So if we can get some of those headwinds to shift or to be a little more benign, you'll really see, I think, the power of what our operating -- our operation and sourcing teams are delivering year in and year out."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","And Rick, I would think about it as almost half being operating efficiencies in terms of cost savings in our plants, and production at about 50% on sourcing initiatives that are reducing raw material costs into our plants.",38,"And Rick, I would think about it as almost half being operating efficiencies in terms of cost savings in our plants, and production at about 50% on sourcing initiatives that are reducing raw material costs into our plants."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. This does conclude our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments.",25,"Thank you. This does conclude our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Great, thank you. I'd like to thank all of you for joining us here today. And I'd also like to take this opportunity, as I always do, to thank Bard employees around the world for their dedication, commitment and very strong execution throughout 2015. We l",63,"Great, thank you. I'd like to thank all of you for joining us here today. And I'd also like to take this opportunity, as I always do, to thank Bard employees around the world for their dedication, commitment and very strong execution throughout 2015. We look forward to catching up with all of you again after the first quarter. Have a good evening."
254131,321219429,923230,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And that does conclude our conference today. Thanks again for your participation and for using AT&T Executive TeleConference services. You may now disconnect.",25,"Thank you. And that does conclude our conference today. Thanks again for your participation and for using AT&T Executive TeleConference services. You may now disconnect."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand",378,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations. The accuracy of these statements are necessarily subject to risks and uncertainties. These statements are not historical in nature, and use words such as anticipate, estimate, expect, project, intend, forecast, plan, believe and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, income tax matters, the outcome of contingencies, such as legal proceedings, the uncertainty of loss revenue estimates, share repurchases, acquisitions, foreign exchange and other economic business competitive and regulatory factors. Please refer to the cautionary statement regarding forward-looking information in Bard's September 30, 2015, 10-Q and the other -- and the information under the caption Risk Factors in the company's 2014 10-K, including disclosure of factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product categories. Reconciliations of non-GAAP measures to the most comparable GAAP measures with respect to the company's historical financial results are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of January 28, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year-end. 
At this time, I will turn the call over to Timothy M. Ring. Please go ahead."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Ernie. Good afternoon, everybody, and welcome to Bard's Fourth Quarter 2015 Earnings Call. I'd like to thank all of you for taking the time to join us today. I'd expect the presentation portion of the call to last about 40 minutes. You may note we",995,"Thanks, Ernie. Good afternoon, everybody, and welcome to Bard's Fourth Quarter 2015 Earnings Call. I'd like to thank all of you for taking the time to join us today. I'd expect the presentation portion of the call to last about 40 minutes. You may note we have also placed a few slides on the Investor Relations page of our website to help you understand some of the moving pieces on our results and guidance and to give you a little more clarity. 
Our discussions today will go as follows: I'll begin with an overview of the results for the fourth quarter; John Weiland, our President and COO, will cover fourth quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you an update on the product development pipeline; and then Chris Holland, our SVP and CFO, will cover the fourth quarter income statement, balance sheet and provide our financial guidance for 2016; and then we'll close with Q&A.
Fourth quarter 2015 net sales totaled $878.8 million. That's essentially flat on an as-reported basis and up 3% on a constant-currency basis over the fourth quarter of last year. Currency impact for the quarter versus prior year was unfavorable by about 300 basis points. Other nonoperating adjustments also negatively affected revenue growth by about 200 basis points in the fourth quarter. Adjusting for these items, our organic growth rate for Q4 of 2015 was 5.5%, which exceeded our guidance from 3 months earlier. We've provided a summary reconciliation of these quarterly revenue results on Slide 3 of the deck provided on the website that I just referenced.
Net sales for the full year were $3.4 billion. That's up 3% as reported and up 6% on a constant-currency basis. That correlates to approximately 6.8% organic growth for the year, compared with our original guidance for the year of 4% to 5%. 
The U.S. launch of the Lutonix drug-coated balloon exceeded our expectations, and we're also pleased to see the acceleration of the rest of the portfolio in 2015. It's notable that every business was at the top or above the revenue guidance ranges we provided a year ago. 
Net income for the fourth quarter was $136.3 million and diluted earnings per share were $1.79. That's up 2% and 4% respectively. Excluding items that affect the comparability of results between periods, which Chris will cover later, fourth quarter 2015 net income and diluted cash earnings per share, which exclude amortization of intangibles, were $164.6 million and $2.43. That's up 4% and 6%, respectively. 
Full year 2015 net income was $135.4 million and diluted EPS was $1.77. Excluding items that affect comparability between periods, full year 2015 net income was $615.8 million and diluted cash EPS was $9.08. That's up 5% and 8%, respectively. These results exceeded our original guidance for the year, despite an estimated additional $0.15 of headwind during the year from a combination of additional FX headwinds and dilution from acquisitions during the year.
Looking at the fourth quarter revenue growth geographically, compared to the prior year on a constant-currency basis, net sales in the U.S. grew 2%. Internationally we grew 5%, with Europe up 7%, Japan down 22% and our other international geographies up 16%. 
To refresh your memory, the decline in Japan is due to the work-down of inventory that was recorded as revenue when we sold into our Japanese joint venture prior to the acquisition of the joint venture. This issue should be substantially behind us after the first quarter of this year. As anticipated in our strategic investment plan, our emerging market sales continued to increase nicely and represented about 10% of our total revenue in the fourth quarter. 
Looking at overall results with some historical context. 3 years ago, we announced our strategic investment plan to invest in advance of the receipt of the Gore royalty. At that time, our organic revenue growth profile was essentially flat. We increased our annual spending in SG&A and R&D by a combined $70 million. We designed the investment plan to return the revenue growth of our portfolio to above-market rates and to put the company in a better position for the longer term. We then said on this call a year ago that 2015 was a very important year of execution for us to begin to see the results from that investment plan. 
As we look at where we are today, our organic growth rate has accelerated, again, to the top tier of the sector. We're pleased with how our teams have executed the plan, and we believe we've built the business in a manner that's sustainable. We've been able to achieve our objectives while continuing to invest in future growth despite absorbing various headwinds along the way. So while we're pleased with the execution of the plan so far, our focus remains solidly on the future. We have many potential opportunities for strong growth in front of us. We believe we have significant room for growth in emerging markets. We also have several technology platforms that we believe provide us with billions of dollars of market opportunity to pursue through new indications and expanded market development and penetration. And the Japan joint venture and Liberator acquisitions provide us better access to customers with delivery platforms that we believe will position us well for the long term. So we remain in investment mode to pursue these opportunities. Our objective remains sustained above-market growth on the top line that we believe should provide an organic engine positioned for reliable and attractive profitability on the bottom line. Chris will give you more details when he lays out our financial guidance.  
We continue to believe that the effective execution of our strategic investment plan will allow us to continue to increase shareholder value over the long term on a sustainable basis. 
With that, let me turn you over now to John Weiland for a review of our fourth quarter product line revenue."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, as usual, I'll be giving all percentage growth data and comparison to the prior-year period on a constant-currency basis, unless otherwise noted.So let's start with Vascular. Total net sales in this category for",893,"Good afternoon, everyone. Before I start, as usual, I'll be giving all percentage growth data and comparison to the prior-year period on a constant-currency basis, unless otherwise noted.
So let's start with Vascular. Total net sales in this category for the quarter were $239.3 million, a decline of 2% on a reported basis and an increase of 1% on a constant-currency basis when compared to Q4 of 2014. Adjusting for the nonoperating items, global Vascular sales were up 5%, with the U.S. business down 3% for the quarter and international up 18%. Sales in our Vascular graft category were up 7% in Q4, which is above trend, driven by some timing issues within our OEM business. 
Excluding the Gore royalty, our Endovascular business grew 4% in the fourth quarter. Within Endovascular, our biopsy line was up 10%, driven by strength in emerging markets. Our peripheral PTA products were up 5% this quarter. As expected, the growth rate here was affected by the anniversary of the significant stocking event for Lutonix in Q4 of 2014, as well as the reduction in Japanese sales due to our inventory adjustment there. 
As Tim said, we are very pleased with the first year of our drug-coated balloon sales in the United States. Sales in Q4 were as expected, and we estimate that end customer use of which more than doubled the prior year. We look forward to expanded adoption of this technology longer term as the market continues to develop. 
Our Stent business was up 4% in the fourth quarter, which is better than recent trends, driven by strength in this product family internationally. And to complete the category, sales in our vena cava filter line were down 28% in the fourth quarter. This was mostly due to a supplier component issue that we expect will be resolved in the next few months. 
Now let's move to Urology. Total net sales were $217.9 million, which is flat versus Q4 of last year on an as-reported basis and up 3% on a constant-currency basis. Excluding the Japanese inventory issue, global growth was 5%, with the United States up 5% and international up 4%. 
The Targeted Temperature Management product saw double-digit growth again this quarter, both domestically and internationally. Our basic drainage business was up 3% in Q4 globally and up 9% in the United States. I.C. Foleys were flat globally and up 7% in the United States. We believe the strong finish to the year in the United States is more related to our sales mix than overall volumes. We saw particular strength in our temperature-sensing products, which are nearly double the ASP of our base product. We continue to see a favorable shift in mix to higher-ASP products. 
Our continence business declined 1% in the prior-year quarter. Sales in urological specialties were up 1%, with our brachytherapy product line up 7%. We do not hold significant brachytherapy inventory in Japan. So that product line benefited from moving to end-customer pricing in the fourth quarter. And sales from our StatLock catheter stabilization line decreased 3% in Q4. 
Before we leave Urology, we're pleased to announce that we completed the acquisition of Liberator Medical last week. As Tim said, this adds a new delivery platform to a strong technology platform, and we're very excited about the possibilities here. 
Now for Oncology. Total net sales in this category were $237.8 million, which was flat compared to the fourth quarter last year on an as-reported basis and up 3% on a constant-currency basis. Adjusting for the Japan inventory issue, global sales were up 4%, with the United States up 2% and international sales up 10%. 
Our port line was down 8% versus the fourth quarter of last year. The Japanese inventory issue contributed to this decline as did timing issues of orders in emerging markets, which were lower than trend in the fourth quarter as we expect to register next-generation devices there in the first quarter of 2016.
PICC revenue growth was 9% in the fourth quarter. Contrary to ports, we saw very few PICCs in Japan currently. So the impact from the acquisition is minimal. Our vascular access ultrasound product line was up 1% this quarter, and our dialysis catheter business was up 9% in the fourth quarter. 
So let's then finish up with Surgical Specialties. Net sales in this category were $152.8 million in the fourth quarter, up 5% on an as-reported basis and 8% on a constant-currency basis. Adjusting for the Japan inventory issue, global sales were up 10%, with United States up 11% and international sales up 7%. 
Our biosurgical product portfolio grew double digits again this quarter, and we're excited about the long-term potential here. 
Our soft tissue repair business grew 9% overall in the fourth quarter. Within that subtotal, our total synthetic hernia products were up 9% this quarter, while our natural tissue products increased 7%. 
We're pleased with the execution and the momentum in our broad product portfolio of synthetic, natural tissue and hybrid products for the treatment of hernia repair. Our fixation business grew 15% in Q4 benefited -- benefiting from the initial launch of new products in this product category. 
Closing out the Surgical category, our performance irrigation business was down 22% this quarter, consistent with expectations. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. 2015 was a pretty busy year with about 40 product launches and several important developments and milestones reached. We expect 2016 to be another year with a robust pipeline and a similar number of launches pla",1100,"Thanks, John, and good afternoon, everyone. 2015 was a pretty busy year with about 40 product launches and several important developments and milestones reached. We expect 2016 to be another year with a robust pipeline and a similar number of launches planned. 
I'll start today with our drug-coated balloon pipeline. We're building inventory for the launch in Q1 of recently approved additional lengths and diameters in the U.S. SFA product line. We've also submitted to FDA, seeking approval for the treatment of lung lesions based on clinical data we've gathered in Europe. 
During the Leipzig Interventional Course, or LINC meeting, this week, investigators are sharing data and updated results from several of our Bard-sponsored studies, as well as results from independent studies of DCBs conducted by clinicians. Some highlights include yesterday's presentation by Dr. Christopher Metzger of updated Lutonix global registry results, including a 93% freedom from TLR at 24 months, now in 229 patients. He also presented results for subgroups, including a first look at freedom from reintervention for patients treated for in-stent restenosis. At 12 months, almost 92% of ISR patients were free from reintervention, and that result was durable with over 88% of patients free from intervention at 24 months. 
Also yesterday, Dr. Sabine Steiner from University Hospital Leipzig presented results from their single-center comparative study of the impact in Lutonix DCBs. This real-world retrospective study included 12-month analysis of 456 patients with SFA and popliteal disease. Though retrospective, the baseline patient and lesion characteristics were pretty well matched. This study treated very difficult patients with an average treated length in both groups of over 280 millimeters. No statistical difference between devices was seen, with freedom from reintervention at 12 months in excess of 82%. Sustained clinical benefit, defined as freedom from an increase in Rutherford Class, was also found to exceed 80% in both groups at 12 months. 
In our Below the Knee IDE, enrollment progresses and we continue to work with FDA to expand patient inclusion and analysis in this important study. At projected recruitment rates, we anticipate we'll continue to enroll patients through 2016, putting PMA submission late in 2017 or likely into 2018. 
On the other hand, our AV access DCB IDE study, which began recruitment in Q2 of 2015, continues to enroll quickly. At current rates, we anticipate enrollment could be complete in late Q1 or Q2 of this year, putting PMA submission slightly ahead of schedule in the first half of 2017. 
The in-stent restenosis IDE study is also ongoing, and we're working toward a projected second half 2016 PMA submission, seeking this expanded indication. 
Around the world, we're also working to expand access to this important technology, with submission for approval expected in the first half of the year in Japan. We also expect enrollment to begin to accelerate in our Levant China study. 
Also in Vascular, the LifeStream Balloon Expandable Covered Stent continues to perform well in Europe. The IDE is in follow-up after completing enrollment in Q3. This clinical study's evaluating the technology for the treatment of iliac artery disease. We remain on schedule for the projected submission of the final module of the PMA in the second half of the year. 
Our COVERA next-generation stent graft, designed for use in AV access, recently received CE Mark, and the IDE was submitted in December. Our current plans have enrollment commencing in Q1. 
And our new Venovo venous stent also received CE Mark in Q4, and our first case was completed in December. In the U.S., we received approval to commence our IDE study a few weeks ago. 
Next, moving to Urology and home care. We're expanding the launch of the new Magic3 Go self-lubricated catheter for female patients as our manufacturing ramps up inventory. We're also building launch quantities of our Magic3 TOUCHLESS, and we anticipate launching the product family this quarter. And in endourology, we expect to launch around the end of Q1 upon FDA clearance the new process [ph] sheath family for flexible ureteroscopy. 
In temperature management, we've released software upgrades for enhanced EMR connectivity and additional user controls. 
Moving to Oncology. The new Site-Rite 8 ultrasound system, which launched in Europe in Q3, has received clearance in the U.S., and we're launching the product this quarter with 3CG diamond and Pinpoint GT capabilities. We continue to believe the combination of ultrasound needle guidance and catheter tracking and tip confirmation in an integrated system will provide a user-friendly and intuitive solution for vascular catheter placement. 
In PICCs, we're awaiting FDA clearance for the launch anticipated in the first half of this year of our new family of chemical-resistant catheters based on a new material designed to resist commonly used chemotherapy solutions, as well as cleaning and disinfecting agents. We're also making steady progress on our new PICC family, designed to reduce the risk of thrombosis or DVT, and remain on plan to begin launching in the back half of the year. 
For the difficult stick IV catheter patients, we're gearing up to launch, around the end of the first quarter, an improved family of AccuCath wire-guided assisted products. These new products are anticipated to launch alongside our new midline catheter, the PowerGlide Pro, also slated for launch this quarter. 
And lastly, for the acute hemodialysis patient, we're preparing for the launch of the new dual-lumen Power Xenesys [ph] catheter, which was cleared by FDA earlier this month. Xenesys [ph] is designed for superior flexibility and kink resistance and flow rates in excess of 400 ml per minute in an 11 French configuration. 
I'll close my portion of the discussion today with surgery. In 2016, we'll continue to expand our Phasix and XenMatrix AB families of products with launches planned throughout the year. In our BioSurgery product family, we're awaiting PMA approval for our new TRIDYNE vascular sealant and continue to anticipate approval and launch of the first in a series of indications in the back half of 2016. We're also working toward the launch of a new Progel sealant configuration, designed to improve visibility during minimally invasive and robotic surgery. 
And finally, in mesh fixation, we're expanding on our recent permanent and resorbable product launches with 2 additional fixation devices slated for later this year. 
And now before I hand you over to Chris, I'd like to invite all of you to our Analyst Day to be held on Monday, May 23, at the New York Palace Hotel at 4:30 p.m. I look forward to seeing you there. 
I've stalled about as long as I can, so I guess, I'll hand it over to Chris now."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John, and good afternoon, everyone. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $33.9 million pretax, a $14.5 million pretax charge for restructuring and p",1805,"Thank you, John, and good afternoon, everyone. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $33.9 million pretax, a $14.5 million pretax charge for restructuring and productivity initiatives and a $4.5 million pretax charge for asset impairments. These items are detailed in the notes to the financial statements and the reconciliation accompanying our Q4 earnings press release. 
Now let's go through the statement of income for the quarter. Gross profit was $550.8 million in Q4 or 63.3% of sales. On an adjusted basis, gross profit was $553.2 million or 63.5% of sales. That's up 40 basis points from the prior year. The headwinds to GP in Q4 included new amortization of about 30 basis points and FX at about 30 basis points. Pricing pressure, which was about 100 basis points of headwind on the revenue line, was 40 basis points of headwind in GP during the quarter. 
On the positive side for GP, mix was favorable by about 40 basis points, and cost improvements and other items drove about 100 basis points of favorability this quarter. For the full year 2015, that brings adjusted gross profit as a percentage of sales to 61.8%, which was at the very high end of our original guidance, down 30 basis points from 2014. FX was a headwind of 30 basis points, price was negative by 40 basis points and new amortization was also 40 basis points. Mix was positive by 30 basis points and cost improvements and other items were about 50 basis points favorable. 
SG&A expenses were $279.3 million for the quarter or 32.1% of sales. On an adjusted basis, SG&A was $271.3 million or 31.2% of sales. That's up 110 basis points from the prior year, primarily as a result of the acquisition of our Japanese joint venture. 
For the full year 2015, adjusted SG&A as a percentage of sales was 29.3%. That's a decrease of 30 basis points from the prior year. SG&A was higher than we guided at the beginning of the year, primarily because of acquisitions, as well as some additional investment spending in the back half of the year, reflective of our strong operating performance. 
R&D expenditures totaled $69.4 million for the fourth quarter or 8% of sales. On an adjusted basis, R&D expense was $64.8 million or 7.4% of sales, a decrease of 80 basis points from the prior year period. 
For the full year 2015, on an adjusted basis, R&D was also 7.4% of sales, which was consistent with our guidance and reflective of a very robust level of investment spent. Interest expense was $11.2 million for the fourth quarter and $44.9 million for the full year. Other income and expense was $32.9 million of expense for the fourth quarter. On an adjusted basis, it was $5 million of income for the quarter and $1.6 million of income for the year. 
The effective tax rate for the quarter was 13.7%. On an adjusted basis, it was 22%, taking us to 24.1% for the full year, right in the middle of the guidance range we provided at the beginning of the year. The quarter, of course, was lower than the full year average due to the renewal of the R&D tax credit in December, which as you now know, has been made permanent. 
That all adds up to cash EPS of $2.43 for Q4, excluding items affecting comparability, bringing us in at $9.08 for the full year on the same basis. That's $0.03 above the high end of our original guidance for the year despite having absorbed roughly $0.15 of additional FX headwind and dilution during the course of the year, which is indicative of the strong operating performance we saw in 2015. 
We repurchased about 600,000 shares of stock in Q4, taking total buybacks in 2015 to approximately 2.7 million shares. The balance sheet as of December 31 reflects cash, restricted cash and short-term investments of $1 billion versus $1.1 billion at September 30. For the full year, AR days were up 0.8 days and inventory days were up 6.9 days, driven by the acquisition of our Japanese JV. 
Capital expenditures totaled $23.6 million for the quarter and $102.9 million for the year. On the liability side, total debt was $1.4 billion as of December 31, no change from September 30. Debt to total cap, at the end of the fourth quarter, was about 49% and total shareholder investment was $1.5 billion at December 31. 
So with a strong 2015 now in the books, let's turn to financial guidance for 2016, excluding the impact of items that affect comparability. For revenue, we project 2016 constant-currency organic revenue growth between 5% and 6%. Beyond organic growth, we'll benefit from incremental revenue in 2016 from the acquisitions of our Japanese JV, as well as Liberator Medical. We also expect to see a nonoperating reduction to revenue from lower sales of EP products to Boston Scientific and we're prepared for a range of levels for the Gore royalty. Therefore, our overall constant currency revenue guidance is between 6% and 8%. 
Our expectations assume no change in the market growth rates from where they've been the last couple of years, which we would characterize as being in the low single digits. Obviously, the strength of the U.S. dollar will continue to be a headwind for U.S. multinational companies in 2016. We estimate that at current rates, we're looking at a revenue headwind related to currency of about 1.5%, which would put our reported revenue guidance for 2016 between 4.5% and 6.5%. 
As far as constant-currency revenue growth in our 4 disease state categories, in 2016, we expect: Vascular revenue growth to be between 3% and 7%; Urology to be between 8% and 11%; Oncology to grow between 5% and 8%; and our Surgical Specialties business to grow between 6% and 9%. To be clear, these are constant-currency growth rates, not organic. We're only providing organic revenue growth guidance at the corporate level. 
As we move down the P&L for financial guidance, we're making one important change in our presentation. As you know, when the sector moved to cash EPS, the vast majority of our peers excluded amortization of intangibles from their entire adjusted P&L. Up until now, we have been reporting amortization in the entire P&L and only excluding it from the EPS number below the line. In order to make it easier for investors to understand our results in context with others in the sector, beginning with 2016, we'll exclude the amortization of intangibles from our entire adjusted P&L. We've provided a reconciliation of the key margin percentages on the Reg G section of our Investor Relations page on our website. And a summary of that reconciliation is provided on Slide 6 of the deck associated with this call. 
So the following guidance excludes items that may affect comparability and amortization of intangibles. We expect our overall gross margin percent to improve in 2016 between 50 and 100 basis points compared to 2015, which translates to a gross margin range between 65.8% and 66.3%. That reflects about 30 basis points of pressure from the FX. 
Pricing pressure continues to be a challenge for us, and we estimate the impact on 2016 to be between 30 and 50 basis points of gross margin headwind. Our cost improvement programs are projected to contribute between 80 and 100 basis points of benefits to GP, and we expect mix to be favorable between 50 to 60 basis points, which includes the positive gross margin impact from our acquisition in Japan. 
We expect SG&A as a percentage of sales to be about the same as 2015 as we continue to increase our investments in emerging markets this year and work to integrate our recent acquisitions. And we expect R&D as a percentage of sales to be in the mid-7% range again this year. This would project our operating margin in 2016 to be between 29% and 29.5%, which is an improvement of 50 to 100 basis points compared to 2015 on the same basis. 
We expect interest expense in 2016 to be between $50 million and $55 million, reflecting higher projected average rates and debt levels compared to 2015. 
Primarily as a result of jurisdictional mix, we expect a slight pause in the cadence of our improvement in the effective tax rate, which we project to be between 25.5% and 26% in 2016. The R&D tax credit is now permanent, so we will not have the sharp reduction in the Q4 effective rate that we have seen the last couple of years. 
So all of that adds up to adjusted cash EPS for 2016, excluding items that affect comparability, between $9.90 and $10.05, representing 9% to 11% reported growth over 2015. This guidance includes a projected negative currency impact of about $0.30 based on today's rates. The suspension of the medical device excise tax represents approximately $0.20 of benefit to us, essentially offsetting 2/3 of our overall estimated currency headwind in 2016 at today's rates. So while we do exclude both the negative impact of currency and the benefit from the MDET suspension, our operational EPS growth forecast would have been between 10% and 12%. 
As we enter 2016, we continue to be in investment mode, with planned, targeted incremental spending in SG&A, particularly in emerging markets, and a continued robust level of investment in R&D. We're pleased that we're able to provide attractive 2016 guidance with strong reported earnings growth. Without having to reduce or delay investments and projects, we believe will provide long-term value to our shareholders. 
In Q1, we expect constant-currency sales growth between 4.5% and 5.5% and reported revenue growth between 2.5% and 3.5%. As was the case in Q4, Q1 revenue guidance reflects the negative impact from the sell-through of existing inventory in Japan. We expect this factor to be behind us by Q2. On an organic basis, we expect Q1 sales growth to be in the 5.5% to 6% range. 
We expect adjusted cash EPS in Q1 2016 to be between $2.14 and $2.18, which reflects the initial dilution from recent acquisitions, as well as a foreign exchange headwind. We expect the dilutive impact from acquisitions, in particular, our joint venture buyout in Japan, to moderate as we move through 2016. Excluding the front-loaded dilution from acquisitions, Q1 adjusted EPS would have been about 10%. So operationally, I expect us to be off to a very solid start to the year as we move into Q1. 
As for capital expenditures, we expect 2016 to be in the $120 million range, and we expect operating cash flow to be in the $700 million range in 2016. 
Thank you for your attention. And with that, I'll turn you back to Tim."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Chris. While we're pleased with our performance in 2015, as I mentioned earlier, we remain very focused on the growth opportunities in front of us and our execution against the plan for those. We look forward to updating you on our continued pr",70,"Thank you, Chris. While we're pleased with our performance in 2015, as I mentioned earlier, we remain very focused on the growth opportunities in front of us and our execution against the plan for those. We look forward to updating you on our continued progress in the coming quarters. 
With that, that concludes the formal part of presentation. I'll now turn you back to the moderator to facilitate the Q&A."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We'll go to Bob Hopkins with Bank of America.",11,"[Operator Instructions] We'll go to Bob Hopkins with Bank of America."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Congrats on the strong finish to the year and the strong guidance. Couple of things I wanted to ask about just in terms of the guidance that you provided. I was wondering, Chris or Tim, if you guys could talk a little bit about some of the assumptions tha",117,"Congrats on the strong finish to the year and the strong guidance. Couple of things I wanted to ask about just in terms of the guidance that you provided. I was wondering, Chris or Tim, if you guys could talk a little bit about some of the assumptions that drive the 2016 guidance. Specifically on buyback and share count for 2016, I'm wondering what you're assuming. And then also, on drug-coated balloons, could you give us a sense as to the contribution to growth in Q4, and the contribution to growth in '16 that you're assuming? I assume it's probably between 1 and 1.5 points of contribution to top line growth, but just wanted to confirm that."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Bob. Thanks for the questions. I think on the buyback side, we're not going to give a specific guidance number. I think we've been pretty consistent as a repurchaser of our stock. I think having said that, we feel really good about the operational m",238,"Sure, Bob. Thanks for the questions. I think on the buyback side, we're not going to give a specific guidance number. I think we've been pretty consistent as a repurchaser of our stock. I think having said that, we feel really good about the operational momentum in the business. So I think we'll continue to have the latitude to maintain a lot of flexibility with the balance sheet. And while we'll certainly be an active repurchaser, I think we've got a lot of flexibility as we move into '16 given what we see as really strong operating performance straight down the P&L. I think from a Lutonix standpoint, we're really happy about where we are. Q4 came in as we expected it to be. Obviously, overall, we're ahead of our guidance for the quarter. And I think as we move into '16, we're -- we like to talk about not being about one big thing. I think we're trying to really focus on the entire portfolio. We feel terrific about Lutonix's momentum going into '16. I think some of the data that John referenced, that's just hot off the press out of LINC, continues to show a great clinical positioning of the product. That frankly continues to get better the more we see some of this real-world data coming out. So it's a component of what we think is a really strong organic growth profile coming into '16."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Fair enough. And then, Tim, just on emerging markets, we've heard a lot of discussion out of other companies on emerging markets today. And it sounds like for you guys, the growth continues to be strong. But I just wanted to ask your views on emergi",87,"Okay. Fair enough. And then, Tim, just on emerging markets, we've heard a lot of discussion out of other companies on emerging markets today. And it sounds like for you guys, the growth continues to be strong. But I just wanted to ask your views on emerging markets you're exiting 2015 and beginning 2016. In Q4, did you see the same kind of growth trends that you've seen in the last couple of quarters? And just any highlights on emerging markets or specific geographies would be helpful."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We haven't really seen a change from the trends that we've seen. Clearly, we pay attention to what others are seeing and feeling in emerging markets. I think it might be kind of the mix of the geographies where we're strong and have a sizable presen",98,"Sure. We haven't really seen a change from the trends that we've seen. Clearly, we pay attention to what others are seeing and feeling in emerging markets. I think it might be kind of the mix of the geographies where we're strong and have a sizable presence. And some of the geographies that seem to be causing others more of an issue, either it's the mix of our operating in those geographies that don't seem to be impacted, and/or we're not very strong in some of those other geographies. So John, I don't know if you want to"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add is that I think one of the unusual natures of our business is we're really still rolling out the portfolio of products into a lot of these markets. In fact, we had 252 new product approvals in 2015. That was up from 114 in 2014. So",114,"The only thing I'd add is that I think one of the unusual natures of our business is we're really still rolling out the portfolio of products into a lot of these markets. In fact, we had 252 new product approvals in 2015. That was up from 114 in 2014. So we have a bolus of new products yet that are still in regulatory agencies around the world waiting for approvals. All those are a couple of waves that are coming through our international businesses through 2016. I think that's a little unique to us, based on the investments that we've made and the product mix that we're developing in for these markets."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Let's go to the line of Larry Keusch with Raymond James.",12,"Let's go to the line of Larry Keusch with Raymond James."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So could we start off just, Tim, maybe I know that you said that you assume the environment is sort of where it's been, but I'm wondering as you kind of move through the fourth quarter and into 2016, was there anything notable that you might have been see",55,"So could we start off just, Tim, maybe I know that you said that you assume the environment is sort of where it's been, but I'm wondering as you kind of move through the fourth quarter and into 2016, was there anything notable that you might have been seeing that was changing in the U.S.?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No. We didn't detect any notable difference really at all. John, I don't know if you want to.",18,"No. We didn't detect any notable difference really at all. John, I don't know if you want to."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I think that we didn't see any trends that would cause us to believe it's different from what we experienced through the majority of 2015.",26,"No, I think that we didn't see any trends that would cause us to believe it's different from what we experienced through the majority of 2015."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, terrific. And then, Tim, look, you -- on the home side, you obviously did the Liberator deal. You did Rochester a while back. Can you sort of help us think about just what the strategy now is for the home now? You've got some enhanced distribution.",67,"Okay, terrific. And then, Tim, look, you -- on the home side, you obviously did the Liberator deal. You did Rochester a while back. Can you sort of help us think about just what the strategy now is for the home now? You've got some enhanced distribution. You obviously have some new products flowing through, which John talked about, but where we go with the home strategy?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So look, I think it's coming together. We're still figuring it out as we go here. And I do think we do know and are certain of the trends, right. So hospitals are trying to take care of more people outside of hospitals. And obviously, we've paid atte",168,"Yes. So look, I think it's coming together. We're still figuring it out as we go here. And I do think we do know and are certain of the trends, right. So hospitals are trying to take care of more people outside of hospitals. And obviously, we've paid attention to that. We've done a lot of work relative to understanding that dynamic. We think we understand very much the difference between a good solid product model and a service model, and the profitability and sustainable growth differences between those 2. So I like the way we're positioned. I'd say we're still understanding it and trying to figure out where to plug and play in that kind of an environment. But we're optimistic about it, which is why we pulled the trigger on Liberator. We felt we needed that platform as a missing piece to solving that puzzle. So we're pleased with that, and I think you'll continue to hear more from us in the future on that front."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Larry, I think just the one thing I'd add and I think it's important, as you think about the strategy, both Rochester and Liberator were movements into the home, but based on the back of our strength in Urology. And I think as we said when we did Rocheste",163,"Larry, I think just the one thing I'd add and I think it's important, as you think about the strategy, both Rochester and Liberator were movements into the home, but based on the back of our strength in Urology. And I think as we said when we did Rochester, and I'll repeat it again, now that we've got this really interesting platform, it works just on the back of a Urology entry strategy into the home for us. What it's given us is clearly these other capabilities that we can then begin to really think about how we can leverage into some other category areas. But we don't need to do that to make this -- both the Rochester and the Liberator now in combination very successful and really accretive to us for a long period of time. So I'd characterize it as a lower-risk build of a new capability into an adjacency on the back of some core strengths we already have."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Brooks West with Piper Jaffray.",12,"Next, we'll go to the line of Brooks West with Piper Jaffray."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just had a question on margins, maybe more theoretical. Chris, you're getting back to the margin profile that you had in 2012, which I think was a big kind of milestone for investors, maybe a little bit ahead of gross margins, almost there in operating",109,"I just had a question on margins, maybe more theoretical. Chris, you're getting back to the margin profile that you had in 2012, which I think was a big kind of milestone for investors, maybe a little bit ahead of gross margins, almost there in operating margins. I'm just wondering, you've got leverage left in the business and specifically, from the emerging markets investments that you made. How do you think about running the business going forward? You kind of get the 30% operating margin and reinvest from there? Is there significant upside to where you might see operating margins progress from here? I'm just curious your thoughts there."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think what we've been saying now for a number of years, Brooks, is we're focused on driving margins higher, certainly back to the levels we were at. We made good progress in '15 and we've now committed to making additional significant progress in '",160,"Yes. I think what we've been saying now for a number of years, Brooks, is we're focused on driving margins higher, certainly back to the levels we were at. We made good progress in '15 and we've now committed to making additional significant progress in '16. As we do that, we're continuing to balance that objective with longer-term investments that make all of this sustainable. So we're not giving a longer-term margin goal that we get to and then we think about running the business differently. We're making investments in China as we go into '16, and making investments in other areas in the business, but still committing to 50 to 100 basis points of operating margin performance. We'll continue to try to strike that balance. Obviously, there'll be headwinds that come our way along the way, but as Tim said, this is all about sustainability. And we like where we're at, we like the opportunities in front of us."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add to what Chris said is that when you look at our guidance for 2016, you'd note -- and in our 2015 results, you'd note the strength of the contributions of our operating manufacturing teams around the world. That's a core capabili",91,"And the only thing I'd add to what Chris said is that when you look at our guidance for 2016, you'd note -- and in our 2015 results, you'd note the strength of the contributions of our operating manufacturing teams around the world. That's a core capability that we believe we'll deliver every year for the corporation moving downstream. And it gives us a lot of -- I think a lot of strength and the ability to make a lot of moves strategically, depending on where we see the opportunities."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just one on the acquisition environment, if I could. There's been a lot of speculation on consolidation, perhaps this year in medtech. I'm just wondering, it seems like there's still a disconnect between valuation expectations from sellers and bu",65,"And then just one on the acquisition environment, if I could. There's been a lot of speculation on consolidation, perhaps this year in medtech. I'm just wondering, it seems like there's still a disconnect between valuation expectations from sellers and buyers. I'm wondering if you're seeing that change at all or how your expectations might be for kind of the rest of the year here."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think it's hard to comment specifically, Brooks. Obviously, there's been a lot of volatility in the market. Certain stocks have settled at much lower levels. Certainly, sellers always have a long memory in terms of recent highs. So I think all of that n",152,"I think it's hard to comment specifically, Brooks. Obviously, there's been a lot of volatility in the market. Certain stocks have settled at much lower levels. Certainly, sellers always have a long memory in terms of recent highs. So I think all of that noise doesn't really affect us, frankly. We're very focused on a number of key criteria. And transactions need to make sense to us from a whole other set of perspectives as well as obviously from a valuation perspective. So we're obviously in a world here with a lot of market volatility, but I don't think it changes the things we're focused on. And we looked at a lot of things in '15. We'll continue to be very active in looking, but we'll pull the trigger on things that meet a whole bunch of criteria and we can get at a price that makes sense for our shareholders."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we go to the line of David Roman with Goldman Sachs.",12,"Next, we go to the line of David Roman with Goldman Sachs."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to start off with one clarification question around the EPS guidance. Can you just help us tease out what the deal-related dilution is in your guidance, and if that $0.25 number you provided around Medicon still holds and how that tracks througho",75,"I wanted to start off with one clarification question around the EPS guidance. Can you just help us tease out what the deal-related dilution is in your guidance, and if that $0.25 number you provided around Medicon still holds and how that tracks throughout the course of the year. I think you said it was mostly Q1 weighted. But if -- any more detail you could provide around the dilution from deals would be helpful."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, so the Medicon dilution in the year, David, is about $0.20. It's -- about half of that actually hits us in Q1, again, because you've got obviously the full P&L with the reduction in sales as well. And the other acquisition, with the Vascular Pathways",128,"Yes, so the Medicon dilution in the year, David, is about $0.20. It's -- about half of that actually hits us in Q1, again, because you've got obviously the full P&L with the reduction in sales as well. And the other acquisition, with the Vascular Pathways acquisition, as we're really ramping up some of the R&D spending around those, the products that were acquired are also more heavily impacted in Q1 before we launch the new AccuCath. So the dilution from Medicon's still a good $0.20 number for the full year. The other acquisitions, Vascular Pathways, cost us $0.03 to $0.05 in 2015. It'll be a little bit less than that during the course of 2016. But obviously, all of that's fully loaded into the $9.90 to $10.05."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And then on -- maybe on Japan specifically, you could help us think about the opportunity that exists in front of you and at least the way we thought of that was 2 pieces. There's obviously the price recovery from shifting from distr",117,"Okay. That's helpful. And then on -- maybe on Japan specifically, you could help us think about the opportunity that exists in front of you and at least the way we thought of that was 2 pieces. There's obviously the price recovery from shifting from distributor to direct. But then I think there's also a fairly significant marketer opportunity across at least 3 of your 4 categories. So could you maybe help us think about the cadence at which we might be able to recognize that benefit, and if it's sort of a similar playbook to what you've been able to execute in emerging markets and how we should think about the contribution to growth going forward?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. I'll start and maybe John Weiland wants to jump in. I wouldn't compare it to an emerging market. And the models that we are running are different. It's more of a mature market model. Maybe it's a little bit of a hybrid in the sense that because we h",168,"Okay. I'll start and maybe John Weiland wants to jump in. I wouldn't compare it to an emerging market. And the models that we are running are different. It's more of a mature market model. Maybe it's a little bit of a hybrid in the sense that because we haven't had total control in management over all of these selling and marketing resources, some of the things that we do relative to training and some of the management, generally that practices we have around the world, haven't been fully implemented there. And we do think that implementing those in Japan will have a positive influence. But that underlying growth rate of that market isn't anywhere close to what the emerging markets are. So we see this as -- we continue to invest in getting some of the clinical trials and some of the market investment build-out of training, et cetera, clinical trials, having control of that, we felt was an important thing for the long term in Japan."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the only thing I'd add is we have 191 salespeople in Japan. They will now be fully integrated in the Bard's selling model, which I think will be a significant momentum builder for us. And I think that the product lines, which we expect to come out",90,"I think the only thing I'd add is we have 191 salespeople in Japan. They will now be fully integrated in the Bard's selling model, which I think will be a significant momentum builder for us. And I think that the product lines, which we expect to come out of our own internal R&D and clinical base, this has been largely a Urology business historically. As we move our competence into Oncology, Endovascular, into surgery, I think that's where we believe we're going to have the bigger payback from."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And maybe just one more on a longer-term basis. As you look at the acquisition, Medicon as well as Liberator, I think you've talked about both being accretive on a go-forward business. Do you think you're tangibly getting closer to h",69,"Okay. That's helpful. And maybe just one more on a longer-term basis. As you look at the acquisition, Medicon as well as Liberator, I think you've talked about both being accretive on a go-forward business. Do you think you're tangibly getting closer to having a higher degree of confidence in being able to steal [ph] the ""Gore hole"" as we look toward the -- a much more outer-year period."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think these are just 2 more examples of all the things we're trying to do to grow the business in a way that we've got a really strong organic engine, with lots of different growth platforms that are hopefully increasingly accretive, as we approach the",85,"I think these are just 2 more examples of all the things we're trying to do to grow the business in a way that we've got a really strong organic engine, with lots of different growth platforms that are hopefully increasingly accretive, as we approach the end of '19 and '20. So these are just consistent with, I think, everything we're trying to do to build a really strong sustainable organic engine that looks attractive when it's compared to other alternatives in this sector."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we go to the line of Mike Weinstein with JP Morgan.",12,"Next, we go to the line of Mike Weinstein with JP Morgan."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, can you just walk me through the impact of Medicon buy-in on your organic growth, both this quarter and then as we -- more importantly as we roll through 2016?",31,"Chris, can you just walk me through the impact of Medicon buy-in on your organic growth, both this quarter and then as we -- more importantly as we roll through 2016?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It'll be -- it's about 2 points in Q1, Mike, in comparison to prior year. The thing about comparing it to last year is we were selling in dollars into Japan last year, right. And so the -- as the yen has weakened and we're now consolidating the JV, there'",79,"It'll be -- it's about 2 points in Q1, Mike, in comparison to prior year. The thing about comparing it to last year is we were selling in dollars into Japan last year, right. And so the -- as the yen has weakened and we're now consolidating the JV, there's a negative impact to organic, really over the course of the year. But it's somewhat muted compared to what we're seeing in Q1 because of the inventory sell-through."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","But when we look at your organic growth, as you guys are characterizing it here, you're expecting a lower number, obviously, in the first quarter because of Medicon, and then a much higher number over the back half -- certainly over the back half of the y",47,"But when we look at your organic growth, as you guys are characterizing it here, you're expecting a lower number, obviously, in the first quarter because of Medicon, and then a much higher number over the back half -- certainly over the back half of the year."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's excluded from organic growth, Mike, in the 5% to 6% guidance.",13,"It's excluded from organic growth, Mike, in the 5% to 6% guidance."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So the Medicon impact is excluded from that?",8,"So the Medicon impact is excluded from that?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And that's in your nonoperational items?",7,"And that's in your nonoperational items?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, exactly.",2,"Yes, exactly."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So you're including that in that, okay.",8,"Okay. So you're including that in that, okay."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, so it's totally pulled out.",6,"Yes, so it's totally pulled out."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then, Chris, when you get to that $0.30 impact from FX off of just 150 basis points on the top line, can you just -- could you bridge us on that, because just the math implies there's a 60% pretax drop there, but obviously, it's tied to the Japanese d",51,"And then, Chris, when you get to that $0.30 impact from FX off of just 150 basis points on the top line, can you just -- could you bridge us on that, because just the math implies there's a 60% pretax drop there, but obviously, it's tied to the Japanese distributor."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's driven by Japan, Mike. So again, the way to think about is last year, the JV was hedged at 1.02 on the yen. This year, we're naked on the yen. So it's really -- and we have 100% of the exposure to the JV compared to 50% last year. So the $0.20 of dil",71,"It's driven by Japan, Mike. So again, the way to think about is last year, the JV was hedged at 1.02 on the yen. This year, we're naked on the yen. So it's really -- and we have 100% of the exposure to the JV compared to 50% last year. So the $0.20 of dilution is really all from the impact of the yen when you compare '15 to '16."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we go to the line of David Lewis with Morgan Stanley.",12,"Next, we go to the line of David Lewis with Morgan Stanley."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe one for Chris and one for Tim. So Chris, you have 2 deals in '16, Medicon and Liberator. They have this muted effect on '16, both with the yen exposure in Medicon and the reinvestment in Liberator, but there's this, hopefully, bigger effect in '17.",123,"Maybe one for Chris and one for Tim. So Chris, you have 2 deals in '16, Medicon and Liberator. They have this muted effect on '16, both with the yen exposure in Medicon and the reinvestment in Liberator, but there's this, hopefully, bigger effect in '17. We think these deals could be at least $0.25, $0.30 accretive in '17. So I know you've been reluctant to provide the returns on Medicon, but is there anything you can tell us about the potential returns of Medicon or accretion Medicon relative to the '16 dilution? And give us a sense of the relative magnitude of the Liberator investment in '16, so we can start thinking about how this begin to hit the P&L in '17."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that hopefully you'll join us about a year from now and I'll give you a lot more visibility to that. No, I think seriously, they both become accretive going into '17. The Liberator platform is strategic to us, so we are making significant investme",164,"I think that hopefully you'll join us about a year from now and I'll give you a lot more visibility to that. No, I think seriously, they both become accretive going into '17. The Liberator platform is strategic to us, so we are making significant investments in '16. And we've got a lot of work integrating Medicon, and to John's point, turning that sales force into a Bard sales force engine. I think as we move into '17, between now and then, obviously, lots of other things are going to happen. Those will be 2 nice tailwinds. But I'm not going to call out specific accretion from them in '17 and have you guys make assumptions before we wrap everything up and think about what kind of commitment we want to make for '17. But those are 2 nice tailwinds that we'll have, and then we'll reassess additional investments -- incremental investments as we get closer to seeing how '17 is rolling up."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think one of the things to think about in the Liberator and in our home strategy in general in Urology, is that unlike most homecare segments -- most homecare segments are episodic. A patient gets home from the hospital. They're getting care at home for",116,"I think one of the things to think about in the Liberator and in our home strategy in general in Urology, is that unlike most homecare segments -- most homecare segments are episodic. A patient gets home from the hospital. They're getting care at home for a given period of time. They get well and they move off the rolls. That's not the case in the urological segment. Most of these patients are on catheterization for the rest of their life. So you'd build -- to naturally build the business year after year after year, as you add more patients to your segments, Liberator and Rochester help us do that, and they're both hand in glove."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Very helpful. And then, Tim, just coming back to this notion of drop-through. And I think it seems like the message you have for shareholders is you're moving towards this durable, kind of, 6% top, 10% bottom line model. I look at the presentation,",112,"Okay. Very helpful. And then, Tim, just coming back to this notion of drop-through. And I think it seems like the message you have for shareholders is you're moving towards this durable, kind of, 6% top, 10% bottom line model. I look at the presentation, the PowerPoint you provided and obviously, underlying growth rates are in excess of 10% earnings. So maybe just give us a sense of do you think you can deliver greater than 10% earnings growth? Or is this sort of 300 to 400 basis points of leverage on whatever top line you put up? Is that sort of the model that we should continue to expire and expect?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, the guidance we just gave for the earnings is the guidance. So I'm not going to change that during the course of the call here. But if you go back even historically and look at some of the leverage between our revenue and our earnings, it's been abo",121,"Well, the guidance we just gave for the earnings is the guidance. So I'm not going to change that during the course of the call here. But if you go back even historically and look at some of the leverage between our revenue and our earnings, it's been about that kind of a range. We were 8% and 12s, 10 years ago. And you can get that kind of range which we think gives us a very fair return to shareholders, and also gives us the flexibility to invest in the business of -- for future growth. And it's that balance between those 2 that we manage, and we think that's a good balance, at least -- certainly for this year."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Kristen Stewart with Deutsche Bank.",12,"Next, we'll go to the line of Kristen Stewart with Deutsche Bank."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess most of my questions were taken, so I guess, just thinking about, I guess, just acquisitions and just kind of appetite now. Are you seeing any -- how do you expect kind of the rollout in 2016? Do you continue to think the pace of tuck-in acquisiti",67,"I guess most of my questions were taken, so I guess, just thinking about, I guess, just acquisitions and just kind of appetite now. Are you seeing any -- how do you expect kind of the rollout in 2016? Do you continue to think the pace of tuck-in acquisitions will accelerate from here? I know it's kind of been asked in a couple of different ways but..."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","We haven't changed our strategy at all relative to acquisitions despite the commentary earlier about valuations perhaps changing around. We have a very disciplined set of filters that we look at, and it starts with strategic first. And we don't see any re",123,"We haven't changed our strategy at all relative to acquisitions despite the commentary earlier about valuations perhaps changing around. We have a very disciplined set of filters that we look at, and it starts with strategic first. And we don't see any reason to change that. I would say our pipeline is extremely full. I do know, for example, just already this year, we've had meetings with the -- well over 50 different companies and technologies, et cetera, which is a very strong start for this early in the year. So that cadence isn't changed really; the effort, momentum, the resources are all what they were. So we don't feel any differently about our profile in terms of doing acquisitions going forward."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Do you think the suspension of the medical device tax perhaps changes sellers' minds, especially on the small company level, in terms of their desire to sell up maybe more in the near term or",35,"Do you think the suspension of the medical device tax perhaps changes sellers' minds, especially on the small company level, in terms of their desire to sell up maybe more in the near term or"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","No I haven't had that or heard that portrayed by anybody yet.",13,"No I haven't had that or heard that portrayed by anybody yet."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then, Chris, I guess you had mentioned -- in terms of the guidance, you'd mentioned a -- it seems a wide range of, I guess, scenarios with the Gore royalty. I was just wondering if you could share what those wide range of scenarios are. Or if yo",85,"Okay. And then, Chris, I guess you had mentioned -- in terms of the guidance, you'd mentioned a -- it seems a wide range of, I guess, scenarios with the Gore royalty. I was just wondering if you could share what those wide range of scenarios are. Or if you had any sense of change in terms of the cadence of what that could be? Anything, I don't know if you just said that to include just different possibilities or if there's something behind that."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","That's how we've been approaching it, Kristen, so there's not a change. Obviously, it's been flat to down. Obviously, there's some FX component to that, that we frankly don't have visibility into. And we're making commitments to you guys, and we take it r",118,"That's how we've been approaching it, Kristen, so there's not a change. Obviously, it's been flat to down. Obviously, there's some FX component to that, that we frankly don't have visibility into. And we're making commitments to you guys, and we take it really seriously. And we understand we may see some variability there, but we continue to not have visibility to the royalty until it comes in the door. And so I think the same dynamic that's been in play for a while continues to be in play. It's just we need to make sure that we've got business plans that can deliver on the commitments we're making to you, without visibility to that one item."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","It's not, unlike, Kristen, our other businesses. I mean we give you a range for the businesses that we run and know something about. And there's a high and low end to those, too, and the Gore thing is not dissimilar, it's just we don't have any control ov",51,"It's not, unlike, Kristen, our other businesses. I mean we give you a range for the businesses that we run and know something about. And there's a high and low end to those, too, and the Gore thing is not dissimilar, it's just we don't have any control over it."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go to the line of Dave Turkaly with the JMP Securities.",13,"We'll go to the line of Dave Turkaly with the JMP Securities."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just quickly on the Liberator deal. I've kind of asked a couple of times sort of the buy versus build and I wonder if you could spend a moment on, sort of, why that was a buy decision, sort of what the secret sauce is there that you gained?",50,"And just quickly on the Liberator deal. I've kind of asked a couple of times sort of the buy versus build and I wonder if you could spend a moment on, sort of, why that was a buy decision, sort of what the secret sauce is there that you gained?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, David. We -- on the back of Rochester, one of the things we spent the last couple of years doing is getting really smart on the DME space. And we obviously came to a strategic conclusion that we wanted to control our destiny, and Liberator, really,",223,"Sure, David. We -- on the back of Rochester, one of the things we spent the last couple of years doing is getting really smart on the DME space. And we obviously came to a strategic conclusion that we wanted to control our destiny, and Liberator, really, in Urology, is the market-leading, highest-quality provider of Urology-related products. There's no question. If you look at their metrics, the quality of their billing, the quality of their customer service and in really the great partnerships they have with all the leading manufacturers, they were, frankly, the only platform that would have fit what we were looking for. And so the complexity of building a nationwide DME distribution, having all of the licenses and all the capability to build and -- bill and ship to Medicare patients in virtually all the 50 states, and to do that at the volume of transactions that they need to do it at, is something that frankly would have not been economically viable for us to try to build. So we're really fortunate that, that team is now part of the Bard family, and welcome them. And really again, they were the only -- they're really the only company that was going to allow us to pursue this strategy, so we really feel great about having them on board now."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just on the tip navigation or confirmation on the PICC side. We've seen some news from competition, I guess. Penetration today, where does that stand? And I guess, how big of an opportunity do you think that is for you guys moving forward?",45,"And then just on the tip navigation or confirmation on the PICC side. We've seen some news from competition, I guess. Penetration today, where does that stand? And I guess, how big of an opportunity do you think that is for you guys moving forward?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we're very well penetrated. We don't give that number out for competitive reasons, but we have a high degree of penetration of our base business. We continue to add segments to that, as you can see by the new product launches that we talk about year",125,"Well, we're very well penetrated. We don't give that number out for competitive reasons, but we have a high degree of penetration of our base business. We continue to add segments to that, as you can see by the new product launches that we talk about year in and year out within that segment. So we're not slowing down at all. And at the same time, if you look at some of the new product lines that we're bringing to the PICC area, John talked about them tonight. You add some of those important competitive differentiators to our already strong differentiated position, we think our position only gets stronger and stronger in the months and years to come versus any competitive offerings in the way."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, and as John said, we've been trying to move the needle here, and move the game and the goal post time after time. So as we've added Pinpoint GT, which is rolling out this quarter, it's a new technology to further improve and simplify the placement of",142,"Yes, and as John said, we've been trying to move the needle here, and move the game and the goal post time after time. So as we've added Pinpoint GT, which is rolling out this quarter, it's a new technology to further improve and simplify the placement of our devices. We already have, of course, the ultrasound capability, which is pretty unique to us on an integrated basis; and then our tip-tracking technology, the Sherlock; and then, of course, we also continue to improve upon our final tip confirmation technology. And so we continue to add new algorithms and new ways to make that better, like 3CG Diamond. So we think we're going to continue to do that. We've got a few other tricks up our sleeve, and we'll -- as we get further down the pathway here, we'll talk about them."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Matt Taylor with Barclays.",11,"Next, we'll go to the line of Matt Taylor with Barclays."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","So I wanted to just ask one. You were going through some of the new products and lines of the Lutonix balloon that you're coming out with here in the beginning of the year. I'm just wondering if you thought that would make a material difference in the app",75,"So I wanted to just ask one. You were going through some of the new products and lines of the Lutonix balloon that you're coming out with here in the beginning of the year. I'm just wondering if you thought that would make a material difference in the applicability and the growth rate, or if there are any other catalysts that you're looking for in '16 that you think could meaningfully juice your DCB sales."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","So I think there's a few things that we've got in there. We talked about the longer lengths. So we've submitted data, seeking approval for treatment of patients with lengths up to about 300 millimeters, so about twice the length that we have now. That cou",176,"So I think there's a few things that we've got in there. We talked about the longer lengths. So we've submitted data, seeking approval for treatment of patients with lengths up to about 300 millimeters, so about twice the length that we have now. That could potentially open up the market. In-stent restenosis, probably a lot of that is going on today, but having the ability to promote that is going to be helpful. And some of the other sizes, we talked about. We've got some other launches that we hope will come in this year, that we think will be helpful. And then obviously, expanding indications is going to be key. Below the Knee AV access, which is a little more near term for the U.S. market, and it's an area where we're particularly strong anyway. With our stent graph technology, as well as some of the other products we have for dialysis patients, I think give us what we think is a pretty good opportunity for DCB and our ability to leverage that."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then I was just curious on Liberator. Really 2, kind of minor questions. One is you can kind of see their mix in the last 10K, in terms of what they distributed. I was wondering if you could help us understand how much of that revenue is going",89,"Great. And then I was just curious on Liberator. Really 2, kind of minor questions. One is you can kind of see their mix in the last 10K, in terms of what they distributed. I was wondering if you could help us understand how much of that revenue is going through your different segments. And then also, I guess, what was your history with them? You're working with them before. How much product was yours going through that channel? And what else can you bring now to the table?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So just to be clear, we're selling through them today and prior to the acquisition, just Urology products, and we were a pretty small part of their volume, so probably less than 10% overall. They've been a good -- a very high-quality partner to us.",88,"Sure. So just to be clear, we're selling through them today and prior to the acquisition, just Urology products, and we were a pretty small part of their volume, so probably less than 10% overall. They've been a good -- a very high-quality partner to us. Again, they're the leading independent Urology DME, and so they have Urology, Ostomy and some Mastectomy products, but again, we're only selling Urology products to them today. And that's certainly obviously going to continue to be the case for the foreseeable future."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. I guess what else can you, kind of, bring into the channel right away? Or maybe where you see that expanding down the road?",25,"Okay. I guess what else can you, kind of, bring into the channel right away? Or maybe where you see that expanding down the road?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think that's -- that was the point I was trying to make. We're obviously, to John's commentary, around the expansion of our ISE catheter portfolio. That's continued to become much more robust, and that's really the first R&D products coming out of",164,"Yes, I think that's -- that was the point I was trying to make. We're obviously, to John's commentary, around the expansion of our ISE catheter portfolio. That's continued to become much more robust, and that's really the first R&D products coming out of the Rochester R&D engine. This acquisition and this strategy is a winner for us just within Urology. And that's what we're focused on integrating Liberator, getting this off to a very strong start. We've talked about investing in the platform and expanding it, including the sales force that's supporting it. Those are the near-term milestones that we're focused on. What we're going to have now is this aperture into the home that's going to allow us to think more broadly beyond Urology. Again, we don't need to do that to make this successful, but that's something that I think you should just look for, really, over the coming years as opposed to anything within the next 12 or 18 months."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","And our final question will come from the line of Rick Wise with Stifel.",14,"And our final question will come from the line of Rick Wise with Stifel."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","A little more on Lutonix. You highlighted, John, the AV Access, BTK, in-stent restenosis indications that are coming up. Just can you give us some color on the indication opportunity? Is it 50% bigger? Is it double the current opportunity you're tackling?",52,"A little more on Lutonix. You highlighted, John, the AV Access, BTK, in-stent restenosis indications that are coming up. Just can you give us some color on the indication opportunity? Is it 50% bigger? Is it double the current opportunity you're tackling? What are we looking, and what are you looking at?"
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think if we look -- the SFA -- if you kind of look in that broad category, I think the SFA is a big part of the overall market opportunity. I think Below the Knee is -- I'm not the marketing guy so I'm looking at John Weiland here. But I think it'",96,"Well, I think if we look -- the SFA -- if you kind of look in that broad category, I think the SFA is a big part of the overall market opportunity. I think Below the Knee is -- I'm not the marketing guy so I'm looking at John Weiland here. But I think it's 20%, 30% of the SFA opportunity; AV Access, kind of in that same ballpark. So certainly, significant incremental opportunities. But the SFA probably makes up about half of the overall -- maybe a little more than half of the overall opportunity."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the other thing to think about, Rick, is that after a little bit over a year into this now, physicians now are getting to the point that have started using DCBs on some of their patients. They're not only looking at the data, they're looking at th",132,"I think the other thing to think about, Rick, is that after a little bit over a year into this now, physicians now are getting to the point that have started using DCBs on some of their patients. They're not only looking at the data, they're looking at the fact that the patients aren't coming back for reintervention. And as patients don't come back for reinterventions, they get great confidence in using the device on more and more and more patients in the future. And I think we like -- we'd like that in combination with the real-life data that's coming out on our product, and the fact that we're generating those kinds of results with 50% less drug on than other players in the space in the United States right now."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think just to add a little bit to that, I think physicians are still sort of figuring out what's the right treatment paradigm, and how do they optimize the outcomes for their patients. And so we certainly hear in our interaction with customers that",97,"Yes, I think just to add a little bit to that, I think physicians are still sort of figuring out what's the right treatment paradigm, and how do they optimize the outcomes for their patients. And so we certainly hear in our interaction with customers that the DCB gives them an important tool in the toolbox but exactly how they combine that with other therapies is still sort of under development. So as John said, there's a lot of work going on out there, and I think there's a lot of penetration opportunity still ahead of us."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes. And just one last one. Just the 100 basis point cost-reduction benefits that we saw. Just remind me again where that came from, and how sustainable that is? Is there more to come of that magnitude in '16? I just wasn't clear on that point.",46,"Yes. And just one last one. Just the 100 basis point cost-reduction benefits that we saw. Just remind me again where that came from, and how sustainable that is? Is there more to come of that magnitude in '16? I just wasn't clear on that point."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Rick. And then John referenced that being a real core strength of the company and actually, within our guidance for 2016, we're projecting 80 to 100 basis points of incremental benefit from all the initiatives that our manufacturing and sourcing tea",160,"Sure, Rick. And then John referenced that being a real core strength of the company and actually, within our guidance for 2016, we're projecting 80 to 100 basis points of incremental benefit from all the initiatives that our manufacturing and sourcing teams will be undertaking in the course of '16. So that is something that we believe does have a long runway. It's not easy, but our guys are superb at doing it. And they delivered in '15 and they're telling us and we're expecting them to deliver a similar magnitude in '16. I think the unfortunate thing is with what FX has been doing and iron price as well, that's been mitigating a lot of that benefit. So if we can get some of those headwinds to shift or to be a little more benign, you'll really see, I think, the power of what our operating -- our operations and sourcing teams are delivering year in and year out."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","And, Rick, I would think about it as almost half being operating efficiencies in terms of cost savings in our plants, and production at about 50% on sourcing initiatives that are reducing raw material costs into our plants.",38,"And, Rick, I would think about it as almost half being operating efficiencies in terms of cost savings in our plants, and production at about 50% on sourcing initiatives that are reducing raw material costs into our plants."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. This does conclude our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments.",25,"Thank you. This does conclude our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Executives","Great, thank you. I'd like to thank all of you for joining us here today. And I'd also like to take this opportunity, as I always do, to thank Bard employees around the world for their dedication, commitment and very strong execution throughout 2015. We l",63,"Great, thank you. I'd like to thank all of you for joining us here today. And I'd also like to take this opportunity, as I always do, to thank Bard employees around the world for their dedication, commitment and very strong execution throughout 2015. We look forward to catching up with all of you again after the first quarter. Have a good evening."
254131,321219429,923357,"CR Bard Inc., Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And that does conclude our conference today. Thanks again for your participation and for using AT&T Executive TeleConference services. You may now disconnect.",25,"Thank you. And that does conclude our conference today. Thanks again for your participation and for using AT&T Executive TeleConference services. You may now disconnect."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand r",270,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors each in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of April 27, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period.
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. Good afternoon, and welcome to Bard's First Quarter of 2016 Earnings Conference Call, and thanks to all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 30 minutes, and we're going t",909,"Thank you. Good afternoon, and welcome to Bard's First Quarter of 2016 Earnings Conference Call, and thanks to all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 30 minutes, and we're going to try and keep the total call to about an hour. There is a slide deck available on the Investor Relations page of our website intended to help explain some of the moving pieces in our results and guidance.
The discussions today will go as follows: I'll begin with an overview of the results for the quarter; John Weiland, our President and COO, will review first quarter product line revenue; John DeFord, our Senior Vice President of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; lastly, Chris Holland, our Senior VP and CFO, will review the first quarter income statement and balance sheet as well as our expectations for the second quarter and the full year. And then finally, we'll close with Q&A.
First quarter 2016 net sales totaled $873.5 million. That's up 7% over the first quarter last year on an as-reported basis and up 8.5% on a constant currency basis. Currency impact for the quarter versus the same quarter last year was unfavorable by about 190 basis points. Our organic revenue growth this quarter was 9%, which was significantly better than our guidance of 5.5% to 6%. 
Net income for the first quarter was $116.2 million, and diluted earnings per share were $1.54. That's down 17% and 15%, respectively. Excluding amortization and certain items have affected the comparability of results between periods, which Chris will cover later, first quarter 2016 net income and diluted earnings per share were $177 million and $2.34. That's up 10%, 11%, respectively. This was also significantly above our expectations and represents a pretty good start to the year. 
Looking at revenue growth geographically compared to the same quarter last year, first quarter net sales in the U.S. grew 9% compared to a year ago. On a constant currency basis, in Europe, we were up 5%, Japan was down 16% and our other international businesses were up 20%. As a reminder, the reduction in Japan is due to the workdown of inventory that was recorded as revenue when we sold it to our joint venture prior to the acquisition in the fourth quarter of last year. As we move into the second quarter, that inventory workdown is substantially complete, and we are benefiting from recording revenue at the customer level. 
Our emerging market geographies continued their impressive growth in the first quarter with every major geography contributing double-digit growth. China was particularly exceptional. Our investments over the last couple of years have strengthened our position in this faster-growing markets. Emerging markets represented 10% of sales in Q1 compared to just 8% a year ago. And that meaningful mix shift is occurring even with high single-digit growth in the U.S. 
Accelerating the revenue growth of the company has been the purpose of our plan for the last several years. As we said many times, we believe investing in faster-growth platforms and geographies accomplishes that objective by shifting the mix of the portfolio. While these aren't metrics we plan to disclose on a regular basis, it may be appropriate as we pass the 3-year anniversary of the announcement of our strategic investment plan, to compare the growth profile of the business then versus now. Q1 2013, when we first announced our plan, our organic growth was essentially flat. At that time, between 35% and 40% of our organic portfolio was declining, and between 10% and 15% of the portfolio was growing double digits. 
After 3 years of significant focused investments in these faster-growth areas, that mix has literally been inverted. In Q1 of 2016, only 10% to 15% of our organic portfolio's declining and between 35% and 40% of the portfolio's growing double digits. We remain in investment mode, and we believe we are just in the early stages of seeing the returns on our past investments. Our focus has been and is to build platforms and capabilities that we expect will provide sustainable growth above the sector for years to come. If you followed us for very long, you know it's not uncommon for us to have a good start to the year, but we don't typically change full year guidance after only 1 quarter. In fact, in my 24 years here, I think we've only done it once. However, given the strong performance in the first quarter and the breadth of the strength, both geographically and from a product perspective, we already expect to exceed the full year guidance we gave you 3 months ago. We're not going to get too far ahead of ourselves because there's a lot of year left and a lot of work in front of us. Chris will cover the details with you a little bit later. 
Having said that, we're very pleased with the execution of the investment plan so far. We're moving on multiple fronts across product platforms and geographies. We are growing faster than our peers and we expect that to continue. We like the position we're in and we intend to continue to invest to maintain that position. 
So with that as an introduction, let me now turn you over to John Weiland for a review of our product line revenue."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise. So we'll begin with Vascular. Total net sales were $23",1149,"Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise. So we'll begin with Vascular. Total net sales were $239.5 million, up 3% over last year on a reported basis and up 5% on a constant currency basis. U.S. Vascular sales were up 3% in the first quarter and international sales were up 10%. Excluding the Gore royalty, EP sales to Boston Scientific and the temporary reduction in Japan sales due to the acquisition, global Vascular sales grew 12%. 
Sales in our surgical graft category grew 3% this quarter, within the range of recent experience. Our Endovascular business was up 9% in the first quarter. Within Endovascular, our biopsy products were well above trend at 16% growth in Q1 with strong growth in the United States and emerging markets. There was good momentum in this business, but the strong 2015 we had provided some tougher comps in the coming quarters. 
Our peripheral PTA line increased 19% in the first quarter with our Lutonix DCB growing significantly. We are pleased with how our teams have executed here, and we expect that the expanding real-world data around effectiveness and safety will continue to support the selection of the Lutonix drug-coated balloon as the first line of therapy for peripheral artery disease. I'll remind you that in the first quarter of 2015 was a relatively easy comp due to the significant initial stocking in the fourth quarter of 2014, and the upcoming quarters have some more difficult comps as we saw stocking for Boston Scientific in the second quarter and third quarter of 2015 related to our distribution agreement with them. 
Our Stent business declined 1% in the first quarter compared to the prior year, impacted by the acquisition in Japan. And our vena cava filter line grew 3% in the quarter.
Now let's move to Urology. Total net sales were $216.7 million, up 5% versus the first quarter of last year on a reported basis and up 7% on a constant currency basis. Excluding the impact from Japan and the acquisition of Liberator Medical, global Urology sales were still up 5%, with the United States also up 5% and international up 3%. 
We saw healthy double-digit growth in our Targeted Temperature Management products again this quarter. Our basic drainage business was up 5% in Q1. In this category, we benefited from the new sales from Liberator, but had declines related to the inventory in Japan. If you exclude both of those, the business was still up 5% globally and up 6% in the United States, with our ICE Foley business up 4% globally and also up 4% in the United States. 
Looking at the last several quarters, we would characterize the results here as stable, but not necessarily accelerating on a macro level. We do see specific growth driven by a few new products of ours, both in the hospital and in the home.
Our continence business was up 22% in Q1, but would've been flat excluding Liberator and Japan. I'll remind you that the Liberator platform added ostomy products to our venue -- to our revenue and those are recorded in continence. 
Sales in urological specialties were up 8% in Q1 with our brachytherapy business also up 8%. As we said last quarter, we did not keep significant stocking inventory in Japan on the brachytherapy products. So we began recognizing customer level pricing in Q4 when we closed the acquisition. And finally, stand-alone sales of our StatLock catheter stabilization line decreased 5% in Q1.
Next up is Oncology. Total net sales in this category were $241.9 million, an increase of 8% over Q1 last year on a reported basis and up 10% on a constant currency basis. We worked through the Japanese inventory a little quicker in this business and began to benefit from end customer sales in Japan in the first quarter. Excluding Japan, global Oncology sales were up 8%, with the United States up 6% and international sales up 15%.
Our port business rebounded from the temporary issues we told you about last quarter and grew 8% over Q1 of last year. Our PICC revenue was up 9% globally. As our largest single product line, we continue to expect PICCs to be a meaningful source of growth for us, especially in international markets where PICC penetration is in its very early days.
And to close out the category, our vascular access ultrasound product line grew 15% this quarter as we launched our new Site-Rite 8 platform. And our dialysis catheter product line was up 12%.
Now let's finish with Surgical Specialties. Total net sales in this category were $151.4 million, up 11% on a reported basis and up 13% on a constant currency basis. The impact to this business from the Japan acquisition was minimal. Excluding Japan, the global sales growth was still 13%, with United States sales of 12% and international sales of 14% in the quarter. 
Our performance irrigation business declined 6% in Q1 as we anniversary-ed the discontinuation of certain products in this category. Our soft tissue repair business grew 13% this quarter, which is the strongest growth we've seen for this category since Q3 of 2010. 
As we've seen over the last few years, the growth in synthetic hernia and biologic hernia are inversely related as procedures move from one to the other. This quarter saw a significant in reduction in overall natural tissue hernia, which declined 19% despite very good growth in our Xen AB platform. However, our synthetic hernia business grew 19%, which is the strongest growth we've seen in this product line since the first quarter of 2004, 12 years ago. While this business is mostly in the United stage -- States, which is benefiting from our new Phasix material, our emerging markets are growing nicely with our legacy portfolio. 
Because our mix in soft tissue is more than 5:1, in favor of synthetics, as positions move from biologics to synthetics or hybrids, we typically do well in that exchange as demonstrated this quarter by the strong performance in total soft tissue repair. 
Our hernia fixation line grew 37% this quarter as our new products are having an impact as anticipated. As we told you, we have the broadest portfolio in hernia repair across all types of products, from wide range of synthetics to hybrids, to natural tissue and now antibiotic-coated natural tissue. We are working with physicians to identify the right product for the right patient and provide a wide range of options for them.
Finally, our BioSurgery business grew in the healthy double digits again this quarter, and we believe continues to be a significant long-term growth opportunity for us.
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks for joining us, and good evening, everyone. With the Analyst Day in about a month, I'm just going to hit some of the highlights today, starting with our drug-coated balloon pipeline where we've launched our new 7-millimeter diameter products. And i",841,"Thanks for joining us, and good evening, everyone. With the Analyst Day in about a month, I'm just going to hit some of the highlights today, starting with our drug-coated balloon pipeline where we've launched our new 7-millimeter diameter products. And in early April, we also launched our full line of compatible DCBs. So now every balloon size for the SFA indication is available in a 5 per inch compatible configuration giving us a competitive advantage. After our submission last quarter of our long lesion supplement, we're hopeful for a late second half launch for the treatment of lesions up to 300 millimeters in length. In our Below the Knee IDE, enrollment is beginning to accelerate after FDA approved the expansion of our inclusion criteria in mid-Q1. 
At projected recruitment rates, we continue to anticipate enrollment through 2016, putting PMA submission likely in the first half of 2018. 
Moving to the AV access DCB IDE study. We completed enrollment in Q1 and are now in the 6-month follow-up window. Though these things are a little hard to predict precisely, we believe we should have results sometime in Q4, and we anticipate PMA submission in Q1 of 2017, ahead of our previous schedule. Assuming normal review timing, we expect a second half 2017 U.S. launch. We're also anticipating the submission of our in-stent restenosis PMA supplement in the next couple of months. 
Around the world, we're working to expand access to this important technology. For example, are shown in submission for the SFA indication occurred in the end of Q1, seeking approval in Japan, and we began enrollment in our China study a few weeks ago. 
Also in Vascular, the live stream balloon expandable covered stent trial was fully enrolled in Q3 of 2015. The primary efficacy analysis will be performed with a 9-month follow-up in the treatment of iliac artery disease. Our current projected timeline continues to support submission of our final PMA module before year-end. 
Our COVERA next-generation stent graph IDE is under review at FDA, and we anticipate commencing enrollment upon approval. COVERA's design for use in the AV access circuit. Also in stents, our vivo vena stent is doing well in Europe, and we commenced enrollment in our U.S. IDE just a couple of weeks ago. We anticipate enrollment through 2016 with follow-up through 2017 and PMA submission in 2018. 
Our biopsy business launched 8 new products, including Encore Inspire, Encore Ultra and the mission semi-automatic biopsy family this quarter in Asia while launching 18 new products in Latin America and the Middle East. 
Next, moving to Urology and home care. We exited Q1 with launches in all 4 of our franchises. First, for the home care market, we launched our new Magic3 TOUCHLESS intermittent self-catheterization platform. We also launched our new proxy sheath family for flexible ureteroscopy in our endourology family, and we launched our new fully daily care kit designed to help health care workers adhere to best practices in daily full catheter care and maintenance in our basic drainage segment. In Targeted Temperature Management, we launched some new adult pad sizes to support temperature control over a broader range of patient sizes. 
Moving to Oncology. We're still working with FDA seeking clearance for the launch anticipated later this quarter of our new family of chemical-resistant catheters. We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis, or DVT, and remain on plan to begin launching in the back half of the year. 
For the difficult stick IV catheter patients, we began to launch of our AccuCath wire-guided assisted products earlier this month with additional sizes to launch over the next couple of quarters. These new products are complementary to our new midline catheter, the PowerGlide Pro, slated for launch upon FDA clearance. 
Lastly, in Q1, we launched our new dual-lumen power Xenesys catheter designed for superior flexibility, kink resistance and flow rates in excess of 400 mills [ph] per minute in a small 11-fringe [ph] catheter configuration. 
I'll close my portion of the discussion today with surgery. Just a few days ago, we received PMA approval for our new TRIDYNE aortic sealant, and we're preparing to launch this new product around the end of this quarter. We're also working toward the launch of a new Progel sealant configuration designed to improve visibility during minimally invasive and robotic surgery and expect PMA submission this quarter with approval and launch around the end of year. We're also expanding our portfolio with Phasix resorbable mesh with additional sizes anticipated to launch in the back half of the year. 
And finally, in mesh fixation, we anticipate expanding on our recent permanent and resorbable product launches, with 2 additional resorbable fixation devices slated for later this year. 
Now before I hand you over to Chris, I'd like to remind all of you to join us at our Analyst Day on Monday, May 23, at the New York Palace hotel at 4:30 p.m. I look forward to seeing you there. And now here's Chris."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We had acquisition-related items of $4.5 million pretax, a $9.8 million pretax charge for restructuring and productivity initiatives, and",1046,"Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We had acquisition-related items of $4.5 million pretax, a $9.8 million pretax charge for restructuring and productivity initiatives, and we booked expense of $48.9 million for product liability matters, which principally is related to litigation on IVC filters. The P&L impact of these items is detailed in the notes to the financial statements and in the reconciliation accompanying our Q1 earnings press release.
Now let's go through the statement of income for the quarter, and I'll remind you that our adjusted numbers now exclude the amortization of intangibles from the entire P&L, and the references to prior year are on that same basis. Gross profit was $553.1 million or 63.3% of sales for Q1. On an adjusted basis, GP was $581.2 million or 66.5% of sales. That's up 210 basis points from the prior year quarter and better than we expected. FX cost us about 20 basis points in GP for the quarter. Price pressure drove 40 basis points on the revenue line in Q1 and 20 basis points of headwind on GPs, which was significantly better than our expectations and the best result we've seen since 2010. We still expect price to be more of a headwind going forward, but we're certainly happy with the Q1 results. Our cost improvements and other items drove 90 basis points of benefit to GPs this quarter and mix was favorable by 160 basis points, which includes the gross profit benefit from acquiring our Japanese JV. As we look to Q2, we expect gross margin to be over 100 basis points better than Q2 of 2015. And for the full year, we're comfortable with our guidance for gross profit improvement. 
SG&A expenses were $270.6 million for the quarter or 31% of sales. On an adjusted basis, SG&A was $266.5 million or 30.5% of sales, an increase of 180 basis points over last year. This is reflective of the timing of the 2 recent acquisitions, and we expect Q2 will also be higher than prior year as well. We still expect the full year to be about the same as 2015 as a percentage of sales as we integrate the acquisitions and leverage our infrastructure on higher sales throughout the year. 
R&D expenditures totaled $68.3 million for the first quarter or 7.8% of sales on a reported basis. On an adjusted basis, R&D was $66.8 million or 7.6% of sales, up 20 basis points from Q1 of last year and consistent with our guidance. Interest expense was $11.3 million for the quarter. Other income expense was $60 million of expense for the first quarter as reported and $1.9 million of income on an adjusted basis. The effective tax rate for the quarter was 18.7% on a reported basis and 25.8% on an adjusted basis, right in the middle of our full year guidance. 
Diluted shares for the period were 75.2 million, and we purchased 897,000 shares in the first quarter at an average price of $186.57. The net result is adjusted EPS of $2.34, which was well above our expectations for the quarter. This overachievement was driven by the strong sales and a slight easing of FX headwinds. The balance sheet, as of March 31, reflects cash, restricted cash and short-term investments of approximately $1 billion, essentially no change from December 31. For the quarter, accounts receivable days were up 1.2 days and inventory days were up 6.3 days. Both of these increases are related to the recent acquisitions. Capital expenditures totaled $20.5 million for the quarter. 
On the liability side, total debt was $1.7 billion as of March 31 compared to $1.4 billion at the end of December. Debt to total cap at the end of the first quarter was about 53%, and total shareholder investment was $1.5 billion at March 31. 
Turning now to guidance. In Q2, we're expecting constant currency sales growth between 6.5% and 8%, with reported sales growth between 5.5% and 7%, inferring an FX headwind of approximately 1% on the revenue line. This assumes organic growth between 5.5% and 6% for the second quarter. From an adjusted EPS standpoint, excluding items affecting comparability and the amortization of intangibles, we see the second quarter in the range of $2.43 to $2.47. 
Given such a strong operational start to 2016, along with an easing of FX headwinds, we're comfortable raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 7% and 8.5%, with reported sales growth between 6% and 8%, inferring a currency headwind of between 50 and 100 basis points. 
On an organic basis, we had originally guided the year to be between 5% and 6%, but are increasing that range meaningfully today to be between 6% and 6.5%. It's not lost on us, and we're sure it's not lost on you that we did meaningfully better than that in Q1. To be clear, we see good momentum in the business and continued strength in our positioning. However, there were several product lines this quarter well above trend. China was exceptionally strong, and I just highlighted price headwind was abnormally low. So before we take the sustainability of some of these factors to the bank, we think it is prudent to get a little deeper into the year. 
We're also increasing our full year adjusted EPS guidance range to be between $10.05 and $10.18, which is just about $0.15 above our original guidance range at the midpoint and represents 11% to 12% growth over 2015. At current rates, we expect foreign exchange to be approximately $0.20 of headwind for the full year. So on an FX-neutral basis, we are guiding to 13% to 14% growth. Given the strength of our operating performance, the success of our investment program and the demonstrated ability of our teams to execute against commitments, we plan to accelerate certain investments and targeted projects and geographies, beginning in Q2 and throughout the remainder of the year. We believe this disciplined investment approach will help provide sustainable profitable growth and value for our shareholders for years to come. 
And with that, I'll turn you back to Tim."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] With that, Kathy?",30,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] With that, Kathy?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question will come from Bob Hopkins with the Bank of America.",16,"[Operator Instructions] And our first question will come from Bob Hopkins with the Bank of America."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","So 2 things, Tim, for you. Before I ask a Bard specific question, one of the other things that isn't lost on all of us on this call is really the whole medtech space is reporting very strong Q1 organic growth numbers from cardio to ortho to general surger",74,"So 2 things, Tim, for you. Before I ask a Bard specific question, one of the other things that isn't lost on all of us on this call is really the whole medtech space is reporting very strong Q1 organic growth numbers from cardio to ortho to general surgery. So I just wanted to get your take on kind of what you're seeing out there in terms of surgical procedure volumes and trends generally."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I mean, I think there is no denying that the observation you made, it does seem like everyone's doing a little bit better. I still think there's a lot of things that we're still trying to understand and navigate as health care and changes and what th",129,"Yes. I mean, I think there is no denying that the observation you made, it does seem like everyone's doing a little bit better. I still think there's a lot of things that we're still trying to understand and navigate as health care and changes and what that means. The only thing I could point to, Bob, that has been constant, and that is that as employment rates over time -- over a very long period of time historically have improved health care spending has for like 4 years increased along with that. So it feels like things have been a little bit better. But again, because it is a different kind of environment with all the different dynamics, it's still a little bit tough to predict, I think."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just to follow up maybe on that same question so 2 quick things. One, just sort of a standard question. We're selling these even for you guys this quarter. And then more specifically, Bard had a particularly strong quarter with 9% organic growth.",101,"And then just to follow up maybe on that same question so 2 quick things. One, just sort of a standard question. We're selling these even for you guys this quarter. And then more specifically, Bard had a particularly strong quarter with 9% organic growth. That's a nice acceleration from what we've seen. So can you just talk from a Bard perspective, like what drove the incremental growth? Maybe it seems like emerging markets or maybe even above the 20% level that you've been seeing. Just talk about what got better this quarter and if the selling days are even out?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We were strong literally across the board. We did have some easier comps in certain sectors, which Chris can get into more details, Bob. But in general, the investment plans working the execution teams done a great job around the world, executing ver",85,"Yes. We were strong literally across the board. We did have some easier comps in certain sectors, which Chris can get into more details, Bob. But in general, the investment plans working the execution teams done a great job around the world, executing very well. We had some new products that hit their stride pretty quickly. Lutonix continues to do well. Surgery, as John noted, the highest it's been synthetics in over a decade. So it's really across the board. It's not any one thing."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'd just add, Bob. I think just a couple of things we tried to highlight that really sort of surprised us as we came to the quarter. Again, price was better than we expected and well below trend. Biopsy, as John highlighted, had a really strong quarter an",180,"I'd just add, Bob. I think just a couple of things we tried to highlight that really sort of surprised us as we came to the quarter. Again, price was better than we expected and well below trend. Biopsy, as John highlighted, had a really strong quarter and probably the easiest comp of the year for us, but terrific momentum there. And Lutonix had its easiest comp of the year as well. And soft tissue, as John highlighted, was just clearly above trend and with the exceptional strength in synthetics. And China had an exceptional quarter, above trend. So it was really a situation where everybody performed as we expected, and then we've got I'll call it at this point, several really nice surprises. And then from a selling day standpoint, it's hard to measure exactly, but there probably was some benefit, Bob. But again, it's -- it was a tailwind, but it's hard to be too specific. And we generally don't call it out when it goes the other way either, but it probably helped a little bit."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Roman with Goldman Sachs.",10,"Our next question is from David Roman with Goldman Sachs."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","I want to see if you could follow up a little bit on Japan and give us a little bit more detail about how we should think about that region unfolding as you move to a full direct model. And maybe give us some specifics on where you see the biggest opportu",71,"I want to see if you could follow up a little bit on Japan and give us a little bit more detail about how we should think about that region unfolding as you move to a full direct model. And maybe give us some specifics on where you see the biggest opportunities and how we should think about that contributing to growth, both throughout 2016 and as we think longer term."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, David, first of all, we're off to a good start, frankly. I mean, the integrations gone very well so far. And obviously, we're dealing with the inventory sell-through, but the business actually did a bit better than we had expected anyway. I",168,"Yes, I think, David, first of all, we're off to a good start, frankly. I mean, the integrations gone very well so far. And obviously, we're dealing with the inventory sell-through, but the business actually did a bit better than we had expected anyway. I think we're realigning the sales force a bit and getting them focused in areas where we, to your point, really see more opportunity. And I would certainly be both within surgery. We talked about upticks in general being extremely underpenetrated in Japan. We think that's a really exciting growth area for us. And probably most prominently within Vascular, we've got Lutonix approvals coming down the pipeline here in fairly short order and having controlled that direct sales force ourselves, getting them aligned the right way and getting them motivated and ready for those launches again relative to the old ownership structure. We just feel we're in a position to maximize that opportunity in a way we just would haven't been able to otherwise."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","The only other thing I would add if you were to look at at the macro level the product mix within the global portfolio by Urology, Oncology, surgical and Vascular were fairly evenly balanced, at least amongst the top 3, with surgical lagging a little bit",126,"The only other thing I would add if you were to look at at the macro level the product mix within the global portfolio by Urology, Oncology, surgical and Vascular were fairly evenly balanced, at least amongst the top 3, with surgical lagging a little bit behind. That is not the way our Japan business looks today. We're very heavily dominated in Urology. Clearly, the faster-growing segments are the other 3, and that's where we have the smallest amount of revenue coming from in Japan. So it's our expectation that, that will get realigned with this structural change as well as our investments moving forward. And we would expect that product mix to shift and look more like over time what it'd look like everywhere else."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And then maybe just on the spending side. It looks like you took the opportunity to reinvest in SG&A this quarter, given some of the strength in the top line. But it looks you said at the beginning of the year, CapEx is running a little bi",100,"That's helpful. And then maybe just on the spending side. It looks like you took the opportunity to reinvest in SG&A this quarter, given some of the strength in the top line. But it looks you said at the beginning of the year, CapEx is running a little bit lower. So how should we think about the balance of cash spending through the rest of the year as well as how the P&L discretionary line item should compare to your original guidance. I know you gave SG&A, but maybe just an update on R&D and CapEx would be helpful."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","All right. We guided to $120 million of CapEx spend for the full year. I think we'll probably still get close to that number. I don't expect it to be materially different either way. And as we highlighted at the end of the comments, we are in the face of",140,"All right. We guided to $120 million of CapEx spend for the full year. I think we'll probably still get close to that number. I don't expect it to be materially different either way. And as we highlighted at the end of the comments, we are in the face of the strength really going to accelerate spending on some several additional R&D projects, several additional sales force expansion projects, several additional clinical trials. And also, we're adding additional resources within our health economics infrastructure across the company as well. So it'll be spread between SG&A and R&D. We'll still be in line with our full year guidance as a percentage of sales, but we're going to take advantage of the strength again to really accelerate some investments that we think will be helpful as we move into '17 and beyond."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go next to Mike Weinstein with JPMorgan.",9,"We'll go next to Mike Weinstein with JPMorgan."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just following up on that, Chris. If you guys at the analyst meeting can talk a little bit more about where you're putting those extra dollars and that would probably be helpful to everybody.",34,"Just following up on that, Chris. If you guys at the analyst meeting can talk a little bit more about where you're putting those extra dollars and that would probably be helpful to everybody."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Mike.",2,"Sure, Mike."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","So let me circle back to really Bob's first question, which is you look at some of these businesses, the ones that are above trend. And I just want to understand, you gave numbers on a bunch that were obviously very strong, things like urological specialt",123,"So let me circle back to really Bob's first question, which is you look at some of these businesses, the ones that are above trend. And I just want to understand, you gave numbers on a bunch that were obviously very strong, things like urological specialties up 8% brachytherapy up 8%, the synthetic hernia repair business, which running with 8%, 9% last year was up 19% this quarter. All those businesses that had real above trends, was that explain it U.S. versus OUS was that U.S. that was significantly above trend? Was it U.S. and then China? Can you just maybe geographically help us there? Because a lot of what we're seeing is U.S. outperformance in a number of different end markets."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I think U.S. was strong, Mike, in really all of those, so it's -- we had 9% growth in the U.S. and 8% organic growth in U.S. So it was all the categories we highlighted were strong. China is going great guns for us, and so biopsy in China, the hernia busi",168,"I think U.S. was strong, Mike, in really all of those, so it's -- we had 9% growth in the U.S. and 8% organic growth in U.S. So it was all the categories we highlighted were strong. China is going great guns for us, and so biopsy in China, the hernia business in China, the PICC franchise in China. And as we talked about last year, I think it's an example of where we accelerated some investments, we started to build the direct sales force in BioSurgery in China last year, and this quarter is the first quarter where we're really seeing the fruits of those efforts in China. The brachy business performed again in Japan better because there was really no inventory in Japan. And so we're getting direct-to-customer pricing there in the quarter. So it's really across the board, and the U.S. was certainly stronger. But again, where we had made investments is where we've also seen some acceleration in some of these other geographies."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And tell me how you thought about just the guidance upgrade for the balance of the year. Is just the organic revenue growth of 5.5% to 6% for the second quarter and it kind of that's what you're basically implying for the second half basically assuming th",94,"And tell me how you thought about just the guidance upgrade for the balance of the year. Is just the organic revenue growth of 5.5% to 6% for the second quarter and it kind of that's what you're basically implying for the second half basically assuming that you go back to your prior trendline expectations and just as assuming that what we saw incremental in the first quarter was a 1-quarter event, and therefore, the upside is that if it's not just a 1-quarter event, then we're going to get the benefit of that?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think there's a bad way to think about it. I mean, that's really how we saw the year coming in was 5% to 6%. I think we called out a couple of areas that were above trend and a couple of areas that were easy comps that obviously, we're not countin",162,"I don't think there's a bad way to think about it. I mean, that's really how we saw the year coming in was 5% to 6%. I think we called out a couple of areas that were above trend and a couple of areas that were easy comps that obviously, we're not counting on the rest of the year. And again, pricing was a positive surprise for us as well. So we feel great about 6% to 6.5% for the full year. And as we said, we're not going to get too far ahead of ourselves. We'll see how Q2 goes and then we'll take it from there. But I think great start to the year. We think appropriate guidance for the rest of the year. And as I think you've seen from us in the past, we'll try as we move through the year, try to make the right decisions, both from an investment standpoint and from a guidance standpoint."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And Chris, just one clarification and then jump in. On Japan, so you're going to go from a headwind because on the top line because of the JV to buy into a tailwind. Can you just help us with the math on what that might mean to the top line over the next",55,"And Chris, just one clarification and then jump in. On Japan, so you're going to go from a headwind because on the top line because of the JV to buy into a tailwind. Can you just help us with the math on what that might mean to the top line over the next few quarters?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. And so we'll have this sort of interesting phenomena where reported and constant currency growth will accelerate through the back part of the year, largely because of the impact of Japan. But we're pulling it entirely out of organic. So we're not ben",114,"Yes. And so we'll have this sort of interesting phenomena where reported and constant currency growth will accelerate through the back part of the year, largely because of the impact of Japan. But we're pulling it entirely out of organic. So we're not benefiting at all over the course of the year when we're talking about organic growth from Japan. So we guided for Q2. Q3 will be somewhat higher than that and Q4 will be somewhat higher than that from a reported and constant currency basis. But again, organic should be relatively consistent over the course of the next 3 quarters. It's how we're seeing the business as we sit here right now."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question now from David Lewis with Morgan Stanley.",11,"We have a question now from David Lewis with Morgan Stanley."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim, just sticking with this idea of trying to understand kind of the macro versus the micro drivers of the business. If I take the 4 segments of Bard, it looks the margins surgical and Oncology, you did better than Vascular and neurology kind of on a rel",106,"Tim, just sticking with this idea of trying to understand kind of the macro versus the micro drivers of the business. If I take the 4 segments of Bard, it looks the margins surgical and Oncology, you did better than Vascular and neurology kind of on a relative basis. If you sort of think about house utilization activity or sort of U.S. mix or their product pipelines and these businesses, the surgical and Oncology versus Vascular, Urology makes sense, either relative to the products in the businesses or makes sense relative to the U.S. focus or things you've seen in the past on utilization or acuity."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'm not sure there's a common thread where you can weave them altogether. There's different things driving each of the different businesses. Surgical, obviously, there's been a lot of investment made in that business over the last few years and a lot of n",253,"I'm not sure there's a common thread where you can weave them altogether. There's different things driving each of the different businesses. Surgical, obviously, there's been a lot of investment made in that business over the last few years and a lot of new products are coming out, as John cited out in his review. So that's doing well. That's also one of the key investment areas in emerging markets. So you've got those 2 things there. Clearly, Oncology, there's always new products kind of flowing through there, but that's one of the biggest drivers in emerging markets, especially in China. So again, you've got kind of both themes there as well. Vascular continues to do well. The PTA line, Lutonix in the U.S. continues to do well. And Urology, even across the board. Clearly, TTM continues to do well. The acquisitions that we've made continue to perform well. And the uptake in the U.S. seems to have become more steady. When you talk to hospital CEOs, I'm hearing more of them talk about some of their issues being things like nursing turnover, again being a big issue. We haven't really heard that, at least I am from a lot of hospital CEOs for several years now. So that's an indication perhaps that volumes are coming back or other opportunities for nurses outside of hospitals one or and above of those things. So just generally those are the themes that would kind of go through each of those areas you've called out."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's been very helpful. And I guess, the second kind of Bard a couple of years you're going to invest to drive that organic growth and you talked a lot about the 6 and 10 models 6% organic top and 10% on the bottom. I'm not getting too excited over here",109,"That's been very helpful. And I guess, the second kind of Bard a couple of years you're going to invest to drive that organic growth and you talked a lot about the 6 and 10 models 6% organic top and 10% on the bottom. I'm not getting too excited over here but with a 12% earnings growth but I think it bears asking you it is you start getting above 6%, 7% organic growth as you did this quarter, does it start to become any diminishing return where investors can expect better than 10% earnings if that organic growth is going to be in excess of 7% organic."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I think just to be clear, I think what you might be referencing is our historical spreads between our revenue and our earnings growth. Having said that, and as Chris pointed out, we also -- we don't run this business quarter-to-quarter. We run it over the",132,"I think just to be clear, I think what you might be referencing is our historical spreads between our revenue and our earnings growth. Having said that, and as Chris pointed out, we also -- we don't run this business quarter-to-quarter. We run it over the long term. Company was founded in 1907. So none of us here are doing this on a quarter-to-quarter basis. We're constantly looking to have a very well-tuned process about how we'll turn on investments over time, and we've always done that. When we do a little bit better, were able return on more. But it's not like we have to go out and collect ideas. We've got a pipeline of things that we can invest in. It's just a question when we start turning those on."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, David, is as we talked about pretty consistently, we do believe the model, and especially the product mix where we're getting growth from does and should allow us to generate 50 to 100 basis points of operating margin improvement a",155,"The only thing I'd add, David, is as we talked about pretty consistently, we do believe the model, and especially the product mix where we're getting growth from does and should allow us to generate 50 to 100 basis points of operating margin improvement annually. And so as we grow the top line consistently in the mid-single digits, and obviously, utilize the free cash flow that we have on top of that, you do get to that kind of map that we have a year like this year where we're obviously looking at performing a little it better in the back. You're seeing good earnings growth on top of that as well. So it's -- the importance is the health of the model and continuing to keep it healthy. And we think, again, letting too much drop-through when we're leaving good investments on the table is not the right approach from a long-term standpoint."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Or next, we have Larry Keusch with Raymond James.",9,"Or next, we have Larry Keusch with Raymond James."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, maybe just to start the GM, I think on the adjusted basis you did 66.5% and I think the guidance is 66% for the year. So can you just help us, again, just think through with that starting point why there won't be potentially some upside particularl",58,"Chris, maybe just to start the GM, I think on the adjusted basis you did 66.5% and I think the guidance is 66% for the year. So can you just help us, again, just think through with that starting point why there won't be potentially some upside particularly as you start to recognize some of the Japan benefits?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And some of the Japan -- from a gross margins standpoint, some of the Japan benefits were impacting mix in Q1. So as the sales that would already previously made into the joint venture then gets sold out the door to the customer, that incremental pricing",179,"And some of the Japan -- from a gross margins standpoint, some of the Japan benefits were impacting mix in Q1. So as the sales that would already previously made into the joint venture then gets sold out the door to the customer, that incremental pricing right is gross margin. We're obviously no longer booking sales as we fill the pipe into the JV. So mix, as we expected for the full year from the JV, would be a positive contributor. It's actually more prominent in Q1 because there's fewer sales that we're booking into the JV. So I think the way to think about gross margin over the full year is actually we'll probably be pretty consistent quarter-to-quarter here on out as that -- as we see the normalization of Japan over time. And again, we're not expecting to see the kind of pricing environment we necessarily saw in Q1 for the full year. So I expect to see a fairly consistent gross margin trajectory over the course of the year as we're looking at it right now."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then I'll just sneak 2 other quick ones in here. Just on staying on the topic of Japan. You had indicated that you had expected dilution about $0.20 with $0.10 occurring in the first quarter again just given some of the changes in the FX rates.",133,"Okay. And then I'll just sneak 2 other quick ones in here. Just on staying on the topic of Japan. You had indicated that you had expected dilution about $0.20 with $0.10 occurring in the first quarter again just given some of the changes in the FX rates. I want to just check back in on that. And then specifically on price, again, I hear you loud and clear that this is below kind of the levels that we've been seeing as of late. But was there anything specific in the quarter that allowed you to get the better pricing or perhaps in another way, is there another thing to think about it as we move through the year that would influence pricing negatively? Or are you just trying to stay conservative there?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This is John. Let me deal with the price issue first. There was no special onetime item that impacted us positively from a price standpoint. We had a pretty good performance across all of our businesses as well as our geographies. And we had annualized a",76,"This is John. Let me deal with the price issue first. There was no special onetime item that impacted us positively from a price standpoint. We had a pretty good performance across all of our businesses as well as our geographies. And we had annualized a few of the headwinds that we had early last year. We talked about which was on port pricing that had an impact as well. I'll turn you back to Chris."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","On the currency front, Larry, just in general, currency was about $0.02 better than we had expected in the quarter. Probably a little more than half of that was related to the yen. So we were sort of $0.01 better as we thought about Japan. $0.01 or $0.02",161,"On the currency front, Larry, just in general, currency was about $0.02 better than we had expected in the quarter. Probably a little more than half of that was related to the yen. So we were sort of $0.01 better as we thought about Japan. $0.01 or $0.02 better as we talk about Japan coming into the year. And again, for the full year, we expect about $0.20 of headwind, at least as we sit here today, given where the yen is and the euro and the rest of the basket, which again is about $0.10 better on a full year basis than we had anticipated. But obviously, as we all know, currencies can move the other way pretty quickly as well. So there'll be less dilution in Japan at the yen stays where it's at, and again we're really focused on executing the integration. And if we execute well, hopefully, we'll do a little bit better from an operational standpoint."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Amit Hazan with Citi.",9,"Our next question is from Amit Hazan with Citi."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe I'll ask the first question on drug-coated balloon and Lutonix. You started out I think last quarter, you talked about end customer usage. You were pretty positive on that, more than doubling versus the prior year. It sounds like you were pretty pos",64,"Maybe I'll ask the first question on drug-coated balloon and Lutonix. You started out I think last quarter, you talked about end customer usage. You were pretty positive on that, more than doubling versus the prior year. It sounds like you were pretty positive again this quarter. Can you give some color on whether that was kind of a sustainable type of growth?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me deal with the DCB perspective. I think that we feel very good about where we were with DCBs in Q1. We saw great execution from the sale side of things. We like our pipeline right now as we look downstream. John talked about all the new launches. We",116,"Let me deal with the DCB perspective. I think that we feel very good about where we were with DCBs in Q1. We saw great execution from the sale side of things. We like our pipeline right now as we look downstream. John talked about all the new launches. We'll talk about and that we have upcoming. We'll talk about more of that again in May when we get together from a pipeline standpoint. But I think if you combine what we're seeing happening in the field from a sales force execution standpoint, combined with what we consider to be robust new indications and product extensions of platforms, we feel great where we are right now."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And maybe this is front running a little bit, but I'll throw it out there anyway just a little bit of a mid- long-term question your surgery you had recent presentation struck me a little bit it was addressing your kind of long-term market op",112,"Fair enough. And maybe this is front running a little bit, but I'll throw it out there anyway just a little bit of a mid- long-term question your surgery you had recent presentation struck me a little bit it was addressing your kind of long-term market opportunities and actually the biggest category you guys cited surgery you cited as billion-dollar opportunity going to $3 billion in 2020. So I wanted just maybe get a little bit of your color on what's behind that and what you see in your current pipeline or market product that helps you play in what you're essentially seeing tripling of that market in the next 5 years."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. John DeFord here. Just a couple of things. First off, right now, we have a fairly limited product offering. So we've got a long sealant, and we've got a couple of hemostasis technologies. So we -- based on those initial platforms, we anticipate expa",151,"Sure. John DeFord here. Just a couple of things. First off, right now, we have a fairly limited product offering. So we've got a long sealant, and we've got a couple of hemostasis technologies. So we -- based on those initial platforms, we anticipate expanding. So today, I talked to you about a new technology that we developed internally, the TRIDYNE aortic sealant. We just received PMA approval after a very successful clinical study. We intend to launch that. It's getting us to a brand-new space with bigger opportunity. Like that, we have in our pipeline a number of other technologies and next-generations that we think are going to expand the area that we play in. So there's a pretty broad market right now for BioSurgery, but we're in a very small sliver of that. And over the next several years, we see us getting into some of the larger pieces."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And we're looking to do that both internally and externally, and we're looking all the time for additional technologies to add into the fold. I think what's important to understand is we now have a great direct selling force in the U.S. and as I mentioned",90,"And we're looking to do that both internally and externally, and we're looking all the time for additional technologies to add into the fold. I think what's important to understand is we now have a great direct selling force in the U.S. and as I mentioned, in China and we're pursuing other geographies. So part of its just maximizing the opportunity with the existing products, but you should very much expect us to continue to broaden the product portfolio, both through internal and external activities over the coming years."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Kristen Stewart with Deutsche Bank.",11,"And we'll go next to Kristen Stewart with Deutsche Bank."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","I was just wondering if you could give us the components to get to your organic numbers, the Gore and I think it mentioned also something with Boston Scientific and then I guess, the total adjustment for the joint venture.",40,"I was just wondering if you could give us the components to get to your organic numbers, the Gore and I think it mentioned also something with Boston Scientific and then I guess, the total adjustment for the joint venture."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Kristen, there's actually a slide in the deck that we posted to the website, which provides the combination of those items. So you can see Vascular was negatively impacted by 7 points, and that's both the Gore royalty, the decline in the EP sales to Bosto",132,"Kristen, there's actually a slide in the deck that we posted to the website, which provides the combination of those items. So you can see Vascular was negatively impacted by 7 points, and that's both the Gore royalty, the decline in the EP sales to Boston Scientific and the impact of the pen JV. So Vascular grew 12% organic, adjusting for those items. Urology, we're taking Liberator out, and it was the big impact in Japan, which sort of offset each other to a large degree in Urology grew 5% organic. Oncology grew 8% organic, which is the adjustment associated with Japan. And then surgical, there was a very minor impact there, so both constant currency and organic in surgery were 13%. So that's the level of granularity we're providing for you."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then Gore's 38.4, I guess, on the slide?",10,"And then Gore's 38.4, I guess, on the slide?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Right.",1,"Right."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then with respect to the Analyst Day, I know last or 3 years ago, as you mentioned, you gave the 3-year plan and clearly, congratulations. You've gotten there. Will you be providing another kind of outlook, I guess, for the next 3 or kind of any",58,"Okay. And then with respect to the Analyst Day, I know last or 3 years ago, as you mentioned, you gave the 3-year plan and clearly, congratulations. You've gotten there. Will you be providing another kind of outlook, I guess, for the next 3 or kind of anything with a longer-term goals with the analyst meeting is that."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This will be kind of an update overview of the investments to the question that was asked earlier that we're making now, little bit more detail on portfolio review, some of our geographic plans, that kind of thing. But we will not be providing any additio",51,"This will be kind of an update overview of the investments to the question that was asked earlier that we're making now, little bit more detail on portfolio review, some of our geographic plans, that kind of thing. But we will not be providing any additional guidance at that meeting."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Will you allow John to make his jokes.",8,"Will you allow John to make his jokes."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","That's why you have to schedule advanced.",8,"That's why you have to schedule advanced."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. Even try to sneak it in, they like throw the hook out.",14,"Thank you. Even try to sneak it in, they like throw the hook out."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Well, you can make those off line.",7,"Well, you can make those off line."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'll have to.",4,"I'll have to."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We're approaching the top of the hour I'm going to apologize to everybody else in line. We're going to do one more question and then we're going to wrap it up.",32,"We're approaching the top of the hour I'm going to apologize to everybody else in line. We're going to do one more question and then we're going to wrap it up."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","The final question will come from Dave Turkaly with GMP Securities.",11,"The final question will come from Dave Turkaly with GMP Securities."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Back to the gross margin just quickly. I know that mix was 160 basis points. And I think you mentioned cost improvements of 90. Can you just remind us where you are in those cost improvement programs? I know in the past you talked about material input cos",82,"Back to the gross margin just quickly. I know that mix was 160 basis points. And I think you mentioned cost improvements of 90. Can you just remind us where you are in those cost improvement programs? I know in the past you talked about material input cost is an area of focus and potentially as a lever moving ahead. But do you think we'll have improvements like that as we look forward? Where could the gross margin had based on those?"
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This is the improvements that we talk about in the P&L is not about one big program. And it's our normal organic way of operating the business, focused primarily on both materials costs and on improvements in our variances to flow out of our effecting ope",105,"This is the improvements that we talk about in the P&L is not about one big program. And it's our normal organic way of operating the business, focused primarily on both materials costs and on improvements in our variances to flow out of our effecting operations and efficiencies. So as you can see, we had one small charge that Chris talked about for efficiencies that will help us in the future. But it's not one big program. This is the normal way we operate year in and year out, and we're focused on it constantly improving the -- our cost positions and our profits."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","So David, the only thing I'd add is we guided for the full year cost of 80 to 100 basis points. And really, the team tasked with achieving 50 to 100 basis points year in, year out. And so in a moderate FX environment and a more moderate price environment,",111,"So David, the only thing I'd add is we guided for the full year cost of 80 to 100 basis points. And really, the team tasked with achieving 50 to 100 basis points year in, year out. And so in a moderate FX environment and a more moderate price environment, we feel really good about have been able to control our destinies to drive GPs higher. And then obviously mix. Everything we've done from an investment standpoint to shift the portfolio to higher-growth and higher-margin products are both tailwinds to gross margin. Again at execute those are 2 things we can control. And then FX is obviously something that we can't."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","One really quick-follow up. I know just actually to get your thoughts on sort of the biologics in the hernia repair area. Is there a functional problem there? And do you think the synthetic business can remain that strong? I guess, I'd like your thoughts",52,"One really quick-follow up. I know just actually to get your thoughts on sort of the biologics in the hernia repair area. Is there a functional problem there? And do you think the synthetic business can remain that strong? I guess, I'd like your thoughts on what is actually driving that."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think there's any functional problem. I think what's really happening is that as these hybrid technologies get into the market and has a better understanding of what product works best in what patient, you're beginning to see some of the shake out",139,"I don't think there's any functional problem. I think what's really happening is that as these hybrid technologies get into the market and has a better understanding of what product works best in what patient, you're beginning to see some of the shake out here. So I think it's nothing sort of structural, but more greater knowledge, greater science and just a normal shakeout of where it does when is it best to use a biologic when is it best to use a pure synthetic when it some of the hybrid technologies and that we now have? And so we're beginning to see some of that shakeout. And I think at that information comes together, we're also doing everything we can to help our customers determine what's the best product for every patient that walks in the door."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And then the key to success there is to have an product in each of the categories for every patient. And we're the only one who has that. So we're clearly taking share given our portfolio right now exactly.",39,"And then the key to success there is to have an product in each of the categories for every patient. And we're the only one who has that. So we're clearly taking share given our portfolio right now exactly."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. Then I'll turn the call back over to Bard's management for closing remarks.",15,"Thank you. Then I'll turn the call back over to Bard's management for closing remarks."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much, Kathy. And I'd like to thank all of you for joining us this afternoon. We will see you, hopefully, at our analyst meeting, and if not, we'll talk to you again of the quarter. I'd also like to think all of Bard's employees around the w",66,"Thank you very much, Kathy. And I'd like to thank all of you for joining us this afternoon. We will see you, hopefully, at our analyst meeting, and if not, we'll talk to you again of the quarter. I'd also like to think all of Bard's employees around the world for all their hard work and a very strong start for the year. Thanks. Good night."
254131,329843971,964954,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using AT&T Executive TeleConference. You may now disconnect.",27,"Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using AT&T Executive TeleConference. You may now disconnect."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand r",270,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors each in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of April 27, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period.
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. Good afternoon, and welcome to Bard's First Quarter of 2016 Earnings Conference Call. And thanks to all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 30 minutes, and we're going t",910,"Thank you. Good afternoon, and welcome to Bard's First Quarter of 2016 Earnings Conference Call. And thanks to all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 30 minutes, and we're going to try and keep the total call to about an hour. There is a slide deck available on the Investor Relations page of our website intended to help explain some of the moving pieces in our results and guidance.
The discussions today will go as follows: I'll begin with an overview of the results for the quarter; John Weiland, our President and COO, will review first quarter product line revenue; John DeFord, our Senior Vice President of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; lastly, Chris Holland, our Senior VP and CFO, will review the first quarter income statement and balance sheet as well as our expectations for the second quarter and the full year. And then finally, we'll close with Q&A.
First quarter 2016 net sales totaled $873.5 million. That's up 7% over the first quarter last year on an as-reported basis and up 8.5% on a constant-currency basis. Currency impact for the quarter versus the same quarter last year was unfavorable by about 190 basis points. Our organic revenue growth this quarter was 9%, which was significantly better than our guidance of 5.5% to 6%.
Net income for the first quarter was $116.2 million, and diluted earnings per share were $1.54. That's down 17% and 15%, respectively. Excluding amortization and certain items that have affected the comparability of results between periods, which Chris will cover later, first quarter 2016 net income and diluted earnings per share were $177 million and $2.34. That's up 10% and 11%, respectively. This was also significantly above our expectations and represents a pretty good start to the year.
Looking at revenue growth geographically compared to the same quarter last year, first quarter net sales in the U.S. grew 9% compared to a year ago. On a constant-currency basis, in Europe, we were up 5%, Japan was down 16% and our other international businesses were up 20%. As a reminder, the reduction in Japan is due to the workdown of inventory that was recorded as revenue when we sold it to our joint venture prior to the acquisition in the fourth quarter of last year. As we move into the second quarter, that inventory workdown is substantially complete, and we are benefiting from recording revenue at the customer level.
Our emerging market geographies continued their impressive growth in the first quarter, with every major geography, contributing double-digit growth. China was particularly exceptional. Our investments over the last couple of years have strengthened our position in these faster-growing markets. Emerging markets represented 10% of sales in Q1 compared to just 8% a year ago. And that meaningful mix shift is occurring even with high single-digit growth in the U.S. 
Accelerating the revenue growth of the company has been the purpose of our plan for the last several years. As we said many times, we believe investing in faster-growth platforms and geographies accomplishes that objective by shifting the mix of the portfolio. While these aren't metrics we plan to disclose on a regular basis, it may be appropriate as we pass the 3-year anniversary of the announcement of our strategic investment plan, to compare the growth profile of the business then versus now. Q1 2013, when we first announced our plan, our organic growth was essentially flat. At that time, between 35% and 40% of our organic portfolio was declining, and between 10% and 15% of the portfolio was growing double digits.
After 3 years of significant focused investments in these faster-growth areas, that mix has literally been inverted. In Q1 of 2016, only 10% to 15% of our organic portfolio was declining and between 35% and 40% of the portfolio was growing double digits. We remained in investment mode, and we believe we are just in the early stages of seeing the returns on our past investments. Our focus has been and is to build platforms and capabilities that we expect will provide sustainable growth above the sector for years to come. If you followed us for very long, it's not uncommon for us to have a good start to the year, but we don't typically change full year guidance after only 1 quarter. In fact, in my 24 years here, I think we've only done it once. However, given the strong performance in the first quarter and the breadth of the strength, both geographically and from a product perspective, we already expect to exceed the full year guidance we gave you 3 months ago. We're not going to get too far ahead of ourselves because there's a lot of the year left and a lot of work in front of us. Chris will cover the details with you a little bit later. 
Having said that, we're very pleased with the execution of the investment plan, so far. We're moving on multiple fronts across product platforms and geographies. We are growing faster than our peers, and we expect that to continue. We like the position we're in and we intend to continue to invest to maintain that position.
So with that as an introduction, let me now turn it over to John Weiland for a review of our product line revenue."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant-currency basis, unless noted otherwise. So we'll begin with Vascular. Total net sales were $23",1144,"Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant-currency basis, unless noted otherwise. So we'll begin with Vascular. Total net sales were $239.5 million, up 3% over last year on a reported basis and up 5% on a constant-currency basis. U.S. Vascular sales were up 3% in the first quarter and international sales were up 10%. Excluding the Gore royalty, EP sales to Boston Scientific and the temporary reduction in Japan sales due to the acquisition, global Vascular sales grew 12%.
Sales in our surgical graft category grew 3% this quarter, within a range of recent experience. Our Endovascular business was up 9% in the first quarter. Within Endovascular, our biopsy products were well above trend at 16% growth in Q1 with strong growth in the United States and emerging markets. There was good momentum in this business, but the strong 2015 we had provided some tougher comps in the coming quarters.
Our peripheral PTA line increased 19% in the first quarter with our Lutonix DCB growing significantly. We are pleased with how our teams have executed here, and we expect that the expanding real-world data around effectiveness and safety will continue to support the selection of the Lutonix drug-coated balloon as the first line of therapy for peripheral artery disease. I'll remind you that in the first quarter of 2015 was a relatively easy comp due to the significant initial stocking in the fourth quarter of 2014, and the upcoming quarters have some more difficult comps as we saw stocking for Boston Scientific in the second quarter and third quarter of 2015 related to our distribution agreement with them.
Our Stent business declined 1% in the first quarter compared to the prior year, impacted by the acquisition in Japan. And our vena cava filter line grew 3% in the quarter.
Now let's move to Urology. Total net sales were $216.7 million, up 5% versus the first quarter of last year on a reported basis and up 7% on a constant-currency basis. Excluding the impact from Japan and the acquisition of Liberator Medical, global Urology sales were still up 5%, with the United States also up 5% and international up 3%. 
We saw healthy double-digit growth in our Targeted Temperature Management products again this quarter. Our basic drainage business was up 5% in Q1. In this category, we benefited from the new sales from Liberator, but had declines related to the inventory in Japan. If you exclude both of those, the business was still up 5% globally and up 6% in the United States, with our I.C. Foleys business up 4% globally and also up 4% in the United States. 
Looking at the last several quarters, we would characterize the results here as stable, but not necessarily accelerating on a macro level. We do see specific growth driven by a few new products of ours, both in the hospital and in the home.
Our continence business was up 22% in Q1, but would have been flat excluding Liberator and Japan. I'll remind you that the Liberator platform added Ostomy products to our venue -- to our revenue and those are recorded in continence. 
Sales in urological specialties were up 8% in Q1 with our brachytherapy business also up 8%. As we said last quarter, we did not keep significant stocking inventory in Japan on the brachytherapy products. So we began recognizing customer level pricing in Q4 when we closed the acquisition. And finally, stand-alone sales of our StatLock catheter stabilization line decreased 5% in Q1.
Next up is Oncology. Total net sales in this category were $241.9 million, an increase of 8% over Q1 last year on a reported basis and up 10% on a constant-currency basis. We worked with the Japanese inventory a little quicker in this business and began to benefit from end customer sales in Japan in the first quarter. Excluding Japan, global Oncology sales were up 8%, with the United States up 6% and international sales up 15%.
Our port business rebounded from the temporary issues we told you about last quarter and grew 8% over Q1 of last year. Our PICC revenue was up 9% globally. As our largest single product line, we continue to expect PICCs to be a meaningful source of growth for us, especially in international markets where PICC penetration is in its very early days.
And to close out the category, our vascular access ultrasound product line grew 15% this quarter as we launched our new Site-Rite 8 platform. And our dialysis catheter product line was up 12%.
Now let's finish with Surgical Specialties. Total net sales in this category were $151.4 million, up 11% on a reported basis and up 13% on a constant-currency basis. The impact to this business from the Japan acquisition was minimal. Excluding Japan, the global sales growth was still 13%, with United States sales of 12% and international sales of 14% in the quarter.
Our performance irrigation business declined 6% in Q1 as we anniversary-ed the discontinuation of certain products in this category. Our soft tissue repair business grew 13% this quarter, which is the strongest growth we've seen for this category since Q3 of 2010.
As we've seen over the last few years, the growth in synthetic hernia and biologic hernia are inversely related as procedures move from one to the other. This quarter saw a significant reduction in overall natural tissue hernia, which declined 19% despite very good growth in our Xen AB platform. However, our synthetic hernia business grew 19%, which is the strongest growth we've seen in this product line since the first quarter of 2004, 12 years ago. While this business is mostly in the United stage -- States, which is benefiting from our new Phasix material, our emerging markets are growing nicely with our legacy portfolio.
Because our mix in soft tissue is more than 5:1, in favor of synthetics, as positions move from biologics to synthetics or hybrids, we typically do well in that exchange as demonstrated this quarter by the strong performance in total soft tissue repair.
Our hernia fixation line grew 37% this quarter as our new products are having an impact as anticipated. As we told you, we have the broadest portfolio in hernia repair across all types of products, from wide range of synthetics to hybrids, to natural tissue and now antibiotic-coated natural tissue. We are working with physicians to identify the right product for the right patient and provide a wide range of options for them.
Finally, our BioSurgery business grew in the healthy double digits again this quarter, and we believe continues to be a significant long-term growth opportunity for us.
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks for joining us, and good evening, everyone. With the Analyst Day in about a month, I'm just going to hit some of the highlights today, starting with our drug-coated balloon pipeline where we've launched our new 7-millimeter diameter products. And i",845,"Thanks for joining us, and good evening, everyone. With the Analyst Day in about a month, I'm just going to hit some of the highlights today, starting with our drug-coated balloon pipeline where we've launched our new 7-millimeter diameter products. And in early April, we also launched our full line of 5 per inch compatible DCBs. So now every balloon size for the SFA indication is available in a 5 per inch compatible configuration giving us a competitive advantage. After our submission last quarter of our long lesion supplement, we're hopeful for a late second half launch for the treatment of lesions up to 300 millimeters in length. In our Below the Knee IDE, enrollment is beginning to accelerate after FDA approved the expansion of our inclusion criteria in mid-Q1.
At projected recruitment rates, we continue to anticipate enrollment through 2016, putting PMA submission likely in the first half of 2018.
Moving to the AV access DCB IDE study. We completed enrollment in Q1 and are now in the 6-month follow-up window. Though these things are a little hard to predict precisely, we believe we should have results sometime in Q4, and we anticipate PMA submission in Q1 of 2017, ahead of our previous schedule. Assuming normal review timing, we expect a second half 2017 U.S. launch. We're also anticipating the submission of our in-stent restenosis PMA supplement in the next couple of months.
Around the world, we're working to expand access to this important technology. For example, are shown in submission for the SFA indication occurred at the end of Q1, seeking approval in Japan. And we began enrollment in our China study a few weeks ago.
Also in Vascular, the LifeStream Balloon Expandable Covered Stent trial was fully enrolled in Q3 of 2015. The primary efficacy analysis will be performed with a 9-month follow-up in the treatment of iliac artery disease. Our current projected time line continues to support submission of our final PMA module before year-end.
Our COVERA next-generation stent graph IDE is under review at FDA, and we anticipate commencing enrollment upon approval. COVERA's design for use in the AV access circuit. Also in the stents, our Venovo venous stent is doing well in Europe, and we commenced enrollment in our U.S. IDE just a couple of weeks ago. We anticipate enrollment through 2016 with follow-up through 2017 and PMA submission in 2018.
Our biopsy business launched 8 new products, including EnCor Enspire, EnCor Ultra and the Mission semi-automatic biopsy family this quarter in Asia while launching 18 new products in Latin America and the Middle East.
Next, moving to Urology and home care. We exited Q1 with launches in all 4 of our franchises. First, for the home care market, we launched our new Magic3 TOUCHLESS intermittent self-catheterization platform. We also launched our new proxy sheath family for flexible ureteroscopy in our endourology family. And we launched our new fully daily care kit designed to help health care workers adhere to best practices in daily full catheter care and maintenance in our basic drainage segment. In Targeted Temperature Management, we launched some new adult pad sizes to support temperature control over a broader range of patient sizes.
Moving to Oncology. We're still working with FDA seeking clearance for the launch anticipated later this quarter of our new family of chemical-resistant catheters. We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis, or DVT, and remain on plan to begin launching in the back half of the year. 
For the difficult stick IV catheter patients, we began to launch of our AccuCath wire-guided assisted products earlier this month with additional sizes to launch over the next couple of quarters. These new products are complementary to our new midline catheter, the PowerGlide Pro, slated for launch upon FDA clearance.
Lastly, in Q1, we launched our new dual-lumen Power Xenosys [ph] catheter designed for superior flexibility, kink resistance and flow rates in excess of 400 ml per minute in a small 11 French catheter configuration.
I'll close my portion of the discussion today with surgery. Just a few days ago, we received PMA approval for our new TRIDYNE aortic sealant, and we're preparing to launch this new product around the end of this quarter. We're also working toward the launch of a new Progel sealant configuration designed to improve visibility during minimally invasive and robotic surgery. And expect PMA submission this quarter with approval and launch around the end of year. We're also expanding our portfolio with Phasix resorbable mesh with additional sizes anticipated to launch in the back half of the year.
And finally, in mesh fixation, we anticipate expanding on our recent permanent and resorbable product launches, with 2 additional resorbable fixation devices slated for later this year.
Now before I hand you over to Chris, I'd like to remind all of you to join us at our Analyst Day on Monday, May 23, at the New York Palace hotel at 4:30 p.m. I look forward to seeing you there. And now here's Chris."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We had acquisition-related items of $4.5 million pretax, a $9.8 million pretax charge for restructuring and productivity initiatives, and",1048,"Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We had acquisition-related items of $4.5 million pretax, a $9.8 million pretax charge for restructuring and productivity initiatives, and we booked expense of $48.9 million for product liability matters, which principally is related to litigation on IVC filters. The P&L impact of these items is detailed in the notes to the financial statements and in the reconciliation accompanying our Q1 earnings press release.
Now let's go through the statement of income for the quarter, and I'll remind you that our adjusted numbers now exclude the amortization of intangibles from the entire P&L, and the references to prior year are on that same basis. Gross profit was $553.1 million or 63.3% of sales for Q1. On an adjusted basis, GP was $581.2 million or 66.5% of sales. That's up 210 basis points from the prior year quarter and better than we expected. FX cost us about 20 basis points in GP for the quarter. Price pressure drove 40 basis points on the revenue line in Q1 and 20 basis points of headwind on GPs, which was significantly better than our expectations and the best result we've seen since 2010. We still expect price to be more of a headwind going forward, but we're certainly happy with the Q1 results. Our cost improvements and other items drove 90 basis points of benefit to GPs this quarter and mix was favorable by 160 basis points, which includes the gross profit benefit from acquiring our Japanese JV. As we look to Q2, we expect gross margin to be over 100 basis points better than Q2 of 2015. And for the full year, we're comfortable with our guidance for gross profit improvement.
SG&A expenses were $270.6 million for the quarter or 31% of sales. On an adjusted basis, SG&A was $266.5 million or 30.5% of sales, an increase of 180 basis points over last year. This is reflective of the timing of the 2 recent acquisitions, and we expect Q2 will also be higher than prior year as well. We still expect the full year to be about the same as 2015 as a percentage of sales as we integrate the acquisitions and leverage our infrastructure on higher sales throughout the year.
R&D expenditures totaled $68.3 million for the first quarter or 7.8% of sales on a reported basis. On an adjusted basis, R&D was $66.8 million or 7.6% of sales, up 20 basis points from Q1 of last year and consistent with our guidance. Interest expense was $11.3 million for the quarter. Other income and expense was $60 million of expense for the first quarter as reported and $1.9 million of income on an adjusted basis. The effective tax rate for the quarter was 18.7% on a reported basis and 25.8% on an adjusted basis, right in the middle of our full year guidance.
Diluted shares for the period were 75.2 million, and we purchased 897,000 shares in the first quarter at an average price of $186.57. The net result is adjusted EPS of $2.34, which was well above our expectations for the quarter. This overachievement was driven by the strong sales fee and a slight easing of FX headwinds. The balance sheet, as of March 31, reflects cash, restricted cash and short-term investments of approximately $1 billion, essentially no change from December 31. For the quarter, accounts receivable days were up 1.2 days and inventory days were up 6.3 days. Both of these increases are related to the recent acquisitions. Capital expenditures totaled $20.5 million for the quarter.
On the liability side, total debt was $1.7 billion as of March 31 compared to $1.4 billion at the end of December. Debt to total cap at the end of the first quarter was about 53%, and total shareholder investment was $1.5 billion at March 31.
Turning now to guidance. In Q2, we're expecting constant currency sales growth between 6.5% and 8%, with reported sales growth between 5.5% and 7%, inferring an FX headwind of approximately 1% on the revenue line. This assumes organic growth between 5.5% and 6% for the second quarter. From an adjusted EPS standpoint, excluding items affecting comparability and the amortization of intangibles, we see the second quarter in the range of $2.43 to $2.47.
Given such a strong operational start to 2016, along with an easing of FX headwinds, we're comfortable raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 7% and 8.5%, with reported sales growth between 6% and 8%, inferring a currency headwind of between 50 and 100 basis points.
On an organic basis, we had originally guided the year to be between 5% and 6%, but are increasing that range meaningfully today to be between 6% and 6.5%. It's not lost on us, and we're sure it's not lost on you that we did meaningfully better than that in Q1. To be clear, we see good momentum in the business and continued strength in our positioning. However, there were several product lines this quarter well above trend. China was exceptionally strong, and I just highlighted price headwind was abnormally low. So before we take the sustainability of some of these factors to the bank, we think it is prudent to get a little deeper into the year.
We're also increasing our full year adjusted EPS guidance range to be between $10.05 and $10.18, which is just about $0.15 above our original guidance range at the midpoint and represents 11% to 12% growth over 2015. At current rates, we expect foreign exchange to be approximately $0.20 of headwind for the full year. So on an FX-neutral basis, we are guiding to 13% to 14% growth. Given the strength of our operating performance, the success of our investment program and the demonstrated ability of our teams to execute against commitments, we plan to accelerate certain investments and targeted projects and geographies, beginning in Q2 and throughout the remainder of the year. We believe this disciplined investment approach will help provide sustainable, profitable growth and value for our shareholders for years to come. 
And with that, I'll turn you back to Tim."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] With that, Kathy?",30,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] With that, Kathy?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question will come from Bob Hopkins with the Bank of America.",16,"[Operator Instructions] And our first question will come from Bob Hopkins with the Bank of America."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","So 2 things, Tim, for you. Before I ask a Bard specific question, one of the other things that isn't lost on all of us on this call is really the whole medtech space is reporting very strong Q1 organic growth numbers from cardio to ortho to general surger",74,"So 2 things, Tim, for you. Before I ask a Bard specific question, one of the other things that isn't lost on all of us on this call is really the whole medtech space is reporting very strong Q1 organic growth numbers from cardio to ortho to general surgery. So I just wanted to get your take on kind of what you're seeing out there in terms of surgical procedure volumes and trends generally."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I mean, I think there is no denying that the observation you made, it does seem like everyone is doing a little bit better. I still think there's a lot of things that we're still trying to understand and navigate as health care and changes and what t",130,"Yes. I mean, I think there is no denying that the observation you made, it does seem like everyone is doing a little bit better. I still think there's a lot of things that we're still trying to understand and navigate as health care and changes and what that means. The only thing I could point to, Bob, that has been constant, and that is that as unemployment rates over time -- over a very long period of time historically have improved, health care spending has for like 4 years increased along with that. So it feels like things have been a little bit better. But again, because it is a different kind of environment with all the different dynamics, it's still a little bit tough to predict, I think."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just to follow up maybe on that same question. So 2 quick things. One, just sort of a standard question. We're selling these even for you guys this quarter. And then more specifically, Bard had a particularly strong quarter with 9% organic growth",101,"And then just to follow up maybe on that same question. So 2 quick things. One, just sort of a standard question. We're selling these even for you guys this quarter. And then more specifically, Bard had a particularly strong quarter with 9% organic growth. That's a nice acceleration from what we've seen. So can you just talk from a Bard perspective, like what drove the incremental growth? Maybe it seems like emerging markets or maybe even above the 20% level that you've been seeing. Just talk about what got better this quarter and if the selling days are even out?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We were strong literally across the board. We did have some easier comps in certain sectors, which Chris can get into more details, Bob. But in general, the investment plans working the execution is that teams have done a great job around the world,",88,"Yes. We were strong literally across the board. We did have some easier comps in certain sectors, which Chris can get into more details, Bob. But in general, the investment plans working the execution is that teams have done a great job around the world, executing very well. We had some new products that hit their stride pretty quickly. Lutonix continues to do well. Surgery, as John noted, the highest it's been synthetics in over a decade. So it's really across the board. It's not any one thing."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'd just add, Bob. I think just a couple of things we tried to highlight that really sort of surprised us as we came to the quarter. Again, price was better than we expected and well below trend. Biopsy, as John highlighted, had a really strong quarter an",180,"I'd just add, Bob. I think just a couple of things we tried to highlight that really sort of surprised us as we came to the quarter. Again, price was better than we expected and well below trend. Biopsy, as John highlighted, had a really strong quarter and probably the easiest comp of the year for us, but terrific momentum there. And Lutonix had its easiest comp of the year as well. And soft tissue, as John highlighted, was just clearly above trend and with the exceptional strength in synthetics. And China had an exceptional quarter, above trend. So it was really a situation where everybody performed as we expected, and then we've got I'll call it at this point, several really nice surprises. And then from a selling day standpoint, it's hard to measure exactly, but there probably was some benefit, Bob. But again, it's -- it was a tailwind, but it's hard to be too specific. And we generally don't call it out when it goes the other way either, but it probably helped a little bit."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Roman with Goldman Sachs.",10,"Our next question is from David Roman with Goldman Sachs."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","I want to see if you could follow up a little bit on Japan and give us a little bit more detail about how we should think about that region unfolding as you move to a full direct model. And maybe give us some specifics on where you see the biggest opportu",71,"I want to see if you could follow up a little bit on Japan and give us a little bit more detail about how we should think about that region unfolding as you move to a full direct model. And maybe give us some specifics on where you see the biggest opportunities, and how we should think about that contributing to growth, both throughout 2016 and as we think longer term."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, David, first of all, we're off to a good start, frankly. I mean, the integrations gone very well so far. And obviously, we're dealing with the inventory sell-through, but the business actually did a bit better than we had expected anyway. I",170,"Yes, I think, David, first of all, we're off to a good start, frankly. I mean, the integrations gone very well so far. And obviously, we're dealing with the inventory sell-through, but the business actually did a bit better than we had expected anyway. I think we're realigning the sales force a bit and getting them focused in areas where we, to your point, really see more opportunity. And I would certainly be both within surgery. We talked about upticks in general being extremely underpenetrated in Japan. We think that's a really exciting growth area for us. And probably most prominently within Vascular, we've got LifeStent and Lutonix approvals coming down the pipeline here in fairly short order and having controlled that direct sales force ourselves, getting them aligned the right way and getting them motivated and ready for those launches, again, relative to the old ownership structure. We just feel we're in a position to maximize that opportunity in a way we just wouldn't have been able to otherwise."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","The only other thing I would add if you were to look at, at a macro level the product mix within the global portfolio by Urology, Oncology, Surgical and Vascular were fairly evenly balanced, at least amongst the top 3, with surgical lagging a little bit b",126,"The only other thing I would add if you were to look at, at a macro level the product mix within the global portfolio by Urology, Oncology, Surgical and Vascular were fairly evenly balanced, at least amongst the top 3, with surgical lagging a little bit behind. That is not the way our Japan business looks today. We're very heavily dominated in Urology. Clearly, the faster-growing segments are the other 3, and that's where we have the smallest amount of revenue coming from in Japan. So it's our expectation that, that will get realigned with this structural change as well as our investments moving forward. And we would expect that product mix to shift and look more like over time what it'd look like everywhere else."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And then maybe just on the spending side. It looks like you took the opportunity to reinvest in SG&A this quarter, given some of the strengths in the top line. But it looks like that -- you said at the beginning of the year, CapEx is runni",103,"That's helpful. And then maybe just on the spending side. It looks like you took the opportunity to reinvest in SG&A this quarter, given some of the strengths in the top line. But it looks like that -- you said at the beginning of the year, CapEx is running a little bit lower. So how should we think about the balance of cash spending through the rest of the year as well as how the P&L discretionary line item should compare to your original guidance. I know you gave SG&A, but maybe just an update on R&D and CapEx would be helpful."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","All right. We guided to $120 million of CapEx spend for the full year. I think we'll probably still get close to that number. I don't expect it to be materially different either way. And as we highlighted at the end of the comments, we are in the face of",141,"All right. We guided to $120 million of CapEx spend for the full year. I think we'll probably still get close to that number. I don't expect it to be materially different either way. And as we highlighted at the end of the comments, we are in the face of the strength, really, going to accelerate spending on some -- several additional R&D projects, several additional sales force expansion projects, several additional clinical trials. And also, we're adding additional resources within our health economics infrastructure across the company as well. So it'll be spread between SG&A and R&D. We'll still be in line with our full year guidance as a percentage of sales, but we're going to take advantage of the strength again to really accelerate some investments that we think will be helpful as we move into '17 and beyond."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go next to Mike Weinstein with JPMorgan.",9,"We'll go next to Mike Weinstein with JPMorgan."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just following up on that, Chris. If you guys at the analyst meeting can talk a little bit more about where you're putting those extra dollars and that would probably be helpful to everybody.",34,"Just following up on that, Chris. If you guys at the analyst meeting can talk a little bit more about where you're putting those extra dollars and that would probably be helpful to everybody."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Mike.",2,"Sure, Mike."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","So let me circle back to, really, Bob's first question, which is you look at some of these businesses, the ones that are above trend. And I just want to understand, you gave numbers on a bunch that were obviously very strong, things like urological specia",122,"So let me circle back to, really, Bob's first question, which is you look at some of these businesses, the ones that are above trend. And I just want to understand, you gave numbers on a bunch that were obviously very strong, things like urological specialties up 8%; brachytherapy up 8%; the synthetic hernia repair business, which running with 8%, 9% last year was up 19% this quarter. All those businesses that had real above trends, was that explain it U.S. versus OUS. Was that U.S. that was significantly above trend? Was it U.S. and then China? Can you just maybe geographically help us there? Because a lot of what we're seeing is U.S. outperformance in a number of different end markets."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I think U.S. was strong, Mike, in really all of those, so it's -- we had 9% growth in the U.S. and 8% organic growth in U.S. So it was all the categories we highlighted were strong. China is going great guns for us, and so biopsy in China, the hernia busi",168,"I think U.S. was strong, Mike, in really all of those, so it's -- we had 9% growth in the U.S. and 8% organic growth in U.S. So it was all the categories we highlighted were strong. China is going great guns for us, and so biopsy in China, the hernia business in China, the PICC franchise in China. And as we talked about last year, I think it's an example of where we accelerated some investments, we started to build the direct sales force in BioSurgery in China last year, and this quarter is the first quarter where we're really seeing the fruits of those efforts in China. The brachy business performed again in Japan better because there was really no inventory in Japan. And so we're getting direct-to-customer pricing there in the quarter. So it's really across the board, and the U.S. was certainly stronger. But again, where we had made investments is where we've also seen some acceleration in some of these other geographies."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And tell me how you thought about just the guidance upgrade for the balance of the year. Is just the organic revenue growth of 5.5% to 6% for the second quarter and it kind of -- that's what you're basically implying for the second half. You're basically",98,"And tell me how you thought about just the guidance upgrade for the balance of the year. Is just the organic revenue growth of 5.5% to 6% for the second quarter and it kind of -- that's what you're basically implying for the second half. You're basically assuming that you go back to your prior trendline expectations and just -- for now assuming that what we saw incremental in the first quarter was a 1-quarter event, and therefore, the upside is that if it's not just a 1-quarter event, then we're going to get the benefit of that?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think there's a bad way to think about it. I mean, that's really how we saw the year coming in was 5% to 6%. I think we called out a couple of areas that were above trend and a couple of areas that were easy comps that obviously, we're not countin",162,"I don't think there's a bad way to think about it. I mean, that's really how we saw the year coming in was 5% to 6%. I think we called out a couple of areas that were above trend and a couple of areas that were easy comps that obviously, we're not counting on the rest of the year. And again, pricing was a positive surprise for us as well. So we feel great about 6% to 6.5% for the full year. And as we said, we're not going to get too far ahead of ourselves. We'll see how Q2 goes and then we'll take it from there. But I think great start to the year. We think appropriate guidance for the rest of the year. And as I think you've seen from us in the past, we'll try as we move through the year, try to make the right decisions, both from an investment standpoint and from a guidance standpoint."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And Chris, just one clarification and let some others jump in. On Japan, so you're going to go from a headwind because on the top line, because of the JV to buy into a tailwind. Can you just help us with the math on what that might mean to the top line ov",57,"And Chris, just one clarification and let some others jump in. On Japan, so you're going to go from a headwind because on the top line, because of the JV to buy into a tailwind. Can you just help us with the math on what that might mean to the top line over the next few quarters?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. And so we'll have this sort of interesting phenomena where reported and constant currency growth will accelerate through the back part of the year, largely because of the impact of Japan. But we're pulling it entirely out of organic. So we're not ben",113,"Yes. And so we'll have this sort of interesting phenomena where reported and constant currency growth will accelerate through the back part of the year, largely because of the impact of Japan. But we're pulling it entirely out of organic. So we're not benefiting at all over the course of the year when we're talking about organic growth from Japan. So we guided for Q2. Q3 will be somewhat higher than that and Q4 will be somewhat higher than that from a reported and constant-currency basis. But again, organic should be relatively consistent over the course of the next 3 quarters. It's how we're seeing the business as we sit here right now."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question now from David Lewis with Morgan Stanley.",11,"We have a question now from David Lewis with Morgan Stanley."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim, just sticking with this idea of trying to understand kind of the macro versus the micro drivers of the business. If I take the 4 segments of Bard, it looks like the margins surgical and Oncology, you did better than Vascular and neurology kind of on",107,"Tim, just sticking with this idea of trying to understand kind of the macro versus the micro drivers of the business. If I take the 4 segments of Bard, it looks like the margins surgical and Oncology, you did better than Vascular and neurology kind of on a relative basis. If you sort of think about house utilization activity or sort of U.S. mix or their product pipelines in these businesses, the surgical and Oncology versus Vascular, Urology makes sense, either relative to the products in the businesses or makes sense relative to the U.S. focus or things you've seen in the past on utilization or acuity."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'm not sure there's a common thread where you can weave them altogether. There's different things driving each of the different businesses. Surgical, obviously, there's been a lot of investment made in that business over the last few years and a lot of n",254,"I'm not sure there's a common thread where you can weave them altogether. There's different things driving each of the different businesses. Surgical, obviously, there's been a lot of investment made in that business over the last few years and a lot of new products are coming out, as John cited out in his review. So that's doing well. That's also one of the key investment areas in emerging markets. So you've got those 2 things there. They're clearly, Oncology, there's always new products kind of flowing through there, but that's one of the biggest drivers in emerging markets, especially in China. So again, you've got kind of both themes there as well. Vascular continues to do well. The PTA line, Lutonix in the U.S. continues to do well. And Urology, even across the board, clearly, TTM continues to do well. The acquisitions that we've made continue to perform well. And the uptake in the U.S. seems to have become more steady. When you talk to hospital CEOs, I'm hearing more of them talk about some of their issues being things like nursing turnover, again being a big issue. We really haven't heard that, at least I haven't from a lot of hospital CEOs for several years now. So that's an indication perhaps that volumes are coming back or other opportunities for nurses outside of hospitals one or and above of those things. So just generally those are the themes that would kind of go through each of those areas you've called out."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's been very helpful. And I guess, the second kind of Bard these last couple of years has been you're going to invest to drive that organic growth and you talked a lot about the 6 and 10 models; 6% organic top and 10% on the bottom. I'm not getting to",111,"That's been very helpful. And I guess, the second kind of Bard these last couple of years has been you're going to invest to drive that organic growth and you talked a lot about the 6 and 10 models; 6% organic top and 10% on the bottom. I'm not getting too excited over here. But with a 12% earnings growth, but I think it bears asking you if you start getting above 6%, 7% organic growth as you did this quarter, does it start to become any diminishing return where investors can expect better than 10% earnings if that organic growth is going to be in excess of 7% organic."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I think just to be clear, I think what you might be referencing is our historical spreads between our revenue and our earnings growth. Having said that, and as Chris pointed out, we also -- we don't run this business quarter-to-quarter. We run it over the",133,"I think just to be clear, I think what you might be referencing is our historical spreads between our revenue and our earnings growth. Having said that, and as Chris pointed out, we also -- we don't run this business quarter-to-quarter. We run it over the long term. Company was founded in 1907. So none of us here are doing this on a quarter-to-quarter basis. We're constantly looking to have a very well-tuned process about how we'll turn on investments over time, and we've always done that. When we do a little bit better, we're able to turn on more. But it's not like we have to go out and collect ideas. We've got a pipeline of things that we can invest in. It's just a question when we start turning those on."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, David, is as we talked about pretty consistently, we do believe the model, and especially the product mix where we're getting growth from does and should allow us to generate 50 to 100 basis points of operating margin improvement a",153,"The only thing I'd add, David, is as we talked about pretty consistently, we do believe the model, and especially the product mix where we're getting growth from does and should allow us to generate 50 to 100 basis points of operating margin improvement annually. And so as we grow the top line consistently in the mid-single digits, and obviously, utilize the free cash flow that we have on top of that, you do get to that kind of math. We have a year like this year, where we're obviously looking at performing a little bit better than that. You're seeing good earnings growth on top of that as well. So it's -- the importance is the health of the model and continuing to keep it healthy. And we think, again, letting too much drop-through when we're leaving good investments on the table is not the right approach from a long-term standpoint."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","And next, we have Larry Keusch with Raymond James.",9,"And next, we have Larry Keusch with Raymond James."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, maybe just to start the GM, I think on the adjusted basis you did 66.5%. I think the guidance is 66% for the year. So can you just help us, again, just think through with that starting point why there won't be potentially some upside particularly a",57,"Chris, maybe just to start the GM, I think on the adjusted basis you did 66.5%. I think the guidance is 66% for the year. So can you just help us, again, just think through with that starting point why there won't be potentially some upside particularly as you start to recognize some of the Japan benefits?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And some of the Japan -- from a gross margins standpoint, Larry, some of the Japan benefits are -- were impacting mix in Q1. So as the sales that would already previously made into the joint venture then gets sold out the door to the customer, that increm",183,"And some of the Japan -- from a gross margins standpoint, Larry, some of the Japan benefits are -- were impacting mix in Q1. So as the sales that would already previously made into the joint venture then gets sold out the door to the customer, that incremental pricing right is gross margin. We're obviously no longer booking sales as we fill the pipe into the JV. So mix, as we expected for the full year from the JV, would be a positive contributor. It's actually more prominent in Q1 because there's fewer sales that we're booking into the JV. So I think the way to think about gross margin over the full year is actually -- we'll probably be pretty consistent quarter-to-quarter here on out as that -- as we see the normalization of Japan over time. And again, we're not expecting to see the kind of pricing environment we necessarily saw in Q1 for the full year. So I expect to see a fairly consistent gross margin trajectory over the course of the year as we're looking at it right now."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then I'll just sneak 2 other quick ones in here. Just on -- staying on the topic of Japan. You had indicated that you had expected dilution about $0.20 with $0.10 occurring in the first quarter, again, just given some of the changes in the FX ra",134,"Okay. And then I'll just sneak 2 other quick ones in here. Just on -- staying on the topic of Japan. You had indicated that you had expected dilution about $0.20 with $0.10 occurring in the first quarter, again, just given some of the changes in the FX rates. I want to just check back in on that. And then specifically on price, again, I hear you loud and clear that this is below kind of the levels that we've been seeing as of late. But was there anything specific in the quarter that allows you to get the better pricing or perhaps in another way, is there another thing to think about it as we move through the year that would influence pricing negatively? Or are you just trying to stay conservative there?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This is John. Let me deal with the price issue first. No, there was no special onetime item that impacted us positively from a price standpoint. We had a pretty good performance across all of our businesses as well as our geographies. And we had annualize",77,"This is John. Let me deal with the price issue first. No, there was no special onetime item that impacted us positively from a price standpoint. We had a pretty good performance across all of our businesses as well as our geographies. And we had annualized a few of the headwinds that we had early last year. We talked about which was on port pricing that had an impact as well. I'll turn you back to Chris."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","On the currency front, Larry, just in general, currency was about $0.02 better than we had expected in the quarter. Probably a little more than half of that was related to the yen. So we were sort of $0.01 better as we thought about Japan. $0.01 or $0.02",161,"On the currency front, Larry, just in general, currency was about $0.02 better than we had expected in the quarter. Probably a little more than half of that was related to the yen. So we were sort of $0.01 better as we thought about Japan. $0.01 or $0.02 better as we talk about Japan coming into the year. And again, for the full year, we expect about $0.20 of headwind, at least as we sit here today, given where the yen is and the euro and the rest of the basket, which again is about $0.10 better on a full year basis than we had anticipated. But obviously, as we all know, currencies can move the other way pretty quickly as well. So there'll be less dilution in Japan as the yen stays where it's at. And again we're really focused on executing the integration. And if we execute well, hopefully, we'll do a little bit better from an operational standpoint."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Amit Hazan with Citi.",9,"Our next question is from Amit Hazan with Citi."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe I'll ask the first question on drug-coated balloon and Lutonix. You started out I think last quarter, you talked about end customer usage. You were pretty positive on that, more than doubling versus the prior year. It sounds like you were pretty pos",64,"Maybe I'll ask the first question on drug-coated balloon and Lutonix. You started out I think last quarter, you talked about end customer usage. You were pretty positive on that, more than doubling versus the prior year. It sounds like you were pretty positive again this quarter. Can you give some color on whether that was kind of a sustainable type of growth?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me deal with the DCB perspective. I think that we feel very good about where we were with DCBs in Q1. We saw great execution from the sale side of things. We like our pipeline right now as we look downstream. John talked about all the new launches. We",116,"Let me deal with the DCB perspective. I think that we feel very good about where we were with DCBs in Q1. We saw great execution from the sale side of things. We like our pipeline right now as we look downstream. John talked about all the new launches. We'll talk about and that we have upcoming. We'll talk about more of that again in May when we get together from a pipeline standpoint. But I think if you combine what we're seeing happening in the field from a sales force execution standpoint, combined with what we consider to be robust new indications and product extensions of platforms, we feel great where we are right now."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And maybe this is front running [indiscernible] a little bit, but I'll throw it out there anyway just a little bit of a mid- long-term question about surgery. You had a slide in some of your recent presentation that struck me a little bit it",123,"Fair enough. And maybe this is front running [indiscernible] a little bit, but I'll throw it out there anyway just a little bit of a mid- long-term question about surgery. You had a slide in some of your recent presentation that struck me a little bit it was addressing your kind of long-term market opportunities and actually the biggest category you guys cited -- surgery you cited as $1 billion opportunity going to $3 billion in 2020. So I wanted just maybe get a little bit of your color on what's behind that and what you see in your current pipeline or market product that helps you play in what you're essentially seeing as tripling of that market in the next 5 years."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. John DeFord here. Just a couple of things. First off, right now, we have a fairly limited product offering. So we've got a long sealant, and we've got a couple of hemostasis technologies. So we -- based on those initial platforms, we anticipate expa",151,"Sure. John DeFord here. Just a couple of things. First off, right now, we have a fairly limited product offering. So we've got a long sealant, and we've got a couple of hemostasis technologies. So we -- based on those initial platforms, we anticipate expanding. So today, I talked to you about a new technology that we developed internally, the TRIDYNE aortic sealant. We just received PMA approval after a very successful clinical study. We intend to launch that. That's getting us into a brand-new space with bigger opportunity. Like that, we have in our pipeline a number of other technologies and next-generations that we think are going to expand the area that we play in. So there's a pretty broad market right now for BioSurgery, but we're in a very small sliver of that. And over the next several years, we see us getting into some of the larger pieces."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And, Amit, we're looking to do that both internally and externally, and we're looking all the time for additional technologies to add into the fold. I think what's important to understand is we now have a great direct selling force in the U.S. and as I me",90,"And, Amit, we're looking to do that both internally and externally, and we're looking all the time for additional technologies to add into the fold. I think what's important to understand is we now have a great direct selling force in the U.S. and as I mentioned, in China and we're pursuing other geographies. So part of its just maximizing the opportunity with the existing products, but you should very much expect us to continue to broaden the product portfolio, both through internal and external activities over the coming years."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Kristen Stewart with Deutsche Bank.",11,"And we'll go next to Kristen Stewart with Deutsche Bank."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","I was just wondering if you could give us the components to get to your organic numbers, the Gore and I think you've mentioned, also, something with Boston Scientific and then I guess, the total adjustment for the joint venture.",40,"I was just wondering if you could give us the components to get to your organic numbers, the Gore and I think you've mentioned, also, something with Boston Scientific and then I guess, the total adjustment for the joint venture."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Kristen, there's actually a slide in the deck that we posted to the website, which provides the combination of those items. So you can see Vascular was negatively impacted by 7 points, and that's both the Gore royalty, the decline in the EP sales to Bosto",133,"Kristen, there's actually a slide in the deck that we posted to the website, which provides the combination of those items. So you can see Vascular was negatively impacted by 7 points, and that's both the Gore royalty, the decline in the EP sales to Boston Scientific and the impact of the Japanese [ph] JV. So Vascular grew 12% organic, adjusting for those items. Urology, we're taking Liberator out, and it was the big impact in Japan, which sort of offset each other to a large degree and Urology grew 5% organic. Oncology grew 8% organic, which is the adjustment associated with Japan. And then surgical, there was a very minor impact there, so both constant currency and organic in surgery were 13%. So that's the level of granularity we're providing for you."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then Gore's $38.4 million, I guess, on the slide?",11,"And then Gore's $38.4 million, I guess, on the slide?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Right.",1,"Right."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then with respect to the Analyst Day, I know last or 3 years ago, as you mentioned, you gave the 3-year plan and clearly, congratulations. You've gotten there. Will you be providing another kind of outlook, I guess, for the next 3 or kind of any",57,"Okay. And then with respect to the Analyst Day, I know last or 3 years ago, as you mentioned, you gave the 3-year plan and clearly, congratulations. You've gotten there. Will you be providing another kind of outlook, I guess, for the next 3 or kind of anything with longer-term goals with the analyst meeting is that..."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This will be kind of an update overview of the investments to the question that was asked earlier that we're making now, a little bit more detail on portfolio review, some of our geographic plans, that kind of thing. But we will not be providing any addit",52,"This will be kind of an update overview of the investments to the question that was asked earlier that we're making now, a little bit more detail on portfolio review, some of our geographic plans, that kind of thing. But we will not be providing any additional guidance at that meeting."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Will you allow John to make his jokes.",8,"Will you allow John to make his jokes."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","No, John is working already. That's why we had to schedule so far in advance...",15,"No, John is working already. That's why we had to schedule so far in advance..."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","They won't let me, even when I try to sneak it in, they like throw the hook out.",19,"They won't let me, even when I try to sneak it in, they like throw the hook out."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Well, you can make those off line.",7,"Well, you can make those off line."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'll have to.",4,"I'll have to."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We're approaching the top of the hour I'm going to apologize to everybody else in line. We're going to do one more question and then we're going to wrap it up.",32,"We're approaching the top of the hour I'm going to apologize to everybody else in line. We're going to do one more question and then we're going to wrap it up."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","And the final question will come from Dave Turkaly with JMP Securities.",12,"And the final question will come from Dave Turkaly with JMP Securities."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Back to the gross margin, just quickly. I know that mix was 160 basis points. And I think you mentioned cost improvements of 90. Can you just remind us where you are in those cost improvement programs? I know in the past you talked about material input co",82,"Back to the gross margin, just quickly. I know that mix was 160 basis points. And I think you mentioned cost improvements of 90. Can you just remind us where you are in those cost improvement programs? I know in the past you talked about material input cost is an area of focus and potentially as a lever moving ahead. But do you think we'll have improvements like that as we look forward? Where could the gross margin head based on those?"
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This is the improvements that we talk about in the P&L, it's not about one big program. And it's our normal organic way of operating the business, focused primarily on both materials costs and on improvements in our variances to flow out of our manufactur",106,"This is the improvements that we talk about in the P&L, it's not about one big program. And it's our normal organic way of operating the business, focused primarily on both materials costs and on improvements in our variances to flow out of our manufacturing operations and efficiencies. So -- and as you can see, we had one small charge that Chris talked about for efficiencies that will help us in the future. But it's not one big program. This is the normal way we operate year in and year out, and we're focused on constantly improving the -- our cost positions and our profits."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","So David, the only thing I'd add is we guided for the full year cost of 80 to 100 basis points. And really, the team tasked with achieving 50 to 100 basis points year in, year out. And so in a moderate FX environment and a more moderate price environment,",113,"So David, the only thing I'd add is we guided for the full year cost of 80 to 100 basis points. And really, the team tasked with achieving 50 to 100 basis points year in, year out. And so in a moderate FX environment and a more moderate price environment, we feel really good about our -- been able to control our destiny to drive GPs higher. And then obviously mix. Everything we've done from an investment standpoint to shift the portfolio to higher-growth and higher-margin products are both tailwinds to gross margin. Again if we execute those are 2 things we can control. And then FX is obviously something that we can't."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","One really quick-follow up. I know it's just actually to get your thoughts on sort of the biologics in the hernia repair area. Is there a functional problem there? And do you think the synthetic business can remain that strong? I guess, I'd like your thou",53,"One really quick-follow up. I know it's just actually to get your thoughts on sort of the biologics in the hernia repair area. Is there a functional problem there? And do you think the synthetic business can remain that strong? I guess, I'd like your thoughts on what is actually driving that."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think there's any functional problem. I think what's really happening is that as these hybrid technologies get into the market and has a better understanding of what product works best in what patient, you're beginning to see some of the shake out",141,"I don't think there's any functional problem. I think what's really happening is that as these hybrid technologies get into the market and has a better understanding of what product works best in what patient, you're beginning to see some of the shake out here. So I think it's nothing sort of structural, but more greater knowledge, greater science and just a normal shakeout of where -- when is it best to use a biologic, when is it best to use a pure synthetic, when is it best to use some of the hybrid technologies that we now have? And so we're beginning to see some of that shakeout. And I think as that information comes together. We're also doing everything we can to help our customers determine what's the best product for every patient that walks in the door."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And then the key to success there is to have the product in each of the categories for every patient. And we're the only one who has that. So we're clearly taking share given our portfolio right now exactly.",39,"And then the key to success there is to have the product in each of the categories for every patient. And we're the only one who has that. So we're clearly taking share given our portfolio right now exactly."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. Then I'll turn the call back over to Bard's management for closing remarks.",15,"Thank you. Then I'll turn the call back over to Bard's management for closing remarks."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much, Kathy. And I'd like to thank all of you for joining us this afternoon. We will see you, hopefully, at our analyst meeting, and if not, we'll talk to you again at the end of the quarter. I'd also like to think all of Bard's employees a",69,"Thank you very much, Kathy. And I'd like to thank all of you for joining us this afternoon. We will see you, hopefully, at our analyst meeting, and if not, we'll talk to you again at the end of the quarter. I'd also like to think all of Bard's employees around the world for all their hard work and a very strong start for the year. Thanks. Good night."
254131,329843971,965187,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using AT&T Executive TeleConference. You may now disconnect.",27,"Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using AT&T Executive TeleConference. You may now disconnect."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand r",270,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors each in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of April 27, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period.
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. Good afternoon, and welcome to Bard's First Quarter of 2016 Earnings Conference Call. And thanks to all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 30 minutes, and we're going t",910,"Thank you. Good afternoon, and welcome to Bard's First Quarter of 2016 Earnings Conference Call. And thanks to all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 30 minutes, and we're going to try and keep the total call to about an hour. There is a slide deck available on the Investor Relations page of our website intended to help explain some of the moving pieces in our results and guidance.
The discussions today will go as follows: I'll begin with an overview of the results for the quarter; John Weiland, our President and COO, will review first quarter product line revenue; John DeFord, our Senior Vice President of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; lastly, Chris Holland, our Senior VP and CFO, will review the first quarter income statement and balance sheet as well as our expectations for the second quarter and the full year. And then finally, we'll close with Q&A.
First quarter 2016 net sales totaled $873.5 million. That's up 7% over the first quarter last year on an as-reported basis and up 8.5% on a constant-currency basis. Currency impact for the quarter versus the same quarter last year was unfavorable by about 190 basis points. Our organic revenue growth this quarter was 9%, which was significantly better than our guidance of 5.5% to 6%.
Net income for the first quarter was $116.2 million, and diluted earnings per share were $1.54. That's down 17% and 15%, respectively. Excluding amortization and certain items that have affected the comparability of results between periods, which Chris will cover later, first quarter 2016 net income and diluted earnings per share were $177 million and $2.34. That's up 10% and 11%, respectively. This was also significantly above our expectations and represents a pretty good start to the year.
Looking at revenue growth geographically compared to the same quarter last year, first quarter net sales in the U.S. grew 9% compared to a year ago. On a constant-currency basis, in Europe, we were up 5%, Japan was down 16% and our other international businesses were up 20%. As a reminder, the reduction in Japan is due to the workdown of inventory that was recorded as revenue when we sold it to our joint venture prior to the acquisition in the fourth quarter of last year. As we move into the second quarter, that inventory workdown is substantially complete, and we are benefiting from recording revenue at the customer level.
Our emerging market geographies continued their impressive growth in the first quarter, with every major geography, contributing double-digit growth. China was particularly exceptional. Our investments over the last couple of years have strengthened our position in these faster-growing markets. Emerging markets represented 10% of sales in Q1 compared to just 8% a year ago. And that meaningful mix shift is occurring even with high single-digit growth in the U.S. 
Accelerating the revenue growth of the company has been the purpose of our plan for the last several years. As we said many times, we believe investing in faster-growth platforms and geographies accomplishes that objective by shifting the mix of the portfolio. While these aren't metrics we plan to disclose on a regular basis, it may be appropriate as we pass the 3-year anniversary of the announcement of our strategic investment plan, to compare the growth profile of the business then versus now. Q1 2013, when we first announced our plan, our organic growth was essentially flat. At that time, between 35% and 40% of our organic portfolio was declining, and between 10% and 15% of the portfolio was growing double digits.
After 3 years of significant focused investments in these faster-growth areas, that mix has literally been inverted. In Q1 of 2016, only 10% to 15% of our organic portfolio was declining and between 35% and 40% of the portfolio was growing double digits. We remained in investment mode, and we believe we are just in the early stages of seeing the returns on our past investments. Our focus has been and is to build platforms and capabilities that we expect will provide sustainable growth above the sector for years to come. If you followed us for very long, it's not uncommon for us to have a good start to the year, but we don't typically change full year guidance after only 1 quarter. In fact, in my 24 years here, I think we've only done it once. However, given the strong performance in the first quarter and the breadth of the strength, both geographically and from a product perspective, we already expect to exceed the full year guidance we gave you 3 months ago. We're not going to get too far ahead of ourselves because there's a lot of the year left and a lot of work in front of us. Chris will cover the details with you a little bit later. 
Having said that, we're very pleased with the execution of the investment plan, so far. We're moving on multiple fronts across product platforms and geographies. We are growing faster than our peers, and we expect that to continue. We like the position we're in and we intend to continue to invest to maintain that position.
So with that as an introduction, let me now turn it over to John Weiland for a review of our product line revenue."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant-currency basis, unless noted otherwise. So we'll begin with Vascular. Total net sales were $23",1144,"Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant-currency basis, unless noted otherwise. So we'll begin with Vascular. Total net sales were $239.5 million, up 3% over last year on a reported basis and up 5% on a constant-currency basis. U.S. Vascular sales were up 3% in the first quarter and international sales were up 10%. Excluding the Gore royalty, EP sales to Boston Scientific and the temporary reduction in Japan sales due to the acquisition, global Vascular sales grew 12%.
Sales in our surgical graft category grew 3% this quarter, within a range of recent experience. Our Endovascular business was up 9% in the first quarter. Within Endovascular, our biopsy products were well above trend at 16% growth in Q1 with strong growth in the United States and emerging markets. There was good momentum in this business, but the strong 2015 we had provided some tougher comps in the coming quarters.
Our peripheral PTA line increased 19% in the first quarter with our Lutonix DCB growing significantly. We are pleased with how our teams have executed here, and we expect that the expanding real-world data around effectiveness and safety will continue to support the selection of the Lutonix drug-coated balloon as the first line of therapy for peripheral artery disease. I'll remind you that in the first quarter of 2015 was a relatively easy comp due to the significant initial stocking in the fourth quarter of 2014, and the upcoming quarters have some more difficult comps as we saw stocking for Boston Scientific in the second quarter and third quarter of 2015 related to our distribution agreement with them.
Our Stent business declined 1% in the first quarter compared to the prior year, impacted by the acquisition in Japan. And our vena cava filter line grew 3% in the quarter.
Now let's move to Urology. Total net sales were $216.7 million, up 5% versus the first quarter of last year on a reported basis and up 7% on a constant-currency basis. Excluding the impact from Japan and the acquisition of Liberator Medical, global Urology sales were still up 5%, with the United States also up 5% and international up 3%. 
We saw healthy double-digit growth in our Targeted Temperature Management products again this quarter. Our basic drainage business was up 5% in Q1. In this category, we benefited from the new sales from Liberator, but had declines related to the inventory in Japan. If you exclude both of those, the business was still up 5% globally and up 6% in the United States, with our I.C. Foleys business up 4% globally and also up 4% in the United States. 
Looking at the last several quarters, we would characterize the results here as stable, but not necessarily accelerating on a macro level. We do see specific growth driven by a few new products of ours, both in the hospital and in the home.
Our continence business was up 22% in Q1, but would have been flat excluding Liberator and Japan. I'll remind you that the Liberator platform added Ostomy products to our venue -- to our revenue and those are recorded in continence. 
Sales in urological specialties were up 8% in Q1 with our brachytherapy business also up 8%. As we said last quarter, we did not keep significant stocking inventory in Japan on the brachytherapy products. So we began recognizing customer level pricing in Q4 when we closed the acquisition. And finally, stand-alone sales of our StatLock catheter stabilization line decreased 5% in Q1.
Next up is Oncology. Total net sales in this category were $241.9 million, an increase of 8% over Q1 last year on a reported basis and up 10% on a constant-currency basis. We worked with the Japanese inventory a little quicker in this business and began to benefit from end customer sales in Japan in the first quarter. Excluding Japan, global Oncology sales were up 8%, with the United States up 6% and international sales up 15%.
Our port business rebounded from the temporary issues we told you about last quarter and grew 8% over Q1 of last year. Our PICC revenue was up 9% globally. As our largest single product line, we continue to expect PICCs to be a meaningful source of growth for us, especially in international markets where PICC penetration is in its very early days.
And to close out the category, our vascular access ultrasound product line grew 15% this quarter as we launched our new Site-Rite 8 platform. And our dialysis catheter product line was up 12%.
Now let's finish with Surgical Specialties. Total net sales in this category were $151.4 million, up 11% on a reported basis and up 13% on a constant-currency basis. The impact to this business from the Japan acquisition was minimal. Excluding Japan, the global sales growth was still 13%, with United States sales of 12% and international sales of 14% in the quarter.
Our performance irrigation business declined 6% in Q1 as we anniversary-ed the discontinuation of certain products in this category. Our soft tissue repair business grew 13% this quarter, which is the strongest growth we've seen for this category since Q3 of 2010.
As we've seen over the last few years, the growth in synthetic hernia and biologic hernia are inversely related as procedures move from one to the other. This quarter saw a significant reduction in overall natural tissue hernia, which declined 19% despite very good growth in our Xen AB platform. However, our synthetic hernia business grew 19%, which is the strongest growth we've seen in this product line since the first quarter of 2004, 12 years ago. While this business is mostly in the United stage -- States, which is benefiting from our new Phasix material, our emerging markets are growing nicely with our legacy portfolio.
Because our mix in soft tissue is more than 5:1, in favor of synthetics, as physicians move from biologics to synthetics or hybrids, we typically do well in that exchange as demonstrated this quarter by the strong performance in total soft tissue repair.
Our hernia fixation line grew 37% this quarter as our new products are having an impact as anticipated. As we told you, we have the broadest portfolio in hernia repair across all types of products, from wide range of synthetics to hybrids, to natural tissue and now antibiotic-coated natural tissue. We are working with physicians to identify the right product for the right patient and provide a wide range of options for them.
Finally, our BioSurgery business grew in the healthy double digits again this quarter, and we believe continues to be a significant long-term growth opportunity for us.
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks for joining us, and good evening, everyone. With the Analyst Day in about a month, I'm just going to hit some of the highlights today, starting with our drug-coated balloon pipeline where we've launched our new 7-millimeter diameter products. And i",846,"Thanks for joining us, and good evening, everyone. With the Analyst Day in about a month, I'm just going to hit some of the highlights today, starting with our drug-coated balloon pipeline where we've launched our new 7-millimeter diameter products. And in early April, we also launched our full line of 5 per inch compatible DCBs. So now every balloon size for the SFA indication is available in a 5 per inch compatible configuration giving us a competitive advantage. After our submission last quarter of our long lesion supplement, we're hopeful for a late second half launch for the treatment of lesions up to 300 millimeters in length. In our Below the Knee IDE, enrollment is beginning to accelerate after FDA approved the expansion of our inclusion criteria in mid-Q1.
At projected recruitment rates, we continue to anticipate enrollment through 2016, putting PMA submission likely in the first half of 2018.
Moving to the AV access DCB IDE study. We completed enrollment in Q1 and are now in the 6-month follow-up window. Though these things are a little hard to predict precisely, we believe we should have results sometime in Q4, and we anticipate PMA submission in Q1 of 2017, ahead of our previous schedule. Assuming normal review timing, we expect a second half 2017 U.S. launch. We're also anticipating the submission of our in-stent restenosis PMA supplement in the next couple of months.
Around the world, we're working to expand access to this important technology. For example, our shown in submission for the SFA indication occurred at the end of Q1, seeking approval in Japan. And we began enrollment in our Levant China study a few weeks ago.
Also in Vascular, the LifeStream Balloon Expandable Covered Stent trial was fully enrolled in Q3 of 2015. The primary efficacy analysis will be performed with a 9-month follow-up in the treatment of iliac artery disease. Our current projected time line continues to support submission of our final PMA module before year-end.
Our COVERA next-generation stent graph IDE is under review at FDA, and we anticipate commencing enrollment upon approval. COVERA's design for use in the AV access circuit. Also in the stents, our Venovo venous stent is doing well in Europe, and we commenced enrollment in our U.S. IDE just a couple of weeks ago. We anticipate enrollment through 2016 with follow-up through 2017 and PMA submission in 2018.
Our biopsy business launched 8 new products, including EnCor Enspire, EnCor Ultra and the Mission semi-automatic biopsy family this quarter in Asia while launching 18 new products in Latin America and the Middle East.
Next, moving to Urology and home care. We exited Q1 with launches in all 4 of our franchises. First, for the home care market, we launched our new Magic3 TOUCHLESS intermittent self-catheterization platform. We also launched our new proxy sheath family for flexible ureteroscopy in our endourology family. And we launched our new Foley daily care kit designed to help health care workers adhere to best practices in daily Foley catheter care and maintenance in our basic drainage segment. In Targeted Temperature Management, we launched some new adult pad sizes to support temperature control over a broader range of patient sizes.
Moving to Oncology. We're still working with FDA seeking clearance for the launch anticipated later this quarter of our new family of chemical-resistant catheters. We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis, or DVT, and remain on plan to begin launching in the back half of the year. 
For the difficult stick IV catheter patients, we began to launch of our AccuCath wire-guided assisted products earlier this month with additional sizes to launch over the next couple of quarters. These new products are complementary to our new midline catheter, the PowerGlide Pro, slated for launch upon FDA clearance.
Lastly, in Q1, we launched our new dual-lumen Power Xenosys [ph] catheter designed for superior flexibility, kink resistance and flow rates in excess of 400 ml per minute in a small 11 French catheter configuration.
I'll close my portion of the discussion today with surgery. Just a few days ago, we received PMA approval for our new TRIDYNE aortic sealant, and we're preparing to launch this new product around the end of this quarter. We're also working toward the launch of a new Progel sealant configuration designed to improve visibility during minimally invasive and robotic surgery. And expect PMA submission this quarter with approval and launch around the end of year. We're also expanding our portfolio with Phasix resorbable mesh with additional sizes anticipated to launch in the back half of the year.
And finally, in mesh fixation, we anticipate expanding on our recent permanent and resorbable product launches, with 2 additional resorbable fixation devices slated for later this year.
Now before I hand you over to Chris, I'd like to remind all of you to join us at our Analyst Day on Monday, May 23, at the New York Palace hotel at 4:30 p.m. I look forward to seeing you there. And now here's Chris."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We had acquisition-related items of $4.5 million pretax, a $9.8 million pretax charge for restructuring and productivity initiatives, and",1048,"Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We had acquisition-related items of $4.5 million pretax, a $9.8 million pretax charge for restructuring and productivity initiatives, and we booked expense of $48.9 million for product liability matters, which principally is related to litigation on IVC filters. The P&L impact of these items is detailed in the notes to the financial statements and in the reconciliation accompanying our Q1 earnings press release.
Now let's go through the statement of income for the quarter, and I'll remind you that our adjusted numbers now exclude the amortization of intangibles from the entire P&L, and the references to prior year are on that same basis. Gross profit was $553.1 million or 63.3% of sales for Q1. On an adjusted basis, GP was $581.2 million or 66.5% of sales. That's up 210 basis points from the prior year quarter and better than we expected. FX cost us about 20 basis points in GP for the quarter. Price pressure drove 40 basis points on the revenue line in Q1 and 20 basis points of headwind on GPs, which was significantly better than our expectations and the best result we've seen since 2010. We still expect price to be more of a headwind going forward, but we're certainly happy with the Q1 results. Our cost improvements and other items drove 90 basis points of benefit to GPs this quarter and mix was favorable by 160 basis points, which includes the gross profit benefit from acquiring our Japanese JV. As we look to Q2, we expect gross margin to be over 100 basis points better than Q2 of 2015. And for the full year, we're comfortable with our guidance for gross profit improvement.
SG&A expenses were $270.6 million for the quarter or 31% of sales. On an adjusted basis, SG&A was $266.5 million or 30.5% of sales, an increase of 180 basis points over last year. This is reflective of the timing of the 2 recent acquisitions, and we expect Q2 will also be higher than prior year as well. We still expect the full year to be about the same as 2015 as a percentage of sales as we integrate the acquisitions and leverage our infrastructure on higher sales throughout the year.
R&D expenditures totaled $68.3 million for the first quarter or 7.8% of sales on a reported basis. On an adjusted basis, R&D was $66.8 million or 7.6% of sales, up 20 basis points from Q1 of last year and consistent with our guidance. Interest expense was $11.3 million for the quarter. Other income and expense was $60 million of expense for the first quarter as reported and $1.9 million of income on an adjusted basis. The effective tax rate for the quarter was 18.7% on a reported basis and 25.8% on an adjusted basis, right in the middle of our full year guidance.
Diluted shares for the period were 75.2 million, and we purchased 897,000 shares in the first quarter at an average price of $186.57. The net result is adjusted EPS of $2.34, which was well above our expectations for the quarter. This overachievement was driven by the strong sales fee and a slight easing of FX headwinds. The balance sheet, as of March 31, reflects cash, restricted cash and short-term investments of approximately $1 billion, essentially no change from December 31. For the quarter, accounts receivable days were up 1.2 days and inventory days were up 6.3 days. Both of these increases are related to the recent acquisitions. Capital expenditures totaled $20.5 million for the quarter.
On the liability side, total debt was $1.7 billion as of March 31 compared to $1.4 billion at the end of December. Debt to total cap at the end of the first quarter was about 53%, and total shareholder investment was $1.5 billion at March 31.
Turning now to guidance. In Q2, we're expecting constant currency sales growth between 6.5% and 8%, with reported sales growth between 5.5% and 7%, inferring an FX headwind of approximately 1% on the revenue line. This assumes organic growth between 5.5% and 6% for the second quarter. From an adjusted EPS standpoint, excluding items affecting comparability and the amortization of intangibles, we see the second quarter in the range of $2.43 to $2.47.
Given such a strong operational start to 2016, along with an easing of FX headwinds, we're comfortable raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 7% and 8.5%, with reported sales growth between 6% and 8%, inferring a currency headwind of between 50 and 100 basis points.
On an organic basis, we had originally guided the year to be between 5% and 6%, but are increasing that range meaningfully today to be between 6% and 6.5%. It's not lost on us, and we're sure it's not lost on you that we did meaningfully better than that in Q1. To be clear, we see good momentum in the business and continued strength in our positioning. However, there were several product lines this quarter well above trend. China was exceptionally strong, and I just highlighted price headwind was abnormally low. So before we take the sustainability of some of these factors to the bank, we think it is prudent to get a little deeper into the year.
We're also increasing our full year adjusted EPS guidance range to be between $10.05 and $10.18, which is just about $0.15 above our original guidance range at the midpoint and represents 11% to 12% growth over 2015. At current rates, we expect foreign exchange to be approximately $0.20 of headwind for the full year. So on an FX-neutral basis, we are guiding to 13% to 14% growth. Given the strength of our operating performance, the success of our investment program and the demonstrated ability of our teams to execute against commitments, we plan to accelerate certain investments in targeted projects and geographies, beginning in Q2 and throughout the remainder of the year. We believe this disciplined investment approach will help provide sustainable, profitable growth and value for our shareholders for years to come. 
And with that, I'll turn you back to Tim."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] With that, Kathy?",30,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] With that, Kathy?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question will come from Bob Hopkins with the Bank of America.",16,"[Operator Instructions] And our first question will come from Bob Hopkins with the Bank of America."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","So 2 things, Tim, for you. Before I ask a Bard specific question, one of the other things that isn't lost on all of us on this call is really the whole medtech space is reporting very strong Q1 organic growth numbers from cardio to ortho to general surger",74,"So 2 things, Tim, for you. Before I ask a Bard specific question, one of the other things that isn't lost on all of us on this call is really the whole medtech space is reporting very strong Q1 organic growth numbers from cardio to ortho to general surgery. So I just wanted to get your take on kind of what you're seeing out there in terms of surgical procedure volumes and trends generally."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I mean, I think there is no denying that the observation you made, it does seem like everyone is doing a little bit better. I still think there's a lot of things that we're still trying to understand and navigate as health care evolves and changes an",131,"Yes. I mean, I think there is no denying that the observation you made, it does seem like everyone is doing a little bit better. I still think there's a lot of things that we're still trying to understand and navigate as health care evolves and changes and what that means. The only thing I could point to, Bob, that has been constant, and that is that as unemployment rates over time -- over a very long period of time historically have improved, health care spending has for like 4 years increased along with that. So it feels like things have been a little bit better. But again, because it is a different kind of environment with all the different dynamics, it's still a little bit tough to predict, I think."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just to follow up maybe on that same question. So 2 quick things. One, just sort of a standard question. We're selling these even for you guys this quarter. And then more specifically, Bard had a particularly strong quarter with 9% organic growth",101,"And then just to follow up maybe on that same question. So 2 quick things. One, just sort of a standard question. We're selling these even for you guys this quarter. And then more specifically, Bard had a particularly strong quarter with 9% organic growth. That's a nice acceleration from what we've seen. So can you just talk from a Bard perspective, like what drove the incremental growth? Maybe it seems like emerging markets or maybe even above the 20% level that you've been seeing. Just talk about what got better this quarter and if the selling days are even up?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We were strong literally across the board. We did have some easier comps in certain sectors, which Chris can get into more details, Bob. But in general, the investment plans working the execution is that teams have done a great job around the world,",88,"Yes. We were strong literally across the board. We did have some easier comps in certain sectors, which Chris can get into more details, Bob. But in general, the investment plans working the execution is that teams have done a great job around the world, executing very well. We had some new products that hit their stride pretty quickly. Lutonix continues to do well. Surgery, as John noted, the highest it's been synthetics in over a decade. So it's really across the board. It's not any one thing."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'd just add, Bob. I think just a couple of things we tried to highlight that really sort of surprised us as we came to the quarter. Again, price was better than we expected and well below trend. Biopsy, as John highlighted, had a really strong quarter an",180,"I'd just add, Bob. I think just a couple of things we tried to highlight that really sort of surprised us as we came to the quarter. Again, price was better than we expected and well below trend. Biopsy, as John highlighted, had a really strong quarter and probably the easiest comp of the year for us, but terrific momentum there. And Lutonix had its easiest comp of the year as well. And soft tissue, as John highlighted, was just clearly above trend and with the exceptional strength in synthetics. And China had an exceptional quarter, above trend. So it was really a situation where everybody performed as we expected, and then we've got I'll call it at this point, several really nice surprises. And then from a selling day standpoint, it's hard to measure exactly, but there probably was some benefit, Bob. But again, it's -- it was a tailwind, but it's hard to be too specific. And we generally don't call it out when it goes the other way either, but it probably helped a little bit."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Roman with Goldman Sachs.",10,"Our next question is from David Roman with Goldman Sachs."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","I want to see if you could follow up a little bit on Japan and give us a little bit more detail about how we should think about that region unfolding as you move to a full direct model. And maybe give us some specifics on where you see the biggest opportu",71,"I want to see if you could follow up a little bit on Japan and give us a little bit more detail about how we should think about that region unfolding as you move to a full direct model. And maybe give us some specifics on where you see the biggest opportunities, and how we should think about that contributing to growth, both throughout 2016 and as we think longer term."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, David, first of all, we're off to a good start, frankly. I mean, the integrations gone very well so far. And obviously, we're dealing with the inventory sell-through, but the business actually did a bit better than we had expected anyway. I",170,"Yes, I think, David, first of all, we're off to a good start, frankly. I mean, the integrations gone very well so far. And obviously, we're dealing with the inventory sell-through, but the business actually did a bit better than we had expected anyway. I think we're realigning the sales force a bit and getting them focused in areas where we, to your point, really see more opportunity. And I would certainly be both within surgery. We talked about PICC in general being extremely underpenetrated in Japan. We think that's a really exciting growth area for us. And probably most prominently within Vascular, we've got LifeStent and Lutonix approvals coming down the pipeline here in fairly short order and having controlled that direct sales force ourselves, getting them aligned the right way and getting them motivated and ready for those launches, again, relative to the old ownership structure. We just feel we're in a position to maximize that opportunity in a way we just wouldn't have been able to otherwise."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","The only other thing I would add if you were to look at, at a macro level the product mix within the global portfolio by Urology, Oncology, Surgical and Vascular were fairly evenly balanced, at least amongst the top 3, with surgical lagging a little bit b",126,"The only other thing I would add if you were to look at, at a macro level the product mix within the global portfolio by Urology, Oncology, Surgical and Vascular were fairly evenly balanced, at least amongst the top 3, with surgical lagging a little bit behind. That is not the way our Japan business looks today. We're very heavily dominated in Urology. Clearly, the faster-growing segments are the other 3, and that's where we have the smallest amount of revenue coming from in Japan. So it's our expectation that, that will get realigned with this structural change as well as our investments moving forward. And we would expect that product mix to shift and look more like over time what it'd look like everywhere else."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And then maybe just on the spending side. It looks like you took the opportunity to reinvest in SG&A this quarter, given some of the strength in the top line. But it looks like that -- you said at the beginning of the year, CapEx is runnin",103,"That's helpful. And then maybe just on the spending side. It looks like you took the opportunity to reinvest in SG&A this quarter, given some of the strength in the top line. But it looks like that -- you said at the beginning of the year, CapEx is running a little bit lower. So how should we think about the balance of cash spending through the rest of the year as well as how the P&L discretionary line item should compare to your original guidance. I know you gave SG&A, but maybe just an update on R&D and CapEx would be helpful."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","All right. We guided to $120 million of CapEx spend for the full year. I think we'll probably still get close to that number. I don't expect it to be materially different either way. And as we highlighted at the end of the comments, we are in the face of",141,"All right. We guided to $120 million of CapEx spend for the full year. I think we'll probably still get close to that number. I don't expect it to be materially different either way. And as we highlighted at the end of the comments, we are in the face of the strength, really, going to accelerate spending on some -- several additional R&D projects, several additional sales force expansion projects, several additional clinical trials. And also, we're adding additional resources within our health economics infrastructure across the company as well. So it'll be spread between SG&A and R&D. We'll still be in line with our full year guidance as a percentage of sales, but we're going to take advantage of the strength again to really accelerate some investments that we think will be helpful as we move into '17 and beyond."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go next to Mike Weinstein with JPMorgan.",9,"We'll go next to Mike Weinstein with JPMorgan."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just following up on that, Chris. If you guys at the analyst meeting can talk a little bit more about where you're putting those extra dollars and that would probably be helpful to everybody.",34,"Just following up on that, Chris. If you guys at the analyst meeting can talk a little bit more about where you're putting those extra dollars and that would probably be helpful to everybody."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Mike.",2,"Sure, Mike."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","So let me circle back to, really, Bob's first question, which is you look at some of these businesses, the ones that are above trend. And I just want to understand, you gave numbers on a bunch that were obviously very strong, things like urological specia",122,"So let me circle back to, really, Bob's first question, which is you look at some of these businesses, the ones that are above trend. And I just want to understand, you gave numbers on a bunch that were obviously very strong, things like urological specialties up 8%; brachytherapy up 8%; the synthetic hernia repair business, which running with 8%, 9% last year was up 19% this quarter. All those businesses that had real above trends, was that explain it U.S. versus OUS. Was that U.S. that was significantly above trend? Was it U.S. and then China? Can you just maybe geographically help us there? Because a lot of what we're seeing is U.S. outperformance in a number of different end markets."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I think U.S. was strong, Mike, in really all of those, so it's -- we had 9% growth in the U.S. and 8% organic growth in U.S. So it was all the categories we highlighted were strong. China is going great guns for us, and so biopsy in China, the hernia busi",168,"I think U.S. was strong, Mike, in really all of those, so it's -- we had 9% growth in the U.S. and 8% organic growth in U.S. So it was all the categories we highlighted were strong. China is going great guns for us, and so biopsy in China, the hernia business in China, the PICC franchise in China. And as we talked about last year, I think it's an example of where we accelerated some investments, we started to build the direct sales force in BioSurgery in China last year, and this quarter is the first quarter where we're really seeing the fruits of those efforts in China. The brachy business performed again in Japan better because there was really no inventory in Japan. And so we're getting direct-to-customer pricing there in the quarter. So it's really across the board, and the U.S. was certainly stronger. But again, where we had made investments is where we've also seen some acceleration in some of these other geographies."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And tell me how you thought about just the guidance upgrade for the balance of the year. Is just the organic revenue growth of 5.5% to 6% for the second quarter and it kind of -- that's what you're basically implying for the second half. You're basically",98,"And tell me how you thought about just the guidance upgrade for the balance of the year. Is just the organic revenue growth of 5.5% to 6% for the second quarter and it kind of -- that's what you're basically implying for the second half. You're basically assuming that you go back to your prior trendline expectations and just -- for now assuming that what we saw incremental in the first quarter was a 1-quarter event, and therefore, the upside is that if it's not just a 1-quarter event, then we're going to get the benefit of that?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think that's a bad way to think about it. I mean, that's really how we saw the year coming in was 5% to 6%. I think we called out a couple of areas that were above trend and a couple of areas that were easy comps that obviously, we're not counting",162,"I don't think that's a bad way to think about it. I mean, that's really how we saw the year coming in was 5% to 6%. I think we called out a couple of areas that were above trend and a couple of areas that were easy comps that obviously, we're not counting on the rest of the year. And again, pricing was a positive surprise for us as well. So we feel great about 6% to 6.5% for the full year. And as we said, we're not going to get too far ahead of ourselves. We'll see how Q2 goes and then we'll take it from there. But I think great start to the year. We think appropriate guidance for the rest of the year. And as I think you've seen from us in the past, we'll try as we move through the year, try to make the right decisions, both from an investment standpoint and from a guidance standpoint."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And Chris, just one clarification and let some others jump in. On Japan, so you're going to go from a headwind because on the top line, because of the JV to buy into a tailwind. Can you just help us with the math on what that might mean to the top line ov",57,"And Chris, just one clarification and let some others jump in. On Japan, so you're going to go from a headwind because on the top line, because of the JV to buy into a tailwind. Can you just help us with the math on what that might mean to the top line over the next few quarters?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. And so we'll have this sort of interesting phenomena where reported and constant currency growth will accelerate through the back part of the year, largely because of the impact of Japan. But we're pulling it entirely out of organic. So we're not ben",113,"Yes. And so we'll have this sort of interesting phenomena where reported and constant currency growth will accelerate through the back part of the year, largely because of the impact of Japan. But we're pulling it entirely out of organic. So we're not benefiting at all over the course of the year when we're talking about organic growth from Japan. So we guided for Q2. Q3 will be somewhat higher than that and Q4 will be somewhat higher than that from a reported and constant-currency basis. But again, organic should be relatively consistent over the course of the next 3 quarters. It's how we're seeing the business as we sit here right now."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question now from David Lewis with Morgan Stanley.",11,"We have a question now from David Lewis with Morgan Stanley."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim, just sticking with this idea of trying to understand kind of the macro versus the micro drivers of the business. If I take the 4 segments of Bard, it looks like the margins surgical and Oncology, you did better than Vascular and neurology kind of on",107,"Tim, just sticking with this idea of trying to understand kind of the macro versus the micro drivers of the business. If I take the 4 segments of Bard, it looks like the margins surgical and Oncology, you did better than Vascular and neurology kind of on a relative basis. If you sort of think about hospital utilization acuity or sort of U.S. mix or their product pipelines in these businesses, the surgical and Oncology versus Vascular, Urology makes sense, either relative to the products in the businesses or makes sense relative to the U.S. focus or things you've seen in the past on utilization or acuity."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'm not sure there's a common thread where you can weave them altogether. There's different things driving each of the different businesses. Surgical, obviously, there's been a lot of investment made in that business over the last few years and a lot of n",254,"I'm not sure there's a common thread where you can weave them altogether. There's different things driving each of the different businesses. Surgical, obviously, there's been a lot of investment made in that business over the last few years and a lot of new products are coming out, as John cited out in his review. So that's doing well. That's also one of the key investment areas in emerging markets. So you've got those 2 things there. They're clearly, Oncology, there's always new products kind of flowing through there, but that's one of the biggest drivers in emerging markets, especially in China. So again, you've got kind of both themes there as well. Vascular continues to do well. The PTA line, Lutonix in the U.S. continues to do well. And Urology, even across the board, clearly, TTM continues to do well. The acquisitions that we've made continue to perform well. And the uptake in the U.S. seems to have become more steady. When you talk to hospital CEOs, I'm hearing more of them talk about some of their issues being things like nursing turnover, again being a big issue. We really haven't heard that, at least I haven't from a lot of hospital CEOs for several years now. So that's an indication perhaps that volumes are coming back or other opportunities for nurses outside of hospitals one or and both of those things. So just generally those are the themes that would kind of go through each of those areas you've called out."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's been very helpful. And I guess, the second tenet of Bard these last couple of years has been you're going to invest to drive that organic growth and you talked a lot about the 6 and 10 models; 6% organic top and 10% on the bottom. I'm not getting t",111,"That's been very helpful. And I guess, the second tenet of Bard these last couple of years has been you're going to invest to drive that organic growth and you talked a lot about the 6 and 10 models; 6% organic top and 10% on the bottom. I'm not getting too excited over here. But with a 12% earnings growth, but I think it bears asking you if you start getting above 6%, 7% organic growth as you did this quarter, does it start to become any diminishing return where investors can expect better than 10% earnings if that organic growth is going to be in excess of 7% organic."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I think just to be clear, I think what you might be referencing is our historical spreads between our revenue and our earnings growth. Having said that, and as Chris pointed out, we also -- we don't run this business quarter-to-quarter. We run it over the",133,"I think just to be clear, I think what you might be referencing is our historical spreads between our revenue and our earnings growth. Having said that, and as Chris pointed out, we also -- we don't run this business quarter-to-quarter. We run it over the long term. Company was founded in 1907. So none of us here are doing this on a quarter-to-quarter basis. We're constantly looking to have a very well-tuned process about how we'll turn on investments over time, and we've always done that. When we do a little bit better, we're able to turn on more. But it's not like we have to go out and collect ideas. We've got a pipeline of things that we can invest in. It's just a question when we start turning those on."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, David, is as we talked about pretty consistently, we do believe the model, and especially the product mix where we're getting growth from does and should allow us to generate 50 to 100 basis points of operating margin improvement a",153,"The only thing I'd add, David, is as we talked about pretty consistently, we do believe the model, and especially the product mix where we're getting growth from does and should allow us to generate 50 to 100 basis points of operating margin improvement annually. And so as we grow the top line consistently in the mid-single digits, and obviously, utilize the free cash flow that we have on top of that, you do get to that kind of math. We have a year like this year, where we're obviously looking at performing a little bit better than that. You're seeing good earnings growth on top of that as well. So it's -- the importance is the health of the model and continuing to keep it healthy. And we think, again, letting too much drop-through when we're leaving good investments on the table is not the right approach from a long-term standpoint."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","And next, we have Larry Keusch with Raymond James.",9,"And next, we have Larry Keusch with Raymond James."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, maybe just to start the GM, I think on the adjusted basis you did 66.5%. I think the guidance is 66% for the year. So can you just help us, again, just think through with that starting point why there won't be potentially some upside particularly a",57,"Chris, maybe just to start the GM, I think on the adjusted basis you did 66.5%. I think the guidance is 66% for the year. So can you just help us, again, just think through with that starting point why there won't be potentially some upside particularly as you start to recognize some of the Japan benefits?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And some of the Japan -- from a gross margins standpoint, Larry, some of the Japan benefits are -- were impacting mix in Q1. So as the sales that would already previously made into the joint venture then gets sold out the door to the customer, that increm",183,"And some of the Japan -- from a gross margins standpoint, Larry, some of the Japan benefits are -- were impacting mix in Q1. So as the sales that would already previously made into the joint venture then gets sold out the door to the customer, that incremental pricing right is gross margin. We're obviously no longer booking sales as we fill the pipe into the JV. So mix, as we expected for the full year from the JV, would be a positive contributor. It's actually more prominent in Q1 because there's fewer sales that we're booking into the JV. So I think the way to think about gross margin over the full year is actually -- we'll probably be pretty consistent quarter-to-quarter here on out as that -- as we see the normalization of Japan over time. And again, we're not expecting to see the kind of pricing environment we necessarily saw in Q1 for the full year. So I expect to see a fairly consistent gross margin trajectory over the course of the year as we're looking at it right now."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then I'll just sneak 2 other quick ones in here. Just on -- staying on the topic of Japan. You had indicated that you had expected dilution about $0.20 with $0.10 occurring in the first quarter, again, just given some of the changes in the FX ra",134,"Okay. And then I'll just sneak 2 other quick ones in here. Just on -- staying on the topic of Japan. You had indicated that you had expected dilution about $0.20 with $0.10 occurring in the first quarter, again, just given some of the changes in the FX rates. I want to just check back in on that. And then specifically on price, again, I hear you loud and clear that this is below kind of the levels that we've been seeing as of late. But was there anything specific in the quarter that allows you to get the better pricing or perhaps in another way, is there another thing to think about it as we move through the year that would influence pricing negatively? Or are you just trying to stay conservative there?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This is John. Let me deal with the price issue first. No, there was no special onetime item that impacted us positively from a price standpoint. We had a pretty good performance across all of our businesses as well as our geographies. And we had annualize",77,"This is John. Let me deal with the price issue first. No, there was no special onetime item that impacted us positively from a price standpoint. We had a pretty good performance across all of our businesses as well as our geographies. And we had annualized a few of the headwinds that we had early last year. We talked about which was on port pricing that had an impact as well. I'll turn you back to Chris."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","On the currency front, Larry, just in general, currency was about $0.02 better than we had expected in the quarter. Probably a little more than half of that was related to the yen. So we were sort of $0.01 better as we thought about Japan. $0.01 or $0.02",161,"On the currency front, Larry, just in general, currency was about $0.02 better than we had expected in the quarter. Probably a little more than half of that was related to the yen. So we were sort of $0.01 better as we thought about Japan. $0.01 or $0.02 better as we talk about Japan coming into the year. And again, for the full year, we expect about $0.20 of headwind, at least as we sit here today, given where the yen is and the euro and the rest of the basket, which again is about $0.10 better on a full year basis than we had anticipated. But obviously, as we all know, currencies can move the other way pretty quickly as well. So there'll be less dilution in Japan if the yen stays where it's at. And again we're really focused on executing the integration. And if we execute well, hopefully, we'll do a little bit better from an operational standpoint."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Amit Hazan with Citi.",9,"Our next question is from Amit Hazan with Citi."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe I'll ask the first question on drug-coated balloon and Lutonix. You started out I think last quarter, you talked about end customer usage. You were pretty positive on that, more than doubling versus the prior year. It sounds like you were pretty pos",64,"Maybe I'll ask the first question on drug-coated balloon and Lutonix. You started out I think last quarter, you talked about end customer usage. You were pretty positive on that, more than doubling versus the prior year. It sounds like you were pretty positive again this quarter. Can you give some color on whether that was kind of a sustainable type of growth?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me deal with the DCB perspective. I think that we feel very good about where we were with DCBs in Q1. We saw great execution from the sale side of things. We like our pipeline right now as we look downstream. John talked about all the new launches. We",116,"Let me deal with the DCB perspective. I think that we feel very good about where we were with DCBs in Q1. We saw great execution from the sale side of things. We like our pipeline right now as we look downstream. John talked about all the new launches. We'll talk about and that we have upcoming. We'll talk about more of that again in May when we get together from a pipeline standpoint. But I think if you combine what we're seeing happening in the field from a sales force execution standpoint, combined with what we consider to be robust new indications and product extensions of platforms, we feel great where we are right now."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And maybe this is front running [indiscernible] a little bit, but I'll throw it out there anyway just a little bit of a mid- long-term question, BioSurgery. You had a slide in some of your recent presentation that struck me a little bit it wa",122,"Fair enough. And maybe this is front running [indiscernible] a little bit, but I'll throw it out there anyway just a little bit of a mid- long-term question, BioSurgery. You had a slide in some of your recent presentation that struck me a little bit it was addressing your kind of long-term market opportunities and actually the biggest category you guys cited -- BioSurgery you cited as $1 billion opportunity going to $3 billion in 2020. So I wanted just maybe get a little bit of your color on what's behind that and what you see in your current pipeline or market product that helps you play in what you're essentially seeing as tripling of that market in the next 5 years."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. John DeFord here. Just a couple of things. First off, right now, we have a fairly limited product offering. So we've got a lung sealant, and we've got a couple of hemostasis technologies. So we -- based on those initial platforms, we anticipate expa",150,"Sure. John DeFord here. Just a couple of things. First off, right now, we have a fairly limited product offering. So we've got a lung sealant, and we've got a couple of hemostasis technologies. So we -- based on those initial platforms, we anticipate expanding. So today, I talked to you about a new technology that we developed internally, the TRIDYNE aortic sealant. We just received PMA approval after a very successful clinical study. We intend to launch that. That's getting us into a brand-new space with bigger opportunity. Like that, we have in our pipeline a number of other technologies and next-generations that we think are going to expand the area that we play in. So there's a pretty broad market right now for BioSurgery, but we're in a small sliver of that. And over the next several years, we see us getting into some of the larger pieces."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And, Amit, we're looking to do that both internally and externally, and we're looking all the time for additional technologies to add into the fold. I think what's important to understand is we now have a great direct selling force in the U.S. and as I me",90,"And, Amit, we're looking to do that both internally and externally, and we're looking all the time for additional technologies to add into the fold. I think what's important to understand is we now have a great direct selling force in the U.S. and as I mentioned, in China and we're pursuing other geographies. So part of its just maximizing the opportunity with the existing products, but you should very much expect us to continue to broaden the product portfolio, both through internal and external activities over the coming years."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Kristen Stewart with Deutsche Bank.",11,"And we'll go next to Kristen Stewart with Deutsche Bank."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","I was just wondering if you could give us the components to get to your organic numbers, the Gore and I think you've mentioned, also, something with Boston Scientific and then I guess, the total adjustment for the joint venture.",40,"I was just wondering if you could give us the components to get to your organic numbers, the Gore and I think you've mentioned, also, something with Boston Scientific and then I guess, the total adjustment for the joint venture."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Kristen, there's actually a slide in the deck that we posted to the website, which provides the combination of those items. So you can see Vascular was negatively impacted by 7 points, and that's both the Gore royalty, the decline in the EP sales to Bosto",132,"Kristen, there's actually a slide in the deck that we posted to the website, which provides the combination of those items. So you can see Vascular was negatively impacted by 7 points, and that's both the Gore royalty, the decline in the EP sales to Boston Scientific and the impact of the Japan JV. So Vascular grew 12% organic, adjusting for those items. Urology, we're taking Liberator out, and it was the big impact in Japan, which sort of offset each other to a large degree and Urology grew 5% organic. Oncology grew 8% organic, which is the adjustment associated with Japan. And then surgical, there was a very minor impact there, so both constant currency and organic in surgery were 13%. So that's the level of granularity we're providing for you."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then Gore's $38.4 million, I guess, on the slide?",11,"And then Gore's $38.4 million, I guess, on the slide?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Right.",1,"Right."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then with respect to the Analyst Day, I know last or 3 years ago, as you mentioned, you gave the 3-year plan and clearly, congratulations. You've gotten there. Will you be providing another kind of outlook, I guess, for the next 3 or kind of any",61,"Okay. And then with respect to the Analyst Day, I know last or 3 years ago, as you mentioned, you gave the 3-year plan and clearly, congratulations. You've gotten there. Will you be providing another kind of outlook, I guess, for the next 3 or kind of anything with longer-term goals with the analyst meeting, is that what we should expect?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This will be kind of an update overview of the investments to the question that was asked earlier that we're making now, a little bit more detail on portfolio review, some of our geographic plans, that kind of thing. But we will not be providing any addit",52,"This will be kind of an update overview of the investments to the question that was asked earlier that we're making now, a little bit more detail on portfolio review, some of our geographic plans, that kind of thing. But we will not be providing any additional guidance at that meeting."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Will you allow John to make his jokes?",8,"Will you allow John to make his jokes?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","No, John is working already. That's why we had to schedule so far in advance...",15,"No, John is working already. That's why we had to schedule so far in advance..."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","They won't let me, even when I try to sneak it in, they like throw the hook out.",19,"They won't let me, even when I try to sneak it in, they like throw the hook out."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Well, you can make those off line.",7,"Well, you can make those off line."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I'll have to.",4,"I'll have to."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","We're approaching the top of the hour I'm going to apologize to everybody else in line. We're going to do one more question and then we're going to wrap it up.",32,"We're approaching the top of the hour I'm going to apologize to everybody else in line. We're going to do one more question and then we're going to wrap it up."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","And the final question will come from Dave Turkaly with JMP Securities.",12,"And the final question will come from Dave Turkaly with JMP Securities."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","Back to the gross margin, just quickly. I know that mix was 160 basis points. And I think you mentioned cost improvements of 90. Can you just remind us where you are in those cost improvement programs? I know in the past you talked about material input co",82,"Back to the gross margin, just quickly. I know that mix was 160 basis points. And I think you mentioned cost improvements of 90. Can you just remind us where you are in those cost improvement programs? I know in the past you talked about material input cost is an area of focus and potentially as a lever moving ahead. But do you think we'll have improvements like that as we look forward? Where could the gross margin head based on those?"
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","This is the improvements that we talk about in the P&L, it's not about one big program. And it's our normal organic way of operating the business, focused primarily on both materials costs and on improvements in our variances to flow out of our manufactur",106,"This is the improvements that we talk about in the P&L, it's not about one big program. And it's our normal organic way of operating the business, focused primarily on both materials costs and on improvements in our variances to flow out of our manufacturing operations and efficiencies. So -- and as you can see, we had one small charge that Chris talked about for efficiencies that will help us in the future. But it's not one big program. This is the normal way we operate year in and year out, and we're focused on constantly improving the -- our cost positions in our products."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","So David, the only thing I'd add is we guided for the full year cost of 80 to 100 basis points. And really, the team tasked with achieving 50 to 100 basis points year in, year out. And so in a moderate FX environment and a more moderate price environment,",113,"So David, the only thing I'd add is we guided for the full year cost of 80 to 100 basis points. And really, the team tasked with achieving 50 to 100 basis points year in, year out. And so in a moderate FX environment and a more moderate price environment, we feel really good about our -- been able to control our destiny to drive GPs higher. And then obviously mix. Everything we've done from an investment standpoint to shift the portfolio to higher-growth and higher-margin products are both tailwinds to gross margin. Again if we execute those are 2 things we can control. And then FX is obviously something that we can't."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Analysts","One really quick-follow up. I know it's just actually to get your thoughts on sort of the biologics in the hernia repair area. Is there a functional problem there? And do you think the synthetic business can remain that strong? I guess, I'd like your thou",53,"One really quick-follow up. I know it's just actually to get your thoughts on sort of the biologics in the hernia repair area. Is there a functional problem there? And do you think the synthetic business can remain that strong? I guess, I'd like your thoughts on what is actually driving that."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think there's any functional problem. I think what's really happening is that as these hybrid technologies get into the market and has a better understanding of what product works best in what patient, you're beginning to see some of the shake out",141,"I don't think there's any functional problem. I think what's really happening is that as these hybrid technologies get into the market and has a better understanding of what product works best in what patient, you're beginning to see some of the shake out here. So I think it's nothing sort of structural, but more greater knowledge, greater science and just a normal shakeout of where -- when is it best to use a biologic, when is it best to use a pure synthetic, when is it best to use some of the hybrid technologies that we now have? And so we're beginning to see some of that shakeout. And I think as that information comes together. We're also doing everything we can to help our customers determine what's the best product for every patient that walks in the door."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","And then the key to success there is to have the best product in each of the categories for every patient. And we're the only one who has that. So we're clearly taking share given our portfolio right now exactly.",40,"And then the key to success there is to have the best product in each of the categories for every patient. And we're the only one who has that. So we're clearly taking share given our portfolio right now exactly."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. Then I'll turn the call back over to Bard's management for closing remarks.",15,"Thank you. Then I'll turn the call back over to Bard's management for closing remarks."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much, Kathy. And I'd like to thank all of you for joining us this afternoon. We will see you, hopefully, at our analyst meeting, and if not, we'll talk to you again at the end of the quarter. I'd also like to think all of Bard's employees a",69,"Thank you very much, Kathy. And I'd like to thank all of you for joining us this afternoon. We will see you, hopefully, at our analyst meeting, and if not, we'll talk to you again at the end of the quarter. I'd also like to think all of Bard's employees around the world for all their hard work and a very strong start for the year. Thanks. Good night."
254131,329843971,965262,"CR Bard Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using AT&T Executive TeleConference. You may now disconnect.",27,"Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using AT&T Executive TeleConference. You may now disconnect."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand",277,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's March 31, 2016 Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of July 26, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I would expected the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an ho",521,"Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I would expected the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck that's available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The discussion today will go as follows: I'll begin with an overview of the results for the second quarter of 2016; John Weiland, our President and COO, will review second quarter product line revenue; John DeFord, our Senior Vice President, Science, Technology and Clinical Affairs, will give you a brief update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will go over the second quarter income statement and balance sheet as well as our expectations for the third quarter and the remainder of the year. And then finally, we'll close with Q&A.
Second quarter 2016 net sales totaled $931.5 million. That's up 8% over Q2 of last year on an as-reported basis and up 9% on a constant currency basis. The currency impact for the quarter versus the same quarter last year was unfavorable by about 70 basis points. 
The organic growth rate was approximately 6.4% this quarter, which exceeded our expectations. As we told you earlier, the prior year Q2 included the initial stocking of Lutonix by Boston Scientific. And when you factor that in, our organic sales growth would have been above 7%. 
Net income for the second quarter of 2016 was $159.2 million, and diluted earnings per share were $2.11. Excluding amortization of intangibles and items that affect the comparability of results between periods, which Chris will cover later, adjusted second quarter 2016 net income and diluted earnings per share were $192.2 million and $2.54. That's up 11% and 12%, respectively. These adjusted results exceeded the guidance we provided for the quarter, and the first half of the year has come in stronger than we had projected at the beginning of the year. 
Looking at revenue growth geographically compared to the same quarter last year, Q2 net sales in the U.S. increased 7% on a constant currency basis, Europe grew 7%. Japan was up 29%, benefiting from moving to customer pricing after the acquisition of our JV partner, and our other international businesses grew 15%. We continue to see strong growth in emerging markets, which represented 10% of our total sales in the second quarter. 
As John Weiland takes you through the product lines, you'll see that we continue to have sustained momentum across all of our businesses even in the face of the tougher comps that we previewed for you last quarter. We continue to believe that executing our strategy will position us to continue to achieve an above-market revenue growth rate for the overall portfolio with attractive returns for shareholders. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's begin with Vascular. Total net sales were $25",777,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. 
So let's begin with Vascular. Total net sales were $255.3 million, up 3% over last year on both an as-reported and constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 6% in Q2, with the United States business up 3% and international up 12%. 
Sales in our surgical graft category were up 5% in the second quarter, within the range of recent experience. Our Endovascular business grew 6% in the second quarter. Our peripheral PTA line grew 10% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. The growth rates may look a little lumpy quarter-to-quarter from stocking events in the prior year, but we track average daily sales as a metric, and we continue to see good sequential momentum in both the United States and internationally. And we have third-party data that shows us maintaining our leadership position in this important long-term market opportunity. 
Our Stent business grew 1% in the second quarter, and sales in our vena cava filter line were down 13%. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally despite running up against the tougher comps we talked about last quarter. 
Now let's go to Urology. Total net sales were $240.0 million, up 15% on an as-reported and up 16% on a constant currency basis compared to the second quarter of 2015. The combination of the first full quarter of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in the category. Excluding these 2 acquisitions, the United States business was up 4%, while internationally, we grew 5%. 
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 6%, both globally and in the United States, with our infection control Foley business up 2% globally and 3% in the United States. 
Our Targeted Temperature Management products grew 19% this quarter, demonstrating continued momentum in this significant long-term opportunity. 
Our continence business was up 34% in the second quarter, all driven by the benefit from the new acquisitions. 
Sales in urological specialties were up 9% this quarter, including our brachytherapy business, which grew 7%, driven by Japan. 
And finally, in this category, stand-alone sales of our StatLock catheter stabilization line decreased 5% in Q2. 
Now let's go to Oncology. Total net sales in this category were $252.4 million, an increase of 7% as reported and 8% on a constant currency basis over Q2 last year. The Japan acquisition added 200 basis points to growth globally. Excluding that, sales in the United States were up 4%, and international sales were up 13%. 
Our port business was up 4% versus the second quarter of last year. Our PICC business was up 10% this quarter, with continued impressive growth outside of the United States. As you'll hear from John DeFord, we continue to advance our PICC and midline portfolio. 
Our Vascular Access Ultrasound product line grew 4% this quarter. And to close out the category, our dialysis access product line was up 13%. 
So let's conclude with our Surgical Specialties business. Total net sales in this category were $159.9 million, up 11% as reported and 12% on a constant currency basis. United States sales were up 11%, and international sales were up 13% this quarter, excluding the impact from Japan, which was minimum. 
Our performance irrigation business was down 3% now represents less than 1% of our total company sales. Our soft tissue repair business continued its strong momentum, growing 12% in Q2. Our broad product offering and our value-added programs that help customers select the right product for the patient are having a significant impact on the treatment paradigm, with more procedures shifting from natural tissue to our synthetic hernia portfolio and specifically, our Phasix material. Our synthetics business grew 18% this quarter, while our natural tissue products declined 27%. 
In our hernia fixation business, which is included in soft tissue repair subtotal, grew 49% this quarter on the continued impact from our recent product launches here. 
Closing out the surgical category in the second quarter, our BioSurgery business grew 16% and now represents between 20% and 25% of our Surgical Specialties business. This continues to represent a significant long-term opportunity for us. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. We'll start with our drug-co",766,"Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. 
We'll start with our drug-coated balloon pipeline. Our long leash in supplement is under review at FDA, and we're hopeful for approval of this expanded indication for the treatment of lesions up to 300 millimeters in length around year-end. In our Below the Knee IDE, enrollment is progressing and we're optimistic regarding our discussions with the FDA to bring this important treatment option to patients. The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a look at our results in Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late-Q4 2017 U.S. launch. 
We're also on track to submit clinical data for the in-stent restenosis PMA later this quarter. 
In Japan, our shown in submission for the Lutonix SFA indication is under review, and we anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began last quarter. 
Also in Vascular, in Q2, we launched our new True Blow value plasty balloon family. This proprietary product is designed to reduce the stress placed on the heart by allowing blood to flow through the device during the procedure with limited restriction and back pressure. Early clinical results have also shown that in most cases, rapid pacing to reduce blood pressure has not been required. 
Also in Q2, we received FDA approval for the life stent system, with indications covering the entire artery. The life stent platform is now
[Audio Gap]
of 2 new stone basket configurations in our Sky Light platform, providing a full range of sizes. And in Targeted Temperature Management, this quarter, we received IDE approval for our new neurogenic fever prevention and control clinical study. This study will evaluate the use of the Arctic Sun system in this new indication. The study is anticipated to enroll more than 1,000 patients and will probably take about 3 years to complete. 
Moving to Oncology, we've had a very busy few weeks since the Analyst Day. We received clearance on our new chemical-resistant PowerPICC family named the PowerPICC EtOH. This new family will begin launching this quarter and is especially designed with a proprietary material that maintains all of the benefit of the PowerPICC and can withstand greater exposure to the sometimes harsh chemistry used in today's therapies. 
We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis or DVT. We remain on plan to launch products in this new family in the back half of the year. 
We also received FDA clearance on our new power midline and clearance for our PowerGlide Pro family of intermediate well catheters. Both of these products just launched and are shipping to customers. 
This quarter, we added 3 new applications to our tip confirmation portfolio for pediatrics, ports and central lines due to launch of first-generation system in Europe. We're also developing an advanced version slated for launch in the U.S. and other geographies later this year. 
I'll close my portion of prepared remarks today with surgery. As we discussed a few weeks ago, the TRIDYNE aortic sealant was approved by the FDA, and we're preparing to launch in the back half of this year. We're also working toward the launch of the Progel Emerald sealant, designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to anticipate the launch of additional Phasix resorbable mesh sizes throughout the remainder of the year. This expansion is planned to provide surgeons and their patients the largest and most comprehensive size matrix in the market, including a 50-centimeter by 50-centimeter mesh. 
On the clinical front, we've completed 1-year follow-up in our Phasix clinical study of over 100 ventral hernia patients and expect results to be presented and published later this year. Similarly, additional clinical data for our XenMatrix AB product family is expected to be released later this year. 
And finally, in mesh fixation, we anticipate launching the 15-count [ph] version of our OPTIFIX resorbable fixation device in Q4, with further launches in this category expected in the first half of 2017. 
I know we went through this quickly. Thanks for your attention. I think we covered 26 new products in about 6 minutes, so now I'll turn you over to Chris."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restruc",855,"Thank you, John. Let start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restructuring and productivity initiatives. P&L impact to these items is detailed in the notes to the financial statement and the reconciliation accompanying our Q2 earnings press release. 
Now let's go through the statement of income for the quarter. Gross profit was $580.5 million or 62.3% of sales for Q2. On an adjusted basis, GP was $616.2 million or 66.2% of sales, up 140 basis points from the prior year quarter and better than the expected. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in GP, continuing the solid performance we saw in Q1. And FX was about 80 basis points of headwind to gross margin for the quarter. Mix was favorable by 110 basis points, which includes a positive impact from our Japanese business, and our cost improvement efforts drove approximately 120 basis points of favorability in Q2. 
Our cost savings and margin improvement programs are on track, and we now expect to exceed the original full year guidance for GPs that we gave you in January. 
SG&A expenses were $278.5 million for the quarter or 29.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 29.7%, 70 basis points above the prior year. Consistent with how we guided the full year as we integrate the recent acquisitions, we expect this leverage to improve somewhat in the second half. 
I would reiterate that as we see opportunities to do so, we will continue to make incremental investments in certain targeted areas, including, for example, emerging markets and our health economics capabilities. 
R&D expenditures totaled $71.3 million for the second quarter or 7.7% of sales on a reported basis. On an adjusted basis, R&D expenses as a percentage of sales was 7.6%, up 30 basis points from the prior year and consistent with our full year guidance. We do expect a somewhat higher level of R&D investment spending in Q3. 
Interest expense was $13.4 million for the second quarter, and other income and expense was $9.6 million of expense for the second quarter as reported and $2.1 million of income on an adjusted basis. The effective tax rate for the quarter was 25.4%, down 60 basis points from the prior year. 
Diluted shares for the period were 75.2 million, and we repurchased approximately 103,000 shares during the second quarter. The net result is adjusted EPS of $2.54, which excludes items affecting comparability and the amortization of intangibles. This was above the range we provided for the quarter, driven primarily by the overachievement in sales. 
The balance sheet as of June 30, reflects cash, restricted cash and short-term investments of $1 billion, similar to March 31. For the quarter, accounts receivables days were down 2.1 days, and inventory days were up 6.8 days, as we responded to recent inventory depletion from increased demand. Capital expenditures totaled $17.9 million for the quarter. 
On the liability side, total debt was $1.6 billion as of June 30 compared to $1.7 billion at March 31. Debt-to-total capital at the end of the second quarter was about 50%, and total shareholder investment was $1.6 billion at June 30. 
Moving to financial guidance. Given the strong first half of the year, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 8% and 9%, with reported sales growth between 7% and 8%, now implying a currency headwind of about 1%. On an organic basis, we had originally guided the year to be between 5% and 6%, but now expect that range to be between 6.5% and 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.10 and $10.20, representing 11% to 12% growth. U.S. dollar has strengthened somewhat since our last earnings call, and we now expect foreign exchange to be between $0.25 and $0.28 of headwind for the full year. So on an FX-neutral basis, we're guiding to 14% to 15% growth for all of 2016. 
For Q3, we're expecting constant currency sales growth between 8% and 9%, with reported sales growth between 7% and 8%, also implying an FX headwind of about 1% on the revenue line. This assumes organic growth between 6% and 6.5% for the third quarter. 
From an adjusted EPS standpoint, we forecast third quarter in the range of $2.51 to $2.55, representing 10% to 12% growth on a reported basis. 
In summary, the first half of the year has gone well from both a sales and profitability perspective. As we now move to the second half, we remain focused on our continued execution, including smartly investing in strategic opportunities. The overall objective of our balanced efforts is to drive attractive and sustainable revenue growth, profitability and shareholder returns over the long term. 
I'll now turn the call back to Tim."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?",29,"Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America.",15,"[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So good solid Q2. Wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers and now you've",92,"So good solid Q2. Wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers and now you've reported Q2 results. So with that in mind, can you give us a sense as to what you're seeing broadly with surgical procedure volumes in the second quarter versus the first quarter? Just want to see if you're picking up on anything that's kind of worth noting."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky. So hard to predict where that moves. There's a lot of moving parts that affect health care usage these da",96,"Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky. So hard to predict where that moves. There's a lot of moving parts that affect health care usage these days in the U.S., in particular, as you know. But as we watch other companies report, obviously, we've seen good healthy growth in the quarter. So it appears that the improvement seems to be holding, at least, over the flattish levels that it been the last few years."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there, but just want to try to get a specific as we can kind of growing at the same",91,"And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there, but just want to try to get a specific as we can kind of growing at the same rate they've been the last couple of quarters? And then maybe if you could just give us a quick comment on hernia and how sustainable these low double-digit growth rates are that you've been achieving here these last couple of quarters."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll let John Weiland address both of those issues.",10,"Sure. I'll let John Weiland address both of those issues."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across the board. So we don't have any concerns there about our ability to continu",182,"Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across the board. So we don't have any concerns there about our ability to continue to grow. And I think that you hit the nail on the head in terms of growth in our surgery business. And in particular, our synthetic hernia, which is the largest segment in hernia repair by far for us, had some of the finest growth we've seen in 8 to 10 years. And in fact, the independent market share data that we saw for Q1 saw us pick up 7 share points in Q1 alone. So we have great momentum driven by the new product portfolio and the -- and as well as the products that we said that we're going to be launching, such as the new products in fixation. So I think if you look at biologics, fixation and synthetics, so I think we're hitting on all cylinders there in surgery right now."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question -- I'm sorry, did you have something to add? Okay, we'll go to Brooks West with Piper Jaffray.",21,"Our next question -- I'm sorry, did you have something to add? Okay, we'll go to Brooks West with Piper Jaffray."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom on for Brooks. If I could, I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat that an average U.S. rep has a customer value of about $4 million annually and",95,"This is Tom on for Brooks. If I could, I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat that an average U.S. rep has a customer value of about $4 million annually and then in emerging markets rep was closer to $700,000. Just kind of hopeful that you could help us think about what that right study state number is for emerging markets rep. And it's something like half or $2 million fair or how should we think about that?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Don't sell everything. So by def",145,"Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Don't sell everything. So by definition and design, we're much more targeted in these markets. So you're never going to get a comparable dollar value per bag or it would be an exception for probably some [indiscernible] and on a rep-per-rep basis just based on the volume of SKUs that we're going to put in emerging market bag versus the U.S. bag. So it's a tough number for us to know for sure, but I'm not sure the answer's worth the chase. I think it's more directional in terms of potential of the headcount versus trying to get to a mathematical answer."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. S",132,"And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. So by definition, when you're building these markets from scratch, it takes an awful lot of effort in terms of training, in terms of identifying the right individuals to train. So we're always going to be chasing that. I think the other dimension is that, for example, we had a 225 reps last year in emerging markets, continue to add more this year. So it philosophy and our investment plan continues to we're always going to be chasing this number because that's our first source of adding new reps."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and perhaps, what the biggest opportunities in that geography are for Bard.",41,"Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and perhaps, what the biggest opportunities in that geography are for Bard."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right produc",149,"Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right product lines. That's gone extremely well. I think that we certainly have benefited by the change in the yen. That has improved the profitability for us and has allowed us to continue to make investments in that business where applicable. And I think if we look at our overall portfolio, we have to say that in the Vascular area and the area of Oncology, they are the 2 areas that were underpenetrated in Japan and that we're putting more resources and more capabilities in our existing business over there. That's where we think we have the most significant growth opportunities."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question will come from David Lewis with Morgan Stanley.",11,"Our next question will come from David Lewis with Morgan Stanley."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And al",64,"This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And also, can you speak to any selling day impacts we should be aware of for the back half?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think for the full back half, it's going to -- there's within quarters, there's a little bit of noise, but there shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, frankly, in Q2",130,"I think for the full back half, it's going to -- there's within quarters, there's a little bit of noise, but there shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, frankly, in Q2. And I think the math allows you to get to growth rates that, frankly, are pretty consistent, certainly at the high end of the range, but consistent with what we delivered in Q2. And that's -- frankly, that's really solid constant currency reported revenue growth and really solid, and I'd say, high-quality net income and EPS growth. So again, there's a range, Scott, for reasons. But I think the math allows you to show continued really strong performance through the next 2 quarters."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on home care market?",31,"Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on home care market?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that were",112,"Yes, I think similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that were behind the acquisition that really capturing more prescriptions and having those prescriptions then end up within Liberator family over time. So the growth rates, we obviously gave you some color on what Urology and what the different categories look like on an organic basis. But Liberator is growing exactly as we had hoped. And frankly, we're little bit ahead of where we thought we would be at this stage of the game."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Mike Weinstein with JPMorgan.",10,"And we'll go next to Mike Weinstein with JPMorgan."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Robbie Mark in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed, b",82,"This is Robbie Mark in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed, but also Urology and Vascular. Both really good numbers, Urology, 4% organic, Vascular at 6%. So maybe you could just touch on those for a minute and talk about what's driving that, particularly in Vascular."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","John, you want to take that?",6,"John, you want to take that?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had with we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we st",228,"Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had with we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we stand on the potential new indications for Lutonix, which in our minds will be a great competitive edge for us in that business. Our biopsy business has been tremendously strong and our emerging markets performance, particularly China in biopsy, has been terrific. Urology, we talked about the components of Urology. The Urology market, if you look at the basic drainage business, is not growing in the United States at all. In fact, it's relatively flat, maybe up 1%. But some of the new product offerings that we've introduced into that market, especially our Sure Step tray, has allowed hospitals to upgrade within their own existing framework. And that's given us a mixed differential, which is driving really a substantial portion of growth in basic drainage for us. And I'd also like to add, one of the areas that may not come out, but we have had excellent growth in Europe. They had another terrific quarter this quarter for us. And we've always been delighted with our growth in emerging markets, and that continues to be a really big positive for the corporation."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And maybe if I could just follow up on that. You mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?",39,"And maybe if I could just follow up on that. You mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the share question, we reference data that we've seen from third parties. I continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong sequential",205,"I think the share question, we reference data that we've seen from third parties. I continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong sequential growth within our business. I think the estimates that folks had coming into this year, Europe is still a relatively small number, where we continue to take share there as well. That's frankly been held back, I think, as folks wait for some Below the Knee data, which we're anxious to be the one to provide them for. So we think that data went and if does arrive, will really allow the opening of the European market and really have that growth really kick back in again. So we're -- I think we're pleased with how the market's growing. We're pleased with how we're continuing to hold and gain share. And most importantly, I think when we look out over the next 2, 3, 4 years, the portfolio of indications that we're going to have within the company, within Lutonix and the DCB franchise is going to be absolutely unrivaled. And we think that really sets us up in a very unique position."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all commerce, real-life views show",54,"The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all commerce, real-life views shows just tremendous efficacy of the Lutonix product line."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question comes from Larry Keusch with Raymond James.",10,"Our next question comes from Larry Keusch with Raymond James."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim or John, I wanted to come back to PICCs. 10% growth in the quarter. Obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So I was just hoping if you could help us dec",71,"Tim or John, I wanted to come back to PICCs. 10% growth in the quarter. Obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So I was just hoping if you could help us deconstruct that 10% a little bit, put in the context of the market and what products are really driving that for you."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and mid-lines in Europe. That has been an excel",120,"Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and mid-lines in Europe. That has been an excellent arena for us. We're starting to gain momentum in Japan based on the emphasis that we talked about before. And we continue to have strong growth in the United States. So it's a very balanced approach that where we're trying to grow PICCs. It's a core franchise for us. We're making the investments where we need to continue that growth on tracking. We like what we're seeing around the world in PICCs right now."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And part of",96,"The only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And part of what you're seeing is as actually executing against that opportunity. And to John's point, tremendous growth in Europe. A huge untapped opportunity in Japan and China we're creating that market as we go and seeing tremendous growth there that we think has a lot of legs still to come."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","And I'd just jump in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years.",41,"And I'd just jump in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","John, that actually was just a segue way to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put",79,"John, that actually was just a segue way to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put the chemical-resistant into perspective. Is that kind of a nice to have? And really the thromboresistant product is going to be the next real big growth driver? Or am I thinking about that incorrectly?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not rea",111,"Well, I think that one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not really ready to talk about today that'll bring that more to light as we go out into the future. But then our Provina family, which is what we're calling our thromboresistant DVT-resistant technology, we'll begin launching that. And we do things that both of those are going to fit important niches in the marketplace. And I think we're just really excited to have them both out there."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Terrific. And then -- and Chris, quickly, just help me understand. I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross marg",68,"Okay. Terrific. And then -- and Chris, quickly, just help me understand. I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross margin. And then separately, just your thoughts on the second half for price given what we've seen in the first half."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. It's a little bit of",71,"Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. It's a little bit of a hangover into Q2 and a very slight hangover the rest of the year, but it was really that Japan factor that caused that sequential move."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then price for the second half?",7,"And then price for the second half?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we're obviously really pleased that the first 6 months and the teams are frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflect",82,"I think we're obviously really pleased that the first 6 months and the teams are frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflected in our ability to provide the higher sales guidance. But we're certainly not ready to say 40 basis points is the new normal. But certainly, I think between 50 and 100 is probably what we're thinking about."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","We now have a question from Kristen Stewart from Deutsche Bank.",11,"We now have a question from Kristen Stewart from Deutsche Bank."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just want to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think the first quarter you guys had 9% organic growth, then it was 7.1% both great numbers. But",119,"I just want to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think the first quarter you guys had 9% organic growth, then it was 7.1% both great numbers. But I'm just wondering what kind of those just kind of quarter-over-quarter or year-over-year rather comp issue or because it sounds like everything is continuing to go very well in the marketplace and it sounds like a comment suggest more of a continued strengthening. And it looked like the U.S. was up 9 last quarter and up 7. So I'm just wondering if it's just simply year-over-year comparison or if there is..."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was by far our easiest comp of the year, coming out of t",242,"Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was by far our easiest comp of the year, coming out of that big Q4 and working through some inventory in Q1. Flip to Q2, we're obviously don't have that and then also have the headwind associated with the Boston stocking order. We had talked about ports. There was a drag. We had a weak Q4 as we got ready for some new product launches in Q1. So ports were very strong in Q1. Biopsy was also incredibly strong in Q1 on the back of China. In China, in general, we called out that China had an absolute phenomenal Q1. Some of that was again as we're building out the BioSurgery sales force, there were some stocking that went on as well. China had a terrific Q2, but certainly, somewhat slower then again an unusual Q1. So I think the message we wanted to have you understand coming out of Q1, terrific quarter. Some more onetime items, but leading into a Q2 that was going to be also very strong organically. So actually, the good news is it came out exactly as we had thought, and the items that were more of a tailwind in Q1, indeed, played out the way we thought in Q2."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So would it be fair, I guess, to think about I guess, the first half as the run rate? Because I guess, it's more of like an 8. And I guess your guidance now is more of a 6.5% to 7%.",42,"Okay. So would it be fair, I guess, to think about I guess, the first half as the run rate? Because I guess, it's more of like an 8. And I guess your guidance now is more of a 6.5% to 7%."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that -- I mean, that 6.5% to 7% I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact over last year. We had noted we launched a numbe",145,"I think that -- I mean, that 6.5% to 7% I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact over last year. We had noted we launched a number of Lutonix additional lengths in Q3, and so Boston needed to stock all of those lengths in Q3 as well. So they'll be a stocking phenomenon in Q3. It'll be a little bit less than the Q2 stocking, but just to let you know that that's coming as well. So I think the way we're seeing the business is we're growing pretty comfortably in that 6.5-ish percent organic range. And it's really balanced, which I think is very important and I think speaks to the quality of the overall results."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So a little bit better volumes and a little bit better price from.",14,"Okay. So a little bit better volumes and a little bit better price from."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And also just curious going back and be doing just a look at Rochester. Were you guys able to get to the level of margin improvement from a gross",59,"Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And also just curious going back and be doing just a look at Rochester. Were you guys able to get to the level of margin improvement from a gross margin perspective with that deal now that it's almost 3 years?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facilities is actually still ongoing this year. We'll complete it towards the end of this year and earl",84,"Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facilities is actually still ongoing this year. We'll complete it towards the end of this year and early in '17. And it's been a lot of work for the team, but we feel good about how we're trending there and feel really good about that acquisition overall for sure and certainly as we now augmented it with Liberator."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think the valuations always need to make sense to us. And that needs to be on top of a strategic",131,"I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think the valuations always need to make sense to us. And that needs to be on top of a strategic rationale that's pretty compelling. And so again, we haven't announced anything because we're not trying to find the things that make sense. But I think the takeaway you should have is that we're continuing to be disciplined and stick to the strategy that we've laid out for you. And the kinds of things we've done recently, we're trying to find more of those. And I'm confident we will, but just through the first 6 months. The stars haven't aligned."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Matt Taylor with the Barclays.",10,"Our next question is from Matt Taylor with the Barclays."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number",73,"So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number. And then you talked about the benefit of Liberator in Japan. Can you parse those out between, I guess, the contribution to Urology?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, you were doing this because the Japan impact on top of the acquisitions is pretty important. So again, and I'm not going to give you the spec",202,"Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, you were doing this because the Japan impact on top of the acquisitions is pretty important. So again, and I'm not going to give you the specific numbers. But Urology, again, stripping out the impact of Liberator and the impact of Japan, grew 4% organic for us in the quarter, which again is a very solid result. Vascular, were a big drag from sales of EP products to Boston. We had continued the OEM product for them through all of last years. They stood up their own manufacturing. And so they have been building inventory this time last year. And there buying very, very little from us now. So big drag there. And the Gore royalty of $39 million. When you strip all of those out as well as the Japan impact, Vascular grew 6 organic overall. And then again, that's in the phase of the Lutonix stocking order as well, which we've called out as about 70 basis points overall to total organic. So the 6.4 becomes a 7.1 when you adjust for the Lutonix stocking."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from jus",51,"Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from just Bard expanding its footprint and infrastructure."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","We saw another quarter where we're grown about 20% overall. John said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good about the sec",127,"We saw another quarter where we're grown about 20% overall. John said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good about the second half and going forward there. To John's other point, in China, we're creating a lot of these markets as we go. And so while there's been a lot of noise about slowdowns and macro factors impacting growth rates, we haven't seen that in China. PICCs are going terrifically well. Biopsy is going terrifically well. We're now building an app built a direct BioSurgery sales force and excited about that opportunity. We have our Lutonix SFA trial enrolling in China."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Just launched a new biopsy product there.",7,"Just launched a new biopsy product there."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term. And given the market o",95,"As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term. And given the market opportunities we're targeting. And as Tim said, we're pretty targeted about the products that we bring to market there. And they're generally trying to serve a very specific need. In some cases, a need that's not yet been met by other products and PICCs the best example in China."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I would add, though, to it that we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too.",32,"I would add, though, to it that we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Anthony Petrone with Jeffrey's.",10,"And we'll go next to Anthony Petrone with Jeffrey's."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point? And when that agreement gets renewed. And then the longer-term",72,"Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point? And when that agreement gets renewed. And then the longer-term target of $1.5 billion by 2020 for the category, I'm just wondering how much of that is Below the Knee indications and then one strategy question to follow up with."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","If you look at our EP business, when we entered into that agreement and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall business. I",88,"If you look at our EP business, when we entered into that agreement and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall business. It doesn't mean it's not important in certain segments that you're focusing on, and it doesn't mean the partnership is not going well. But it is not a large percentage, by any sense of imagination in terms of our overall Lutonix business."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","In terms of the market size, Anthony, we target the Below the Knee opportunity at about $350 million globally by 2020. SFA and popliteal in the 8 50 range globally. And then other indications, including AV access, which we're really excited about where we",95,"In terms of the market size, Anthony, we target the Below the Knee opportunity at about $350 million globally by 2020. SFA and popliteal in the 8 50 range globally. And then other indications, including AV access, which we're really excited about where we are clinically there at another $250 million. And what really excites us, when you look across all those indications in 2020, we're the only company. We believe that's going to have approvals in all those areas, and we think that is going to really position us well over that time frame."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And just a strategy one. The reverse on the M&A environment, when you consider the valuations here have improved, I'm just wondering if the divestitures have moved out the priority scale for assets that are maybe slower growing and not as",53,"That's helpful. And just a strategy one. The reverse on the M&A environment, when you consider the valuations here have improved, I'm just wondering if the divestitures have moved out the priority scale for assets that are maybe slower growing and not as core of the business at this point in time."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we -- I think of the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out with a ne",100,"Yes, we -- I think of the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out with a next-gen product, that are in decline. But we'd much rather have the management time focused on growth, and we've got plenty of opportunities with investments that we've made to do that rather than focusing on a product line here and there that might be a bit of a drag."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And our next question will come from Matt Mishan with KeyBanc.",11,"And our next question will come from Matt Mishan with KeyBanc."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","First question from me is can you help me walk from your previous earnings guidance to your new guidance I think by about $0.09 in the quarter, but only raised EPS guidance by about 4. And you also were able to bump the sales guidance.",45,"First question from me is can you help me walk from your previous earnings guidance to your new guidance I think by about $0.09 in the quarter, but only raised EPS guidance by about 4. And you also were able to bump the sales guidance."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year actually has worsened by call it $0.05 to $0.08, so at the midpoint, sort of $0.6.5. And it's really, for us, driven",264,"Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year actually has worsened by call it $0.05 to $0.08, so at the midpoint, sort of $0.6.5. And it's really, for us, driven by the pound, the RMB has sort of quietly weakened relative to the dollar. The euro, Aussie dollar, Canadian dollars have all moved relatively materially. Now it was very late in Q2, but as we sit here today, those are all going to cost us in combination $0.06 or $0.07. So effectively, offset virtually all of the beat to the consensus number in Q2. And as we talked about on the Q1 call, and as I reiterated again today, we're continuing to invest incrementally as we have the opportunity to do so. So I think the strength of the operating performance so far is allowing us to continue to make investments this year that coming into the year, we frankly didn't think we were going in position to do. And we think that's the right thing to do for the long term. I think looking at Q2 of an 8 3 [ph] reported and a 12 reported bottom line, very high quality. And us taking some of the upside that we've delivered to invest back into the business we think is in the right balance. And you're seeing us continue to do that, and that's frankly also reflected in the guidance that we've just laid out for the remainder of the full year."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","That would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, we're seeing the size of the opportunity in our ability to invest. And as you can see, that's a large, large clinical trial. Th",83,"That would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, we're seeing the size of the opportunity in our ability to invest. And as you can see, that's a large, large clinical trial. That's an example of some of the things that we turned on when we saw we had a little bit of an opportunity based in our performance. And that is only one example, quite frankly."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last",69,"Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last year. And then how should we be thinking about the comparison  fourth quarter comparison in particular, from Japan and Medicon?"
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","So Q3, there'll be less of an impact in Q3, and then even lesser impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a full qu",98,"So Q3, there'll be less of an impact in Q3, and then even lesser impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a full quarter of sales through to the customers compared to last year where again we had to work through the inventory that was resident at the JV when we closed that transaction in early November. So there's couple of puts and takes related to both of those."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Just one clarification there, Matt. The EP step-down really begun in Q4, so Q3 would still be significant reduction, similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less.",37,"Just one clarification there, Matt. The EP step-down really begun in Q4, so Q3 would still be significant reduction, similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments.",24,"And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll tal",52,"Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll talk to you again next quarter."
254131,370602062,1012689,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect.",28,"Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand",277,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's March 31, 2016 Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of July 26, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I'd expect the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an hour. I'",519,"Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I'd expect the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck that's available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The discussion today will go as follows: I'll begin with an overview of the results for the second quarter of 2016; John Weiland, our President and COO, will review second quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you a brief update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will go over the second quarter income statement and balance sheet as well as our expectations for the third quarter and the remainder of the year; and then finally, we'll close with Q&A.
Second quarter 2016 net sales totaled $931.5 million. That's up 8% over Q2 of last year on an as-reported basis and up 9% on a constant currency basis. The currency impact for the quarter versus the same quarter last year was unfavorable by about 70 basis points. 
The organic growth rate was approximately 6.4% this quarter, which exceeded our expectations. As we told you earlier, the prior year Q2 included the initial stocking of Lutonix by Boston Scientific. And when you factor that in, our organic sales growth would have been above 7%. 
Net income for the second quarter of 2016 was $159.2 million, and diluted earnings per share were $2.11. Excluding amortization of intangibles and items that affect the comparability of results between periods, which Chris will cover later, adjusted second quarter 2016 net income and diluted earnings per share were $192.2 million and $2.54. That's up 11% and 12%, respectively. These adjusted results exceeded the guidance we provided for the quarter, and the first half of the year has come in stronger than we had projected at the beginning of the year. 
Looking at revenue growth geographically compared to the same quarter last year, Q2 net sales in the U.S. increased 7% on a constant currency basis; Europe grew 7%; Japan was up 29%, benefiting from moving the customer pricing after the acquisition of our JV partner; and our other international businesses grew 15%. We continue to see strong growth in emerging markets, which represented 10% of our total sales in the second quarter. 
As John Weiland takes you through the product lines, you'll see that we continue to have sustained momentum across all of our businesses even in the face of the tougher comps that we previewed for you last quarter. We continue to believe that executing our strategy will position us to continue to achieve an above-market revenue growth rate for the overall portfolio with attractive returns for shareholders. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's begin with Vascular. Total net sales were $25",775,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. 
So let's begin with Vascular. Total net sales were $255.3 million, up 3% over last year on both an as-reported and constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 6% in Q2, with the United States business, up 3%; and international up 12%. 
Sales in our Surgical Graft category were up 5% in the second quarter, within the range of recent experience. Our Endovascular business grew 6% in the second quarter. Our peripheral PTA line grew 10% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. The growth rates may look a little lumpy quarter-to-quarter from stocking events in the prior year, but we track average daily sales as a metric, and we continue to see good sequential momentum in both the United States and internationally. And we have third-party data that shows us maintaining our leadership position in this important long-term market opportunity. 
Our Stent business grew 1% in the second quarter, and sales in our vena cava filter line were down 13%. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally despite running up against the tougher comps we talked about last quarter. 
Now let's go to Urology. Total net sales were $240.0 million, up 15% on an as-reported and up 16% on a constant currency basis compared to the second quarter of 2015. The combination of the first full quarter of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in the category. Excluding these 2 acquisitions, the United States business was up 4% while, internationally, we grew 5%. 
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 6%, both globally and in the United States, with our infection control Foley business up 2% globally and 3% in the United States. 
Our Targeted Temperature Management products grew 19% this quarter, demonstrating continued momentum in this significant long-term opportunity. 
Our continence business was up 34% in the second quarter, all driven by the benefit from the new acquisitions. 
Sales in Urological Specialties were up 9% this quarter, including our brachytherapy business, which grew 7%, driven by Japan. 
And finally, in this category, stand-alone sales of our StatLock catheter-stabilization line decreased 5% in Q2. 
Now let's go to Oncology. Total net sales in this category were $252.4 million, an increase of 7% as-reported and 8% on a constant currency basis over Q2 last year. The Japan acquisition added 200 basis points to growth globally. Excluding that, sales in the United States were up 4%, and international sales were up 13%. 
Our port business was up 4% versus the second quarter of last year. Our PICC business was up 10% this quarter, with continued impressive growth outside of the United States. As you'll hear from John DeFord, we continue to advance our PICC and midline portfolio. 
Our vascular access ultrasound product line grew 4% this quarter. And to close out the category, our Dialysis Access product line was up 13%. 
So let's conclude with our Surgical Specialties business. Total net sales in this category were $159.9 million, up 11% as-reported and 12% on a constant currency basis. United States sales were up 11%, and international sales were up 13% this quarter, excluding the impact from Japan, which was minimum. 
Our Performance Irrigation business was down 3%, and now represents less than 1% of our total company sales. Our soft tissue repair business continued its strong momentum, growing 12% in Q2. Our broad product offering and our value-added programs that help customers select the right product for the patient are having a significant impact on the treatment paradigm, with more procedures shifting from natural tissue to our synthetic hernia portfolio and, specifically, our Phasix material. Our synthetics business grew 18% this quarter, while our natural tissue products declined 27%. 
In our hernia fixation business, which is included in soft tissue repair subtotal, grew 49% this quarter on the continued impact from our recent product launches here. 
Closing out the surgical category, in the second quarter, our BioSurgery business grew 16% and now represents between 20% and 25% of our Surgical Specialties business. This continues to represent a significant long-term opportunity for us. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. We'll start with our drug-co",1000,"Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. 
We'll start with our drug-coated balloon pipeline. Our long lesion supplement is under review at FDA, and we're hopeful for approval of this expanded indication for the treatment of lesions up to 300 millimeters in length around year-end. In our Below-the-Knee IDE, enrollment is progressing, and we're optimistic regarding our discussions with the FDA to bring this important treatment option to patients. The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a look at our results in Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late-Q4 2017 U.S. launch. 
We're also on track to submit clinical data for the in-stent restenosis PMA later this quarter. 
In Japan, our shown in submission for the Lutonix SFA indication is under review, and we anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began last quarter. 
Also in Vascular, in Q2, we launched our new True Flow Valvuloplasty balloon family. This proprietary product is designed to reduce the stress placed on the heart by allowing blood to flow through the device during the procedure with limited restriction and back pressure. Early clinical results have also shown that, in most cases, rapid pacing to reduce blood pressure has not been required. 
Also in Q2, we received FDA approval for the LifeStent system, with indications covering the entire popliteal artery. The LifeStent platform is now the first and only self-expanding stent in the U.S. with this indication. Labeling is being updated, and our launch and education programs will commence this quarter. 
In stent grafts, LifeStream Balloon Expandable covered stent trial has completed follow-up, and the final PMA module was submitted last week to FDA, with approval and launch expected in mid-2017.
Our Covera next-generation AV access circuit stent graft received IDE approval a couple of weeks ago, and we anticipate commencing enrollment later this quarter or in early Q4. We expect enrollment will take about a year.
Our Venovo venous stent IDE study is in active recruitment. We anticipate enrollment throughout this year with follow-up in 2017 and PMA submission in 2018.
In biopsy, we just began the rollout of the ENCOR ENSPIRE system in China. In addition, the UltraCor Twirl breast biopsy marker just launched in the U.S. and Europe about a quarter ahead of our schedule.
Now moving to Urology and home care, we continue to advance our broad-based initiatives designed to reduce catheter-associated urinary tract infections through the launch of additional SURESTEP Foley Trays and our new SURESTEP Daily Care product. The SURESTEP Trays are helping standardize indwelling catheter placement around known guidelines. Our SURESTEP Daily Care product extends the solution to the maintenance phase and supports compliance to cleaning standards and awareness of indwelling time. Customers find this particularly helpful, especially in light of increasing nursing turnover.
In endourology, Q2 heralded the launch of 2 new stone basket configurations in our SkyLite platform, providing a full range of sizes. And in Targeted Temperature Management, this quarter, we received IDE approval for our new neurogenic fever prevention and control clinical study. This study will evaluate the use of the ARCTIC SUN system in this new indication. The study is anticipated to enroll more than 1,000 patients and will probably take about 3 years to complete. 
Moving to Oncology, we've had a very busy few weeks since the Analyst Day. We received clearance on our new chemical-resistant PowerPICC family named the PowerPICC EtOH. This new family will begin launching this quarter and is especially designed with a proprietary material that maintains all of the benefits of the PowerPICC and can withstand greater exposure to the sometimes harsh chemistry used in today's therapies. 
We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis or DVT. We remain on plan to launch products in this new family in the back half of the year. 
We also received FDA clearance on our new power midline and clearance for our PowerGlide Pro family of intermediate dwell catheters. Both of these products just launched and are shipping to customers. 
This quarter, we added 3 new applications to our Tip Confirmation portfolio for pediatrics, ports and central lines due to launch of a first-generation system in Europe. We're also developing an advanced version slated for launch in the U.S. and other geographies later this year. 
I'll close my portion of prepared remarks today with surgery. As we discussed a few weeks ago, the TRIDYNE aortic sealant was approved by the FDA, and we're preparing to launch in the back half of this year. We're also working toward the launch of the Progel Emerald sealant, designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to anticipate the launch of additional Phasix resorbable mesh sizes throughout the remainder of the year. This expansion is planned to provide surgeons and their patients the largest and most comprehensive size matrix in the market, including a 50-centimeter by 50-centimeter mesh. 
On the clinical front, we've completed 1-year follow-up in our Phasix clinical study of over 100 ventral hernia patients and expect results to be presented and published later this year. Similarly, additional clinical data for our XenMatrix AB product family is expected to be released later this year. 
And finally, in mesh fixation, we anticipate launching the 15-count version of our OPTIFIX resorbable fixation device in Q4, with further launches in this category expected in the first half of 2017. 
I know we went through this quickly. Thanks for your attention. I think we covered 26 new products in about 6 minutes, so now I'll turn you over to Chris."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restr",855,"Thank you, John. Let's start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restructuring and productivity initiatives. P&L impact to these items is detailed in the notes to the financial statement and the reconciliation accompanying our Q2 earnings press release. 
Now let's go through the statement of income for the quarter. Gross profit was $580.5 million or 62.3% of sales for Q2. On an adjusted basis, GP was $616.2 million or 66.2% of sales, up 140 basis points from the prior year quarter and better than we expected. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in GP, continuing the solid performance we saw in Q1. And FX was about 80 basis points of headwind to gross margin for the quarter. Mix was favorable by 110 basis points, which includes the positive impact from our Japanese business, and our cost improvement efforts drove approximately 120 basis points of favorability in Q2. 
Our cost savings and margin improvement programs are on track, and we now expect to exceed the original full year guidance for GP that we gave you in January. 
SG&A expenses were $278.5 million for the quarter or 29.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 29.7%, 70 basis points above the prior year. Consistent with how we guided the full year, as we integrate the recent acquisitions, we expect this leverage to improve somewhat in the second half. 
I would reiterate that as we see opportunities to do so, we will continue to make incremental investments in certain targeted areas, including, for example, emerging markets and our health economics capabilities. 
R&D expenditures totaled $71.3 million for the second quarter or 7.7% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.6%, up 30 basis points from the prior year and consistent with our full year guidance. We do expect a somewhat higher level of R&D investment spending in Q3. 
Interest expense was $13.4 million for the second quarter, and other income and expense was $9.6 million of expense for the second quarter as reported and $2.1 million of income on an adjusted basis. The effective tax rate for the quarter was 25.4%, down 60 basis points from the prior year. 
Diluted shares for the period were 75.2 million, and we repurchased approximately 103,000 shares during the second quarter. The net result is adjusted EPS of $2.54, which excludes items affecting comparability and the amortization of intangibles. This was above the range we provided for the quarter, driven primarily by the overachievement in sales. 
The balance sheet as of June 30, reflects cash, restricted cash and short-term investments of $1 billion, similar to March 31. For the quarter, accounts receivables days were down 2.1 days, and inventory days were up 6.8 days, as we responded to recent inventory depletion from increased demand. Capital expenditures totaled $17.9 million for the quarter. 
On the liability side, total debt was $1.6 billion as of June 30 compared to $1.7 billion at March 31. Debt-to-total capital at the end of the second quarter was about 50%, and total shareholder investment was $1.6 billion at June 30. 
Moving to financial guidance. Given the strong first half of the year, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 8% and 9%, with reported sales growth between 7% and 8%, now implying a currency headwind of about 1%. On an organic basis, we had originally guided the year to be between 5% and 6% but now expect that range to be between 6.5% and 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.10 and $10.20, representing 11% to 12% growth. U.S. dollar has strengthened somewhat since our last earnings call, and we now expect foreign exchange to be between $0.25 and $0.28 of headwind for the full year. So on an FX-neutral basis, we're guiding to 14% to 15% growth for all of 2016. 
For Q3, we're expecting constant currency sales growth between 8% and 9%, with reported sales growth between 7% and 8%, also implying an FX headwind of about 1% on the revenue line. This assumes organic growth between 6% and 6.5% for the third quarter. 
From an adjusted EPS standpoint, we forecast third quarter in the range of $2.51 to $2.55, representing 10% to 12% growth on a reported basis. 
In summary, the first half of the year has gone well from both a sales and profitability perspective. As we now move to the second half, we remain focused on our continued execution, including smartly investing in strategic opportunities. The overall objective of our balanced efforts is to drive attractive and sustainable revenue growth, profitability and shareholder returns over the long term. 
I'll now turn the call back to Tim."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?",29,"Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America.",15,"[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So good solid Q2. Tim, I wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers, and no",94,"So good solid Q2. Tim, I wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers, and now you've reported Q2 results. So with that in mind, can you give us a sense as to what you're seeing broadly with surgical procedure volumes in the second quarter versus the first quarter? Just want to see if you're picking up on anything that's kind of worth noting."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky, so hard to predict where that moves. There's a lot of moving parts that affect health care usage these da",96,"Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky, so hard to predict where that moves. There's a lot of moving parts that affect health care usage these days in the U.S., in particular, as you know. But as we watch other companies report, obviously, we've seen good healthy growth in the quarter. So it appears that the improvement seems to be holding, at least, over the flattish levels that it'd been the last few years."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there. But just want to try to get as specific as we can, are they kind of growing a",93,"And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there. But just want to try to get as specific as we can, are they kind of growing at the same rate they've been the last couple of quarters? And then maybe if you could just give us a quick comment on hernia and how sustainable these low double-digit growth rates are that you've been achieving here these last couple of quarters."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll let John Weiland address both of those issues.",10,"Sure. I'll let John Weiland address both of those issues."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across-the-board. So we don't have any concerns there about our ability to continu",179,"Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across-the-board. So we don't have any concerns there about our ability to continue to grow. And I think that you hit the nail on the head in terms of growth in our surgery business. And in particular, our synthetic hernia, which is the largest segment in hernia repair by far for us, had some of the finest growth we've seen in 8 to 10 years. And in fact, the independent market share data that we saw for Q1 saw us pick up 7 share points in Q1 alone. So we have great momentum driven by the new product portfolio and the -- and as well as the products that we said that we're going to be launching, such as the new products in fixation. So I think if you look at biologics, fixation and synthetics, I think we're hitting on all cylinders there in surgery right now."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question, we'll go to Brooks West with Piper Jaffray.",11,"Our next question, we'll go to Brooks West with Piper Jaffray."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom Bakas on for Brooks. If I could I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat, at an average U.S. rep, has a customer value of about $4 million annually",95,"This is Tom Bakas on for Brooks. If I could I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat, at an average U.S. rep, has a customer value of about $4 million annually and then an emerging markets rep was closer to $700,000. I just kind of hope you could help us think about what the right study state number is for emerging markets rep. And if something like half or 2 million fair, how should we think about that?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Don't sell everything."" So by de",147,"Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Don't sell everything."" So by definition and design, we're much more targeted in these markets. So you're never going to get a comparable dollar value per bag or it would be an exception for probably some unique reason on a rep-per-rep basis just based on the volume of SKUs that we're going to put in an emerging market bag versus the U.S. bag. So it's a tough number for us to know for sure, but I'm not sure the answer's worth the chase, I think it's more directional in terms of the potential of the headcount versus trying to get to a mathematical answer."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. S",134,"And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. So by definition, when you're building these markets from scratch, it takes an awful lot of effort in terms of training, in terms of identifying the right individuals to train. So we're always going to be chasing that. I think the other dimension is that, for example, we had 225 reps last year in emerging markets, continued to add more this year. So if our philosophy and our investment plan continues to fold out, we're always going to be chasing this number because that's our first source of adding new reps."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and, perhaps, what the biggest opportunities in that geography are for Bard.",41,"Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and, perhaps, what the biggest opportunities in that geography are for Bard."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right produc",149,"Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right product lines. That's gone extremely well. I think that we certainly have benefited by the change in the yen. That has improved the profitability for us and has allowed us to continue to make investments in that business where applicable. And I think if we look at our overall portfolio, we have to say that in the vascular area and the area of oncology, they are the 2 areas that were underpenetrated in Japan and that we're putting more resources and more capabilities in our existing business over there. That's where we think we have the most significant growth opportunities."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question will come from David Lewis with Morgan Stanley.",11,"Our next question will come from David Lewis with Morgan Stanley."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And al",64,"This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And also, can you speak to any selling day impacts we should be aware of for the back half?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think for the full back half, it's going to -- there's -- within quarters, there's a little bit of noise, but there really shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, fran",133,"I think for the full back half, it's going to -- there's -- within quarters, there's a little bit of noise, but there really shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, frankly, in Q2. And I think the math allows you to get to growth rates that, frankly, are pretty consistent, certainly, at the high end of the range, but consistent with what we delivered in Q2. And that's -- frankly, that's really solid constant currency and reported revenue growth and really solid and, I'd say, high-quality net income and EPS growth. So again, there's a range, Scott, for reasons. But I think the math allows you to show continued, really strong performance through the next 2 quarters."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on the home care market?",32,"Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on the home care market?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that wer",114,"Yes, I think, similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that were behind the acquisition of really capturing more prescriptions and having those prescriptions that then end up within Liberator family over time. So the growth rates, we obviously gave you some color on what urology and what the different categories look like on an organic basis. But Liberator is growing exactly as we had hoped. And frankly, we're a little bit ahead of where we thought we would be at this stage of the game."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Mike Weinstein with JPMorgan.",10,"And we'll go next to Mike Weinstein with JPMorgan."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Robbie Marcus in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed,",83,"This is Robbie Marcus in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed, but also Urology and Vascular. Both really good numbers, Urology, up 4% organic; Vascular, up 6%. So maybe you could just touch on those for a minute and talk about what's driving that, particularly in Vascular."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","John, do you want to take that?",7,"John, do you want to take that?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had, we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we stand",227,"Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had, we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we stand on the potential new indications for Lutonix which, in our minds, will be a great competitive edge for us in that business. Our biopsy business has been tremendously strong, and our emerging markets performance, particularly China in biopsy, has been terrific. Urology, we talked about the components of Urology. The urology market, if you look at the basic drainage business, is not growing in the United States at all. In fact, it's relatively flat, maybe up 1%. But some of the new product offerings that we have introduced into that market, especially our SURESTEP Tray, has allowed hospitals to upgrade within their own existing framework and it's given us a mixed differential, which is driving, really, a substantial portion of growth in basic drainage for us. And I'd also like to add, one of the areas that may not come out, but we have had excellent growth in Europe. They had another terrific quarter this quarter for us. And we've always been delighted with our growth in emerging markets, and that continues to be, a really, big positive for the corporation."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And maybe if I could just follow up on that, you mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?",39,"And maybe if I could just follow up on that, you mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the share question, we've referenced data that we've seen from third parties that continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong seque",204,"I think the share question, we've referenced data that we've seen from third parties that continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong sequential growth within our business. I think the estimates that folks had coming into this year, Europe is still a relatively small number where we continue to take share there as well. That's frankly been held back, I think, as folks wait for some Below-the-Knee data, which we're anxious to be the one to provide them for. So we think that data, when and if it does arrive, will really allow the opening of the European market and really have that growth really kick back in again. So we're -- I think we're pleased with how the market's growing. We're pleased with how we're continuing to hold and gain share. And most importantly, I think when we look out over the next 2, 3, 4 years, the portfolio of indications that we're going to have within the company, within Lutonix and the DCB franchise is going to be absolutely unrivaled. And we think that really sets us up in a very unique position."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all-comers, real-life use, shows j",53,"The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all-comers, real-life use, shows just tremendous efficacy of the Lutonix product line."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question comes from Larry Keusch with Raymond James.",10,"Our next question comes from Larry Keusch with Raymond James."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim or John, I wanted to come back to PICCs, 10% growth in the quarter, obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So just hoping if you could help us deconstru",68,"Tim or John, I wanted to come back to PICCs, 10% growth in the quarter, obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So just hoping if you could help us deconstruct that 10% a little bit, put into context of the market and what products are really driving that for you."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and midlines in Europe. That has been an excell",122,"Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and midlines in Europe. That has been an excellent arena for us. We're starting to gain momentum in Japan based on the emphasis that we talked about before, and we continue to have strong growth in the United States. So it's a very balanced approach of where we're trying to grow PICCs. It's a core franchise for us. We're making the investments where we need to, to continue that growth on track. And we like what we're seeing around the world in PICCs right now."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, the only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And pa",96,"Yes, the only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And part of what you're seeing is us actually executing against that opportunity. And to John's point, tremendous growth in Europe, a huge untapped opportunity in Japan and China, we're creating that market as we go and seeing tremendous growth there that we think has a lot of legs still to come."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Can I just -- jumping in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years.",41,"Can I just -- jumping in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So John, that actually was just a segue to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put t",78,"So John, that actually was just a segue to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put the chemical-resistant into perspective. Is that kind of nice to have? And really the thromboresistant product is going to be the next real big growth driver? Or am I thinking about that incorrectly?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that, one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not re",111,"Well, I think that, one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not really ready to talk about today that'll bring that more to light as we go out into the future, but then our PROVENA family, which is what we're calling our thromboresistant, DVT-resistant technology, we'll begin launching that. And we do think that both of those are going to fit important niches in the marketplace. And I think we're just really excited to have them both out there."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Terrific. And then -- and Chris, quickly, just help me understand -- I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross ma",69,"Okay. Terrific. And then -- and Chris, quickly, just help me understand -- I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross margin and then, separately, just your thoughts on the second half for price given what we've seen in the first half."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. There's a little bit",72,"Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. There's a little bit of hang over into Q2 and a very slight hang over the rest of the year, but it was really that Japan factor that caused that sequential move."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then price for the second half?",7,"And then price for the second half?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we're obviously really pleased that the first 6 months and the teams are, frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflec",82,"I think we're obviously really pleased that the first 6 months and the teams are, frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflected in our ability to provide the higher sales guidance. But we're certainly not ready to say 40 basis points is the new normal. But certainly, I think between 50 and 100 is probably what we're thinking about."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","We now have a question from Kristen Stewart from Deutsche Bank.",11,"We now have a question from Kristen Stewart from Deutsche Bank."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think, in the first quarter, you guys had 9% organic growth, then it was 7.1%, both very great",120,"I just wanted to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think, in the first quarter, you guys had 9% organic growth, then it was 7.1%, both very great numbers. But I'm just wondering what kind of those just kind of quarter-over-quarter -- or year-over-year, rather, comp issue or -- because it sounds like everything is continuing to go very well in the marketplace, and it sounds like your comments suggest more continued strengthening. And it looked like the U.S. was up 9 last quarter, and up 7. So I'm just wondering if it's just simply year-over-year comparison or if it's..."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls as a couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was, by far, our easiest comp of the year, coming o",244,"Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls as a couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was, by far, our easiest comp of the year, coming out of that big Q4 and working through some inventory in Q1. Flip to Q2, we obviously don't have that and then also have the headwind associated with the Boston stocking order. We had talked about ports. There was a drag. We had a weak Q4 as we got ready for some new product launches in Q1. So ports were very strong in Q1. Biopsy was also incredibly strong in Q1 on the back of China. And China, in general, we called out that China had an absolutely phenomenal Q1. Some of that was again as we're building out the BioSurgery sales force, there was some stocking that went on as well. China had a terrific Q2 but, certainly, somewhat slower than, again, an unusual Q1. So I think the message we wanted to have you understand coming out of Q1, terrific quarter, some more onetime items, but leading into a Q2 that was going to be also very strong organically. So actually, the good news is it came out exactly as we had thought, and the items that were more of a tailwind in Q1 indeed played out the way we thought in Q2."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So would it be fair, I guess, to think about, I guess, the first half as the run rate? Because then, I guess, it's more of like an 8%. And I guess your guidance now is more of a 6.5% to 7%.",43,"Okay. So would it be fair, I guess, to think about, I guess, the first half as the run rate? Because then, I guess, it's more of like an 8%. And I guess your guidance now is more of a 6.5% to 7%."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that -- I mean, that 6.5% to 7%, I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact. Over last year, we had noted we launched a num",145,"I think that -- I mean, that 6.5% to 7%, I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact. Over last year, we had noted we launched a number of Lutonix additional lengths in Q3, and so Boston needed to stock all of those lengths in Q3 as well. So there'll be a stocking phenomenon in Q3. It'll be a little bit less than the Q2 stocking, but just to let you know that that's coming as well. So I think the way we're seeing the business is we're growing pretty comfortably in that 6.5-ish percent organic range, and it's really balanced, which I think is very important and I think speaks to the quality of the overall results."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So a little bit better volumes and a little bit better price in [indiscernible].",15,"Okay. So a little bit better volumes and a little bit better price in [indiscernible]."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And I'm also just curious going back and be doing just a look at Rochester, were you guys able to get to the level of margin improvement from a gr",60,"Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And I'm also just curious going back and be doing just a look at Rochester, were you guys able to get to the level of margin improvement from a gross margin perspective with that deal now that it's almost 3 years?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facility is actually still ongoing this year. We'll complete it towards the end of this year and early",84,"Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facility is actually still ongoing this year. We'll complete it towards the end of this year and early in '17. And it's been a lot of work for the team, but we feel good about how we're trending there and feel really good about that acquisition overall for sure and certainly as we now augmented it with Liberator."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","You want to comment about acquisitions.",6,"You want to comment about acquisitions."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think valuations always need to make sense to us. And that needs to be on top of a strategi",130,"Yes, I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think valuations always need to make sense to us. And that needs to be on top of a strategic rationale that's pretty compelling. And so again, we hadn't announced anything because we're not trying to find the things that make sense. But I think the takeaway you should have is that we're continuing to be disciplined and stick to the strategy that we've laid out for you. And the kinds of things we've done recently, we're trying to find more of those. And I'm confident we will, but just through the first 6 months, the stars haven't aligned."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Matt Taylor with Barclays.",9,"Our next question is from Matt Taylor with Barclays."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number",73,"So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number. And then you talked about the benefit of Liberator in Japan. Can you parse those out between, I guess, the contribution to Urology?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, we were doing this because the Japan impact on top of the acquisitions is pretty important. So again, the -- and I'm not going to give you th",204,"Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, we were doing this because the Japan impact on top of the acquisitions is pretty important. So again, the -- and I'm not going to give you the specific numbers but Urology, again, stripping out the impact of Liberator and the impact of Japan, grew 4% organic for us in the quarter which, again, is a very solid result. Vascular were a big drag from sales of EP products to Boston, we had continued the OEM product for them through all of last year as they stood up their own manufacturing. And so they have been building inventory this time last year. And they're buying very, very little from us now. So big drag there. And the Gore royalty of $39 million. When you strip all of those out as well as the Japan impact, Vascular grew 6 organic overall. And again, that's in the face of the Lutonix stocking order as well, which we've called out as about 70 basis points overall to total organic. So the 6.4 becomes a 7.1 when you adjust for the Lutonix stocking."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from jus",51,"Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from just Bard expanding its footprint and infrastructure."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We saw another quarter where we're growing about 20% overall. John had said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good ab",128,"Yes. We saw another quarter where we're growing about 20% overall. John had said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good about the second half and going forward there. To John's other point, in China, we're creating a lot of these markets as we go. And so while there's been a lot of noise about slowdowns and macro factors impacting growth rates, we haven't seen that in China. PICCs are going terrifically well. Biopsy is going terrifically well. We're now building and have built a direct BioSurgery sales force, excited about that opportunity. We have our Lutonix SFA trial enrolling in China. So..."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","We just launched a new biopsy product there.",8,"We just launched a new biopsy product there."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly, not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term and given the market o",96,"As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly, not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term and given the market opportunities we're targeting. And as Tim said, we're pretty targeted about the products that we bring to market there. And they're generally trying to serve a very specific need. In some cases, a need that's not yet been met by other products, and PICCs is the best example in China."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I would add, though, too, that the -- we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too.",33,"I would add, though, too, that the -- we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Anthony Petrone with Jeffferies.",10,"And we'll go next to Anthony Petrone with Jeffferies."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point and when that agreement gets renewed? And then the longer-term t",70,"Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point and when that agreement gets renewed? And then the longer-term target of $1.5 billion by 2020 for the category, I'm just wondering how much of that is below-the-knee indications, and then one strategy question to follow up with."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, if you look at our EP business, when we entered into that agreement, and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall busi",89,"Well, if you look at our EP business, when we entered into that agreement, and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall business. It doesn't mean it's not important in certain segments that you're focusing on, and it doesn't mean the partnership is not going well. But it is not a large percentage, by any sense of imagination, in terms of our overall Lutonix business."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","In terms of the market size, Anthony, we target the below-the-knee opportunity at about $350 million globally by 2020. SFA and popliteal in the $850 million range globally. And then other indications, including AV access, which we're really excited about",93,"In terms of the market size, Anthony, we target the below-the-knee opportunity at about $350 million globally by 2020. SFA and popliteal in the $850 million range globally. And then other indications, including AV access, which we're really excited about where we are clinically there, at another $250 million. And what really excites us, when you look across all those indications in 2020, we're the only company, we believe, that's going to have approvals in all those areas. And we think that is going to really position us well over that time frame."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And just a strategy one, the reverse on, I guess, the M&A environment. When you consider the valuations here have improved, I'm just wondering if divestitures have moved up the priority scale for assets that are maybe slower growing and no",54,"That's helpful. And just a strategy one, the reverse on, I guess, the M&A environment. When you consider the valuations here have improved, I'm just wondering if divestitures have moved up the priority scale for assets that are maybe slower growing and not as core to the business at this point in time."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, thanks. Yes, I think with the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out",101,"Yes, thanks. Yes, I think with the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out with a next-gen product, that are in decline. But we'd much rather have the management time focused on growth, and we've got plenty of opportunities through the investments that we've made to do that rather than focusing on a product line here or there that might be a bit of a drag."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And our next question will come from Matt Mishan with KeyBanc.",11,"And our next question will come from Matt Mishan with KeyBanc."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","First question from me is can you help me walk from your previous earnings guidance to your new guidance? I thinking it'd be by about $0.09 in the quarter, but only raised the midpoint of the EPS guidance by about 4. And you also were able to bump the sal",51,"First question from me is can you help me walk from your previous earnings guidance to your new guidance? I thinking it'd be by about $0.09 in the quarter, but only raised the midpoint of the EPS guidance by about 4. And you also were able to bump the sales guidance."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year, actually has worsened by, call it, $0.05 to $0.08. So at the midpoint, sort of $0.6.5. And it's really, for us, driv",265,"Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year, actually has worsened by, call it, $0.05 to $0.08. So at the midpoint, sort of $0.6.5. And it's really, for us, driven by the pound. The RMB has sort of quietly weakened relative to the dollar. The euro, Aussie dollar, Canadian dollars have all moved relatively materially. Now it was very late in Q2, but as we sit here today, those are all going to cost us, in combination, $0.06 or $0.07 so, effectively, offset virtually all of the beat to the consensus number in Q2. And as we talked about on the Q1 call, and as I reiterated again today, we're continuing to invest incrementally as we have the opportunity to do so. So I think the strength of the operating performance so far is allowing us to continue to make investments this year that, coming into the year, we frankly didn't think we were going to be in a position to do. And we think that's the right thing to do for the long term. I think looking at Q2 of an 8.3 reported and a 12 reported, bottom line, very high quality. And us taking some of the upside that we've delivered to invest back into the business, we think is in the right balance. And you're seeing us continue to do that, and that's, frankly, also reflected in the guidance that we've just laid out for the remainder of the full year."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think a good example of that would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, seeing the size of the opportunity and our ability and invested in it. And as you can see, that's a l",90,"I think a good example of that would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, seeing the size of the opportunity and our ability and invested in it. And as you can see, that's a large, large clinical trial. That's an example of some of the things that we turned on when we saw we had a little bit of an opportunity based in our performance. And that is only one example, quite frankly."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last",71,"Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last year. And then how should we be thinking about the comparison -- the fourth quarter comparison in particular, from Japan and Medicon?"
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","So Q3, there'll be less of an impact in Q3, and then even less of an impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a ful",101,"So Q3, there'll be less of an impact in Q3, and then even less of an impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a full quarter of sales through to the customer as compared to last year where, again, we had to work through the inventory that was resident at the JV when we closed that transaction in early November. So there's couple of puts and takes related to both of those."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Just one clarification there, Matt. The EP step-down really began in Q4, so Q3 would still be a significant reduction similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less.",38,"Just one clarification there, Matt. The EP step-down really began in Q4, so Q3 would still be a significant reduction similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments.",24,"And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll tal",52,"Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll talk to you again next quarter."
254131,370602062,1012824,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect.",28,"Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand",277,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's March 31, 2016 Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of July 26, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I'd expect the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an hour. I'",519,"Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I'd expect the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck that's available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The discussion today will go as follows: I'll begin with an overview of the results for the second quarter of 2016; John Weiland, our President and COO, will review second quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you a brief update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will go over the second quarter income statement and balance sheet as well as our expectations for the third quarter and the remainder of the year; and then finally, we'll close with Q&A.
Second quarter 2016 net sales totaled $931.5 million. That's up 8% over Q2 of last year on an as-reported basis and up 9% on a constant currency basis. The currency impact for the quarter versus the same quarter last year was unfavorable by about 70 basis points. 
The organic growth rate was approximately 6.4% this quarter, which exceeded our expectations. As we told you earlier, the prior year Q2 included the initial stocking of Lutonix by Boston Scientific. And when you factor that in, our organic sales growth would have been above 7%. 
Net income for the second quarter of 2016 was $159.2 million, and diluted earnings per share were $2.11. Excluding amortization of intangibles and items that affect the comparability of results between periods, which Chris will cover later, adjusted second quarter 2016 net income and diluted earnings per share were $192.2 million and $2.54. That's up 11% and 12%, respectively. These adjusted results exceeded the guidance we provided for the quarter, and the first half of the year has come in stronger than we had projected at the beginning of the year. 
Looking at revenue growth geographically compared to the same quarter last year, Q2 net sales in the U.S. increased 7% on a constant currency basis; Europe grew 7%; Japan was up 29%, benefiting from moving the customer pricing after the acquisition of our JV partner; and our other international businesses grew 15%. We continue to see strong growth in emerging markets, which represented 10% of our total sales in the second quarter. 
As John Weiland takes you through the product lines, you'll see that we continue to have sustained momentum across all of our businesses even in the face of the tougher comps that we previewed for you last quarter. We continue to believe that executing our strategy will position us to continue to achieve an above-market revenue growth rate for the overall portfolio with attractive returns for shareholders. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's begin with Vascular. Total net sales were $25",775,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. 
So let's begin with Vascular. Total net sales were $255.3 million, up 3% over last year on both an as-reported and constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 6% in Q2, with the United States business, up 3%; and international up 12%. 
Sales in our Surgical Graft category were up 5% in the second quarter, within the range of recent experience. Our Endovascular business grew 6% in the second quarter. Our peripheral PTA line grew 10% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. The growth rates may look a little lumpy quarter-to-quarter from stocking events in the prior year, but we track average daily sales as a metric, and we continue to see good sequential momentum in both the United States and internationally. And we have third-party data that shows us maintaining our leadership position in this important long-term market opportunity. 
Our Stent business grew 1% in the second quarter, and sales in our vena cava filter line were down 13%. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally despite running up against the tougher comps we talked about last quarter. 
Now let's go to Urology. Total net sales were $240.0 million, up 15% on an as-reported and up 16% on a constant currency basis compared to the second quarter of 2015. The combination of the first full quarter of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in the category. Excluding these 2 acquisitions, the United States business was up 4% while, internationally, we grew 5%. 
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 6%, both globally and in the United States, with our infection control Foley business up 2% globally and 3% in the United States. 
Our Targeted Temperature Management products grew 19% this quarter, demonstrating continued momentum in this significant long-term opportunity. 
Our continence business was up 34% in the second quarter, all driven by the benefit from the new acquisitions. 
Sales in Urological Specialties were up 9% this quarter, including our brachytherapy business, which grew 7%, driven by Japan. 
And finally, in this category, stand-alone sales of our StatLock catheter-stabilization line decreased 5% in Q2. 
Now let's go to Oncology. Total net sales in this category were $252.4 million, an increase of 7% as-reported and 8% on a constant currency basis over Q2 last year. The Japan acquisition added 200 basis points to growth globally. Excluding that, sales in the United States were up 4%, and international sales were up 13%. 
Our port business was up 4% versus the second quarter of last year. Our PICC business was up 10% this quarter, with continued impressive growth outside of the United States. As you'll hear from John DeFord, we continue to advance our PICC and midline portfolio. 
Our vascular access ultrasound product line grew 4% this quarter. And to close out the category, our Dialysis Access product line was up 13%. 
So let's conclude with our Surgical Specialties business. Total net sales in this category were $159.9 million, up 11% as-reported and 12% on a constant currency basis. United States sales were up 11%, and international sales were up 13% this quarter, excluding the impact from Japan, which was minimal. 
Our Performance Irrigation business was down 3%, and now represents less than 1% of our total company sales. Our soft tissue repair business continued its strong momentum, growing 12% in Q2. Our broad product offering and our value-added programs that help customers select the right product for the patient are having a significant impact on the treatment paradigm, with more procedures shifting from natural tissue to our synthetic hernia portfolio and, specifically, our Phasix material. Our synthetics business grew 18% this quarter, while our natural tissue products declined 27%. 
In our hernia fixation business, which is included in soft tissue repair subtotal, grew 49% this quarter on the continued impact from our recent product launches here. 
Closing out the surgical category, in the second quarter, our BioSurgery business grew 16% and now represents between 20% and 25% of our Surgical Specialties business. This continues to represent a significant long-term opportunity for us. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. We'll start with our drug-co",1000,"Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. 
We'll start with our drug-coated balloon pipeline. Our long lesion supplement is under review at FDA, and we're hopeful for approval of this expanded indication for the treatment of lesions up to 300 millimeters in length around year-end. In our Below-the-Knee IDE, enrollment is progressing, and we're optimistic regarding our discussions with the FDA to bring this important treatment option to patients. The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a look at our results in Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late-Q4 2017 U.S. launch. 
We're also on track to submit clinical data for the in-stent restenosis PMA later this quarter. 
In Japan, our shown in submission for the Lutonix SFA indication is under review, and we anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began last quarter. 
Also in Vascular, in Q2, we launched our new True Flow Valvuloplasty balloon family. This proprietary product is designed to reduce the stress placed on the heart by allowing blood to flow through the device during the procedure with limited restriction and back pressure. Early clinical results have also shown that, in most cases, rapid pacing to reduce blood pressure has not been required. 
Also in Q2, we received FDA approval for the LifeStent system, with indications covering the entire popliteal artery. The LifeStent platform is now the first and only self-expanding stent in the U.S. with this indication. Labeling is being updated, and our launch and education programs will commence this quarter. 
In stent grafts, LifeStream Balloon Expandable covered stent trial has completed follow-up, and the final PMA module was submitted last week to FDA, with approval and launch expected in mid-2017.
Our Covera next-generation AV access circuit stent graft received IDE approval a couple of weeks ago, and we anticipate commencing enrollment later this quarter or in early Q4. We expect enrollment will take about a year.
Our Venovo venous stent IDE study is in active recruitment. We anticipate enrollment throughout this year with follow-up in 2017 and PMA submission in 2018.
In biopsy, we just began the rollout of the ENCOR ENSPIRE system in China. In addition, the UltraCor Twirl breast biopsy marker just launched in the U.S. and Europe about a quarter ahead of our schedule.
Now moving to Urology and home care, we continue to advance our broad-based initiatives designed to reduce catheter-associated urinary tract infections through the launch of additional SURESTEP Foley Trays and our new SURESTEP Daily Care product. The SURESTEP Trays are helping standardize indwelling catheter placement around known guidelines. Our SURESTEP Daily Care product extends the solution to the maintenance phase and supports compliance to cleaning standards and awareness of indwelling time. Customers find this particularly helpful, especially in light of increasing nursing turnover.
In endourology, Q2 heralded the launch of 2 new stone basket configurations in our SkyLite platform, providing a full range of sizes. And in Targeted Temperature Management, this quarter, we received IDE approval for our new neurogenic fever prevention and control clinical study. This study will evaluate the use of the ARCTIC SUN system in this new indication. The study is anticipated to enroll more than 1,000 patients and will probably take about 3 years to complete. 
Moving to Oncology, we've had a very busy few weeks since the Analyst Day. We received clearance on our new chemical-resistant PowerPICC family named the PowerPICC EtOH. This new family will begin launching this quarter and is especially designed with a proprietary material that maintains all of the benefits of the PowerPICC and can withstand greater exposure to the sometimes harsh chemistry used in today's therapies. 
We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis or DVT. We remain on plan to launch products in this new family in the back half of the year. 
We also received FDA clearance on our new power midline and clearance for our PowerGlide Pro family of intermediate dwell catheters. Both of these products just launched and are shipping to customers. 
This quarter, we added 3 new applications to our Tip Confirmation portfolio for pediatrics, ports and central lines due to launch of a first-generation system in Europe. We're also developing an advanced version slated for launch in the U.S. and other geographies later this year. 
I'll close my portion of prepared remarks today with surgery. As we discussed a few weeks ago, the TRIDYNE aortic sealant was approved by the FDA, and we're preparing to launch in the back half of this year. We're also working toward the launch of the Progel Emerald sealant, designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to anticipate the launch of additional Phasix resorbable mesh sizes throughout the remainder of the year. This expansion is planned to provide surgeons and their patients the largest and most comprehensive size matrix in the market, including a 50-centimeter by 50-centimeter mesh. 
On the clinical front, we've completed 1-year follow-up in our Phasix clinical study of over 100 ventral hernia patients and expect results to be presented and published later this year. Similarly, additional clinical data for our XenMatrix AB product family is expected to be released later this year. 
And finally, in mesh fixation, we anticipate launching the 15-count version of our OPTIFIX resorbable fixation device in Q4, with further launches in this category expected in the first half of 2017. 
I know we went through this quickly. Thanks for your attention. I think we covered 26 new products in about 6 minutes, so now I'll turn you over to Chris."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restr",855,"Thank you, John. Let's start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restructuring and productivity initiatives. P&L impact to these items is detailed in the notes to the financial statement and the reconciliation accompanying our Q2 earnings press release. 
Now let's go through the statement of income for the quarter. Gross profit was $580.5 million or 62.3% of sales for Q2. On an adjusted basis, GP was $616.2 million or 66.2% of sales, up 140 basis points from the prior year quarter and better than we expected. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in GP, continuing the solid performance we saw in Q1. And FX was about 80 basis points of headwind to gross margin for the quarter. Mix was favorable by 110 basis points, which includes the positive impact from our Japanese business, and our cost improvement efforts drove approximately 120 basis points of favorability in Q2. 
Our cost savings and margin improvement programs are on track, and we now expect to exceed the original full year guidance for GPs that we gave you in January. 
SG&A expenses were $278.5 million for the quarter or 29.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 29.7%, 70 basis points above the prior year. Consistent with how we guided the full year, as we integrate the recent acquisitions, we expect this leverage to improve somewhat in the second half. 
I would reiterate that as we see opportunities to do so, we will continue to make incremental investments in certain targeted areas, including, for example, emerging markets and our health economics capabilities. 
R&D expenditures totaled $71.3 million for the second quarter or 7.7% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.6%, up 30 basis points from the prior year and consistent with our full year guidance. We do expect a somewhat higher level of R&D investment spending in Q3. 
Interest expense was $13.4 million for the second quarter, and other income and expense was $9.6 million of expense for the second quarter as reported and $2.1 million of income on an adjusted basis. The effective tax rate for the quarter was 25.4%, down 60 basis points from the prior year. 
Diluted shares for the period were 75.2 million, and we repurchased approximately 103,000 shares during the second quarter. The net result is adjusted EPS of $2.54, which excludes items affecting comparability and the amortization of intangibles. This was above the range we provided for the quarter, driven primarily by the overachievement in sales. 
The balance sheet as of June 30, reflects cash, restricted cash and short-term investments of $1 billion, similar to March 31. For the quarter, accounts receivables days were down 2.1 days, and inventory days were up 6.8 days, as we responded to recent inventory depletion from increased demand. Capital expenditures totaled $17.9 million for the quarter. 
On the liability side, total debt was $1.6 billion as of June 30 compared to $1.7 billion at March 31. Debt-to-total capital at the end of the second quarter was about 50%, and total shareholder investment was $1.6 billion at June 30. 
Moving to financial guidance. Given the strong first half of the year, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 8% and 9%, with reported sales growth between 7% and 8%, now implying a currency headwind of about 1%. On an organic basis, we had originally guided the year to be between 5% and 6% but now expect that range to be between 6.5% and 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.10 and $10.20, representing 11% to 12% growth. U.S. dollar has strengthened somewhat since our last earnings call, and we now expect foreign exchange to be between $0.25 and $0.28 of headwind for the full year. So on an FX-neutral basis, we're guiding to 14% to 15% growth for all of 2016. 
For Q3, we're expecting constant currency sales growth between 8% and 9%, with reported sales growth between 7% and 8%, also implying an FX headwind of about 1% on the revenue line. This assumes organic growth between 6% and 6.5% for the third quarter. 
From an adjusted EPS standpoint, we forecast third quarter in the range of $2.51 to $2.55, representing 10% to 12% growth on a reported basis. 
In summary, the first half of the year has gone well from both a sales and profitability perspective. As we now move to the second half, we remain focused on our continued execution, including smartly investing in strategic opportunities. The overall objective of our balanced efforts is to drive attractive and sustainable revenue growth, profitability and shareholder returns over the long term. 
I'll now turn the call back to Tim."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?",29,"Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America.",15,"[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So good solid Q2. Tim, I wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers, and no",94,"So good solid Q2. Tim, I wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers, and now you've reported Q2 results. So with that in mind, can you give us a sense as to what you're seeing broadly with surgical procedure volumes in the second quarter versus the first quarter? Just want to see if you're picking up on anything that's kind of worth noting."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky, so hard to predict where that moves. There's a lot of moving parts that affect health care usage these da",96,"Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky, so hard to predict where that moves. There's a lot of moving parts that affect health care usage these days in the U.S., in particular, as you know. But as we watch other companies report, obviously, we've seen good healthy growth in the quarter. So it appears that the improvement seems to be holding, at least, over the flattish levels that it'd been the last few years."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there. But just want to try to get as specific as we can, are they kind of growing a",93,"And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there. But just want to try to get as specific as we can, are they kind of growing at the same rate they've been the last couple of quarters? And then maybe if you could just give us a quick comment on hernia and how sustainable these low double-digit growth rates are that you've been achieving here these last couple of quarters."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll let John Weiland address both of those issues.",10,"Sure. I'll let John Weiland address both of those issues."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across-the-board. So we don't have any concerns there about our ability to continu",179,"Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across-the-board. So we don't have any concerns there about our ability to continue to grow. And I think that you hit the nail on the head in terms of growth in our surgery business. And in particular, our synthetic hernia, which is the largest segment in hernia repair by far for us, had some of the finest growth we've seen in 8 to 10 years. And in fact, the independent market share data that we saw for Q1 saw us pick up 7 share points in Q1 alone. So we have great momentum driven by the new product portfolio and the -- and as well as the products that we said that we're going to be launching, such as the new products in fixation. So I think if you look at biologics, fixation and synthetics, I think we're hitting on all cylinders there in surgery right now."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question, we'll go to Brooks West with Piper Jaffray.",11,"Our next question, we'll go to Brooks West with Piper Jaffray."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom Bakas on for Brooks. If I could I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat, that an average U.S. rep, has a customer value of about $4 million annual",95,"This is Tom Bakas on for Brooks. If I could I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat, that an average U.S. rep, has a customer value of about $4 million annually and then an emerging markets rep was closer to $700,000. I just kind of hoped you could help us think about what the right steady state number is for emerging markets rep. And if something like half or 2 million fair, how should we think about that?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Go sell everything."" So by defin",147,"Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Go sell everything."" So by definition and design, we're much more targeted in these markets. So you're never going to get a comparable dollar value per bag or it would be an exception for probably some unique reason on a rep-per-rep basis just based on the volume of SKUs that we're going to put in an emerging market bag versus the U.S. bag. So it's a tough number for us to know for sure, but I'm not sure the answer's worth the chase, I think it's more directional in terms of the potential of the headcount versus trying to get to a mathematical answer."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. S",134,"And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. So by definition, when you're building these markets from scratch, it takes an awful lot of effort in terms of training, in terms of identifying the right individuals to train. So we're always going to be chasing that. I think the other dimension is that, for example, we added 225 reps last year in emerging markets, continued to add more this year. So if our philosophy and our investment plan continues to fold out, we're always going to be chasing this number because that's our first source of adding new reps."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and, perhaps, what the biggest opportunities in that geography are for Bard.",41,"Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and, perhaps, what the biggest opportunities in that geography are for Bard."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right produc",149,"Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right product lines. That's gone extremely well. I think that we certainly have benefited by the change in the yen. That has improved the profitability for us and has allowed us to continue to make investments in that business where applicable. And I think if we look at our overall portfolio, we have to say that in the vascular area and the area of oncology, they are the 2 areas that were underpenetrated in Japan and that we're putting more resources and more capabilities in our existing business over there. That's where we think we have the most significant growth opportunities."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question will come from David Lewis with Morgan Stanley.",11,"Our next question will come from David Lewis with Morgan Stanley."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And al",64,"This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And also, can you speak to any selling day impacts we should be aware of for the back half?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think for the full back half, it's going to -- there's -- within quarters, there's a little bit of noise, but there really shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, fran",133,"I think for the full back half, it's going to -- there's -- within quarters, there's a little bit of noise, but there really shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, frankly, in Q2. And I think the math allows you to get to growth rates that, frankly, are pretty consistent, certainly, at the high end of the range, but consistent with what we delivered in Q2. And that's -- frankly, that's really solid constant currency and reported revenue growth and really solid and, I'd say, high-quality net income and EPS growth. So again, there's a range, Scott, for reasons. But I think the math allows you to show continued, really strong performance through the next 2 quarters."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on the home care market?",32,"Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on the home care market?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that wer",114,"Yes, I think, similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that were behind the acquisition of really capturing more prescriptions and having those prescriptions that then end up within Liberator family over time. So the growth rates, we obviously gave you some color on what urology and what the different categories look like on an organic basis. But Liberator is growing exactly as we had hoped. And frankly, we're a little bit ahead of where we thought we would be at this stage of the game."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Mike Weinstein with JPMorgan.",10,"And we'll go next to Mike Weinstein with JPMorgan."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Robbie Marcus in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed,",83,"This is Robbie Marcus in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed, but also Urology and Vascular. Both really good numbers, Urology, up 4% organic; Vascular, up 6%. So maybe you could just touch on those for a minute and talk about what's driving that, particularly in Vascular."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","John, do you want to take that?",7,"John, do you want to take that?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had, we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we stand",227,"Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had, we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we stand on the potential new indications for Lutonix which, in our minds, will be a great competitive edge for us in that business. Our biopsy business has been tremendously strong, and our emerging markets performance, particularly China in biopsy, has been terrific. Urology, we talked about the components of Urology. The urology market, if you look at the basic drainage business, is not growing in the United States at all. In fact, it's relatively flat, maybe up 1%. But some of the new product offerings that we have introduced into that market, especially our SURESTEP Tray, has allowed hospitals to upgrade within their own existing framework and it's given us a mixed differential, which is driving, really, a substantial portion of growth in basic drainage for us. And I'd also like to add, one of the areas that may not come out, but we have had excellent growth in Europe. They had another terrific quarter this quarter for us. And we've always been delighted with our growth in emerging markets, and that continues to be, a really, big positive for the corporation."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And maybe if I could just follow up on that, you mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?",39,"And maybe if I could just follow up on that, you mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the share question, we've referenced data that we've seen from third parties that continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong seque",204,"I think the share question, we've referenced data that we've seen from third parties that continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong sequential growth within our business. I think the estimates that folks had coming into this year, Europe is still a relatively small number where we continue to take share there as well. That's frankly been held back, I think, as folks wait for some Below-the-Knee data, which we're anxious to be the one to provide them for. So we think that data, when and if it does arrive, will really allow the opening of the European market and really have that growth really kick back in again. So we're -- I think we're pleased with how the market's growing. We're pleased with how we're continuing to hold and gain share. And most importantly, I think when we look out over the next 2, 3, 4 years, the portfolio of indications that we're going to have within the company, within Lutonix and the DCB franchise is going to be absolutely unrivaled. And we think that really sets us up in a very unique position."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all-comers, real-life use, shows j",53,"The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all-comers, real-life use, shows just tremendous efficacy of the Lutonix product line."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question comes from Larry Keusch with Raymond James.",10,"Our next question comes from Larry Keusch with Raymond James."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim or John, I wanted to come back to PICCs, 10% growth in the quarter, obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So just hoping if you could help us deconstru",68,"Tim or John, I wanted to come back to PICCs, 10% growth in the quarter, obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So just hoping if you could help us deconstruct that 10% a little bit, put into context of the market and what products are really driving that for you."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and midlines in Europe. That has been an excell",122,"Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and midlines in Europe. That has been an excellent arena for us. We're starting to gain momentum in Japan based on the emphasis that we talked about before, and we continue to have strong growth in the United States. So it's a very balanced approach of where we're trying to grow PICCs. It's a core franchise for us. We're making the investments where we need to, to continue that growth on track. And we like what we're seeing around the world in PICCs right now."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, the only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And pa",96,"Yes, the only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And part of what you're seeing is us actually executing against that opportunity. And to John's point, tremendous growth in Europe, a huge untapped opportunity in Japan and China, we're creating that market as we go and seeing tremendous growth there that we think has a lot of legs still to come."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Can I just -- jumping in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years.",41,"Can I just -- jumping in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So John, that actually was just a segue to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put t",78,"So John, that actually was just a segue to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put the chemical-resistant into perspective. Is that kind of nice to have? And really the thromboresistant product is going to be the next real big growth driver? Or am I thinking about that incorrectly?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that, one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not re",111,"Well, I think that, one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not really ready to talk about today that'll bring that more to light as we go out into the future, but then our PROVENA family, which is what we're calling our thromboresistant, DVT-resistant technology, we'll begin launching that. And we do think that both of those are going to fit important niches in the marketplace. And I think we're just really excited to have them both out there."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Terrific. And then -- and Chris, quickly, just help me understand -- I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross ma",69,"Okay. Terrific. And then -- and Chris, quickly, just help me understand -- I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross margin and then, separately, just your thoughts on the second half for price given what we've seen in the first half."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. There's a little bit",72,"Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. There's a little bit of hang over into Q2 and a very slight hang over the rest of the year, but it was really that Japan factor that caused that sequential move."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then price for the second half?",7,"And then price for the second half?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we're obviously really pleased that the first 6 months and the teams are, frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflec",82,"I think we're obviously really pleased that the first 6 months and the teams are, frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflected in our ability to provide the higher sales guidance. But we're certainly not ready to say 40 basis points is the new normal. But certainly, I think between 50 and 100 is probably what we're thinking about."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","We now have a question from Kristen Stewart from Deutsche Bank.",11,"We now have a question from Kristen Stewart from Deutsche Bank."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think, in the first quarter, you guys had 9% organic growth, then it was 7.1%, both very great",120,"I just wanted to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think, in the first quarter, you guys had 9% organic growth, then it was 7.1%, both very great numbers. But I'm just wondering what kind of those just kind of quarter-over-quarter -- or year-over-year, rather, comp issue or -- because it sounds like everything is continuing to go very well in the marketplace, and it sounds like your comments suggest more continued strengthening. And it looked like the U.S. was up 9 last quarter, and up 7. So I'm just wondering if it's just simply year-over-year comparison or if it's..."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls as a couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was, by far, our easiest comp of the year, coming o",244,"Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls as a couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was, by far, our easiest comp of the year, coming out of that big Q4 and working through some inventory in Q1. Flip to Q2, we obviously don't have that and then also have the headwind associated with the Boston stocking order. We had talked about ports. There was a drag. We had a weak Q4 as we got ready for some new product launches in Q1. So ports were very strong in Q1. Biopsy was also incredibly strong in Q1 on the back of China. And China, in general, we called out that China had an absolutely phenomenal Q1. Some of that was again as we're building out the BioSurgery sales force, there was some stocking that went on as well. China had a terrific Q2 but, certainly, somewhat slower than, again, an unusual Q1. So I think the message we wanted to have you understand coming out of Q1, terrific quarter, some more onetime items, but leading into a Q2 that was going to be also very strong organically. So actually, the good news is it came out exactly as we had thought, and the items that were more of a tailwind in Q1 indeed played out the way we thought in Q2."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So would it be fair, I guess, to think about, I guess, the first half as the run rate? Because then, I guess, it's more of like an 8%. And I guess your guidance now is more of a 6.5% to 7%.",43,"Okay. So would it be fair, I guess, to think about, I guess, the first half as the run rate? Because then, I guess, it's more of like an 8%. And I guess your guidance now is more of a 6.5% to 7%."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that -- I mean, that 6.5% to 7%, I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact. Over last year, we had noted we launched a num",145,"I think that -- I mean, that 6.5% to 7%, I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact. Over last year, we had noted we launched a number of Lutonix additional lengths in Q3, and so Boston needed to stock all of those lengths in Q3 as well. So there'll be a stocking phenomenon in Q3. It'll be a little bit less than the Q2 stocking, but just to let you know that that's coming as well. So I think the way we're seeing the business is we're growing pretty comfortably in that 6.5-ish percent organic range, and it's really balanced, which I think is very important and I think speaks to the quality of the overall results."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So a little bit better volumes and a little bit better price in [indiscernible].",15,"Okay. So a little bit better volumes and a little bit better price in [indiscernible]."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And I'm also just curious going back and be doing just a look at Rochester, were you guys able to get to the level of margin improvement from a gr",60,"Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And I'm also just curious going back and be doing just a look at Rochester, were you guys able to get to the level of margin improvement from a gross margin perspective with that deal now that it's almost 3 years?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facility is actually still ongoing this year. We'll complete it towards the end of this year and early",84,"Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facility is actually still ongoing this year. We'll complete it towards the end of this year and early in '17. And it's been a lot of work for the team, but we feel good about how we're trending there and feel really good about that acquisition overall for sure and certainly as we now augmented it with Liberator."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","You want to comment about acquisitions.",6,"You want to comment about acquisitions."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think valuations always need to make sense to us. And that needs to be on top of a strategi",130,"Yes, I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think valuations always need to make sense to us. And that needs to be on top of a strategic rationale that's pretty compelling. And so again, we hadn't announced anything because we're not trying to find the things that make sense. But I think the takeaway you should have is that we're continuing to be disciplined and stick to the strategy that we've laid out for you. And the kinds of things we've done recently, we're trying to find more of those. And I'm confident we will, but just through the first 6 months, the stars haven't aligned."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Matt Taylor with Barclays.",9,"Our next question is from Matt Taylor with Barclays."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number",73,"So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number. And then you talked about the benefit of Liberator in Japan. Can you parse those out between, I guess, the contribution to Urology?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, we were doing this because the Japan impact on top of the acquisitions is pretty important. So again, the -- and I'm not going to give you th",204,"Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, we were doing this because the Japan impact on top of the acquisitions is pretty important. So again, the -- and I'm not going to give you the specific numbers but Urology, again, stripping out the impact of Liberator and the impact of Japan, grew 4% organic for us in the quarter which, again, is a very solid result. Vascular were a big drag from sales of EP products to Boston, we had continued the OEM product for them through all of last year as they stood up their own manufacturing. And so they have been building inventory this time last year. And they're buying very, very little from us now. So big drag there. And the Gore royalty of $39 million. When you strip all of those out as well as the Japan impact, Vascular grew 6 organic overall. And again, that's in the face of the Lutonix stocking order as well, which we've called out as about 70 basis points overall to total organic. So the 6.4 becomes a 7.1 when you adjust for the Lutonix stocking."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from jus",51,"Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from just Bard expanding its footprint and infrastructure."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We saw another quarter where we're growing about 20% overall. John had said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good ab",128,"Yes. We saw another quarter where we're growing about 20% overall. John had said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good about the second half and going forward there. To John's other point, in China, we're creating a lot of these markets as we go. And so while there's been a lot of noise about slowdowns and macro factors impacting growth rates, we haven't seen that in China. PICCs are going terrifically well. Biopsy is going terrifically well. We're now building and have built a direct BioSurgery sales force, excited about that opportunity. We have our Lutonix SFA trial enrolling in China. So..."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","We just launched a new biopsy product there.",8,"We just launched a new biopsy product there."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly, not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term and given the market o",96,"As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly, not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term and given the market opportunities we're targeting. And as Tim said, we're pretty targeted about the products that we bring to market there. And they're generally trying to serve a very specific need. In some cases, a need that's not being yet met by other products, and PICCs is the best example in China."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I would add, though, too, that the -- we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too.",33,"I would add, though, too, that the -- we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Anthony Petrone with Jeffferies.",10,"And we'll go next to Anthony Petrone with Jeffferies."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point and when that agreement gets renewed? And then the longer-term t",70,"Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point and when that agreement gets renewed? And then the longer-term target of $1.5 billion by 2020 for the category, I'm just wondering how much of that is below-the-knee indications, and then one strategy question to follow up with."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, if you look at our EP business, when we entered into that agreement, and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall busi",89,"Well, if you look at our EP business, when we entered into that agreement, and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall business. It doesn't mean it's not important in certain segments that you're focusing on, and it doesn't mean the partnership is not going well. But it is not a large percentage, by any sense of imagination, in terms of our overall Lutonix business."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","In terms of the market size, Anthony, we target the below-the-knee opportunity at about $350 million globally by 2020. SFA and popliteal in the $850 million range globally. And then other indications, including AV access, which we're really excited about",93,"In terms of the market size, Anthony, we target the below-the-knee opportunity at about $350 million globally by 2020. SFA and popliteal in the $850 million range globally. And then other indications, including AV access, which we're really excited about where we are clinically there, add another $250 million. And what really excites us, when you look across all those indications in 2020, we're the only company, we believe, that's going to have approvals in all those areas. And we think that is going to really position us well over that time frame."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And just a strategy one, the reverse on, I guess, the M&A environment. When you consider the valuations here have improved, I'm just wondering if divestitures have moved up the priority scale for assets that are maybe slower growing and no",54,"That's helpful. And just a strategy one, the reverse on, I guess, the M&A environment. When you consider the valuations here have improved, I'm just wondering if divestitures have moved up the priority scale for assets that are maybe slower growing and not as core to the business at this point in time."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, thanks. Yes, I think with the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out",101,"Yes, thanks. Yes, I think with the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out with a next-gen product, that are in decline. But we'd much rather have the management time focused on growth, and we've got plenty of opportunities through the investments that we've made to do that rather than focusing on a product line here or there that might be a bit of a drag."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And our next question will come from Matt Mishan with KeyBanc.",11,"And our next question will come from Matt Mishan with KeyBanc."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","First question from me is can you help me walk from your previous earnings guidance to your new guidance? I thinking you beat by about $0.09 in the quarter, but only raised the midpoint of the EPS guidance by about 4. And you also were able to bump the sa",51,"First question from me is can you help me walk from your previous earnings guidance to your new guidance? I thinking you beat by about $0.09 in the quarter, but only raised the midpoint of the EPS guidance by about 4. And you also were able to bump the sales guidance."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year, actually has worsened by, call it, $0.05 to $0.08. So at the midpoint, sort of $0.6.5. And it's really, for us, driv",265,"Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year, actually has worsened by, call it, $0.05 to $0.08. So at the midpoint, sort of $0.6.5. And it's really, for us, driven by the pound. The RMB has sort of quietly weakened relative to the dollar. The euro, Aussie dollar, Canadian dollars have all moved relatively materially. Now it was very late in Q2, but as we sit here today, those are all going to cost us, in combination, $0.06 or $0.07 so, effectively, offset virtually all of the beat to the consensus number in Q2. And as we talked about on the Q1 call, and as I reiterated again today, we're continuing to invest incrementally as we have the opportunity to do so. So I think the strength of the operating performance so far is allowing us to continue to make investments this year that, coming into the year, we frankly didn't think we were going to be in a position to do. And we think that's the right thing to do for the long term. I think looking at Q2 of an 8.3 reported and a 12 reported, bottom line, very high quality. And us taking some of the upside that we've delivered to invest back into the business, we think is in the right balance. And you're seeing us continue to do that, and that's, frankly, also reflected in the guidance that we've just laid out for the remainder of the full year."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think a good example of that would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, seeing the size of the opportunity and our ability and invested in it. And as you can see, that's a l",90,"I think a good example of that would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, seeing the size of the opportunity and our ability and invested in it. And as you can see, that's a large, large clinical trial. That's an example of some of the things that we turned on when we saw we had a little bit of an opportunity based in our performance. And that is only one example, quite frankly."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last",71,"Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last year. And then how should we be thinking about the comparison -- the fourth quarter comparison in particular, from Japan and Medicon?"
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","So Q3, there'll be less of an impact in Q3, and then even less of an impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a ful",101,"So Q3, there'll be less of an impact in Q3, and then even less of an impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a full quarter of sales through to the customer as compared to last year where, again, we had to work through the inventory that was resident at the JV when we closed that transaction in early November. So there's couple of puts and takes related to both of those."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Just one clarification there, Matt. The EP step-down really began in Q4, so Q3 would still be a significant reduction similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less.",38,"Just one clarification there, Matt. The EP step-down really began in Q4, so Q3 would still be a significant reduction similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments.",24,"And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll tal",52,"Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll talk to you again next quarter."
254131,370602062,1013012,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect.",28,"Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand",277,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's March 31, 2016 Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of July 26, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I'd expect the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an hour. I'",519,"Thank you, Kathy. Welcome to Bard's Second Quarter 2016 Earnings Call, and thanks for taking the time to join us today. I'd expect the presentation portion of the call to last about 25 minutes, and we're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck that's available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The discussion today will go as follows: I'll begin with an overview of the results for the second quarter of 2016; John Weiland, our President and COO, will review second quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you a brief update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will go over the second quarter income statement and balance sheet as well as our expectations for the third quarter and the remainder of the year; and then finally, we'll close with Q&A.
Second quarter 2016 net sales totaled $931.5 million. That's up 8% over Q2 of last year on an as-reported basis and up 9% on a constant currency basis. The currency impact for the quarter versus the same quarter last year was unfavorable by about 70 basis points. 
The organic growth rate was approximately 6.4% this quarter, which exceeded our expectations. As we told you earlier, the prior year Q2 included the initial stocking of Lutonix by Boston Scientific. And when you factor that in, our organic sales growth would have been above 7%. 
Net income for the second quarter of 2016 was $159.2 million, and diluted earnings per share were $2.11. Excluding amortization of intangibles and items that affect the comparability of results between periods, which Chris will cover later, adjusted second quarter 2016 net income and diluted earnings per share were $192.2 million and $2.54. That's up 11% and 12%, respectively. These adjusted results exceeded the guidance we provided for the quarter, and the first half of the year has come in stronger than we had projected at the beginning of the year. 
Looking at revenue growth geographically compared to the same quarter last year, Q2 net sales in the U.S. increased 7% on a constant currency basis; Europe grew 7%; Japan was up 29%, benefiting from moving the customer pricing after the acquisition of our JV partner; and our other international businesses grew 15%. We continue to see strong growth in emerging markets, which represented 10% of our total sales in the second quarter. 
As John Weiland takes you through the product lines, you'll see that we continue to have sustained momentum across all of our businesses even in the face of the tougher comps that we previewed for you last quarter. We continue to believe that executing our strategy will position us to continue to achieve an above-market revenue growth rate for the overall portfolio with attractive returns for shareholders. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's begin with Vascular. Total net sales were $25",775,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. 
So let's begin with Vascular. Total net sales were $255.3 million, up 3% over last year on both an as-reported and constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 6% in Q2, with the United States business, up 3%; and international up 12%. 
Sales in our Surgical Graft category were up 5% in the second quarter, within the range of recent experience. Our Endovascular business grew 6% in the second quarter. Our peripheral PTA line grew 10% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. The growth rates may look a little lumpy quarter-to-quarter from stocking events in the prior year, but we track average daily sales as a metric, and we continue to see good sequential momentum in both the United States and internationally. And we have third-party data that shows us maintaining our leadership position in this important long-term market opportunity. 
Our Stent business grew 1% in the second quarter, and sales in our vena cava filter line were down 13%. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally despite running up against the tougher comps we talked about last quarter. 
Now let's go to Urology. Total net sales were $240.0 million, up 15% on an as-reported and up 16% on a constant currency basis compared to the second quarter of 2015. The combination of the first full quarter of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in the category. Excluding these 2 acquisitions, the United States business was up 4% while, internationally, we grew 5%. 
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 6%, both globally and in the United States, with our infection control Foley business up 2% globally and 3% in the United States. 
Our Targeted Temperature Management products grew 19% this quarter, demonstrating continued momentum in this significant long-term opportunity. 
Our continence business was up 34% in the second quarter, all driven by the benefit from the new acquisitions. 
Sales in Urological Specialties were up 9% this quarter, including our brachytherapy business, which grew 7%, driven by Japan. 
And finally, in this category, stand-alone sales of our StatLock catheter-stabilization line decreased 5% in Q2. 
Now let's go to Oncology. Total net sales in this category were $252.4 million, an increase of 7% as-reported and 8% on a constant currency basis over Q2 last year. The Japan acquisition added 200 basis points to growth globally. Excluding that, sales in the United States were up 4%, and international sales were up 13%. 
Our port business was up 4% versus the second quarter of last year. Our PICC business was up 10% this quarter, with continued impressive growth outside of the United States. As you'll hear from John DeFord, we continue to advance our PICC and midline portfolio. 
Our vascular access ultrasound product line grew 4% this quarter. And to close out the category, our Dialysis Access product line was up 13%. 
So let's conclude with our Surgical Specialties business. Total net sales in this category were $159.9 million, up 11% as-reported and 12% on a constant currency basis. United States sales were up 11%, and international sales were up 13% this quarter, excluding the impact from Japan, which was minimal. 
Our Performance Irrigation business was down 3%, and now represents less than 1% of our total company sales. Our soft tissue repair business continued its strong momentum, growing 12% in Q2. Our broad product offering and our value-added programs that help customers select the right product for the patient are having a significant impact on the treatment paradigm, with more procedures shifting from natural tissue to our synthetic hernia portfolio and, specifically, our Phasix material. Our synthetics business grew 18% this quarter, while our natural tissue products declined 27%. 
In our hernia fixation business, which is included in soft tissue repair subtotal, grew 49% this quarter on the continued impact from our recent product launches here. 
Closing out the surgical category, in the second quarter, our BioSurgery business grew 16% and now represents between 20% and 25% of our Surgical Specialties business. This continues to represent a significant long-term opportunity for us. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. We'll start with our drug-co",1000,"Thanks, John, and good afternoon, everyone. We covered the pipeline in pretty significant depth just a few weeks ago at the Analyst Day, so I'll try to just give you an update on a few of the key or near-term projects today. 
We'll start with our drug-coated balloon pipeline. Our long lesion supplement is under review at FDA, and we're hopeful for approval of this expanded indication for the treatment of lesions up to 300 millimeters in length around year-end. In our Below-the-Knee IDE, enrollment is progressing, and we're optimistic regarding our discussions with the FDA to bring this important treatment option to patients. The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a look at our results in Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late-Q4 2017 U.S. launch. 
We're also on track to submit clinical data for the in-stent restenosis PMA later this quarter. 
In Japan, our shown in submission for the Lutonix SFA indication is under review, and we anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began last quarter. 
Also in Vascular, in Q2, we launched our new True Flow Valvuloplasty balloon family. This proprietary product is designed to reduce the stress placed on the heart by allowing blood to flow through the device during the procedure with limited restriction and back pressure. Early clinical results have also shown that, in most cases, rapid pacing to reduce blood pressure has not been required. 
Also in Q2, we received FDA approval for the LifeStent system, with indications covering the entire popliteal artery. The LifeStent platform is now the first and only self-expanding stent in the U.S. with this indication. Labeling is being updated, and our launch and education programs will commence this quarter. 
In stent grafts, LifeStream Balloon Expandable covered stent trial has completed follow-up, and the final PMA module was submitted last week to FDA, with approval and launch expected in mid-2017.
Our Covera next-generation AV access circuit stent graft received IDE approval a couple of weeks ago, and we anticipate commencing enrollment later this quarter or in early Q4. We expect enrollment will take about a year.
Our Venovo venous stent IDE study is in active recruitment. We anticipate enrollment throughout this year with follow-up in 2017 and PMA submission in 2018.
In biopsy, we just began the rollout of the ENCOR ENSPIRE system in China. In addition, the UltraCor Twirl breast biopsy marker just launched in the U.S. and Europe about a quarter ahead of our schedule.
Now moving to Urology and home care, we continue to advance our broad-based initiatives designed to reduce catheter-associated urinary tract infections through the launch of additional SURESTEP Foley Trays and our new SURESTEP Daily Care product. The SURESTEP Trays are helping standardize indwelling catheter placement around known guidelines. Our SURESTEP Daily Care product extends the solution to the maintenance phase and supports compliance to cleaning standards and awareness of indwelling time. Customers find this particularly helpful, especially in light of increasing nursing turnover.
In endourology, Q2 heralded the launch of 2 new stone basket configurations in our SkyLite platform, providing a full range of sizes. And in Targeted Temperature Management, this quarter, we received IDE approval for our new neurogenic fever prevention and control clinical study. This study will evaluate the use of the ARCTIC SUN system in this new indication. The study is anticipated to enroll more than 1,000 patients and will probably take about 3 years to complete. 
Moving to Oncology, we've had a very busy few weeks since the Analyst Day. We received clearance on our new chemical-resistant PowerPICC family named the PowerPICC EtOH. This new family will begin launching this quarter and is especially designed with a proprietary material that maintains all of the benefits of the PowerPICC and can withstand greater exposure to the sometimes harsh chemistry used in today's therapies. 
We're also making steady progress on our new PICC family designed to reduce the risk of thrombosis or DVT. We remain on plan to launch products in this new family in the back half of the year. 
We also received FDA clearance on our new power midline and clearance for our PowerGlide Pro family of intermediate dwell catheters. Both of these products just launched and are shipping to customers. 
This quarter, we added 3 new applications to our Tip Confirmation portfolio for pediatrics, ports and central lines due to launch of a first-generation system in Europe. We're also developing an advanced version slated for launch in the U.S. and other geographies later this year. 
I'll close my portion of prepared remarks today with surgery. As we discussed a few weeks ago, the TRIDYNE aortic sealant was approved by the FDA, and we're preparing to launch in the back half of this year. We're also working toward the launch of the Progel Emerald sealant, designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to anticipate the launch of additional Phasix resorbable mesh sizes throughout the remainder of the year. This expansion is planned to provide surgeons and their patients the largest and most comprehensive size matrix in the market, including a 50-centimeter by 50-centimeter mesh. 
On the clinical front, we've completed 1-year follow-up in our Phasix clinical study of over 100 ventral hernia patients and expect results to be presented and published later this year. Similarly, additional clinical data for our XenMatrix AB product family is expected to be released later this year. 
And finally, in mesh fixation, we anticipate launching the 15-count version of our OPTIFIX resorbable fixation device in Q4, with further launches in this category expected in the first half of 2017. 
I know we went through this quickly. Thanks for your attention. I think we covered 26 new products in about 6 minutes, so now I'll turn you over to Chris."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restr",855,"Thank you, John. Let's start with the items that affect the comparability of our results between periods. This quarter, we had acquisition-related items of $3.9 million and an impairment charge of $1.2 million and charges of $11.9 million related to restructuring and productivity initiatives. P&L impact to these items is detailed in the notes to the financial statement and the reconciliation accompanying our Q2 earnings press release. 
Now let's go through the statement of income for the quarter. Gross profit was $580.5 million or 62.3% of sales for Q2. On an adjusted basis, GP was $616.2 million or 66.2% of sales, up 140 basis points from the prior year quarter and better than we expected. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in GP, continuing the solid performance we saw in Q1. And FX was about 80 basis points of headwind to gross margin for the quarter. Mix was favorable by 110 basis points, which includes the positive impact from our Japanese business, and our cost improvement efforts drove approximately 120 basis points of favorability in Q2. 
Our cost savings and margin improvement programs are on track, and we now expect to exceed the original full year guidance for GPs that we gave you in January. 
SG&A expenses were $278.5 million for the quarter or 29.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 29.7%, 70 basis points above the prior year. Consistent with how we guided the full year, as we integrate the recent acquisitions, we expect this leverage to improve somewhat in the second half. 
I would reiterate that as we see opportunities to do so, we will continue to make incremental investments in certain targeted areas, including, for example, emerging markets and our health economics capabilities. 
R&D expenditures totaled $71.3 million for the second quarter or 7.7% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.6%, up 30 basis points from the prior year and consistent with our full year guidance. We do expect a somewhat higher level of R&D investment spending in Q3. 
Interest expense was $13.4 million for the second quarter, and other income and expense was $9.6 million of expense for the second quarter as reported and $2.1 million of income on an adjusted basis. The effective tax rate for the quarter was 25.4%, down 60 basis points from the prior year. 
Diluted shares for the period were 75.2 million, and we repurchased approximately 103,000 shares during the second quarter. The net result is adjusted EPS of $2.54, which excludes items affecting comparability and the amortization of intangibles. This was above the range we provided for the quarter, driven primarily by the overachievement in sales. 
The balance sheet as of June 30, reflects cash, restricted cash and short-term investments of $1 billion, similar to March 31. For the quarter, accounts receivables days were down 2.1 days, and inventory days were up 6.8 days, as we responded to recent inventory depletion from increased demand. Capital expenditures totaled $17.9 million for the quarter. 
On the liability side, total debt was $1.6 billion as of June 30 compared to $1.7 billion at March 31. Debt-to-total capital at the end of the second quarter was about 50%, and total shareholder investment was $1.6 billion at June 30. 
Moving to financial guidance. Given the strong first half of the year, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 8% and 9%, with reported sales growth between 7% and 8%, now implying a currency headwind of about 1%. On an organic basis, we had originally guided the year to be between 5% and 6% but now expect that range to be between 6.5% and 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.10 and $10.20, representing 11% to 12% growth. U.S. dollar has strengthened somewhat since our last earnings call, and we now expect foreign exchange to be between $0.25 and $0.28 of headwind for the full year. So on an FX-neutral basis, we're guiding to 14% to 15% growth for all of 2016. 
For Q3, we're expecting constant currency sales growth between 8% and 9%, with reported sales growth between 7% and 8%, also implying an FX headwind of about 1% on the revenue line. This assumes organic growth between 6% and 6.5% for the third quarter. 
From an adjusted EPS standpoint, we forecast third quarter in the range of $2.51 to $2.55, representing 10% to 12% growth on a reported basis. 
In summary, the first half of the year has gone well from both a sales and profitability perspective. As we now move to the second half, we remain focused on our continued execution, including smartly investing in strategic opportunities. The overall objective of our balanced efforts is to drive attractive and sustainable revenue growth, profitability and shareholder returns over the long term. 
I'll now turn the call back to Tim."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?",29,"Thank you, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. [Operator Instructions] Kathy?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America.",15,"[Operator Instructions] And our first question will come from Bob Hopkins with Bank of America."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So good solid Q2. Tim, I wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers, and no",94,"So good solid Q2. Tim, I wanted to just ask you kind of a big-picture question. Since the first quarter, there were so many questions across the medtech landscape about volumes and what was going on and why everyone was reporting such good numbers, and now you've reported Q2 results. So with that in mind, can you give us a sense as to what you're seeing broadly with surgical procedure volumes in the second quarter versus the first quarter? Just want to see if you're picking up on anything that's kind of worth noting."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky, so hard to predict where that moves. There's a lot of moving parts that affect health care usage these da",96,"Well, I think from my perspective, a thing worth noting is it seems that some of the improvement that we saw in the first quarter seems to be sticky, so hard to predict where that moves. There's a lot of moving parts that affect health care usage these days in the U.S., in particular, as you know. But as we watch other companies report, obviously, we've seen good healthy growth in the quarter. So it appears that the improvement seems to be holding, at least, over the flattish levels that it'd been the last few years."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there. But just want to try to get as specific as we can, are they kind of growing a",93,"And then also, Tim, for you, just 2 other really quick things. Can you just comment on what you're seeing in emerging markets? It sounds like things are still very robust there. But just want to try to get as specific as we can, are they kind of growing at the same rate they've been the last couple of quarters? And then maybe if you could just give us a quick comment on hernia and how sustainable these low double-digit growth rates are that you've been achieving here these last couple of quarters."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll let John Weiland address both of those issues.",10,"Sure. I'll let John Weiland address both of those issues."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across-the-board. So we don't have any concerns there about our ability to continu",179,"Well, I think that if you -- we had a little bit of a slowdown in Latin America this quarter. Otherwise, in emerging markets, we continued the robust growth that we've seen across-the-board. So we don't have any concerns there about our ability to continue to grow. And I think that you hit the nail on the head in terms of growth in our surgery business. And in particular, our synthetic hernia, which is the largest segment in hernia repair by far for us, had some of the finest growth we've seen in 8 to 10 years. And in fact, the independent market share data that we saw for Q1 saw us pick up 7 share points in Q1 alone. So we have great momentum driven by the new product portfolio and the -- and as well as the products that we said that we're going to be launching, such as the new products in fixation. So I think if you look at biologics, fixation and synthetics, I think we're hitting on all cylinders there in surgery right now."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question, we'll go to Brooks West with Piper Jaffray.",11,"Our next question, we'll go to Brooks West with Piper Jaffray."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom Bakas on for Brooks. If I could I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat, that an average U.S. rep, has a customer value of about $4 million annual",95,"This is Tom Bakas on for Brooks. If I could I'd like to start with just following up on Bob's line of questioning on emerging markets. At the Analyst Day, you've mentioned the stat, that an average U.S. rep, has a customer value of about $4 million annually and then an emerging markets rep was closer to $700,000. I just kind of hoped you could help us think about what the right steady state number is for emerging markets rep. And if something like half or 2 million fair, how should we think about that?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Go sell everything."" So by defin",147,"Let me start with that, and then I'll turn it over to John Weiland. So you got to start with the premise that we make like 15,000 SKUs across the company. We don't give every country manager a 15,000 SKU playbook and say, ""Go sell everything."" So by definition and design, we're much more targeted in these markets. So you're never going to get a comparable dollar value per bag or it would be an exception for probably some unique reason on a rep-per-rep basis just based on the volume of SKUs that we're going to put in an emerging market bag versus the U.S. bag. So it's a tough number for us to know for sure, but I'm not sure the answer's worth the chase, I think it's more directional in terms of the potential of the headcount versus trying to get to a mathematical answer."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. S",134,"And I think there's a whole different philosophy in terms of how we're building this business. I mean, we're building these businesses from the ground floor up. We're building the markets as opposed to competing in an already developed and built market. So by definition, when you're building these markets from scratch, it takes an awful lot of effort in terms of training, in terms of identifying the right individuals to train. So we're always going to be chasing that. I think the other dimension is that, for example, we added 225 reps last year in emerging markets, continued to add more this year. So if our philosophy and our investment plan continues to fold out, we're always going to be chasing this number because that's our first source of adding new reps."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and, perhaps, what the biggest opportunities in that geography are for Bard.",41,"Great. And just one quick follow-up, if I may. I was hoping you could just talk about Japan and the full direct model there and just how that's progressing and, perhaps, what the biggest opportunities in that geography are for Bard."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right produc",149,"Well, I think that if we look at our overall results thus far, we're delighted with where we are in Japan in such a short period of time. I think that the -- we're working hard on building our sales force and the right capabilities and in the right product lines. That's gone extremely well. I think that we certainly have benefited by the change in the yen. That has improved the profitability for us and has allowed us to continue to make investments in that business where applicable. And I think if we look at our overall portfolio, we have to say that in the vascular area and the area of oncology, they are the 2 areas that were underpenetrated in Japan and that we're putting more resources and more capabilities in our existing business over there. That's where we think we have the most significant growth opportunities."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question will come from David Lewis with Morgan Stanley.",11,"Our next question will come from David Lewis with Morgan Stanley."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And al",64,"This is actually Scott in for David. Two quick ones for me. Chris, looking at your guidance, the raise to 8% and 9% constant currency seems to suggest some deceleration heading into the back half of the year. Can you talk about what's driving that? And also, can you speak to any selling day impacts we should be aware of for the back half?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think for the full back half, it's going to -- there's -- within quarters, there's a little bit of noise, but there really shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, fran",133,"I think for the full back half, it's going to -- there's -- within quarters, there's a little bit of noise, but there really shouldn't be any selling day impact. And I think the guidance really does imply continued performance a lot like what we saw, frankly, in Q2. And I think the math allows you to get to growth rates that, frankly, are pretty consistent, certainly, at the high end of the range, but consistent with what we delivered in Q2. And that's -- frankly, that's really solid constant currency and reported revenue growth and really solid and, I'd say, high-quality net income and EPS growth. So again, there's a range, Scott, for reasons. But I think the math allows you to show continued, really strong performance through the next 2 quarters."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on the home care market?",32,"Fair enough. And would you also care to comment on what Liberator did in this quarter? And can you give us an update on your longer-term outlook on the home care market?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that wer",114,"Yes, I think, similar to Japan, we're off to terrific start with Liberator, delivering on or, frankly, above the model. We're continuing to integrate the business with our previously existing home care business and really generating the synergies that were behind the acquisition of really capturing more prescriptions and having those prescriptions that then end up within Liberator family over time. So the growth rates, we obviously gave you some color on what urology and what the different categories look like on an organic basis. But Liberator is growing exactly as we had hoped. And frankly, we're a little bit ahead of where we thought we would be at this stage of the game."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Mike Weinstein with JPMorgan.",10,"And we'll go next to Mike Weinstein with JPMorgan."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Robbie Marcus in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed,",83,"This is Robbie Marcus in for Mike. Just wanted to kind of flesh out some of the questions that have been asked already. Again, we saw an outperformance on organic growth, about 6.5%, 6.4% this quarter. A big part of it came from surgical, as we discussed, but also Urology and Vascular. Both really good numbers, Urology, up 4% organic; Vascular, up 6%. So maybe you could just touch on those for a minute and talk about what's driving that, particularly in Vascular."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","John, do you want to take that?",7,"John, do you want to take that?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had, we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we stand",227,"Sure. I think that a number of our new products in Vascular, we've talked about those over the -- during the last session that we had, we're seeing great uptick there. We love where we're at with Lutonix, quite frankly. We're excited about where we stand on the potential new indications for Lutonix which, in our minds, will be a great competitive edge for us in that business. Our biopsy business has been tremendously strong, and our emerging markets performance, particularly China in biopsy, has been terrific. Urology, we talked about the components of Urology. The urology market, if you look at the basic drainage business, is not growing in the United States at all. In fact, it's relatively flat, maybe up 1%. But some of the new product offerings that we have introduced into that market, especially our SURESTEP Tray, has allowed hospitals to upgrade within their own existing framework and it's given us a mixed differential, which is driving, really, a substantial portion of growth in basic drainage for us. And I'd also like to add, one of the areas that may not come out, but we have had excellent growth in Europe. They had another terrific quarter this quarter for us. And we've always been delighted with our growth in emerging markets, and that continues to be, a really, big positive for the corporation."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And maybe if I could just follow up on that, you mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?",39,"And maybe if I could just follow up on that, you mentioned Lutonix still doing really well. Can you comment on what you think the global market is in terms of size and what you think your share is?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the share question, we've referenced data that we've seen from third parties that continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong seque",204,"I think the share question, we've referenced data that we've seen from third parties that continue to say we're holding our own. We're sort of sharing the market together with the other competitor. And as John highlighted, we're seeing really strong sequential growth within our business. I think the estimates that folks had coming into this year, Europe is still a relatively small number where we continue to take share there as well. That's frankly been held back, I think, as folks wait for some Below-the-Knee data, which we're anxious to be the one to provide them for. So we think that data, when and if it does arrive, will really allow the opening of the European market and really have that growth really kick back in again. So we're -- I think we're pleased with how the market's growing. We're pleased with how we're continuing to hold and gain share. And most importantly, I think when we look out over the next 2, 3, 4 years, the portfolio of indications that we're going to have within the company, within Lutonix and the DCB franchise is going to be absolutely unrivaled. And we think that really sets us up in a very unique position."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all-comers, real-life use, shows j",53,"The only thing I'd add to Chris's commentary is that the FDA recently approved our ability to use the 1-year registry data in our labeling and in our promotions of the product. And as you know, that 1-year registry data, all-comers, real-life use, shows just tremendous efficacy of the Lutonix product line."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question comes from Larry Keusch with Raymond James.",10,"Our next question comes from Larry Keusch with Raymond James."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim or John, I wanted to come back to PICCs, 10% growth in the quarter, obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So just hoping if you could help us deconstru",68,"Tim or John, I wanted to come back to PICCs, 10% growth in the quarter, obviously, very impressive. Just I know China is a big opportunity, but I'm not sure how much that's really driving the growth right now. So just hoping if you could help us deconstruct that 10% a little bit, put into context of the market and what products are really driving that for you."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and midlines in Europe. That has been an excell",122,"Sure. Well, as you mentioned, we did have excellent growth within China, for example. That has been a big driver of growth throughout the world. But I will tell you, we've also had tremendous growth in PICCs and midlines in Europe. That has been an excellent arena for us. We're starting to gain momentum in Japan based on the emphasis that we talked about before, and we continue to have strong growth in the United States. So it's a very balanced approach of where we're trying to grow PICCs. It's a core franchise for us. We're making the investments where we need to, to continue that growth on track. And we like what we're seeing around the world in PICCs right now."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, the only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And pa",96,"Yes, the only thing I'd add, Larry, I mean, that slide from the Analyst Day, which was my favorite, was really the map that showed the level of penetration in most of the developed world and really highlighted the opportunity that exists for PICCs. And part of what you're seeing is us actually executing against that opportunity. And to John's point, tremendous growth in Europe, a huge untapped opportunity in Japan and China, we're creating that market as we go and seeing tremendous growth there that we think has a lot of legs still to come."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Can I just -- jumping in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years.",41,"Can I just -- jumping in to add that we've got a lot of great new products. Many of those just launching now, but we've had a real great cadence of product launches in that category over the last several years."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So John, that actually was just a segue to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put t",78,"So John, that actually was just a segue to my next question, and I do have a financial one for Chris. But on that, you got the chemical-resistant PICC approved now. You're obviously working on the thromboresistant version of that. I'm just trying to put the chemical-resistant into perspective. Is that kind of nice to have? And really the thromboresistant product is going to be the next real big growth driver? Or am I thinking about that incorrectly?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think that, one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not re",111,"Well, I think that, one, this is a really new material that we've developed from scratch. We think that as time goes on, the importance of this chemical-resistant technology is going to be significant. And so there's some things in the pipeline I'm not really ready to talk about today that'll bring that more to light as we go out into the future, but then our PROVENA family, which is what we're calling our thromboresistant, DVT-resistant technology, we'll begin launching that. And we do think that both of those are going to fit important niches in the marketplace. And I think we're just really excited to have them both out there."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Terrific. And then -- and Chris, quickly, just help me understand -- I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross ma",69,"Okay. Terrific. And then -- and Chris, quickly, just help me understand -- I think if I got the numbers right, there was a sequential drop in GM despite more than $50 million of incremental sales in the 2Q. So just help me bridge the step-down in gross margin and then, separately, just your thoughts on the second half for price given what we've seen in the first half."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. There's a little bit",72,"Yes, it's really Japan, Larry, again, the Q1 impact was much more pronounced where we were getting the final sell-through to the customer with no incremental costs. So it was pure GP dropping through, and we were largely through that. There's a little bit of hang over into Q2 and a very slight hang over the rest of the year, but it was really that Japan factor that caused that sequential move."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then price for the second half?",7,"And then price for the second half?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we're obviously really pleased that the first 6 months and the teams are, frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflec",82,"I think we're obviously really pleased that the first 6 months and the teams are, frankly, I think, certainly contributing to that outcome. I think we're certainly going to do better than we had anticipated for the full year. I think that's clearly reflected in our ability to provide the higher sales guidance. But we're certainly not ready to say 40 basis points is the new normal. But certainly, I think between 50 and 100 is probably what we're thinking about."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","We now have a question from Kristen Stewart from Deutsche Bank.",11,"We now have a question from Kristen Stewart from Deutsche Bank."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think, in the first quarter, you guys had 9% organic growth, then it was 7.1%, both very great",120,"I just wanted to go back over the organic growth numbers, just to make sure I understood kind of the trends between the first quarter and the second quarter. I think, in the first quarter, you guys had 9% organic growth, then it was 7.1%, both very great numbers. But I'm just wondering what kind of those just kind of quarter-over-quarter -- or year-over-year, rather, comp issue or -- because it sounds like everything is continuing to go very well in the marketplace, and it sounds like your comments suggest more continued strengthening. And it looked like the U.S. was up 9 last quarter, and up 7. So I'm just wondering if it's just simply year-over-year comparison or if it's..."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls as a couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was, by far, our easiest comp of the year, coming o",244,"Sure, Kristen. We actually tried to be pretty prescriptive on the Q1 calls as a couple of items that were really unusual are certainly not going to be repeated in Q2. One of them was the Lutonix comp. Q1 was, by far, our easiest comp of the year, coming out of that big Q4 and working through some inventory in Q1. Flip to Q2, we obviously don't have that and then also have the headwind associated with the Boston stocking order. We had talked about ports. There was a drag. We had a weak Q4 as we got ready for some new product launches in Q1. So ports were very strong in Q1. Biopsy was also incredibly strong in Q1 on the back of China. And China, in general, we called out that China had an absolutely phenomenal Q1. Some of that was again as we're building out the BioSurgery sales force, there was some stocking that went on as well. China had a terrific Q2 but, certainly, somewhat slower than, again, an unusual Q1. So I think the message we wanted to have you understand coming out of Q1, terrific quarter, some more onetime items, but leading into a Q2 that was going to be also very strong organically. So actually, the good news is it came out exactly as we had thought, and the items that were more of a tailwind in Q1 indeed played out the way we thought in Q2."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So would it be fair, I guess, to think about, I guess, the first half as the run rate? Because then, I guess, it's more of like an 8%. And I guess your guidance now is more of a 6.5% to 7%.",43,"Okay. So would it be fair, I guess, to think about, I guess, the first half as the run rate? Because then, I guess, it's more of like an 8%. And I guess your guidance now is more of a 6.5% to 7%."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that -- I mean, that 6.5% to 7%, I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact. Over last year, we had noted we launched a num",145,"I think that -- I mean, that 6.5% to 7%, I think if you normalize Q1 for all of those factors, you actually get in to more the range that we did kind of in Q2. I will highlight Q3 also have a stocking impact. Over last year, we had noted we launched a number of Lutonix additional lengths in Q3, and so Boston needed to stock all of those lengths in Q3 as well. So there'll be a stocking phenomenon in Q3. It'll be a little bit less than the Q2 stocking, but just to let you know that that's coming as well. So I think the way we're seeing the business is we're growing pretty comfortably in that 6.5-ish percent organic range, and it's really balanced, which I think is very important and I think speaks to the quality of the overall results."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So a little bit better volumes and a little bit better price in [indiscernible].",15,"Okay. So a little bit better volumes and a little bit better price in [indiscernible]."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And I'm also just curious going back and be doing just a look at Rochester, were you guys able to get to the level of margin improvement from a gr",60,"Okay. Great. And then just on acquisitions, are you guys seeing any difference in trends that are out there? And I'm also just curious going back and be doing just a look at Rochester, were you guys able to get to the level of margin improvement from a gross margin perspective with that deal now that it's almost 3 years?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facility is actually still ongoing this year. We'll complete it towards the end of this year and early",84,"Yes, we're still actually working through that. We're certainly in the tail end, but a lot of that manufacturing capacity build and standing up of that facility is actually still ongoing this year. We'll complete it towards the end of this year and early in '17. And it's been a lot of work for the team, but we feel good about how we're trending there and feel really good about that acquisition overall for sure and certainly as we now augmented it with Liberator."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","You want to comment about acquisitions.",6,"You want to comment about acquisitions."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think valuations always need to make sense to us. And that needs to be on top of a strategi",130,"Yes, I think more broadly we're continuing to be very active. We've looked at a lot of things this year. We're continuing to look at things as we sit here today. I think valuations always need to make sense to us. And that needs to be on top of a strategic rationale that's pretty compelling. And so again, we hadn't announced anything because we're not trying to find the things that make sense. But I think the takeaway you should have is that we're continuing to be disciplined and stick to the strategy that we've laid out for you. And the kinds of things we've done recently, we're trying to find more of those. And I'm confident we will, but just through the first 6 months, the stars haven't aligned."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Matt Taylor with Barclays.",9,"Our next question is from Matt Taylor with Barclays."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number",73,"So I wanted to start with just some of the moving parts here. And I was hoping you could go over a couple things. I don't think they were specifically given, if you could, just the Gore royalty, the emerging market growth rate, if you can give us a number. And then you talked about the benefit of Liberator in Japan. Can you parse those out between, I guess, the contribution to Urology?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, we were doing this because the Japan impact on top of the acquisitions is pretty important. So again, the -- and I'm not going to give you th",204,"Yes, I think there's a slide, Matt, on Page 4 of the deck that tries to tease all of that out for you. And again, we were doing this because the Japan impact on top of the acquisitions is pretty important. So again, the -- and I'm not going to give you the specific numbers but Urology, again, stripping out the impact of Liberator and the impact of Japan, grew 4% organic for us in the quarter which, again, is a very solid result. Vascular were a big drag from sales of EP products to Boston, we had continued the OEM product for them through all of last year as they stood up their own manufacturing. And so they have been building inventory this time last year. And they're buying very, very little from us now. So big drag there. And the Gore royalty of $39 million. When you strip all of those out as well as the Japan impact, Vascular grew 6 organic overall. And again, that's in the face of the Lutonix stocking order as well, which we've called out as about 70 basis points overall to total organic. So the 6.4 becomes a 7.1 when you adjust for the Lutonix stocking."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from jus",51,"Okay. That helps. And then in EM, it seems like you're still growing really nicely. I was wondering if you could just comment a little bit more there on what you're seeing from an underlying market perspective versus the gains that you're getting from just Bard expanding its footprint and infrastructure."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We saw another quarter where we're growing about 20% overall. John had said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good ab",128,"Yes. We saw another quarter where we're growing about 20% overall. John had said Latin America was a little bit softer. But frankly, we've done a good job, I think, of getting inventories in Latin America to a much better level. And we feel really good about the second half and going forward there. To John's other point, in China, we're creating a lot of these markets as we go. And so while there's been a lot of noise about slowdowns and macro factors impacting growth rates, we haven't seen that in China. PICCs are going terrifically well. Biopsy is going terrifically well. We're now building and have built a direct BioSurgery sales force, excited about that opportunity. We have our Lutonix SFA trial enrolling in China. So..."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","We just launched a new biopsy product there.",8,"We just launched a new biopsy product there."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly, not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term and given the market o",96,"As John had mentioned. So I mean, Latin America's a tough place to do business. Certainly, not going to disagree with that fact. But it's still a relatively small business there. But we're building it the right way for the long term and given the market opportunities we're targeting. And as Tim said, we're pretty targeted about the products that we bring to market there. And they're generally trying to serve a very specific need. In some cases, a need that's not being yet met by other products, and PICCs is the best example in China."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I would add, though, too, that the -- we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too.",33,"I would add, though, too, that the -- we have made a number of investments in the rest of Asia area outside of China, and their results have been stellar to date, too."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And we'll go next to Anthony Petrone with Jeffferies.",10,"And we'll go next to Anthony Petrone with Jeffferies."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point and when that agreement gets renewed? And then the longer-term t",70,"Maybe to start out with a couple on Lutonix and maybe just an update on the Boston Scientific distribution agreement. What percentage of sales are coming from Boston Scientific at this point and when that agreement gets renewed? And then the longer-term target of $1.5 billion by 2020 for the category, I'm just wondering how much of that is below-the-knee indications, and then one strategy question to follow up with."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, if you look at our EP business, when we entered into that agreement, and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall busi",89,"Well, if you look at our EP business, when we entered into that agreement, and it's going extremely well, but the number of accounts they have is a limited number of accounts. And as a result of that, it's a relatively small percentage of our overall business. It doesn't mean it's not important in certain segments that you're focusing on, and it doesn't mean the partnership is not going well. But it is not a large percentage, by any sense of imagination, in terms of our overall Lutonix business."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","In terms of the market size, Anthony, we target the below-the-knee opportunity at about $350 million globally by 2020. SFA and popliteal in the $850 million range globally. And then other indications, including AV access, which we're really excited about",93,"In terms of the market size, Anthony, we target the below-the-knee opportunity at about $350 million globally by 2020. SFA and popliteal in the $850 million range globally. And then other indications, including AV access, which we're really excited about where we are clinically there, add another $250 million. And what really excites us, when you look across all those indications in 2020, we're the only company, we believe, that's going to have approvals in all those areas. And we think that is going to really position us well over that time frame."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And just a strategy one, the reverse on, I guess, the M&A environment. When you consider the valuations here have improved, I'm just wondering if divestitures have moved up the priority scale for assets that are maybe slower growing and no",54,"That's helpful. And just a strategy one, the reverse on, I guess, the M&A environment. When you consider the valuations here have improved, I'm just wondering if divestitures have moved up the priority scale for assets that are maybe slower growing and not as core to the business at this point in time."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, thanks. Yes, I think with the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out",101,"Yes, thanks. Yes, I think with the sale of our EP business a few years ago, I don't see any other businesses within the company that we would divest. Certainly, with as many SKUs as we have, there's always some that are, even by design, when you come out with a next-gen product, that are in decline. But we'd much rather have the management time focused on growth, and we've got plenty of opportunities through the investments that we've made to do that rather than focusing on a product line here or there that might be a bit of a drag."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And our next question will come from Matt Mishan with KeyBanc.",11,"And our next question will come from Matt Mishan with KeyBanc."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","First question from me is can you help me walk from your previous earnings guidance to your new guidance? I'm thinking it'd be by about $0.09 in the quarter, but only raised the midpoint of the EPS guidance by about 4. And you also were able to bump the s",51,"First question from me is can you help me walk from your previous earnings guidance to your new guidance? I'm thinking it'd be by about $0.09 in the quarter, but only raised the midpoint of the EPS guidance by about 4. And you also were able to bump the sales guidance."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year, actually has worsened by, call it, $0.05 to $0.08. So at the midpoint, sort of $0.6.5. And it's really, for us, driv",265,"Yes, sure. And I called it out in my prepared remarks, Matt. FX, for us, relative to where we were when we had guided Q2 in the full year, actually has worsened by, call it, $0.05 to $0.08. So at the midpoint, sort of $0.6.5. And it's really, for us, driven by the pound. The RMB has sort of quietly weakened relative to the dollar. The euro, Aussie dollar, Canadian dollars have all moved relatively materially. Now it was very late in Q2, but as we sit here today, those are all going to cost us, in combination, $0.06 or $0.07 so, effectively, offset virtually all of the beat to the consensus number in Q2. And as we talked about on the Q1 call, and as I reiterated again today, we're continuing to invest incrementally as we have the opportunity to do so. So I think the strength of the operating performance so far is allowing us to continue to make investments this year that, coming into the year, we frankly didn't think we were going to be in a position to do. And we think that's the right thing to do for the long term. I think looking at Q2 of an 8.3 reported and a 12 reported, bottom line, very high quality. And us taking some of the upside that we've delivered to invest back into the business, we think is in the right balance. And you're seeing us continue to do that, and that's, frankly, also reflected in the guidance that we've just laid out for the remainder of the full year."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","I think a good example of that would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, seeing the size of the opportunity and our ability and invested in it. And as you can see, that's a l",90,"I think a good example of that would be the neurogenic fever trial. That was not in our original plans as we started the year. But as we went through it, seeing the size of the opportunity and our ability and invested in it. And as you can see, that's a large, large clinical trial. That's an example of some of the things that we turned on when we saw we had a little bit of an opportunity based in our performance. And that is only one example, quite frankly."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last",71,"Okay. That's very helpful. And then just a couple of modeling questions. Can you help me out with the cadence of the EP sales to Boston Scientific as we walk through the rest of the year? I think you started calling that out in the fourth quarter of last year. And then how should we be thinking about the comparison -- the fourth quarter comparison in particular, from Japan and Medicon?"
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","So Q3, there'll be less of an impact in Q3, and then even less of an impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a ful",101,"So Q3, there'll be less of an impact in Q3, and then even less of an impact in Q4. And once we get into '17, it'll be a very small ongoing level of sales. So we won't have the comp issue anymore. Medicon, there will be a positive impact in Q4 having a full quarter of sales through to the customer as compared to last year where, again, we had to work through the inventory that was resident at the JV when we closed that transaction in early November. So there's couple of puts and takes related to both of those."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Just one clarification there, Matt. The EP step-down really began in Q4, so Q3 would still be a significant reduction similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less.",38,"Just one clarification there, Matt. The EP step-down really began in Q4, so Q3 would still be a significant reduction similar to what you've seen these last couple of quarters. But Q4, that comparable will be much less."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments.",24,"And that does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll tal",52,"Thanks, Kathy. I'd just like to close by thanking all of our employees around the world for a very strong quarter and their commitment to continue the execution of our strategic plan. And with that, thanks to all of you for joining us today, and we'll talk to you again next quarter."
254131,370602062,1014557,"CR Bard Inc., Q2 2016 Earnings Call, Jul 26, 2016",2016-07-26,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect.",28,"Thank you. And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand r",275,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's June 30, 2016, Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of October 25, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period.
At this time, I'll turn the call over to Mr. Timothy Ring. Please go ahead."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Lori. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Conference Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also d",513,"Thank you, Lori. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Conference Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The agenda today will go as follows: I'll begin with an overview of the results for the third quarter; John Weiland, our President and COO, will review third quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you an update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will give you the third quarter income statement, balance sheet as well as our expectations for Q4 and obviously, the full year. And then we'll close with Q&A.
Third quarter 2016 net sales totaled $941.9 million. That's up 9% over the third quarter of last year on an as-reported basis and up 10% on a constant currency basis. Currency impact for the quarter versus Q3 of last year was unfavorable by about 90 basis points.
Our organic revenue growth was 6% for the quarter. Excluding the prior year stocking of Lutonix by Boston Scientific, we estimate that our organic sales growth was 6.4%.
While our recent acquisitions performed above the guidance we've provided, our Targeted Temperature Management business, which can be a little lumpy given timing issues had a soft quarter. John Weiland will take you through the product lines, and Chris will provide guidance. We believe you will see continued strength and momentum across the portfolio. 
Net income for the third quarter was $96.4 million and diluted EPS were $1.27. Excluding amortization of intangibles and items that affected the comparability of results between periods, Chris will cover those later. Adjusted third quarter 2016 net income and diluted earnings per share were $199.5 million and $2.64. That's up 14% and 16%, respectively. These adjusted results well exceeded the guidance we provided for the quarter. 
Looking at revenue growth geographically compared to the same quarter of 2015, net sales in the U.S. increased 7%. On a constant currency basis, Europe grew 5%. Japan was up 44%, benefiting from moving the customer pricing after our acquisition of the joint venture there, and our other international businesses grew 19%. Emerging market growth was strong, yet again, representing 10% of our total sales in Q3. 
The results in Q3 continued to demonstrate the strength of our economic engine, driving organic growth between 6% and 7% on the top line, with attractive returns on the bottom line, even while we had continued to invest significantly for future growth. The results so far this year have exceeded our expectations, and we expect a strong finish to what has been a very strong year so far. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be getting all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.So let's begin with Vascular. Total net sales were $25",779,"Good afternoon, everyone. Before I start, let me point out that I'll be getting all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.
So let's begin with Vascular. Total net sales were $258.1 million, up 3% over last year on an as-reported basis and up 4% on a constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 5% in Q3, with the United States business up 2% and international up 10%.
Sales in our Surgical Graft category were flat in the third quarter. Our Endovascular business grew 7% in the third quarter. Our peripheral PTA line grew 7% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. 
We continue to see strong growth year-over-year in sales of Lutonix to customers, including sequential growth in the United States. Sales in our vena cava filter line were down 18% this quarter. Our Stent business grew 6% in the third quarter, which was the best quarter in 4 years, driven by strength internationally. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally, making -- marking the sixth straight quarter of double-digit growth in this product family. 
Now let's go to Urology. Total net sales were $242.1 million, up 14% as reported and up 15% on a constant currency basis. The combination of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in this category. Excluding these 2 acquisitions, the United States business was up 2% while internationally, we grew 7%.
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 5% globally and 4% in the United States, with our I.C. Foley business up 1% globally and flat in the U.S. 
Our Targeted Temperature Management business grew 4% this quarter. While the sales of our disposable pads grew double digits, as Tim said, the capital portion of this business can be a little lumpy. We continue to believe that this product line has long-term double-digit growth potential. 
Our continence business was up 28% in the third quarter, driven by the benefit from the new acquisitions. Sales in Urological Specialties were up 9% this quarter, including our brachytherapy business, which grew 6%, driven by Japan.
And finally, in this category, stand-alone sales of our StatLock catheter-stabilization line grew 2% in the third quarter.
Let's now go on to Oncology. Total net sales in this category were $258.4 million, an increase of 8% on an as-reported basis and up 9% on a constant currency basis over the third quarter of last year. The Japan acquisition added about 200 basis points to growth globally. Excluding that, sales in the United States were up 3%, and international sales were up 15%. 
Our port business was up 9% versus the third quarter last year. Most of the benefit from -- in this category is from Japan that is in ports. Our PICC revenue was up 8% this quarter with continued strength internationally. Our Vascular Access Ultrasound product line grew 8% this quarter. And to close out the category, our Dialysis Access product line was up 7%.
Let's conclude then with our Surgical Specialties business. Total net sales in this category were $158.8 million, up 14% on both an as-reported and constant currency basis. United States sales were up 11%, and international sales were up 21% this quarter, excluding the impact from Japan, which was minimal.
Our performance irrigation business was down 6%. Our soft tissue repair business delivered its strongest quarter in 6 years, growing 14% in the third quarter. We saw this growth despite continued procedural shifts away from natural tissue products, which declined 35% for us in the third quarter. 
In contrast, our synthetic business, which includes our hybrid Phasix material, grew 23% this quarter, which is the highest growth in more than 10 years. Our mix of synthetic revenue to natural tissue revenue is now greater than 7:1. 
We believe the quality and the breadth of our product offering and our value-added programs help customers select the right product for the patient, which is having a significant impact on the treatment paradigm. 
Our hernia fixation business grew 34% this quarter on the continued impact from our recent product launches here.
Closing out the surgical category, our BioSurgery business grew 22% in Q3, with strong growth in both the United States and outside the United States. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and",727,"Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and in-stent restenosis supplements are under review at FDA, and we're hopeful for approval of both of these expanded indications early next year. 
In our Below the Knee IDE, as we recently announced, the FDA has approved an amendment to our study, supporting the primary efficacy analysis at the 6-month follow-up time point. This is an exciting development, and we're continuing to analyze the potential impact to our approval time line. We think this should put our launch in 2018. 
The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a first look at our results in late Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late Q4 2017 U.S. launch. 
In Japan, our shonen submission for the Lutonix SFA indication remains under review, and we continue to anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began earlier this year.
Also in Vascular, our Lifestream balloon-expandable covered stent trial has completed follow-up, and the final PMA module was submitted last quarter to FDA, with approval and launch expected in mid-2017. 
Our COVERA next-generation AV access circuit stent graft received IDE approvals for both the fistula and the graft study. Both studies began recruitment in Q3, and we expect enrollment will take about a year. 
Our Venovo vena stent IDE is in active recruitment, and we continue to receive positive feedback from Europe where the products commercially available. We anticipate enrollment throughout 2016 with follow-up in 2017 and PMA submission in 2018. 
Next, moving to Urology and home care. We've now launched our female version of the Magic3 Go self-hydrating hydrophilic catheter in Europe, and we've begun direct-to-consumer advertising in this product in the U.S. In Targeted Temperature Management, we anticipate commencing enrollment in our new IDE study of neurogenic fever prevention and control. This study will evaluate the use of the Arctic Sun system in this new indication, and we plan to enroll more than 1,000 patients over the next 3-or-so years. 
Moving to Oncology. We're awaiting 510(k) clearance of our new PROVENA family of PowerPICCs designed to reduce the risk of DBT. We're building inventory in a broad range of single-, double- and triple-lumen configurations and anticipate launching around the end of the year. 
Late in Q2, we launched both our new Power Midline and PowerGlide Pro families of intermediate dual catheters. Early feedback has been very positive on both products, and we anticipate launching additional versions in early 2017. 
On the last call, I announced our European launch of the Delta system, with specific indications for Tip Confirmation for the pediatric patients for ports, PICCs and central lines. The next generation of this system is completing development, and we're planning for U.S. launch around the end of the year. 
I'll close my portion of the discussion today with surgery. First, in BioSurgery, we're preparing for the launch of the TRIDYNE aortic sealant. We hope to get this product to the market before the end of the year, but due to some near-term capacity constraints, we now expect to launch in Q1. We also expect to launch in Q2 of 2017 the Progel Emerald lung sealant that's been designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to launch additional Phasix resorbable mesh sizes and expect to enhance our offerings around the end of the year. This expansion will dramatically increase the range of sizes from 5 to 25 different configurations, providing surgeons and their patients the largest and most comprehensive size matrix in the market.
Expansion of our XenMatrix AB platform with multiple new sizes is also on track for launch in early 2017. After launch, Bard will offer the largest biologically derived graft in the market. 
And finally, in mesh fixation, we've launched the 15-count version of our OPTIFIX resorbable fixation device, with further launches in this category expected in the first half of 2017.
Thanks for your attention. Let me now turn you over to Chris."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges",935,"Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges of $4.6 million related to restructuring and productivity initiatives and a tax credit of $2.6 million related to the completion of certain tax, certain IRS examinations. The P&L impact to these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q3 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $589.7 million or 62.6% of sales for Q3. On an adjusted basis, GP were $624.3 million or 66.3% of sales, up 150 basis points from the prior year quarter. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in gross profit, continuing the solid performance we saw in the first half of the year. And foreign exchange was about a 50 basis point headwind to gross margin this quarter. Mix was favorable by 110 basis points, which includes the positive impact from our Japanese business. And finally, our cost improvement efforts drove approximately 100 basis points of favorability in Q3.
It's been a very strong year for margins for us. And as we told you last quarter, we expect to exceed the original full year guidance for GPs that we gave you in January. 
SG&A expenses were $272.6 million for the quarter or 28.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 28.7%, 20 basis points above the prior year. While we do expect to see decent leverage here in Q4 as we anniversary the acquisition of our Japanese joint venture, we expect to slightly exceed our original estimate for the full year due to incremental investments we've made in certain targeted areas. 
R&D expenditures totaled $74.2 million for the third quarter or 7.9% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.8%, up 30 basis points from the prior year. Again, as we told you last quarter, we expect a somewhat higher level of R&D investment for the full year compared to our original guidance as our strong results have allowed us to fund new opportunities earlier than initially contemplated. We continue to be in investment mode to strengthen the long-term revenue growth potential of the portfolio. 
Interest expense was $14.9 million for the third quarter, and other income and expense was $115.8 million of expense in Q3 as reported or $0.4 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.7%, down 130 basis points from the prior year. We are trending to be at the low end or maybe even slightly better than our original guidance for the full year. 
Diluted shares for the period were 75.3 million, and we repurchased approximately 190,000 shares in the third quarter. The net result is reported EPS of $1.27 and adjusted EPS of $2.64, which excludes items affecting comparability and the amortization of intangibles. This was well above the guidance range we provided for the quarter, reflecting both higher-than-expected sales as well as the continued strong execution by our teams around the world.
The balance sheet as of September 30, reflects cash, restricted cash and short-term investments of $1.15 billion, up slightly from June 30. For the quarter, accounts receivable days were down 1.5 days, and inventory was up 3.1 days. We believe inventory days will decline as we anniversary the recent acquisitions and execute on new product launches that we have been building in front of. Capital expenditures totaled $26 million for the quarter. 
On the liability side, total debt was $1.6 billion as of September 30, no change from June 30. Debt to total capital at the end of the third quarter was about 49%, and total shareholder investment was $1.7 billion at September 30. 
Moving to financial guidance. Given the strong results, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 9% and 10%, with reported sales growth between 8% and 9%, implying the same currency headwind of about 1%. We now expect our full year 2016 organic revenue growth to be around 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.23 and $10.28, representing 13% growth for the year. We now expect foreign exchange to be between $0.23 and $0.25 of headwind for the full year. So on an FX-neutral basis, wer guiding to 15% to 16% EPS growth. 
For Q4, we are expecting constant currency sales growth between 10% and 11%, with reported sales growth between 9.5% and 10.5%, implying an FX headwind of approximately 50 basis points on the revenue line. This assumes organic growth between 6% and 7% for the fourth quarter. From an adjusted EPS standpoint, we forecast the fourth quarter in the range of $2.70 to $2.75, representing 11% to 13% growth on a reported basis. 
As we look ahead, we expect a strong finish to what has been a very strong year of both execution and financial performance. And we're very pleased that we've been able to produce these results while still significantly investing for the long-term health of the business. We look forward to reporting on the full year and providing guidance for 2017 in January. 
Now I'll turn the call back over to Tim."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Lori?",28,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Lori?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray.",16,"[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpo",59,"This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpoint just relative to kind of what we saw in the first half of the year."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes. it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certainly, the f",87,"Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes. it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certainly, the feedback from the various hospital administrators and CEOs, et cetera, we talked to all would amplify that. I think the biggest problem we're hearing them talk about right now is nursing turnover. So haven't heard a lot of negativity about word?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add is that we continued strong results in Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out, in particular, you might remember last quarter, we",98,"The only thing I'd add is that we continued strong results in Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out, in particular, you might remember last quarter, we had a late-quarter growth in Latin America. We've had this quarter the best growth that we've had in 5 quarters, so it was nice to see that business rebound to where we expect it to. And combined with continued very strong growth in emerging markets and, quite frankly, in our European business overall."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just looking at the quarter, there was strong organic growth in word, and it looks like, I mean, your investment some product launches. But I'm just hoping you can give us some color on is this a little more of -- should we expect this to be more",81,"And then just looking at the quarter, there was strong organic growth in word, and it looks like, I mean, your investment some product launches. But I'm just hoping you can give us some color on is this a little more of -- should we expect this to be more of a run rate? Or is this more of a mid-single-digit grower? I just -- it seems like we might not be modeling this appropriately given what we saw this quarter."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique",110,"What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique patient benefits that is very difficult to compete within the marketplace, I'd say, right now. But on top of that, as a result of our new product launches, fixation had outstanding growth in the category and very strong growth in BioSurgery. So really, the 3 major segments in that business for us all had very significant growth rates, and we think that will bode positively for the future."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I would add, the growth rates that you're seeing in our business are above -- significantly above what we think market growth rates. So we're continuing to pick up probably some pretty significant market share.",38,"The only thing I would add, the growth rates that you're seeing in our business are above -- significantly above what we think market growth rates. So we're continuing to pick up probably some pretty significant market share."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from David Lewis with Morgan Stanley.",10,"We have a question from David Lewis with Morgan Stanley."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott Wang in for David. Two questions for me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp adjusted",63,"This is actually Scott Wang in for David. Two questions for me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp adjusted stability on the organic growth line. Is there anything in particular that is driving that deceleration into last quarter of the year?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based balance growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's a",107,"Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based balance growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's always some puts and takes. But as John just articulated from a geographic standpoint, we're continuing to see good balanced growth in the surgical business, in particular, continues to perform well and the other 3 businesses and Lutonix on the Vascular side. So we're not looking to signal any deceleration for sure. Frankly, I think more of the same."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And can we talk a little bit more about Urology strength this quarter? Now some of that was obviously contribution from Liberator and Medicon, but the underlying growth is also pretty strong. Can you talk to us a little bit about what's drivi",63,"Fair enough. And can we talk a little bit more about Urology strength this quarter? Now some of that was obviously contribution from Liberator and Medicon, but the underlying growth is also pretty strong. Can you talk to us a little bit about what's driving that underlying growth trend and maybe give us an update on where you are on the Liberator integration?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market pers",128,"Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market perspective and especially the Magic3 Go female. We have been delighted with what we've seen with the Liberator integration. I'd say that basic drainage, though, was up 4% in the United States without Liberator being in those numbers, so it's a very strong business. Continence business was up 28%. The only really shortfall that we had was Targeted Temperature Management that only grew at 4% versus 15% year-to-date. We think that's a timing issue on capital equipment. So we saw very nice growth across the portfolio."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add there is that we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and, in particular, as it relates to Urology. So some of the new products and th",87,"And the only thing I'd add there is that we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and, in particular, as it relates to Urology. So some of the new products and the tray designs and the programs that we've implemented continue to drive very good growth, absent significant volume growth, frankly. So we're continuing to take share, providing solutions that customers are valuing because it's helping them solve a real problem that they're facing."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Vijay Kumar from Evercore ISI.",10,"We have a question from Vijay Kumar from Evercore ISI."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just maybe on the margins. It really looked like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove the spend on the margin side, I think that would be a helpful starting point.",44,"Just maybe on the margins. It really looked like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove the spend on the margin side, I think that would be a helpful starting point."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all, from a gross margin standpoint we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues t",179,"Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all, from a gross margin standpoint we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues to be positive, driven by over the last couple of years, some of the launches that we've had. And then our operations team continued to deliver excellent results from a cost improvement standpoint. So frankly, the strength that we've seen from strong execution on the gross margin line has allowed us to continue to invest in R&D and SG&A, frankly, ahead of where we had anticipated to be able to coming into the year. So we think it's a terrific ability for us to reinvest into the business while still driving significant operating margin improvement. So it's a model that we're focused on, continuing to replicate. Comes with a lot of hard work from a lot of people, but that's the model. And when we execute well, you get the results that you saw this quarter."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how",69,"Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how this time maybe it's larger than what we're thinking and then what could drive growth on that side, that would be helpful."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start and then turn it over to John for follow-up. So we still think this market is accelerating. And frankly, I would still call it, even in the next year, potentially with another competitor, still a rising tide here. It's still under-penetra",142,"Sure. I'll start and then turn it over to John for follow-up. So we still think this market is accelerating. And frankly, I would still call it, even in the next year, potentially with another competitor, still a rising tide here. It's still under-penetrated, still under-diagnosed. And I think as more use is -- there's more usage experience, physicians are continuing to determine where they want to use DCBs in their treatment protocols, and all of that is very positive. I do think it's kind of interesting, as you look at different nuances in the specifics of the products relative to the model drug and some of the behavior characteristics, certainly, we performed extremely well in our registry data vis--vis all of those metrics. So we feel very good about our own positioning going forward against what we know is expected competition."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications, though, AV access and Below the Knee, we think those 2 markets wo",106,"The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications, though, AV access and Below the Knee, we think those 2 markets would bring approximately $600 million in 2020, and we're working hard to be the first entrant into that space. So while do we do expect some competition in the SFA, we're hopeful that we will be the market enterer in the other 2, which we expect other 2 segments, which we expect to have outstanding growth potential."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us as we talked about, in-stent restenosis and long lesion, we anticipate Q1 2017 launch with those indications mid-2017 the laun",84,"And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us as we talked about, in-stent restenosis and long lesion, we anticipate Q1 2017 launch with those indications mid-2017 the launch of Lutonix in Japan, and then late 2017 in AV access potential for launch. We think that's going to be differentiating and give us and continue to keep us in a leadership position. Then 2018, we've got BPK come along."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Keusch from Raymond James.",11,"And we have a question from Larry Keusch from Raymond James."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just want to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses, puts and takes and capital can be lumpy,",79,"Just want to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses, puts and takes and capital can be lumpy, but I just want to dive a little bit deeper and see if you are potentially seeing anything other than just timing as it relates to just the appetite for capital equipment out there amongst hospitals."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strong right afterward. So we don't see any indicators, which would cause us t",49,"No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strong right afterward. So we don't see any indicators, which would cause us to be concerned about that."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I think our other capital businesses were -- had growth similar to what we have seen in other quarters.",19,"I think our other capital businesses were -- had growth similar to what we have seen in other quarters."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Larry, we expect Q4 to, frankly, be robust, so just to that point.",14,"And Larry, we expect Q4 to, frankly, be robust, so just to that point."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's perfect. And then just sort of bigger picture, I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we head",51,"Okay. That's perfect. And then just sort of bigger picture, I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we head into 2017?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","You answered your own question. We're not going to give guidance on this call for 2017. But your first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth of the market soli",161,"You answered your own question. We're not going to give guidance on this call for 2017. But your first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth of the market solidifying throughout this year. There's nothing that we have seen that would indicate that to change heading into next year. When we set our investment plan back in 2013, we said that you would start to see the results in '15, but we expected that it would be sustainable. So everything we've been doing from then to now, investing in R&D, sales force expansion in emerging markets, the acquisitions that we've made have all been targeted to achieve that kind of an outcome. And we fully expected that above-market growth achievement of 2 to 3 points above the market should continue. So that's kind of the way we feel about it heading out of this year."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'll add to that is one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about 1/3 increase",132,"The only thing I'll add to that is one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about 1/3 increase in our sales forces. And people are still maturing in some of those jobs that we're maybe the later placements into it. And quite frankly, we expect to have pretty robust editions in our sales force again next year in a lot of our high-growth markets. So I think that for making the right investments, as Tim mentioned, to ensure that as the products come through our pipeline and registration pipeline that we're poised and have the right manpower to execute on those."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impa",85,"The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impacting the entire company. And so you've seen it this year. We expect to end this year strong with really balanced and important contributions from all the businesses, which I think you need to have to sustain the kind of growth rates that we're seeing."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Mike Weinstein with JPMorgan.",10,"And we have a question from Mike Weinstein with JPMorgan."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So let me ask just on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask you",140,"So let me ask just on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask you just about mix and as well as the competitive environment. So number one, on mix, we continue to underestimate within the mesh part of the business the opportunity for mix upgrades for your business. So can you give us a sense of where you think you are in that mix upgrade piece of the story within the mesh business? And then second, competitively, we just had word. Is there anything that you've seen new competitively that gives you any pause as to this momentum in the business continuing in 2017?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And if I add on top of that, our BioSurgery margins are well above the corporate average. So with mid-",187,"Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And if I add on top of that, our BioSurgery margins are well above the corporate average. So with mid-teens growth in those and into the 20s for BioSurgery, obviously, that will have a positive impact on our overall margins long term. Relative to ACS, it's interesting, I'm speaking to one of our key leaders in that business this afternoon about the same exact issue. And we have not seen anything that's launching or plans to launch that gives us concern relative to the growth drivers in that business either in the fixation side of things or in the synthetic mesh side of things. We think it's in our Phasix product line and product category has such unique capabilities in terms of providing long-lasting repairs for patients without leaving a mesh behind long term that the benefit to patients is significant and we've not seen anything yet. Although we're always diligent about it, we've not seen anything yet that gives us pause for concern."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics has a place, the Phasix opportunity to offset",137,"Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics has a place, the Phasix opportunity to offset biologics is a terrific win for us. And it's a terrific win for the physician and hospital in a lot of cases. And we're seeing customers because of the breadth of the portfolio literally standardize on Bard's hernia portfolio from basic synthetic to an absorbable synthetic to a biologic. And we're the only one that could even sit down and have that conversation with customers. And there's a lot of advantages, as you can imagine, for them to do that. And that's certainly part of the reason we're driving and capturing share."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","I missed it, if you made some comments just about use of cash during the quarter. But it didn't [indiscernible] there was activity from a buyback standpoint. It would look like it was pretty minimal. Just can you give us thoughts on it seems like you guys",84,"I missed it, if you made some comments just about use of cash during the quarter. But it didn't [indiscernible] there was activity from a buyback standpoint. It would look like it was pretty minimal. Just can you give us thoughts on it seems like you guys have been largely sitting on your cash last couple of quarters, maybe paying down a little bit of your debt. Is there any thought process behind that? Any updated thoughts, Tim, on the environment for business development?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Nothing's changed from our perspective strategically related to the use of cash. Priorities are still the same, acquiring technologies and businesses the first priority. Share buybacks, second, and then dividends, third. So none of that's really cha",128,"Sure. Nothing's changed from our perspective strategically related to the use of cash. Priorities are still the same, acquiring technologies and businesses the first priority. Share buybacks, second, and then dividends, third. So none of that's really changed. As you know, the business development environment is opportunistic and episodic. But relative to our internal efforts, our initiatives, none of that's changed. We're still pedal to the metal in terms of our initiatives globally. Frankly, as we've added business development resources geographically over the last couple of years, they've matured face more, so we feel good about the initiative and the momentum. And I would fully expect to continue to see the same kind of cadence going forward that you've seen over the last couple of years with us."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the co",109,"And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the commitment of shareholders to not do that, we're certainly continuing to deliver on that commitment. So to Tim's point, the priority remains to be strategic. We obviously continue to have a lot flexibility with the balance sheet to do both in a reasonable and appropriate way. And it'll ebb and flow quarter-to-quarter, but we'll continue to be an activity repurchaser in an ordinary course."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Amit Hazan with Citi.",9,"We have a question from Amit Hazan with Citi."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Let me maybe start with nonorganic guidance [indiscernible]. So I think you've raised it a little bit. You're now at 2% to 3% contribution for the year. That's about $85 million at the midpoint. If we think about just the components of that, Liberator, yo",127,"Let me maybe start with nonorganic guidance [indiscernible]. So I think you've raised it a little bit. You're now at 2% to 3% contribution for the year. That's about $85 million at the midpoint. If we think about just the components of that, Liberator, you started out when you acquired it, say, [ph] $70 million for the year. Clearly, you're talking about at being more than $70 million. Medicon is another $30 million net for the year, if I'm doing my math right, so we're already at $100 million. We've got a few other small pieces. Seems to me like we're easily over even high end of that. So maybe give me a sense of what I'm missing on the nonorganic side even to get your guidance."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related",89,"Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related to that year-over-year decline in revenue. To John's point, the acquisitions are both going well from an immigration standpoint, and we're trending out of the model. But when you do the math on all the puts and takes, we're comfortable with the guidance here for the full year."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then let me just ask the second question about PICC. So it would kind of look like just the trend line it's been it's really nice consistent 10%-plus grower. I don't want to pick on it too much, at 9% for the year, so just under that not a big d",155,"Okay. And then let me just ask the second question about PICC. So it would kind of look like just the trend line it's been it's really nice consistent 10%-plus grower. I don't want to pick on it too much, at 9% for the year, so just under that not a big deal, but just want to make sure we're not missing anything there and you're still very comfortable with how PICC performance is going. And related to that, if we kind of go back to the Analyst Day and we think about your discussion today about the pipeline. One thing I haven't seen you guys talk about or at least highlighted new products coming in Oncology there's, I think, nothing there. In the Analyst Day, that was really highlighted. I don't think I heard anything today. So just maybe touch on those 2 points both the PICCs and the pipeline inside of the word."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","We are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date, so we had a very strong quarter in ports. And PICCs were up 8%, whic",88,"We are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date, so we had a very strong quarter in ports. And PICCs were up 8%, which is very similar to our full year growth year-to-date, which is up 9%. So I think we're very comfortable with our 2 leading product lines in the oncology space and our gross I'll let John talk about the pipeline."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, so I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, Powered Glide Pro, and we've got new versions of those launching early next year. I didn't talk t",170,"Yes, so I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, Powered Glide Pro, and we've got new versions of those launching early next year. I didn't talk this call about AccuCath, but we've launched a first couple of versions of that. We've got more launches of those coming up early next year. And I also talked about the pediatric Tip Confirmation technology that we launched in Europe last quarter, and we expect to launch around the end of year here in the U.S. that gives us access for both -- for all products, all venous products so central venous catheters, PICCs and ports in the pediatric case. And then we've got other cases like our chemical-resistant PICCs that I've talked about before that I didn't mention today on the call, but are launching here in the near term as well here. So I think there's a pretty darn robust pipeline there."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins from Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins from Bank of America."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So one thing I want to ask about is emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a quart",104,"So one thing I want to ask about is emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a quarter or 2. And then more recently, it's been back at around 20%. And I'm just curious in this particular quarter, did emerging market growth sustain in that 20% growth range. And as we think forward, what's your confidence that we can continue to see growth around 20%, plus or minus, in emerging markets?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we said many times, we are really developing a lot of those",247,"Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we said many times, we are really developing a lot of those markets from scratch, in particular, biopsy, PICCs, hernia repair. We continue to see great opportunity for growth there. We've built a whole new BioSurgery sales team that has really just started to get their attraction. And we had some pretty interesting investment opportunities for next year sales force-wise there. Latin America, we saw a nice move in the positive direction, and I think as I mentioned, it was our best quarter in Latin America in the last 5 quarters. And that's always been a pretty solid area of growth with us, with the exception of last quarter. So we rebounded significantly, made a great ground there. and I'd say the other area that we haven't talked about an awful lot but we've made a number of investments in, what we call rest of Asia or the smaller markets in Asia that we built our sales forces, build out marketing teams and are getting approvals and registrations for our products and launching those. So I'd say we look at our appetite in emerging markets, it's certainly high. If we look at our investment profile, that's equally high, and we're very optimistic about what you'll see there."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So then just maybe try to pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then also, just wanted to get a quick view, and I apologize if I miss",114,"So then just maybe try to pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then also, just wanted to get a quick view, and I apologize if I missed this, on hernia. And from what you're seeing in the marketplace, is there any sign of any competitive offering that will look interesting? Because obviously, J&J has been exiting some portions of the market, and you guys have been launching great products. So just curious on the competitive landscape what you're seeing in hernia and if you think something around 20% a sustainable in EM."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me take the first part of the M and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month,",249,"So let me take the first part of the M and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month, and we continue to build and invest in that pipeline. So we feel good about that, if you want to think about that. It's almost like another R&D portfolio. It's just products that have already given derisked because they've most likely been launched someplace else already. So it's really a regulatory filing. So that's one component. Second, as John mentioned, we continue to invest and build out sales forces and expand in those geographies, and that will continue with the U.S. World Series beginning tonight to put in kind of a baseball analogy. I don't even think we're in the fifth inning yet in emerging markets, so I'd say it's still in the early innings of the game. And that is further another good metric for us. The enthusiasm level from clinician to be trained on our products almost overwhelms our capability to keep up with a capacity with a demand. So we just opened up another training center in South Asian markets that John has referred to. And that demand continues to be very, very strong. So all of those things really make us believe that we've got a lot of runway left in emerging markets. You want to..."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We had not seen anything in the marketplace right now that gives us pause for concern. We",94,"The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We had not seen anything in the marketplace right now that gives us pause for concern. We think that our broad portfolio and, in particular, the new technologies that are really early into their introduction phase, and based on that end of pipeline coming, we're very comfortable although always diligent about what we see coming up in the marketplace from a competitor."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","We wake up a little afraid every day here.",9,"We wake up a little afraid every day here."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Biegelsen with Wells Fargo.",11,"And we have a question from Larry Biegelsen with Wells Fargo."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's calling in for Larry. So your guided several times this year, both top line, bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. Can you talk about some of the key factors that contributed to the up",71,"It's calling in for Larry. So your guided several times this year, both top line, bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. Can you talk about some of the key factors that contributed to the upside in the guidance race? How much of it was perhaps of the overall market strength, utilization trend versus your execution versus other things."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me start with that. So obviously, we've put together the way we roll up our process, we have budgets, businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built into some of the guidance",119,"So let me start with that. So obviously, we've put together the way we roll up our process, we have budgets, businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built into some of the guidance. The fact of the matter is if everybody performs at the high end of what they told us, we're going to do very well. And that is about execution, both under the product side, the sales force, marketing, everything. Frankly, that has to do with running a business. And when you execute well and you perform pretty well and that's kind of been the way the last several quarters."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I try to really strongly echo that. We are not building in any significant level of conservatism. I think we're completing a year where the execution, to Tim's point, has really been outstanding across the board. And then you get that kind of broad-based",187,"I try to really strongly echo that. We are not building in any significant level of conservatism. I think we're completing a year where the execution, to Tim's point, has really been outstanding across the board. And then you get that kind of broad-based outstanding execution, you're in a position to do what we're doing here, again, for the third time, which is raising guidance. So the based businesses, again, the balance of it, I think it's critically important we are all the businesses are contributing really attractive dividend growth of the acquisitions, as we said, have exceeded our expectations. We're doing better on price. Our operations teams are delivering what they committed to and the mix within the portfolio, frankly, that portfolio -- the growth in surgery is very helpful to mix and to margins, as John highlighted as well. And as those emerging market sales reps become more and more productive, that execution gives us some upside. So it's a lot of little things across a lot of parts of the company that, in combination, really result in really strong top and bottom line performance."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up. So will be presenting data for their DCB product at TCT. Do you have any just kind of thoughts on the data and what we should be thinking about versus the data that you presented both trial and registry data?",46,"Great. And just one quick follow-up. So will be presenting data for their DCB product at TCT. Do you have any just kind of thoughts on the data and what we should be thinking about versus the data that you presented both trial and registry data?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they percent will be in line. If you look at our data, I think consistently",155,"Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they percent will be in line. If you look at our data, I think consistently, as we've gotten in real-world use of our technology, we have similar results to what they've shown previously and what Medtronic shown. So we kind of anticipate all of that, and we think we've got pretty robust data. Obviously, the [indiscernible] was a ""first of a kind"" study, and we've learned a lot from that study, and we've seen and talked about at length, some of the findings on the importance of procedural aspects that. And so when we've seen it in real-world use where they followed those procedural learnings that we've had, we've had really great results, so we think we're going to be pretty similar."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come.",32,"I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We do have one more them, we'll go to Dave Turkaly with GMP Securities.",14,"We do have one more them, we'll go to Dave Turkaly with GMP Securities."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just to follow up, sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. We saw your 24-month registry data. Lot of speculation prior to sort of how people would view this data, what docs would think, I guess,",81,"Just to follow up, sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. We saw your 24-month registry data. Lot of speculation prior to sort of how people would view this data, what docs would think, I guess, do you have any commentary on that? Did that clinicians -- is that something that's brought up by customers? Or is this more of kind of a competitive thing in the marketplace today?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me start. So if you look at the market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare pivotal data for their pivotal data and then the registry data that we presented, clearly, we th",179,"Well, let me start. So if you look at the market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare pivotal data for their pivotal data and then the registry data that we presented, clearly, we think data does make a difference. We think there's other important features and characteristics beyond their data, things that are now just beginning to be better understood relative to the amount of drug use, how much of the drug stays on, the agent that used to bind the drug to the balloon, et cetera, et cetera. All those things come over time, we'll pay up with more usage and more information and data. And that includes things that are going to have to be understood and learned with new entrants to the market. So we generally feel very good about our market position, our growth prospects, our new indications that we've got in the pipeline and the way that the products performed, and we've executed since we launched. John DeFord from anything else?"
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I think part of your question was how much of data is sort of a discussion at meetings and with KOLs as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more preve",134,"I think part of your question was how much of data is sort of a discussion at meetings and with KOLs as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more preventer at the competitive level from company to company than that clinicians necessarily pay that much attention to. It seems like in my interactions with physicians. And so I think data are important. I think safety is really a key point that I think we have a lot of strength in that particular space. And then our long-term data, as we look at our registries and real-world use in long lesions and calcified lesions and in-stent restenosis and all those pieces are continued validation of this technology."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments.",26,"And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Lori. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call.",41,"Thanks, Lori. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call."
254131,403600059,1060747,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you, ladies and gentlemen. This will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect.",29,"Thank you, ladies and gentlemen. This will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand repl",275,"Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's June 30, 2016, Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of October 25, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period.
At this time, I'll turn the call over to Mr. Timothy Ring. Please go ahead."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Laurie. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also direct you",511,"Thank you, Laurie. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The agenda today will go as follows: I'll begin with an overview of the results for the third quarter; John Weiland, our President and COO, will review third quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you an update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will give you the third quarter income statement, balance sheet as well as our expectations for Q4 and, obviously, the full year. And then we'll close with Q&A.
Third quarter 2016 net sales totaled $941.9 million. That's up 9% over the third quarter of last year on an as-reported basis and up 10% on a constant currency basis. Currency impact for the quarter versus Q3 of last year was unfavorable by about 90 basis points.
Our organic revenue growth was 6% for the quarter. Excluding the prior year stocking of Lutonix by Boston Scientific, we estimate that our organic sales growth was 6.4%.
While our recent acquisitions performed above the guidance we've provided, our Targeted Temperature Management business, which can be a little lumpy given timing issues and a soft quarter. John Weiland will take you through the product lines, and Chris will provide guidance. We believe you will see continued strength and momentum across the portfolio. 
Net income for the third quarter was $96.4 million and diluted EPS were $1.27. Excluding amortization of intangibles and items that affected the comparability of results between periods, Chris will cover those later. Adjusted third quarter 2016 net income and diluted earnings per share were $199.5 million and $2.64. That's up 14% and 16%, respectively. These adjusted results well exceeded the guidance we provided for the quarter. 
Looking at revenue growth geographically compared to the same quarter of 2015, net sales in the U.S. increased 7%. On a constant currency basis, Europe grew 5%. Japan was up 44%, benefiting from moving the customer pricing after our acquisitions of joint venture there, and our other international businesses grew 19%. Emerging market growth was strong, yet again, representing 10% of our total sales in Q3. 
The results in Q3 continued to demonstrate the strength of our economic engine, driving organic growth between 6% and 7% on the top line, with attractive returns on the bottom line, even while we had continued to invest significantly for future growth. The results so far this year have exceeded our expectations, and we expect a strong finish to what has been a very strong year so far. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.So let's begin with Vascular. Total net sales were $258",780,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.
So let's begin with Vascular. Total net sales were $258.1 million, up 3% over last year on an as-reported basis and up 4% on a constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 5% in Q3, with the United States business up 2% and international up 10%.
Sales in our Surgical Graft category were flat in the third quarter. Our Endovascular business grew 7% in the third quarter. Our peripheral PTA line grew 7% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. 
We continue to see strong growth year-over-year in sales of Lutonix to customers, including sequential growth in the United States. Sales in our vena cava filter line were down 18% this quarter. Our Stent business grew 6% in the third quarter, which was the best quarter in 4 years, driven by strength internationally. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally, making -- marking the sixth straight quarter of double-digit growth in this product family. 
Now let's go to Urology. Total net sales were $242.1 million, up 14% as reported and up 15% on a constant currency basis. The combination of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in this category. Excluding these 2 acquisitions, the United States business was up 2%, while internationally we grew 7%.
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 5% globally and 4% in the United States, with our I.C. Foley business up 1% globally and flat in the U.S. 
Our Targeted Temperature Management business grew 4% this quarter. While the sales of our disposable pads grew double digits, as Tim said, the capital portion of this business can be a little lumpy. We continue to believe that this product line has long-term double-digit growth potential. 
Our continence business was up 28% in the third quarter, driven by the benefit from the new acquisitions. Sales in Urological Specialties were up 9% this quarter, including our brachytherapy business, which grew 6%, driven by Japan.
And finally, in this category, stand-alone sales of our StatLock catheter-stabilization line grew 2% in the third quarter.
Let's now go on to Oncology. Total net sales in this category were $258.4 million, an increase of 8% on an as-reported basis and up 9% on a constant currency basis over the third quarter of last year. The Japan acquisition added about 200 basis points to growth globally. Excluding that, sales in the United States were up 3%, and international sales were up 15%. 
Our port business was up 9% versus the third quarter last year. Most of the benefit from -- in this category is from Japan and is in ports. Our PICC revenue was up 8% this quarter with continued strength internationally. Our Vascular Access Ultrasound product line grew 8% this quarter. And to close out the category, our Dialysis Access product line was up 7%.
Let's conclude then with our Surgical Specialties business. Total net sales in this category were $158.8 million, up 14% on both an as reported and constant currency basis. United States sales were up 11%, and international sales were up 21% this quarter, excluding the impact from Japan, which was minimal.
Our performance irrigation business was down 6%. Our soft tissue repair business delivered its strongest quarter in 6 years, growing 14% in the third quarter. We saw this growth despite continued procedural shifts away from natural tissue products, which declined 35% for us in the third quarter. 
In contrast, our synthetic business, which includes our hybrid Phasix material, grew 23% this quarter, which is the highest growth in more than 10 years. Our mix of synthetic revenue to natural tissue revenue is now greater than 7:1. 
We believe the quality and the breadth of our product offering and our value-added programs help customers select the right product for the patient, which is having a significant impact on the treatment paradigm. 
Our hernia fixation business grew 34% this quarter on the continued impact from our recent product launches here.
Closing out the surgical category, our BioSurgery business grew 22% in Q3, with strong growth in both the United States and outside the United States. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and",727,"Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and in-stent restenosis supplements are under review at FDA, and we're hopeful for approval of both of these expanded indications early next year. 
In our Below-the-Knee IDE, as we recently announced, the FDA has approved an amendment to our study, supporting the primary efficacy analysis at the 6-month follow-up time point. This is an exciting development, and we're continuing to analyze the potential impact to our approval time line. We think this should put our launch in 2018. 
The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a first look at our results in late Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late Q4 2017 U.S. launch. 
In Japan, our shonen submission for the Lutonix SFA indication remains under review, and we continue to anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began earlier this year.
Also in Vascular, our LifeStream Balloon Expandable covered stent trial has completed follow-up, and the final PMA module was submitted last quarter to FDA, with approval and launch expected in mid-2017. 
Our COVERA next-generation AV access circuit stent graft received IDE approvals for both a fistula and a graft study. Both studies began recruitment in Q3, and we expect enrollment will take about a year. 
Our Venovo vena stent IDE is in active recruitment, and we continue to receive positive feedback from Europe where the products commercially available. We anticipate enrollment throughout 2016 with follow-up in 2017 and PMA submission in 2018. 
Next, moving to Urology and home care. We've now launched our female version of the Magic3 Go self-hydrating hydrophilic catheter in Europe, and we've begun direct-to-consumer advertising in this product in the U.S. In Targeted Temperature Management, we anticipate commencing enrollment in our new IDE study of neurogenic fever prevention and control. This study will evaluate the use of the Arctic Sun system in this new indication, and we plan to enroll more than 1,000 patients over the next 3-or-so years. 
Moving to Oncology. We're awaiting 510(k) clearance of our new PROVENA family of PowerPICCs designed to reduce the risk of DVT. We're building inventory in a broad range of single-, double- and triple-lumen configurations and anticipate launching around the end of the year. 
Late in Q2, we launched both our new Power Midline and PowerGlide Pro families of intermediate dual catheters. Early feedback has been very positive on both products, and we anticipate launching additional versions in early 2017. 
On the last call, I announced our European launch of the Nautilus Delta system, with specific indications for Tip Confirmation for the pediatric patients for ports, PICCs and central lines. The next generation of this system is completing development, and we're planning for U.S. launch around the end of the year. 
I'll close my portion of the discussion today with surgery. First, in BioSurgery, we're preparing for the launch of the TRIDYNE aortic sealant. We hope to get this product to the market before the end of the year, but due to some near-term capacity constraints, we now expect to launch in Q1. We also expect to launch in Q2 of 2017 the Progel Emerald lung sealant that's been designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to launch additional Phasix resorbable mesh sizes and expect to enhance our offerings around the end of the year. This expansion will dramatically increase the range of sizes from 5 to 25 different configurations, providing surgeons and their patients the largest and most comprehensive size matrix in the market.
Expansion of our XenMatrix AB platform with multiple new sizes is also on track for launch in early 2017. After launch, Bard will offer the largest biologically derived graft in the market. 
And finally, in mesh fixation, we've launched the 15-count version of our OPTIFIX resorbable fixation device, with further launches in this category expected in the first half of 2017.
Thanks for your attention. Let me now turn you over to Chris."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges",936,"Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges of $4.6 million related to restructuring and productivity initiatives and a tax credit of $2.6 million related to the completion of certain tax, certain IRS examinations. The P&L impact to these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q3 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $589.7 million or 62.6% of sales for Q3. On an adjusted basis, GPs were $624.3 million or 66.3% of sales, up 150 basis points from the prior year quarter. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in gross profit, continuing the solid performance we saw in the first half of the year. And foreign exchange was about a 50 basis point headwind to gross margin this quarter. Mix was favorable by 110 basis points, which includes the positive impact from our Japanese business. And finally, our cost improvement efforts drove approximately 100 basis points of favorability in Q3.
It's been a very strong year for margins for us. And as we told you last quarter, we expect to exceed the original full year guidance for GPs that we gave you in January. 
SG&A expenses were $272.6 million for the quarter with 28.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 28.7%, 20 basis points above the prior year. While we do expect to see decent leverage here in Q4 as we anniversary the acquisition of our Japanese joint venture, we expect to slightly exceed our original estimate for the full year due to incremental investments we've made in certain targeted areas. 
R&D expenditures totaled $74.2 million for the third quarter or 7.9% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.8%, up 30 basis points from the prior year. Again, as we told you last quarter, we expect a somewhat higher level of R&D investment for the full year compared to our original guidance, as our strong results have allowed us to fund new opportunities earlier than initially contemplated. We continue to be in investment mode to strengthen the long-term revenue growth potential of the portfolio. 
Interest expense was $14.9 million for the third quarter, and other income and expense was $115.8 million of expense in Q3 as reported or $0.4 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.7%, down 130 basis points from the prior year. We are trending to be at the low end or maybe even slightly better than our original guidance for the full year. 
Diluted shares for the period were 75.3 million, and we repurchased approximately 190,000 shares in the third quarter. The net result is reported EPS of $1.27 and adjusted EPS of $2.64, which excludes items affecting comparability and the amortization of intangibles. This was well above the guidance range we provided for the quarter, reflecting both higher-than-expected sales as well as the continued strong execution by our teams around the world.
The balance sheet as of September 30, reflects cash, restricted cash and short-term investments of $1.15 billion, up slightly from June 30. For the quarter, accounts receivable days were down 1.5 days, and inventory was up 3.1 days. We believe inventory days will decline as we anniversary the recent acquisitions and execute on new product launches that we have been building in front of. Capital expenditures totaled $26 million for the quarter. 
On the liability side, total debt was $1.6 billion as of September 30, no change from June 30. Debt to total capital at the end of the third quarter was about 49%, and total shareholder investment was $1.7 billion at September 30. 
Moving to financial guidance. Given the strong results, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 9% and 10%, with reported sales growth between 8% and 9%, implying the same currency headwind of about 1%. We now expect our full year 2016 organic revenue growth to be around 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.23 and $10.28, representing 13% growth for the year. We now expect foreign exchange to be between $0.23 and $0.25 of headwind for the full year. So on an FX-neutral basis, we are guiding to 15% to 16% EPS growth. 
For Q4, we are expecting constant currency sales growth between 10% and 11%, with reported sales growth between 9.5% and 10.5%, implying an FX headwind of approximately 50 basis points on the revenue line. This assumes organic growth between 6% and 7% for the fourth quarter. From an adjusted EPS standpoint, we forecast the fourth quarter in the range of $2.70 to $2.75, representing 11% to 13% growth on a reported basis. 
As we look ahead, we expect a strong finish to what has been a very strong year of both execution and financial performance. And we're very pleased that we've been able to produce these results while still significantly investing for the long-term health of the business. We look forward to reporting on the full year and providing guidance for 2017 in January. 
Now I'll turn the call back over to Tim."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Laurie?",28,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Laurie?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray.",16,"[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpo",59,"This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpoint just relative to kind of what we saw on the first half of the year."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes, because it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certainl",88,"Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes, because it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certainly, the feedback from the various hospital administrators, CEOs, et cetera, we talked to, all would amplify that. I think the biggest problem we're hearing them talk about right now is nursing turnover. So haven't heard a lot of negativity about indiscernible]. John?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add is that we continued strong results from Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out in particular, you might remember the last quarte",99,"The only thing I'd add is that we continued strong results from Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out in particular, you might remember the last quarter, we had a late-quarter growth in Latin America. We've had this quarter the best growth that we've had in 5 quarters. So it was nice to see that business rebound to where we had expected to. And combined with continued very strong growth in emerging markets and, quite frankly, in our European business overall."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then just looking at the quarter, there was strong organic growth in sterical, and it looks like again driven by some product launches. But I'm just hoping you can give us some color on -- is this a little more of -- should we expect this to be",82,"Great. And then just looking at the quarter, there was strong organic growth in sterical, and it looks like again driven by some product launches. But I'm just hoping you can give us some color on -- is this a little more of -- should we expect this to be more of a run rate? Or is this more of a mid-single-digit grower? I just -- it seems like we might not be modeling this appropriately given what we saw this quarter."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique",110,"What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique patient benefits that is very difficult to compete within the marketplace, I'd say, right now. But on top of that, as a result of our new product launches, fixation had outstanding growth in the category and very strong growth in BioSurgery. So really, the 3 major segments in that business for us all have very significant growth rates, and we think that will bode positively for the future."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I would add is the growth rates that you're seeing in our business are above -- significantly above what we think are the market growth rates. So we're continuing to pick up probably some pretty significant market share.",42,"The only thing I would add is the growth rates that you're seeing in our business are above -- significantly above what we think are the market growth rates. So we're continuing to pick up probably some pretty significant market share."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from David Lewis with Morgan Stanley.",10,"We have a question from David Lewis with Morgan Stanley."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott Wang in for David. Two questions from me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp-adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp-adjusted",62,"This is actually Scott Wang in for David. Two questions from me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp-adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp-adjusted stability on the organic growth line. Is there anything in particular that is driving that deceleration into the last quarter of the year?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based balance growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's a",107,"Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based balance growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's always some puts and takes. But as John just articulated from a geographic standpoint, we're continuing to see good balanced growth. And the surgical business, in particular, continues to perform well and the other 3 businesses and Lutonix on the Vascular side. So we're not looking to signal any deceleration for sure. Frankly, I think more of the same."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And can we talk a little bit more about Urology strength this quarter? Now some of that was obviously contribution from Liberator and Medicon, but the underlying growth is also pretty strong. Can you talk to us a little bit about what's drivi",63,"Fair enough. And can we talk a little bit more about Urology strength this quarter? Now some of that was obviously contribution from Liberator and Medicon, but the underlying growth is also pretty strong. Can you talk to us a little bit about what's driving that underlying growth trend and maybe give us an update on where you are on the Liberator integration?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market pers",128,"Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market perspective and especially the Magic3 Go female. We have been delighted with what we've seen with the Liberator integration. I'd say that basic drainage though was up 4% in the United States without Liberator being in those numbers. So it's a very strong business. Continence business was up 28%. The only really shortfall that we had was Targeted Temperature Management that only grew at 4% versus 15% year-to-date. We think that's a timing issue on capital equipment. So we saw very nice growth across the portfolio."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add there is that we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and [indiscernible] in particular, as it relates to Urology. So some of the new",88,"And the only thing I'd add there is that we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and [indiscernible] in particular, as it relates to Urology. So some of the new products and the tray designs and the programs that we've implemented continue to drive very good growth, absent significant volume growth, frankly. So we're continuing to take share, providing solutions that customers are valuing, because it's helping them solve a real problem that they're facing."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Vijay Kumar from Evercore ISI.",10,"We have a question from Vijay Kumar from Evercore ISI."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just maybe on the margins. It really looked like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove the spend on the margin side, I think that would be a helpful starting point.",44,"Just maybe on the margins. It really looked like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove the spend on the margin side, I think that would be a helpful starting point."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all from a gross margin standpoint, we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues t",179,"Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all from a gross margin standpoint, we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues to be positive, driven by over the last couple of years, some of the launches that we've had. And then our operations teams continued to deliver excellent results from a cost improvement standpoint. So frankly, the strength that we've seen from strong execution on the gross margin line has allowed us to continue to invest in R&D and SG&A, frankly ahead of where we had anticipated to be able to coming into the year. So we think it's a terrific ability for us to reinvest into the business while still driving significant operating margin improvement. So it's a model that we're focused on, continuing to replicate. Comes with a lot of hard work from a lot of people, but that's the model. And when we execute well, you get the results that you saw this quarter."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how",69,"Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how this time maybe it's larger than what we're thinking and then what could drive growth on that side, that would be helpful."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start and then turn it over to John Weiland for follow-up. So we still think this market is accelerating. And frankly, I would still call it even in the next year, potentially with another competitor still a rising tide here. It's still underpe",145,"Sure. I'll start and then turn it over to John Weiland for follow-up. So we still think this market is accelerating. And frankly, I would still call it even in the next year, potentially with another competitor still a rising tide here. It's still underpenetrated, still underdiagnosed. And I think as more use is -- there's more usage experience, physicians are continuing to determine whether they want to use DCBs in their treatment protocols, and all of that is very positive. I do think it's kind of interesting as you look at different nuances in the specifics of the products relative to the model drug and some of the behavior characteristics. Certainly, we performed extremely well in our registry data vis--vis all of those metrics. So we feel very good about our own positioning going forward against what we know is expected competition moving ahead."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications though, AV access and Below-the-Knee, we think those 2 markets wou",104,"The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications though, AV access and Below-the-Knee, we think those 2 markets would bring approximately $600 million in 2020, and we're working hard to be the first entrant into that space. So while do we expect some competition in the SFA, we're hopeful that we will be the market enterer in the other 2, which we expect -- other 2 segments, which we expect to have outstanding growth potential."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us as we talked about, in-stent restenosis and long lesion, we anticipate a Q1 2017 launch with those indications, mid-2017 the l",85,"And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us as we talked about, in-stent restenosis and long lesion, we anticipate a Q1 2017 launch with those indications, mid-2017 the launch of Lutonix in Japan, and then late 2017 an AV access potential for launch. We think that's going to be differentiating and give us and continue to keep us in a leadership position. Then 2018, we've got BTK coming along."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Keusch from Raymond James.",11,"And we have a question from Larry Keusch from Raymond James."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just want to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses. Puts and takes and capital can be lumpy,",79,"Just want to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses. Puts and takes and capital can be lumpy, but I just want to dive a little bit deeper and see if you are potentially seeing anything other than just timing as it relates to just the appetite for capital equipment out there amongst hospitals."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strong right afterward. So we don't see any indicators, which would cause us t",49,"No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strong right afterward. So we don't see any indicators, which would cause us to be concerned about that."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I think our other capital businesses were -- had growth similar to what we have seen in other quarters.",19,"I think our other capital businesses were -- had growth similar to what we have seen in other quarters."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Larry, we expect Q4 to frankly be robust, so just to that point.",14,"And Larry, we expect Q4 to frankly be robust, so just to that point."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's perfect. And then just sort of a bigger picture. I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we hea",52,"Okay. That's perfect. And then just sort of a bigger picture. I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we head into 2017?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","You answered your own question. We're not going to give guidance on this call for 2017. So the earlier -- your first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth of t",164,"You answered your own question. We're not going to give guidance on this call for 2017. So the earlier -- your first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth of the market solidifying throughout this year. There's nothing that we have seen that would indicate that to change heading into next year. When we set our investment plan back in 2013, we said that you would start to see the results in '15, but we expected that it would be sustainable. So everything we've been doing from then to now, investing in R&D, sales force expansion in emerging markets, the acquisitions that we've made have all been targeted to achieve that kind of an outcome. And we fully expected that above-market growth achievement of 2 to 3 points above the market should continue. So that's kind of the way we feel about it heading out of this year."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'll add to that is that one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about 1/3 inc",133,"The only thing I'll add to that is that one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about 1/3 increase in our sales forces. And people are still maturing in some of those jobs that we're maybe the later placements into it. And quite frankly, we expect to have pretty robust additions in our sales force again next year in a lot of our high-growth markets. So I think that we're making the right investments, as Tim mentioned, to ensure that as the products come through, our pipeline and registration pipeline that we're poised and have the right manpower to execute on those."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impa",85,"The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impacting the entire company. And so you've seen it this year. We expect to end this year strong with really balanced and important contributions from all the businesses, which I think you need to have to sustain the kind of growth rates that we're seeing."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Mike Weinstein with JPMorgan.",10,"And we have a question from Mike Weinstein with JPMorgan."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So let me ask just some on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask",142,"So let me ask just some on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask you just about mix and as well as the competitive environment. So number one, on mix, we continue to underestimate within the mesh part of the business, the opportunity for mix upgrades for your business. So can you give us a sense of where you think you are in that mix great piece of the story within the mesh business? And then second, competitively, we just had an ECF. Is there anything that you've seen new competitively that gives you any pause as to this momentum in the business continuing in 2017?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And if I would add on top of that, our BioSurgery margins are well above the corporate average. So wit",188,"Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And if I would add on top of that, our BioSurgery margins are well above the corporate average. So with mid-teens growth in those and into the 20s for BioSurgery, obviously, that will have a positive impact on our overall margins long term. Relative to ACS, it's interesting. I'm speaking to one of our key leaders in that business this afternoon about the same exact issue. And we have not seen anything that's launching or plans to launch that gives us concern relative to the growth drivers in that business either in the fixation side of things or in the synthetic mesh side of things. We think it's in our Phasix product line and product category and such unique capabilities in terms of providing long-lasting repairs for patients without leaving a mesh behind long term that the benefit to patients is significant and we've not seen anything yet. Although we're always diligent about it, we've not seen anything yet that gives us pause for concern."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics have a place, the Phasix opportunity to offset",137,"Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics have a place, the Phasix opportunity to offset biologics is a terrific win for us and a terrific win for the physician and the hospital in a lot of cases. And we're seeing customers because of the breadth of the portfolio literally standardize on Bard's hernia portfolio from basic synthetic to an absorbable synthetic to a biologic. And we're the only one that could even sit down and have that conversation with customers. And there's a lot of advantages, as you can imagine, for them to do that. And that's certainly part of the reason we're driving and capturing share."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","I missed it, if you made some comments just about use of cash during the quarter. But it didn't apply. Could you -- there was activity from a buyback standpoint. It would look like it was pretty minimal. Just can you give us thoughts on -- it seems like y",91,"I missed it, if you made some comments just about use of cash during the quarter. But it didn't apply. Could you -- there was activity from a buyback standpoint. It would look like it was pretty minimal. Just can you give us thoughts on -- it seems like you guys have been largely sitting on your cash in the last couple of quarters, maybe paying down a little bit of your debt. Is there any thought process behind that? And any updated thoughts, Tim, on the environment for business development?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Nothing's changed from our perspective strategically relative to the use of cash. Priorities are still the same. Acquiring technologies of businesses are the first priority. Share buybacks, second, and then dividends, third. So none of that's really",131,"Sure. Nothing's changed from our perspective strategically relative to the use of cash. Priorities are still the same. Acquiring technologies of businesses are the first priority. Share buybacks, second, and then dividends, third. So none of that's really changed. As you know, the business development environment is opportunistic and episodic. But relative to our internal efforts, our initiatives, none of that's changed. We're still pedal to the metal in terms of our initiatives globally. Frankly, as we've added business development resources geographically over the last couple of years, they've matured [indiscernible] the space more. So we feel good about the initiative and the momentum. And I would fully expect to continue to see the same kind of cadence going forward that you've seen over the last couple of years with us."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the co",109,"And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the commitment to shareholders to not do that, we're certainly continuing to deliver on that commitment. So to Tim's point, the priority remains to be strategic. We obviously continue to have a lot flexibility with the balance sheet to do both in a reasonable and appropriate way. And it'll ebb and flow quarter-to-quarter, but we'll continue to be an active repurchaser in an ordinary course."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Amit Hazan with Citi.",9,"We have a question from Amit Hazan with Citi."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Let me maybe start with nonorganic guidance. So I think you've raised it a little bit. You're now at 2% to 3% contribution for the year. That's about $85 million at the midpoint. If we think about this, just the components of that, Liberator, you started",127,"Let me maybe start with nonorganic guidance. So I think you've raised it a little bit. You're now at 2% to 3% contribution for the year. That's about $85 million at the midpoint. If we think about this, just the components of that, Liberator, you started out when you acquired it, say, $70 million for the year. Clearly, you're talking about at being more than $70 million. Medicon is another $30 million net for the year, if I'm doing my math right. So we're already at $100 million. We've got a few other small pieces. Seems to me like we're easily over even high end of that. So maybe give me a sense of what I'm missing on the nonorganic side even to get your new guidance."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related",89,"Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related to that year-over-year decline in revenue. To John's point, the acquisitions are both going well from an immigration standpoint, and we're trending out of the model. But when you do the math on all the puts and takes, we're comfortable with the guidance here for the full year."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then let me just ask the second question about PICC. So it would kind of look back, just the trend line it's been, it's really nice consistent 10%-plus grower. I don't want to pick on it too much, at 9% for the year, so just under that, not a bi",162,"Okay. And then let me just ask the second question about PICC. So it would kind of look back, just the trend line it's been, it's really nice consistent 10%-plus grower. I don't want to pick on it too much, at 9% for the year, so just under that, not a big deal, but just want to make sure we're not missing anything there and you're still very comfortable with how PICC performance is going. And related to that, if we kind of go back to the Analyst Day and we think about your discussion today about the pipeline, one thing I haven't seen you guys talk about or at least highlight is new products coming in Oncology, or there's, I think, nothing there. In the Analyst Day, that was really highlighted. And I didn't see -- I just don't think I heard anything today. So just maybe touch on those 2 points, both the PICCs and the pipeline inside of [indiscernible]."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","No, we are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date. So we had a very strong quarter in ports. And PICCs were up 8%,",90,"No, we are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date. So we had a very strong quarter in ports. And PICCs were up 8%, which is very similar to our full year growth year-to-date, which is up 9%. So I think we're very comfortable with our 2 leading product lines in the oncology space and our gross. And I'll let John talk about the pipeline."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, PowerGlide Pro, and we've got new versions of those launching early next year. I didn't talk this",168,"Yes. So I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, PowerGlide Pro, and we've got new versions of those launching early next year. I didn't talk this call about AccuCath, but we've launched a first couple of versions of that. We've got more launches of those coming up early next year. And I also talked about the pediatric Tip Confirmation technology that we launched in Europe last quarter, and we expect to launch around the end of year here in the U.S. that gives us access for both -- for all products, all venous products. So central venous catheters, PICCs and ports in the pediatric case. And then we've got other cases like our chemical-resistant PICCs that I've talked about before that I didn't mention today on the call, but are launching here in the near term as well. So I think there's a pretty darn robust pipeline there."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins from Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins from Bank of America."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So one thing I want to ask about is the emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a q",105,"So one thing I want to ask about is the emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a quarter or 2. And then more recently, it's been back at around 20%. And I'm just curious in this particular quarter, did emerging market growth sustain in that 20% growth range? And as we think forward, what's your confidence that we can continue to see growth around 20%, plus or minus, in emerging markets?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we've said many times, we are really developing a lot of tho",250,"Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we've said many times, we are really developing a lot of those markets from scratch, in particular, biopsy, PICCs, hernia repair. We continue to see great opportunities for growth there. We've built a whole new BioSurgery sales team that has really just started to get their traction. And we have some pretty interesting investment opportunities for next year sales force-wise there. Latin America, we saw a nice move in the positive direction, and I think as I mentioned, it was our best quarter in Latin America in the last 5 quarters. And that's always been a pretty solid area of growth for us, with the exception of last quarter. So we rebounded significantly, made a great ground there. and I'd say the other area that we haven't talked about an awful lot, but we've made a number of investments in, what we call rest of Asia or the smaller markets in Asia that we build out sales forces, build out marketing teams and are getting approvals and registrations for our products and launching those. So I'd say we look at our appetite in emerging markets, it's certainly high. As we -- if we look at our investment profile, that's equally high, and we're very optimistic about what we'll see there."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So then just maybe to try and pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then I also just wanted to get a quick view, and I apologize if I",115,"So then just maybe to try and pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then I also just wanted to get a quick view, and I apologize if I missed this, on hernia. And from what you're seeing in the marketplace, is there any sign of any competitive offering that look interesting? Because obviously, J&J has been exiting some portions of the market, and you guys have been launching great products. So just curious on the competitive landscape what you're seeing on hernia, and if you think something around 20% is sustainable an EM."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me take the first part of the EM, and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month",254,"So let me take the first part of the EM, and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month, and that we continue to build and invest in that pipeline. So we feel good about that, if you want to think about that. It's almost like another R&D portfolio. It's just products that have already been de-risked, because they've most likely been launched someplace else already. So it's really a regulatory filing. So that's one component. Second, as John mentioned, we continue to invest and build out sales forces and expand in those geographies, and that will continue with the U.S. World Series beginning tonight to put in kind of a baseball analogy. I don't even think we're into the fifth inning yet in emerging markets. So I'd say it's still in the early innings of the game. And that is further -- is another good metric for us. The enthusiasm level from clinician to be trained on our products almost overwhelms our capability to keep up with a capacity with the demand. So we just opened up another training center in some of the South Asian markets that John has referred to. And that demand continues to be very, very strong. So all of those things really make us believe that we've got a lot of runway left in emerging markets. You want to...?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We have not seen anything in the marketplace right now that gives us pause for concern. We",98,"The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We have not seen anything in the marketplace right now that gives us pause for concern. We think that our broad portfolio and, in particular, the new technologies that are really early into their introduction phase, and based on that end of the pipeline that we've come in, we're very comfortable, although always diligent about what we see coming up in the marketplace from a competitor."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","We wake up a little afraid everyday here.",8,"We wake up a little afraid everyday here."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Biegelsen with Wells Fargo.",11,"And we have a question from Larry Biegelsen with Wells Fargo."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's Lei Huang calling in for Larry. So you raised guidance several times this year, both top line and bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. But can you talk about some of the key factors t",76,"It's Lei Huang calling in for Larry. So you raised guidance several times this year, both top line and bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. But can you talk about some of the key factors that contributed to the upside in the guidance race? How much of it was perhaps the overall market strength, the utilization trend versus your execution versus other things?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me start with that. So obviously, we put together the way we roll up our process. We have budgets. Businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built in to some of the guidance.",123,"So let me start with that. So obviously, we put together the way we roll up our process. We have budgets. Businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built in to some of the guidance. The fact of the matter is if everybody performs at the high end of what they told us, we're going to do very well. And that is about execution, both on the new product side, the sales force, marketing, everything. Frankly, that has to do with running a business. And when you execute well, you perform pretty well and that's kind of been the way it's been here the last several quarters."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I try to really strongly echo that. We are not building in a significant level of conservatism. I think we're completing a year here, where the execution, to Tim's point, has really been outstanding across the board. And when you get that kind of broad-ba",189,"I try to really strongly echo that. We are not building in a significant level of conservatism. I think we're completing a year here, where the execution, to Tim's point, has really been outstanding across the board. And when you get that kind of broad-based upstanding execution, you are in a position to do what we're doing here, again, for the third time, which is raising guidance. So the base businesses and again the balance of it, I think it's critically important where all the businesses are contributing and really attractive organic growth. The acquisitions, as we've said, have exceeded our expectations. We're doing better on price. Our operations teams are delivering what they committed to and the mix within the portfolio, frankly, that portfolio -- the growth in surgery is very helpful to mix and to margins, as John highlighted as well. And as those emerging market sales reps become more and more productive, that execution gives us some upside. So it's a lot of little things across a lot of parts of the company that, in combination, really result in really strong top and bottom line performance."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up. So Spectranetics will be presenting data for their DCB product at TCT. Do you have any this kind of thoughts on the data and what we should be thinking about, versus the data that you presented both trial and registry",47,"Great. And just one quick follow-up. So Spectranetics will be presenting data for their DCB product at TCT. Do you have any this kind of thoughts on the data and what we should be thinking about, versus the data that you presented both trial and registry data?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they present will be in line. If you look at our data, I think consistently",156,"Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they present will be in line. If you look at our data, I think consistently, as we've gotten in real-world use of our technology, we have similar results to what they've shown previously and what Medtronic shown. So we kind of anticipate all of that, and we think we've got pretty robust data. Obviously, LEVANT 2 was a ""first of a kind"" study, and we've learned a lot from that study, and we've seen and talked about at length, some of the findings on the importance of procedural aspects of that. And so when we've seen it in real-world use where they followed those procedural learnings that we've had, we've had really great results. So we think we're going to be pretty similar."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come.",32,"I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We do have one more question. We'll go to Dave Turkaly with JMP Securities.",14,"We do have one more question. We'll go to Dave Turkaly with JMP Securities."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a follow-up sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. And we saw your 24-month registry data. There was a lot of speculation prior to sort of how people would view this data, what docs would th",86,"Just a follow-up sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. And we saw your 24-month registry data. There was a lot of speculation prior to sort of how people would view this data, what docs would think, I guess. Do you have any commentary on that? Did do clinicians -- is that's something that's brought up by customers? Or is this something more of a kind of competitive thing in the marketplace today?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me start. So if you look at the market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare pivotal data for their pivotal data and then the registry data that we presented, clearly, we th",177,"Well, let me start. So if you look at the market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare pivotal data for their pivotal data and then the registry data that we presented, clearly, we think data does make a difference. We think there's other important features and characteristics beyond the data, things that are now just beginning to be better understood relative to the amount of drug use, how much of the drug stays on, the agent that's used to bind the drug to the balloon, et cetera, et cetera. All those things over time will pay up with more usage and more information and data. And that includes things that are going to have to be understood and learned with new entrants to the market. So we generally feel very good about our market position, our growth prospects, our new indications that we've got in the pipeline and the way that the products performed and we've executed since we've launched. John DeFord, anything else?"
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think part of your question was how much of data is sort of a discussion at meetings and with KOLs, as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more",135,"Yes. I think part of your question was how much of data is sort of a discussion at meetings and with KOLs, as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more bander at the competitive level from company to company than the clinicians necessarily pay that much attention to. It seems like in my interactions with physicians. And so I think data are important. I think safety is really a key point that I think we have a lot of strength in that particular space. And then our long-term data, as we look at our registries and real-world use in long lesions and calcified lesions and in-stent restenosis and all those pieces are continued validation of this technology."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments.",26,"And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Laurie. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call.",41,"Thanks, Laurie. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call."
254131,403600059,1060880,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. Ladies and gentlemen, this will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect.",29,"Thank you. Ladies and gentlemen, this will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand repl",275,"Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's June 30, 2016 Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of October 25, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period.
At this time, I'll turn the call over to Mr. Timothy Ring. Please go ahead."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Laurie. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also direct you",512,"Thank you, Laurie. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The agenda today will go as follows: I'll begin with an overview of the results for the third quarter; John Weiland, our President and COO, will review third quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you an update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will give you the third quarter income statement, balance sheet as well as our expectations for Q4 and, obviously, the full year. And then we'll close with Q&A.
Third quarter 2016 net sales totaled $941.9 million. That's up 9% over the third quarter of last year on an as-reported basis and up 10% on a constant currency basis. Currency impact for the quarter versus Q3 of last year was unfavorable by about 90 basis points.
Our organic revenue growth was 6% for the quarter. Excluding the prior year stocking of Lutonix by Boston Scientific, we estimate that our organic sales growth was 6.4%.
While our recent acquisitions performed above the guidance we've provided, our Targeted Temperature Management business, which can be a little lumpy given timing issues, had a soft quarter. John Weiland will take you through the product lines, and Chris will provide guidance. We believe you will see continued strength and momentum across the portfolio. 
Net income for the third quarter was $96.4 million and diluted EPS were $1.27. Excluding amortization of intangibles and items that affected the comparability of results between periods, Chris will cover those later, adjusted third quarter 2016 net income and diluted earnings per share were $199.5 million and $2.64. That's up 14% and 16%, respectively. These adjusted results well exceeded the guidance we provided for the quarter. 
Looking at revenue growth geographically compared to the same quarter in 2015, net sales in the U.S. increased 7%. On a constant currency basis, Europe grew 5%. Japan was up 44%, benefiting from moving the customer pricing after our acquisition of the joint venture there, and our other international businesses grew 19%. Emerging market growth was strong, yet again, representing 10% of our total sales in Q3. 
The results in Q3 continued to demonstrate the strength of our economic engine, driving organic growth between 6% and 7% on the top line, with attractive returns on the bottom line, even while we have continued to invest significantly for future growth. The results so far this year have exceeded our expectations, and we expect a strong finish to what has been a very strong year so far. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.So let's begin with Vascular. Total net sales were $258",779,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.
So let's begin with Vascular. Total net sales were $258.1 million, up 3% over last year on an as-reported basis and up 4% on a constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 5% in Q3, with the United States business up 2% and international up 10%.
Sales in our Surgical Graft category were flat in the third quarter. Our Endovascular business grew 7% in the third quarter. Our peripheral PTA line grew 7% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. 
We continue to see strong growth year-over-year in sales of Lutonix to customers, including sequential growth in the United States. Sales in our vena cava filter line were down 18% this quarter. Our Stent business grew 6% in the third quarter, which was the best quarter in 4 years, driven by strength internationally. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally, making -- marking the sixth straight quarter of double-digit growth in this product family. 
Now let's go to Urology. Total net sales were $242.1 million, up 14% as reported and up 15% on a constant currency basis. The combination of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in this category. Excluding these 2 acquisitions, the United States business was up 2%, while internationally we grew 7%.
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 5% globally and 4% in the United States, with our I.C. Foley business up 1% globally and flat in the U.S. 
Our Targeted Temperature Management business grew 4% this quarter. While the sales of our disposable pads grew double digits, as Tim said, the capital portion of this business can be a little lumpy. We continue to believe that this product line has long-term double-digit growth potential. 
Our continence business was up 28% in the third quarter, driven by the benefit from the new acquisitions. Sales in Urological Specialties were up 9% this quarter, including our brachytherapy business, which grew 6%, driven by Japan.
And finally, in this category, stand-alone sales of our StatLock catheter-stabilization line grew 2% in the third quarter.
Let's now go on to Oncology. Total net sales in this category were $258.4 million, an increase of 8% on an as-reported basis and up 9% on a constant currency basis over the third quarter of last year. The Japan acquisition added about 200 basis points to growth globally. Excluding that, sales in the United States were up 3%, and international sales were up 15%. 
Our port business was up 9% versus the third quarter last year. Most of the benefit from -- in this category is from Japan and is imports. Our PICC revenue was up 8% this quarter with continued strength internationally. Our Vascular Access Ultrasound product line grew 8% this quarter. And to close out the category, our Dialysis Access product line was up 7%.
Let's conclude then with our Surgical Specialties business. Total net sales in this category were $158.8 million, up 14% on both an as reported and constant currency basis. United States sales were up 11%, and international sales were up 21% this quarter, excluding the impact from Japan, which was minimal.
Our performance irrigation business was down 6%. Our soft tissue repair business delivered its strongest quarter in 6 years, growing 14% in the third quarter. We saw this growth despite continued procedural shifts away from natural tissue products, which declined 35% for us in the third quarter. 
In contrast, our synthetic business, which includes our hybrid Phasix material, grew 23% this quarter, which is the highest growth in more than 10 years. Our mix of synthetic revenue to natural tissue revenue is now greater than 7:1. 
We believe the quality and the breadth of our product offering and our value-added programs help customers select the right product for the patient, which is having a significant impact on the treatment paradigm. 
Our hernia fixation business grew 34% this quarter on the continued impact from our recent product launches here.
Closing out the surgical category, our BioSurgery business grew 22% in Q3, with strong growth in both the United States and outside the United States. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and",729,"Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and in-stent restenosis supplements are under review at FDA, and we're hopeful for approval of both of these expanded indications early next year. 
In our Below-the-Knee IDE, as we recently announced, the FDA has approved an amendment to our study supporting the primary efficacy analysis at the 6-month follow-up time point. This is an exciting development, and we're continuing to analyze the potential impact to our approval time line. We think this should put our launch in 2018. 
The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a first look at our results in late Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late Q4 2017 U.S. launch. 
In Japan, our shonen submission for the Lutonix SFA indication remains under review, and we continue to anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began earlier this year.
Also in Vascular, our LifeStream Balloon Expandable covered stent trial has completed follow-up, and the final PMA module was submitted last quarter to FDA, with approval and launch expected in mid-2017. 
Our COVERA next-generation AV access circuit stent graft received IDE approvals for both a fistula and a graft study. Both studies began recruitment in Q3, and we expect enrollment will take about a year. 
Our Venovo vena stent IDE is in active recruitment, and we continue to receive positive feedback from Europe where the product is commercially available. We anticipate enrollment throughout 2016 with follow-up in 2017 and PMA submission in 2018. 
Next, moving to Urology and home care. We've now launched our female version of the Magic3 Go self-hydrating hydrophilic catheter in Europe, and we've begun direct-to-consumer advertising in this product in the U.S. In Targeted Temperature Management, we anticipate commencing enrollment in our new IDE study of neurogenic fever prevention and control. This study will evaluate the use of the Arctic Sun system in this new indication, and we plan to enroll more than 1,000 patients over the next 3-or-so years. 
Moving to Oncology. We're awaiting 510(k) clearance of our new PROVENA family of PowerPICCs designed to reduce the risk of DVT. We're building inventory in a broad range of single-, double- and triple-lumen configurations and anticipate launching around the end of the year. 
Late in Q2, we launched both our new Power Midline and PowerGlide Pro families of intermediate dual [ph] catheters. Early feedback has been very positive on both products, and we anticipate launching additional versions in early 2017. 
On the last call, I announced our European launch of the Nautilus Delta system, with specific indications for Tip Confirmation for the pediatric patient for ports, PICCs and central lines. The next generation of this system is completing development, and we're planning for U.S. launch around the end of the year. 
I'll close my portion of the discussion today with surgery. First, in BioSurgery, we're preparing for the launch of the TRIDYNE aortic sealant. We hope to get this product to the market before the end of the year, but due to some near-term capacity constraints, we now expect to launch in Q1. We also expect to launch in Q2 of 2017 the Progel Emerald lung sealant that's been designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to launch additional Phasix resorbable mesh sizes and expect to enhance our offerings around the end of the year. This expansion will dramatically increase the range of sizes from 5 to 25 different configurations, providing surgeons and their patients the largest and most comprehensive size matrix in the market.
Expansion of our XenMatrix AB platform, with multiple new sizes, is also on track for launch in early 2017. After launch, Bard will offer the largest biologically derived graft in the market. 
And finally, in mesh fixation, we've launched the 15-count version of our OPTIFIX resorbable fixation device, with further launches in this category expected in the first half of 2017.
Thanks for your attention. Let me now turn you over to Chris."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges",936,"Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges of $4.6 million related to restructuring and productivity initiatives and a tax credit of $2.6 million related to the completion of certain tax -- certain IRS examinations. The P&L impact for these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q3 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $589.7 million or 62.6% of sales for Q3. On an adjusted basis, GPs were $624.3 million or 66.3% of sales, up 150 basis points from the prior year quarter. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in gross profit, continuing the solid performance we saw in the first half of the year. And foreign exchange was about a 50 basis point headwind to gross margin this quarter. Mix was favorable by 110 basis points, which includes the positive impact from our Japanese business. And finally, our cost improvement efforts drove approximately 100 basis points of favorability in Q3.
It's been a very strong year for margins for us. And as we told you last quarter, we expect to exceed the original full year guidance for GPs that we gave you in January. 
SG&A expenses were $272.6 million for the quarter or 28.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 28.7%, 20 basis points above the prior year. While we do expect to see decent leverage here in Q4 as we anniversary the acquisition of our Japanese joint venture, we expect to slightly exceed our original estimate for the full year due to incremental investments we've made in certain targeted areas. 
R&D expenditures totaled $74.2 million for the third quarter or 7.9% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.8%, up 30 basis points from the prior year. Again, as we told you last quarter, we expect a somewhat higher level of R&D investment for the full year, compared to our original guidance, as our strong results have allowed us to fund new opportunities earlier than initially contemplated. We continue to be in investment mode to strengthen the long-term revenue growth potential of the portfolio. 
Interest expense was $14.9 million for the third quarter, and other income and expense was $115.8 million of expense in Q3 as reported or $0.4 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.7%, down 130 basis points from the prior year. We are trending to be at the low end or maybe even slightly better than our original guidance for the full year. 
Diluted shares for the period were 75.3 million, and we repurchased approximately 190,000 shares in the third quarter. The net result is reported EPS of $1.27 and adjusted EPS of $2.64, which excludes items affecting comparability and the amortization of intangibles. This was well above the guidance range we provided for the quarter, reflecting both higher-than-expected sales as well as the continued strong execution by our teams around the world.
The balance sheet as of September 30, reflects cash, restricted cash and short-term investments of $1.15 billion, up slightly from June 30. For the quarter, accounts receivable days were down 1.5 days, and inventory was up 3.1 days. We believe inventory days will decline as we anniversary the recent acquisitions and execute on new product launches that we have been building in front of. Capital expenditures totaled $26 million for the quarter. 
On the liability side, total debt was $1.6 billion as of September 30, no change from June 30. Debt to total capital at the end of the third quarter was about 49%, and total shareholder investment was $1.7 billion at September 30. 
Moving to financial guidance. Given the strong results, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 9% and 10%, with reported sales growth between 8% and 9%, implying the same currency headwind of about 1%. We now expect our full year 2016 organic revenue growth to be around 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.23 and $10.28, representing 13% growth for the year. We now expect foreign exchange to be between $0.23 and $0.25 of headwind for the full year. So on an FX-neutral basis, we are guiding to 15% to 16% EPS growth. 
For Q4, we are expecting constant currency sales growth between 10% and 11%, with reported sales growth between 9.5% and 10.5%, implying an FX headwind of approximately 50 basis points on the revenue line. This assumes organic growth between 6% and 7% for the fourth quarter. From an adjusted EPS standpoint, we forecast the fourth quarter in the range of $2.70 to $2.75, representing 11% to 13% growth on a reported basis. 
As we look ahead, we expect a strong finish to what has been a very strong year of both execution and financial performance. And we're very pleased that we've been able to produce these results while still significantly investing for the long-term health of the business. We look forward to reporting on the full year and providing guidance for 2017 in January. 
Now I'll turn the call back to Tim."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Laurie?",28,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Laurie?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray.",16,"[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpo",59,"This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpoint just relative to kind of what we saw in the first half of the year."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes, at least it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certain",90,"Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes, at least it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certainly, the feedback from the various hospital administrators, the CEOs, et cetera, we talked to, all would amplify that. I think the biggest problem we're hearing them talk about right now is nursing turnover. So haven't heard a lot of negativity about volumes. John?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add is that we continue strong results from Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out in particular, you may remember last quarter, we h",103,"The only thing I'd add is that we continue strong results from Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out in particular, you may remember last quarter, we had a late [ph] quarter of growth in Latin America. We've had this quarter the best growth that we've had in 5 quarters. So it was nice to see that business rebound to where we had expected it [ph] to. And combined with continued very strong growth in emerging markets and, quite frankly, in our European business overall."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then just looking at the quarter, there was strong organic growth in [indiscernible] and it looks like it might have been driven by some product launches. But I'm just hoping you can give us some color on -- is this a little more of a -- should",86,"Great. And then just looking at the quarter, there was strong organic growth in [indiscernible] and it looks like it might have been driven by some product launches. But I'm just hoping you can give us some color on -- is this a little more of a -- should we expect this to be more of a run rate? Or is this more of a mid-single-digit grower? I just -- it seems like we might not be modeling this appropriately given what we saw this quarter."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique",111,"What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique patient benefits that is very difficult to compete with in the marketplace, I'd say, right now. But on top of that, as a result of our new product launches, fixation had outstanding growth in the category and very strong growth in BioSurgery. So really, the 3 major segments in that business for us all have very significant growth rates, and we think that will bode positively for the future."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I would add is the growth rates that you're seeing in our business are above -- significantly above what we think are the market growth rates. So we're continuing to pick up probably some pretty significant market share.",42,"The only thing I would add is the growth rates that you're seeing in our business are above -- significantly above what we think are the market growth rates. So we're continuing to pick up probably some pretty significant market share."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from David Lewis with Morgan Stanley.",10,"We have a question from David Lewis with Morgan Stanley."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott Wang in for David. Two questions from me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp-adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp-adjusted",62,"This is actually Scott Wang in for David. Two questions from me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp-adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp-adjusted stability on the organic growth line. Is there anything in particular that is driving that deceleration into the last quarter of the year?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based, balanced growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's",107,"Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based, balanced growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's always some puts and takes. But as John just articulated, from a geographic standpoint, we're continuing to see good balanced growth. And the surgical business, in particular, continues to perform well and the other 3 businesses and Lutonix on the Vascular side. So we're not looking to signal any deceleration for sure. Frankly, I think more of the same."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And can we talk a little bit more about your Urology strength this quarter? Now some of that was, obviously, contribution from Liberator and Medicon, but the underlying growth was also pretty strong. Can you talk to us a little bit about what",64,"Fair enough. And can we talk a little bit more about your Urology strength this quarter? Now some of that was, obviously, contribution from Liberator and Medicon, but the underlying growth was also pretty strong. Can you talk to us a little bit about what's driving that underlying growth trend and maybe give us an update on where you are on the Liberator integration?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market pers",128,"Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market perspective and especially the Magic3 Go female. We have been delighted with what we've seen with the Liberator integration. I'd say that basic drainage though was up 4% in the United States without Liberator being in those numbers. So it's a very strong business. Continence business was up 28%. The only really shortfall that we had was Targeted Temperature Management that only grew at 4% versus 15% year-to-date. We think that's a timing issue on capital equipment. So we saw very nice growth across the portfolio."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add there is, and we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and [indiscernible] in particular, as it relates to Urology. So some of the new",89,"And the only thing I'd add there is, and we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and [indiscernible] in particular, as it relates to Urology. So some of the new products and the tray designs and the programs that we've implemented continue to drive very good growth, absent significant volume growth, frankly. So we're continuing to take share and providing solutions that customers are valuing because it's helping them solve a real problem that they're facing."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Vijay Kumar from Evercore ISI.",10,"We have a question from Vijay Kumar from Evercore ISI."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just maybe on the margins. It really looks like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove this trend on the margin side, I think that would be a helpful starting point.",44,"Just maybe on the margins. It really looks like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove this trend on the margin side, I think that would be a helpful starting point."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all from a gross margin standpoint, we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues t",180,"Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all from a gross margin standpoint, we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues to be positive, driven by, over the last couple of years, some of the launches that we've had. And then our operations teams continued to deliver excellent results from a cost improvement standpoint. So frankly, the strength that we've seen from strong execution on the gross margin line has allowed us to continue to invest in R&D and SG&A, frankly ahead of where we had anticipated to be able to coming into the year. So we think it's a terrific ability for us to reinvest into the business while still driving significant operating margin improvement. So it's a model that we're focused on continuing to replicate. It comes with a lot of hard work from a lot of people, but that's the model. And when we execute well, you get the results that you saw this quarter."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how",69,"Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how this time maybe it's larger than what we're thinking and then what could drive growth on that side, that would be helpful."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start and then turn it over to the 2 John's here to follow-up. So we still think this market is accelerating. And frankly, I would still call it even in the next year, potentially with another competitor, still a rising tide here. It's still un",148,"Sure. I'll start and then turn it over to the 2 John's here to follow-up. So we still think this market is accelerating. And frankly, I would still call it even in the next year, potentially with another competitor, still a rising tide here. It's still underpenetrated, still underdiagnosed. And I think as more use is -- there's more usage experience, physicians are continuing to determine where they want to use DCBs in their treatment protocols, and all of that is very positive. I do think it's kind of interesting as you look at different nuances in the specifics of the products relative to the amount of drug and some of the behavior characteristics. Certainly, we performed extremely well in our registry data vis--vis all of those metrics. So we feel very good about our own positioning going forward against what we know is expected competition moving ahead."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications though, AV access and Below-the-Knee, we think those 2 markets wou",104,"The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications though, AV access and Below-the-Knee, we think those 2 markets would be approximately $600 million in 2020, and we're working hard to be the first entrant into that space. So while we do expect some competition in the SFA, we're hopeful that we will be the market enterer in the other 2, which we expect -- other 2 segments, which we expect to have outstanding growth potential."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us. As we talked about, in-stent restenosis and long lesion, we anticipate a Q1 2017 launch with those indications, mid-2017 the",86,"And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us. As we talked about, in-stent restenosis and long lesion, we anticipate a Q1 2017 launch with those indications, mid-2017 the launch of Lutonix in Japan, and then late 2017 an AV access potential for launch. We think that's going to be differentiating and give us -- and continue to keep us in a leadership position. Then 2018, we've got BTK coming along."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Keusch from Raymond James.",11,"And we have a question from Larry Keusch from Raymond James."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just wanted to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses have puts and takes and capital can be",80,"Just wanted to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses have puts and takes and capital can be lumpy, but I just want to dive a little bit deeper and see if you are potentially seeing anything other than just timing as it relates to just the appetite for capital equipment out there amongst hospitals."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strongly right afterward. So we don't see any indicators, which would cause us",49,"No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strongly right afterward. So we don't see any indicators, which would cause us to be concerned about that."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think our other capital businesses were -- had growth similar to what we have seen in other quarters.",20,"And I think our other capital businesses were -- had growth similar to what we have seen in other quarters."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Larry, we expect Q4 to, frankly, be robust, so just to that point.",14,"And Larry, we expect Q4 to, frankly, be robust, so just to that point."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's perfect. And then just sort of bigger picture. I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we head",51,"Okay. That's perfect. And then just sort of bigger picture. I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we head into 2017?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","You answered your own question that we're not going to give guidance on this call for 2017. But to the earlier or first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth o",166,"You answered your own question that we're not going to give guidance on this call for 2017. But to the earlier or first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth of the market solidify throughout this year. There's nothing that we have seen that would indicate that could change heading into next year. When we started our investment plan back in 2013, we said that you would start to see the results in '15, but we expected that it would be sustainable. So everything we've been doing from then to now, investing in R&D, sales force expansion in emerging markets, the acquisitions that we've made have all been targeted to achieve that kind of an outcome. And we fully expected that above-market growth achievement of 2 to 3 points above the market should continue. So that's kind of the way we feel about it heading out of this year."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'll add to that is that one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about a 1/3 i",134,"The only thing I'll add to that is that one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about a 1/3 increase in our sales forces. And people are still maturing in some of those jobs that were maybe the later placements into it. And quite frankly, we expect to have pretty robust additions in our sales force again next year in a lot of our high-growth markets. So I think that we're making the right investments, as Tim mentioned, to ensure that as the products come through our pipeline and registration pipeline that we're poised and have the right manpower to execute on those."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impa",85,"The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impacting the entire company. And so you've seen it this year. We expect to end this year strong with really balanced and important contributions from all the businesses, which I think you need to have to sustain the kind of growth rates that we're seeing."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Mike Weinstein with JPMorgan.",10,"And we have a question from Mike Weinstein with JPMorgan."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So let me ask just some on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask",144,"So let me ask just some on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask you just about mix and, as well, the competitive environment. So number one, on mix, I feel like we continue to underestimate within the mesh part of the business, the opportunity for mix upgrade for your business. So can you give us a sense of where you think you are in that mix upgrade piece of the story within the mesh business? And then second, competitively, we just had an ACS. Is there anything that you've seen new competitively that gives you any pause as to this momentum in the business continuing in 2017?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And by that -- on top of that, our BioSurgery margins are well above the corporate average. So with mi",185,"Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And by that -- on top of that, our BioSurgery margins are well above the corporate average. So with mid-teens growth in those and into the 20s for BioSurgery, obviously, that will have a positive impact on our overall margins long term. Relative to ACS, it's interesting. I'm speaking to one of our key leaders in that business this afternoon about the same exact issue. And we have not seen anything that's launching or plans to launch that gives us concern relative to the growth drivers in that business either in the fixation side of things or in the synthetic mesh side of things. We think our Phasix product line and product category has such unique capabilities in terms of providing long-lasting repairs for patients without leaving a mesh behind long term that the benefit to patients is significant and we've not seen anything yet. Although we're always diligent about it, we've not seen anything yet that gives us pause for concern."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics have a place, the Phasix opportunity to offset",137,"Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics have a place, the Phasix opportunity to offset biologics is a terrific win for us and a terrific win for the physician and the hospital in a lot of cases. And we're seeing customers, because of the breadth of the portfolio, literally standardize on Bard's hernia portfolio from basic synthetic to an absorbable synthetic to a biologic. And we're the only one that could even sit down and have that conversation with customers. And there's a lot of advantages, as you can imagine, for them to do that. And that's certainly part of the reason we're driving and capturing share."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, I missed it, if you made some comments just about use of cash during the quarter, but it didn't look like there was activity from a buyback standpoint. It looked like it was pretty minimal. Just can you give us thoughts on -- it seems like you guys",89,"Chris, I missed it, if you made some comments just about use of cash during the quarter, but it didn't look like there was activity from a buyback standpoint. It looked like it was pretty minimal. Just can you give us thoughts on -- it seems like you guys have been largely sitting on your cash in the last couple of quarters, maybe paying down a little bit of your debt. Is there any thought process behind that? And any updated thoughts, Tim, on the environment for business development?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Nothing's changed from our perspective strategically relative to the use of cash. Priorities are still the same. Acquiring technologies of businesses are the first priority. Share buybacks, second, and then dividends, third. So none of that's really",133,"Sure. Nothing's changed from our perspective strategically relative to the use of cash. Priorities are still the same. Acquiring technologies of businesses are the first priority. Share buybacks, second, and then dividends, third. So none of that's really changed. As you know, the business development environment is opportunistic and episodic. But relative to our internal efforts or initiatives, none of that's changed. We're still pedal to the metal in terms of our initiatives globally. Frankly, as we've added business development resources geographically over the last couple of years, they've matured and we're in the space more. So we feel good about the initiative and the momentum. And I would fully expect to continue to see the same kind of cadence going forward that you've seen over the last couple of years with us."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the co",109,"And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the commitment to shareholders to not do that, we're certainly continuing to deliver on that commitment. So to Tim's point, the priority remains to be strategic. We obviously continue to have a lot flexibility with the balance sheet to do both in a reasonable and appropriate way. And it'll ebb and flow quarter-to-quarter, but we'll continue to be an active repurchaser in an ordinary course."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Amit Hazan with Citi.",9,"We have a question from Amit Hazan with Citi."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Let me maybe start with the nonorganic guidance piece. So I think you've raised it a little bit. You're now at 2% to 3% contribution for this year. That's about $85 million at the midpoint. If we think about this, just the components of that, Liberator, y",130,"Let me maybe start with the nonorganic guidance piece. So I think you've raised it a little bit. You're now at 2% to 3% contribution for this year. That's about $85 million at the midpoint. If we think about this, just the components of that, Liberator, you started out, when you acquired it, saying $70 million for the year. Clearly, you're talking about at being more than $70 million. Medicon is another $30 million net for the year, if I'm doing my math right. So we're already at $100 million. We've got a few other small pieces. Seems to me like we're easily over even high end of that. So maybe give me a sense of what I'm missing on the nonorganic side even to get to your new guidance."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related",89,"Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related to that year-over-year decline in revenue. To John's point, the acquisitions are both going well from an immigration standpoint, and we're trending ahead of the model. But when you do the math on all the puts and takes, we're comfortable with the guidance here for the full year."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then let me just ask the second question about PICC. So if would kind of look back, just the trend line, it's been this really nice consistent 10%-plus grower. I don't want to pick on it too much at 9% for the year, so just under that, not a big",165,"Okay. And then let me just ask the second question about PICC. So if would kind of look back, just the trend line, it's been this really nice consistent 10%-plus grower. I don't want to pick on it too much at 9% for the year, so just under that, not a big deal, but just want to make sure we're not missing anything there and you're still very comfortable with how PICC performance is going. And related to that, if we kind of go back to the Analyst Day and we think about your discussion today about the pipeline, one thing I haven't seen you guys talk about or at least highlight is new products coming in Oncology, at least there was, I think, nothing there in the Analyst Day that was really highlighted. And I didn't see -- I just don't think I heard anything today. So just maybe touch on those 2 points, both the PICC and the pipeline inside of the [indiscernible]."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","No, we are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date. So we had a very strong quarter in ports. And PICCs were up 8%,",92,"No, we are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date. So we had a very strong quarter in ports. And PICCs were up 8%, which is very similar to our full year growth year-to-date, which is up 9%. So I think we're very comfortable with our 2 leading product lines in the oncology space and our gross [ph] there. And I'll let John talk about the pipeline."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, PowerGlide Pro, and we've got new versions of those launching early next year. I didn't talk this",168,"Yes. So I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, PowerGlide Pro, and we've got new versions of those launching early next year. I didn't talk this call about AccuCath, but we've launched a first couple of versions of that. We've got more launches of those coming up early next year. And I also talked about the pediatric Tip Confirmation technology that we launched in Europe last quarter, and we expect to launch around the end of year here in the U.S. that gives us access for both -- for all products, all venous products. So central venous catheters, PICCs and ports in the pediatric case. And then we've got other things like our chemical-resistant PICCs that I've talked about before that I didn't mention today on the call, but are launching here in the near term as well. So I think there's a pretty darn robust pipeline there."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins from Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins from Bank of America."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So one thing I wanted to ask about is the emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a",105,"So one thing I wanted to ask about is the emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a quarter or 2. And then more recently, it's been back at around 20%. And I'm just curious in this particular quarter, did emerging market growth sustain in that 20% growth range? And as we think forward, what's your confidence that we can continue to see growth around 20%, plus or minus, in emerging markets?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we've said many times, we are really developing a lot of tho",250,"Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we've said many times, we are really developing a lot of those markets from scratch, in particular, biopsy, PICCs, hernia repair. We continue to see great opportunities for growth there. We've built a whole new BioSurgery sales team that is really just starting to get their traction. And we have some pretty interesting investment opportunities for next year sales force-wise there. Latin America, we saw a nice move in the positive direction, and I think as I mentioned, it was our best quarter in Latin America in the last 5 quarters. And that's always been a pretty solid area of growth for us, with the exception of last quarter. So we rebounded significantly, made up great ground there. and I'd say the other area that we haven't talked about an awful lot, but we've made a number of investments in, what we call rest of Asia or the smaller markets in Asia that we build out sales forces, build out marketing teams and are getting approvals and registrations for our products and launching those. So I'd say we looked at our appetite in emerging markets, it's certainly high. As we -- if we look at our investment profile, that's equally high, and we're very optimistic about what we'll see there."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So then just maybe to try and pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then I also just wanted to get a quick view, and I apologize if I",115,"So then just maybe to try and pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then I also just wanted to get a quick view, and I apologize if I missed this, on hernia. And from what you're seeing in the marketplace, is there any sign of any competitive offerings that look interesting? Because obviously, J&J has been exiting some portions of the market, and you guys have been launching great products. So just curious on the competitive landscape, what you're seeing on hernia, and if you think something around 20% is sustainable in EM."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me take the first part of EM, and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month, an",253,"So let me take the first part of EM, and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month, and that we continue to build and invest in that pipeline. So we feel good about that, if you want to think about that. It's almost like another R&D portfolio. It's just products that have already been de-risked, because they've most likely been launched someplace else already. So it's really a regulatory filing. So that's one component. Second, as John mentioned, we continue to invest and build out sales forces and expand in those geographies, and that will continue with the U.S. World Series beginning tonight to put in kind of a baseball analogy. I don't even think we're into the fifth inning yet in emerging markets. So I'd say it's still in the early innings of the game. And that is further -- is another good metric for us. The enthusiasm level from clinicians to be trained on our products almost overwhelms our capability to keep up with the capacity for the demand. So we just opened up another training center in some of the South Asia markets that John has referred to. And that demand continues to be very, very strong. So all of those things really make us believe that we've got a lot of runway left in emerging markets. You want to...?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We have not seen anything in the marketplace right now that gives us pause for concern. We",97,"The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We have not seen anything in the marketplace right now that gives us pause for concern. We think that our broad portfolio and, in particular, the new technologies that are really early into their introduction phase, and based on that and the pipeline that we have coming, we're very comfortable, although always diligent about what we see coming up in the marketplace from a competitor."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","We wake up a little afraid everyday here.",8,"We wake up a little afraid everyday here."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Biegelsen with Wells Fargo.",11,"And we have a question from Larry Biegelsen with Wells Fargo."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's Lei Huang calling in for Larry. So you raised guidance several times this year, both top line and bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. But can you talk about some of the key factors t",75,"It's Lei Huang calling in for Larry. So you raised guidance several times this year, both top line and bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. But can you talk about some of the key factors that contributed to the upside in the guidance raise? How much of it was perhaps the overall market strength, utilization trend versus your execution versus other things?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me start with that. So obviously, we put together -- the way we roll up our process. We have budgets. Businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built in to some of the guidanc",124,"So let me start with that. So obviously, we put together -- the way we roll up our process. We have budgets. Businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built in to some of the guidance. The fact of the matter is if everybody performs at the high end of what they told us, we're going to do very well. And that is about execution, both on the new product side, the sales force, marketing, everything. Frankly, that has to do with running a business. And when you execute well, you perform pretty well and that's kind of been the way it's been here the last several quarters."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I'd try to really strongly echo that. We are not building in a significant level of conservatism. I think we're completing a year here where the execution, to Tim's point, has really been outstanding across the board. And when you get that kind of broad-b",188,"I'd try to really strongly echo that. We are not building in a significant level of conservatism. I think we're completing a year here where the execution, to Tim's point, has really been outstanding across the board. And when you get that kind of broad-based outstanding execution, you're in a position to do what we're doing here, again, for the third time, which is raising guidance. So the base businesses and again the balance of it, I think it's critically important where all the businesses are contributing really attractive organic growth. The acquisitions, as we've said, have exceeded our expectations. We're doing better on price. Our operations teams are delivering what they committed to and the mix within the portfolio, frankly, the portfolio -- the growth in surgery is very helpful to mix and to margins, as John highlighted as well. And as those emerging market sales reps become more and more productive, that execution gives us some upside. So it's a lot of little things across a lot of parts of the company that, in combination, really result in really strong top and bottom line performance."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up. So Spectranetics will be presenting data for their DCB product at TCT. Do you have any just kind of thoughts on the data and what we should be thinking about versus the data that you presented both trial and registry d",47,"Great. And just one quick follow-up. So Spectranetics will be presenting data for their DCB product at TCT. Do you have any just kind of thoughts on the data and what we should be thinking about versus the data that you presented both trial and registry data?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they present will be in line. If you look at our data, I think consistently",157,"Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they present will be in line. If you look at our data, I think consistently, as we've gotten in real-world use of our technology, we have similar results to what they've shown previously and what Medtronic has shown. So we kind of anticipate all of that, and we think we've got pretty robust data. Obviously, LEVANT 2 was a ""first of a kind"" study, and we learned a lot from that study, and we've seen and talked about, at length, some of the findings on the importance of procedural aspects of that. And so when we've seen it in real-world use where they've followed those procedural learnings that we've had, we've had really great results. So we think we're going to be pretty similar."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come.",32,"I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We do have one more question. We'll go to Dave Turkaly with JMP Securities.",14,"We do have one more question. We'll go to Dave Turkaly with JMP Securities."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a follow-up sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. And we saw your 24-month registry data. There was a lot of speculation prior to launch sort of how people would view this data, what docs w",86,"Just a follow-up sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. And we saw your 24-month registry data. There was a lot of speculation prior to launch sort of how people would view this data, what docs would think, I guess. Do you have any commentary on that? Do clinicians -- is that something that's brought up by customers? Or is this something more of a kind of competitive thing in the marketplace today?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me start. So if you look at market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare our pivotal data for their pivotal data and then the registry data that we presented, clearly, we th",177,"Well, let me start. So if you look at market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare our pivotal data for their pivotal data and then the registry data that we presented, clearly, we think data does make a difference. We think there's other important features and characteristics beyond the data, things that are now just beginning to be better understood relative to the amount of drug use, how much of a drug stays on, the agent that's used to bind the drug to the balloon, et cetera, et cetera. All those things over time will play out with more usage and more information and data. And that includes things that are going to have to be understood and learned with new entrants to the market. So we generally feel very good about our market position, our growth prospects, our new indications that we've got in the pipeline and the way that the products performed and we've executed since we've launched. John DeFord, anything else?"
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think part of your question was how much of data is sort of a discussion at meetings and with KOLs as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more",135,"Yes. I think part of your question was how much of data is sort of a discussion at meetings and with KOLs as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more bander at the competitive level from company to company than the clinicians necessarily pay that much attention to. It seems like in my interactions with physicians. And so I think data are important. I think safety is really a key point that I think we have a lot of strength in that particular space. And then our long-term data, as we look at our registries and real-world use in long lesions and calcified lesions and in-stent restenosis and all those pieces are continued validation of this technology."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments.",26,"And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Laurie. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call.",41,"Thanks, Laurie. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call."
254131,403600059,1060973,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. Ladies and gentlemen, this will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect.",29,"Thank you. Ladies and gentlemen, this will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand repl",275,"Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc. Third Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's June 30, 2016 Form 10-Q and the information under the caption Risk Factors in Bard's 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of historical non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of October 25, 2016, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period.
At this time, I'll turn the call over to Mr. Timothy Ring. Please go ahead."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, Laurie. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also direct you",512,"Thank you, Laurie. Good afternoon, everybody, and welcome to Bard's Third Quarter 2016 Earnings Call. I would expect the presentation portion of the call to last about 25 minutes. We're going to try and keep the total call to an hour. I'll also direct your attention to the slide deck available on the Investor Relations page of our website, which is intended to help explain some of the moving pieces in our results and guidance. 
The agenda today will go as follows: I'll begin with an overview of the results for the third quarter; John Weiland, our President and COO, will review third quarter product line revenue; John DeFord, our Senior VP, Science, Technology and Clinical Affairs, will give you an update on our product pipeline; and then, Chris Holland, our Senior VP and CFO, will give you the third quarter income statement, balance sheet as well as our expectations for Q4 and, obviously, the full year. And then we'll close with Q&A.
Third quarter 2016 net sales totaled $941.9 million. That's up 9% over the third quarter of last year on an as-reported basis and up 10% on a constant currency basis. Currency impact for the quarter versus Q3 of last year was unfavorable by about 90 basis points.
Our organic revenue growth was 6% for the quarter. Excluding the prior year stocking of Lutonix by Boston Scientific, we estimate that our organic sales growth was 6.4%.
While our recent acquisitions performed above the guidance we've provided, our Targeted Temperature Management business, which can be a little lumpy given timing issues, had a soft quarter. John Weiland will take you through the product lines, and Chris will provide guidance. We believe you will see continued strength and momentum across the portfolio. 
Net income for the third quarter was $96.4 million and diluted EPS were $1.27. Excluding amortization of intangibles and items that affected the comparability of results between periods, Chris will cover those later, adjusted third quarter 2016 net income and diluted earnings per share were $199.5 million and $2.64. That's up 14% and 16%, respectively. These adjusted results well exceeded the guidance we provided for the quarter. 
Looking at revenue growth geographically compared to the same quarter in 2015, net sales in the U.S. increased 7%. On a constant currency basis, Europe grew 5%. Japan was up 44%, benefiting from moving the customer pricing after our acquisition of the joint venture there, and our other international businesses grew 19%. Emerging market growth was strong, yet again, representing 10% of our total sales in Q3. 
The results in Q3 continued to demonstrate the strength of our economic engine, driving organic growth between 6% and 7% on the top line, with attractive returns on the bottom line, even while we have continued to invest significantly for future growth. The results so far this year have exceeded our expectations, and we expect a strong finish to what has been a very strong year so far. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.So let's begin with Vascular. Total net sales were $258",779,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless noted otherwise.
So let's begin with Vascular. Total net sales were $258.1 million, up 3% over last year on an as-reported basis and up 4% on a constant currency basis. Excluding the Gore royalty, EP sales to Boston Scientific and Japan sales, global Vascular sales grew 5% in Q3, with the United States business up 2% and international up 10%.
Sales in our Surgical Graft category were flat in the third quarter. Our Endovascular business grew 7% in the third quarter. Our peripheral PTA line grew 7% despite the prior year stocking from the Boston Scientific distribution agreement for Lutonix. 
We continue to see strong growth year-over-year in sales of Lutonix to customers, including sequential growth in the United States. Sales in our vena cava filter line were down 18% this quarter. Our Stent business grew 6% in the third quarter, which was the best quarter in 4 years, driven by strength internationally. And to complete the Vascular category, our biopsy family of products grew 10% this quarter globally, making -- marking the sixth straight quarter of double-digit growth in this product family. 
Now let's go to Urology. Total net sales were $242.1 million, up 14% as reported and up 15% on a constant currency basis. The combination of Liberator Medical sales and the benefit of the Japanese business moving to customer pricing added about 1,200 basis points to the growth in this category. Excluding these 2 acquisitions, the United States business was up 2%, while internationally we grew 7%.
Our basic drainage business was up 19% globally. Excluding the acquisitions, the basic drainage business grew 5% globally and 4% in the United States, with our I.C. Foley business up 1% globally and flat in the U.S. 
Our Targeted Temperature Management business grew 4% this quarter. While the sales of our disposable pads grew double digits, as Tim said, the capital portion of this business can be a little lumpy. We continue to believe that this product line has long-term double-digit growth potential. 
Our continence business was up 28% in the third quarter, driven by the benefit from the new acquisitions. Sales in Urological Specialties were up 9% this quarter, including our brachytherapy business, which grew 6%, driven by Japan.
And finally, in this category, stand-alone sales of our StatLock catheter-stabilization line grew 2% in the third quarter.
Let's now go on to Oncology. Total net sales in this category were $258.4 million, an increase of 8% on an as-reported basis and up 9% on a constant currency basis over the third quarter of last year. The Japan acquisition added about 200 basis points to growth globally. Excluding that, sales in the United States were up 3%, and international sales were up 15%. 
Our port business was up 9% versus the third quarter last year. Most of the benefit from -- in this category is from Japan and is imports. Our PICC revenue was up 8% this quarter with continued strength internationally. Our Vascular Access Ultrasound product line grew 8% this quarter. And to close out the category, our Dialysis Access product line was up 7%.
Let's conclude then with our Surgical Specialties business. Total net sales in this category were $158.8 million, up 14% on both an as reported and constant currency basis. United States sales were up 11%, and international sales were up 21% this quarter, excluding the impact from Japan, which was minimal.
Our performance irrigation business was down 6%. Our soft tissue repair business delivered its strongest quarter in 6 years, growing 14% in the third quarter. We saw this growth despite continued procedural shifts away from natural tissue products, which declined 35% for us in the third quarter. 
In contrast, our synthetic business, which includes our hybrid Phasix material, grew 23% this quarter, which is the highest growth in more than 10 years. Our mix of synthetic revenue to natural tissue revenue is now greater than 7:1. 
We believe the quality and the breadth of our product offering and our value-added programs help customers select the right product for the patient, which is having a significant impact on the treatment paradigm. 
Our hernia fixation business grew 34% this quarter on the continued impact from our recent product launches here.
Closing out the surgical category, our BioSurgery business grew 22% in Q3, with strong growth in both the United States and outside the United States. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for a pipeline update."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and",729,"Thanks, John, and good afternoon, everyone. Let me jump right in with a brief discussion of a few of our highlighted pipeline projects. As we've done over the last few quarters, I'll start with our drug-coated balloon pipeline. First, our long lesion and in-stent restenosis supplements are under review at FDA, and we're hopeful for approval of both of these expanded indications early next year. 
In our Below-the-Knee IDE, as we recently announced, the FDA has approved an amendment to our study supporting the primary efficacy analysis at the 6-month follow-up time point. This is an exciting development, and we're continuing to analyze the potential impact to our approval time line. We think this should put our launch in 2018. 
The AV access DCB IDE study is in follow-up after a very rapid enrollment. We remain on track to get a first look at our results in late Q4, and we anticipate PMA submission in Q1 of 2017. Assuming normal review timing, we expect a late Q4 2017 U.S. launch. 
In Japan, our shonen submission for the Lutonix SFA indication remains under review, and we continue to anticipate a mid-2017 launch. While in China, we continue to enroll in our Levant China study that began earlier this year.
Also in Vascular, our LifeStream Balloon Expandable covered stent trial has completed follow-up, and the final PMA module was submitted last quarter to FDA, with approval and launch expected in mid-2017. 
Our COVERA next-generation AV access circuit stent graft received IDE approvals for both a fistula and a graft study. Both studies began recruitment in Q3, and we expect enrollment will take about a year. 
Our Venovo vena stent IDE is in active recruitment, and we continue to receive positive feedback from Europe where the product is commercially available. We anticipate enrollment throughout 2016 with follow-up in 2017 and PMA submission in 2018. 
Next, moving to Urology and home care. We've now launched our female version of the Magic3 Go self-hydrating hydrophilic catheter in Europe, and we've begun direct-to-consumer advertising in this product in the U.S. In Targeted Temperature Management, we anticipate commencing enrollment in our new IDE study of neurogenic fever prevention and control. This study will evaluate the use of the Arctic Sun system in this new indication, and we plan to enroll more than 1,000 patients over the next 3-or-so years. 
Moving to Oncology. We're awaiting 510(k) clearance of our new PROVENA family of PowerPICCs designed to reduce the risk of DVT. We're building inventory in a broad range of single-, double- and triple-lumen configurations and anticipate launching around the end of the year. 
Late in Q2, we launched both our new Power Midline and PowerGlide Pro families of intermediate dual [ph] catheters. Early feedback has been very positive on both products, and we anticipate launching additional versions in early 2017. 
On the last call, I announced our European launch of the Nautilus Delta system, with specific indications for Tip Confirmation for the pediatric patient for ports, PICCs and central lines. The next generation of this system is completing development, and we're planning for U.S. launch around the end of the year. 
I'll close my portion of the discussion today with surgery. First, in BioSurgery, we're preparing for the launch of the TRIDYNE aortic sealant. We hope to get this product to the market before the end of the year, but due to some near-term capacity constraints, we now expect to launch in Q1. We also expect to launch in Q2 of 2017 the Progel Emerald lung sealant that's been designed to improve visibility during minimally invasive and robotic thoracic surgery. 
In hernia repair, we continue to launch additional Phasix resorbable mesh sizes and expect to enhance our offerings around the end of the year. This expansion will dramatically increase the range of sizes from 5 to 25 different configurations, providing surgeons and their patients the largest and most comprehensive size matrix in the market.
Expansion of our XenMatrix AB platform, with multiple new sizes, is also on track for launch in early 2017. After launch, Bard will offer the largest biologically derived graft in the market. 
And finally, in mesh fixation, we've launched the 15-count version of our OPTIFIX resorbable fixation device, with further launches in this category expected in the first half of 2017.
Thanks for your attention. Let me now turn you over to Chris."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges",936,"Thank you, John. Let's start tonight with the items that affect the comparability of our results between periods. This quarter, we took a charge of $110.6 million for product liability matters. We also had acquisition-related items of $5 million, charges of $4.6 million related to restructuring and productivity initiatives and a tax credit of $2.6 million related to the completion of certain tax -- certain IRS examinations. The P&L impact for these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q3 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $589.7 million or 62.6% of sales for Q3. On an adjusted basis, GPs were $624.3 million or 66.3% of sales, up 150 basis points from the prior year quarter. Price was unfavorable at 40 basis points on the revenue line and about 10 basis points in gross profit, continuing the solid performance we saw in the first half of the year. And foreign exchange was about a 50 basis point headwind to gross margin this quarter. Mix was favorable by 110 basis points, which includes the positive impact from our Japanese business. And finally, our cost improvement efforts drove approximately 100 basis points of favorability in Q3.
It's been a very strong year for margins for us. And as we told you last quarter, we expect to exceed the original full year guidance for GPs that we gave you in January. 
SG&A expenses were $272.6 million for the quarter or 28.9% of sales. On an adjusted basis, SG&A as a percentage of net sales was 28.7%, 20 basis points above the prior year. While we do expect to see decent leverage here in Q4 as we anniversary the acquisition of our Japanese joint venture, we expect to slightly exceed our original estimate for the full year due to incremental investments we've made in certain targeted areas. 
R&D expenditures totaled $74.2 million for the third quarter or 7.9% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.8%, up 30 basis points from the prior year. Again, as we told you last quarter, we expect a somewhat higher level of R&D investment for the full year, compared to our original guidance, as our strong results have allowed us to fund new opportunities earlier than initially contemplated. We continue to be in investment mode to strengthen the long-term revenue growth potential of the portfolio. 
Interest expense was $14.9 million for the third quarter, and other income and expense was $115.8 million of expense in Q3 as reported or $0.4 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.7%, down 130 basis points from the prior year. We are trending to be at the low end or maybe even slightly better than our original guidance for the full year. 
Diluted shares for the period were 75.3 million, and we repurchased approximately 190,000 shares in the third quarter. The net result is reported EPS of $1.27 and adjusted EPS of $2.64, which excludes items affecting comparability and the amortization of intangibles. This was well above the guidance range we provided for the quarter, reflecting both higher-than-expected sales as well as the continued strong execution by our teams around the world.
The balance sheet as of September 30, reflects cash, restricted cash and short-term investments of $1.15 billion, up slightly from June 30. For the quarter, accounts receivable days were down 1.5 days, and inventory was up 3.1 days. We believe inventory days will decline as we anniversary the recent acquisitions and execute on new product launches that we have been building in front of. Capital expenditures totaled $26 million for the quarter. 
On the liability side, total debt was $1.6 billion as of September 30, no change from June 30. Debt to total capital at the end of the third quarter was about 49%, and total shareholder investment was $1.7 billion at September 30. 
Moving to financial guidance. Given the strong results, we are again raising our guidance for the full year on both the top and bottom line. We now expect full year constant currency sales growth to be between 9% and 10%, with reported sales growth between 8% and 9%, implying the same currency headwind of about 1%. We now expect our full year 2016 organic revenue growth to be around 7%. We're also increasing our full year adjusted EPS guidance range to be between $10.23 and $10.28, representing 13% growth for the year. We now expect foreign exchange to be between $0.23 and $0.25 of headwind for the full year. So on an FX-neutral basis, we are guiding to 15% to 16% EPS growth. 
For Q4, we are expecting constant currency sales growth between 10% and 11%, with reported sales growth between 9.5% and 10.5%, implying an FX headwind of approximately 50 basis points on the revenue line. This assumes organic growth between 6% and 7% for the fourth quarter. From an adjusted EPS standpoint, we forecast the fourth quarter in the range of $2.70 to $2.75, representing 11% to 13% growth on a reported basis. 
As we look ahead, we expect a strong finish to what has been a very strong year of both execution and financial performance. And we're very pleased that we've been able to produce these results while still significantly investing for the long-term health of the business. We look forward to reporting on the full year and providing guidance for 2017 in January. 
Now I'll turn the call back to Tim."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Laurie?",28,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to our moderator to facilitate the Q&A session. [Operator Instructions] Laurie?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray.",16,"[Operator Instructions] And the first question is from the line of Brooks West with Piper Jaffray."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpo",59,"This is Tom Bakas on for Brooks. I was hoping, first, you could maybe comment on general trends you're seeing in volumes and maybe if there are any particular regions where you would call out particular strength or weakness from a procedure volume standpoint just relative to kind of what we saw in the first half of the year."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes, at least it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certain",90,"Sure. I'll start, and then I'll turn it over to John Weiland. I think we've seen some stability in volumes, at least it appears that way, and we saw the pickup earlier in the year, and it seems to have remained somewhat stable throughout the year. Certainly, the feedback from the various hospital administrators, the CEOs, et cetera, we talked to, all would amplify that. I think the biggest problem we're hearing them talk about right now is nursing turnover. So haven't heard a lot of negativity about volumes. John?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add is that we continue strong results from Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out in particular, you may remember last quarter, we h",103,"The only thing I'd add is that we continue strong results from Lutonix, which we are delighted about in our Vascular business. We had pretty good strength across the entire portfolio, but I would call out in particular, you may remember last quarter, we had a late [ph] quarter of growth in Latin America. We've had this quarter the best growth that we've had in 5 quarters. So it was nice to see that business rebound to where we had expected it [ph] to. And combined with continued very strong growth in emerging markets and, quite frankly, in our European business overall."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then just looking at the quarter, there was strong organic growth in [indiscernible] and it looks like it might have been driven by some product launches. But I'm just hoping you can give us some color on -- is this a little more of a -- should",86,"Great. And then just looking at the quarter, there was strong organic growth in [indiscernible] and it looks like it might have been driven by some product launches. But I'm just hoping you can give us some color on -- is this a little more of a -- should we expect this to be more of a run rate? Or is this more of a mid-single-digit grower? I just -- it seems like we might not be modeling this appropriately given what we saw this quarter."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique",111,"What we saw in the surgical business overall, we saw very strong growth in our synthetic hernia, really delivered through our new product launches in that category. Most noteworthy of that would be our Phasix product category, which really has very unique patient benefits that is very difficult to compete with in the marketplace, I'd say, right now. But on top of that, as a result of our new product launches, fixation had outstanding growth in the category and very strong growth in BioSurgery. So really, the 3 major segments in that business for us all have very significant growth rates, and we think that will bode positively for the future."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I would add is the growth rates that you're seeing in our business are above -- significantly above what we think are the market growth rates. So we're continuing to pick up probably some pretty significant market share.",42,"The only thing I would add is the growth rates that you're seeing in our business are above -- significantly above what we think are the market growth rates. So we're continuing to pick up probably some pretty significant market share."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from David Lewis with Morgan Stanley.",10,"We have a question from David Lewis with Morgan Stanley."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Scott Wang in for David. Two questions from me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp-adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp-adjusted",62,"This is actually Scott Wang in for David. Two questions from me. Chris, first, looking over your guidance, it looks like you're forecasting a slight comp-adjusted deceleration into the fourth quarter after 3 consecutive quarters of very good comp-adjusted stability on the organic growth line. Is there anything in particular that is driving that deceleration into the last quarter of the year?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based, balanced growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's",107,"Yes, I don't think so. I think we see actually Q4 looking and feeling a lot like the last several quarters with pretty broad-based, balanced growth. And again, we're guiding in the 6% to 7% range, which will have us finishing a full year at 7%. So there's always some puts and takes. But as John just articulated, from a geographic standpoint, we're continuing to see good balanced growth. And the surgical business, in particular, continues to perform well and the other 3 businesses and Lutonix on the Vascular side. So we're not looking to signal any deceleration for sure. Frankly, I think more of the same."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Fair enough. And can we talk a little bit more about your Urology strength this quarter? Now some of that was, obviously, contribution from Liberator and Medicon, but the underlying growth was also pretty strong. Can you talk to us a little bit about what",64,"Fair enough. And can we talk a little bit more about your Urology strength this quarter? Now some of that was, obviously, contribution from Liberator and Medicon, but the underlying growth was also pretty strong. Can you talk to us a little bit about what's driving that underlying growth trend and maybe give us an update on where you are on the Liberator integration?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market pers",128,"Let me handle the Liberator integration first. Liberator has gone extremely well. It's above our model, continues to run above our model. We have a number of new products that are going to be launched, as we mentioned, throughout the Liberator market perspective and especially the Magic3 Go female. We have been delighted with what we've seen with the Liberator integration. I'd say that basic drainage though was up 4% in the United States without Liberator being in those numbers. So it's a very strong business. Continence business was up 28%. The only really shortfall that we had was Targeted Temperature Management that only grew at 4% versus 15% year-to-date. We think that's a timing issue on capital equipment. So we saw very nice growth across the portfolio."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add there is, and we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and [indiscernible] in particular, as it relates to Urology. So some of the new",89,"And the only thing I'd add there is, and we highlighted at the analyst meeting, we're increasingly working strategically with customers to help them deal with infection rates and [indiscernible] in particular, as it relates to Urology. So some of the new products and the tray designs and the programs that we've implemented continue to drive very good growth, absent significant volume growth, frankly. So we're continuing to take share and providing solutions that customers are valuing because it's helping them solve a real problem that they're facing."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Vijay Kumar from Evercore ISI.",10,"We have a question from Vijay Kumar from Evercore ISI."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just maybe on the margins. It really looks like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove this trend on the margin side, I think that would be a helpful starting point.",44,"Just maybe on the margins. It really looks like the increments were really strong in the quarter. If you could just maybe walk us through on what really drove this trend on the margin side, I think that would be a helpful starting point."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all from a gross margin standpoint, we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues t",180,"Sure, Vijay. Thanks. I think as we've seen throughout the year, first of all from a gross margin standpoint, we continue to perform very well. Pricing, as you saw, came in again below, I think, our expectations, which is certainly helpful. Mix continues to be positive, driven by, over the last couple of years, some of the launches that we've had. And then our operations teams continued to deliver excellent results from a cost improvement standpoint. So frankly, the strength that we've seen from strong execution on the gross margin line has allowed us to continue to invest in R&D and SG&A, frankly ahead of where we had anticipated to be able to coming into the year. So we think it's a terrific ability for us to reinvest into the business while still driving significant operating margin improvement. So it's a model that we're focused on continuing to replicate. It comes with a lot of hard work from a lot of people, but that's the model. And when we execute well, you get the results that you saw this quarter."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how",69,"Great. Maybe just one quick follow-up on the product side. Maybe for Tim or John. A lot of questions have gotten us on what happens to Vascular DCBs when you have potential competition coming in next year. So maybe if you could just help us understand how this time maybe it's larger than what we're thinking and then what could drive growth on that side, that would be helpful."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll start and then turn it over to the 2 John's here to follow-up. So we still think this market is accelerating. And frankly, I would still call it even in the next year, potentially with another competitor, still a rising tide here. It's still un",148,"Sure. I'll start and then turn it over to the 2 John's here to follow-up. So we still think this market is accelerating. And frankly, I would still call it even in the next year, potentially with another competitor, still a rising tide here. It's still underpenetrated, still underdiagnosed. And I think as more use is -- there's more usage experience, physicians are continuing to determine where they want to use DCBs in their treatment protocols, and all of that is very positive. I do think it's kind of interesting as you look at different nuances in the specifics of the products relative to the amount of drug and some of the behavior characteristics. Certainly, we performed extremely well in our registry data vis--vis all of those metrics. So we feel very good about our own positioning going forward against what we know is expected competition moving ahead."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications though, AV access and Below-the-Knee, we think those 2 markets wou",104,"The only thing I'd add to that is that we look at that market in the year 2020, we would expect in the SFA popliteal portion of market to be approximately $850 million. The new indications though, AV access and Below-the-Knee, we think those 2 markets would be approximately $600 million in 2020, and we're working hard to be the first entrant into that space. So while we do expect some competition in the SFA, we're hopeful that we will be the market enterer in the other 2, which we expect -- other 2 segments, which we expect to have outstanding growth potential."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us. As we talked about, in-stent restenosis and long lesion, we anticipate a Q1 2017 launch with those indications, mid-2017 the",86,"And Vijay, John DeFord here. Just to kind of walk down the line also on what we think are some differentiated indications for us. As we talked about, in-stent restenosis and long lesion, we anticipate a Q1 2017 launch with those indications, mid-2017 the launch of Lutonix in Japan, and then late 2017 an AV access potential for launch. We think that's going to be differentiating and give us -- and continue to keep us in a leadership position. Then 2018, we've got BTK coming along."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Keusch from Raymond James.",11,"And we have a question from Larry Keusch from Raymond James."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just wanted to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses have puts and takes and capital can be",80,"Just wanted to start for, perhaps, John Weiland. Again, I want to just come back to the Targeted Temperature Management and the comments around the timing of the capital equipment sales. I fully recognize businesses have puts and takes and capital can be lumpy, but I just want to dive a little bit deeper and see if you are potentially seeing anything other than just timing as it relates to just the appetite for capital equipment out there amongst hospitals."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strongly right afterward. So we don't see any indicators, which would cause us",49,"No, I don't think we're seeing anything except timing, quite frankly. And we've had quarters over the years where capital was a little light in that business and came back very strongly right afterward. So we don't see any indicators, which would cause us to be concerned about that."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think our other capital businesses were -- had growth similar to what we have seen in other quarters.",20,"And I think our other capital businesses were -- had growth similar to what we have seen in other quarters."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Larry, we expect Q4 to, frankly, be robust, so just to that point.",14,"And Larry, we expect Q4 to, frankly, be robust, so just to that point."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's perfect. And then just sort of bigger picture. I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we head",51,"Okay. That's perfect. And then just sort of bigger picture. I know you're not going to provide 2017 guidance here today, but can you just help us think a little bit sort of broadly about some of the puts and takes that we should be considering as we head into 2017?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","You answered your own question that we're not going to give guidance on this call for 2017. But to the earlier or first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth o",166,"You answered your own question that we're not going to give guidance on this call for 2017. But to the earlier or first question asked in terms of trends or momentum, whatever you want to describe it as, we've seen some traction in the underlying growth of the market solidify throughout this year. There's nothing that we have seen that would indicate that could change heading into next year. When we started our investment plan back in 2013, we said that you would start to see the results in '15, but we expected that it would be sustainable. So everything we've been doing from then to now, investing in R&D, sales force expansion in emerging markets, the acquisitions that we've made have all been targeted to achieve that kind of an outcome. And we fully expected that above-market growth achievement of 2 to 3 points above the market should continue. So that's kind of the way we feel about it heading out of this year."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'll add to that is that one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about a 1/3 i",134,"The only thing I'll add to that is that one of the statistics that we don't often talk about is that if you look at our sales forces around the globe, we've increased our sales forces over the last 3 years by approximately 400 people. That's about a 1/3 increase in our sales forces. And people are still maturing in some of those jobs that were maybe the later placements into it. And quite frankly, we expect to have pretty robust additions in our sales force again next year in a lot of our high-growth markets. So I think that we're making the right investments, as Tim mentioned, to ensure that as the products come through our pipeline and registration pipeline that we're poised and have the right manpower to execute on those."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impa",85,"The only thing I'd add, frankly, that gives us again continued comfort around the sustainability question is just the balance in the portfolio, right? There's growth and there's new product launches and there's sales force investments that are really impacting the entire company. And so you've seen it this year. We expect to end this year strong with really balanced and important contributions from all the businesses, which I think you need to have to sustain the kind of growth rates that we're seeing."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Mike Weinstein with JPMorgan.",10,"And we have a question from Mike Weinstein with JPMorgan."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So let me ask just some on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask",144,"So let me ask just some on the surgery business, if I could start. Obviously, the surgery business has been growing well above trend now for the last few quarters. That's on a bunch of new products. It's on share gains, and it's on mix. So let me just ask you just about mix and, as well, the competitive environment. So number one, on mix, I feel like we continue to underestimate within the mesh part of the business, the opportunity for mix upgrade for your business. So can you give us a sense of where you think you are in that mix upgrade piece of the story within the mesh business? And then second, competitively, we just had an ACS. Is there anything that you've seen new competitively that gives you any pause as to this momentum in the business continuing in 2017?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And by that -- on top of that, our BioSurgery margins are well above the corporate average. So with mi",185,"Mike, relative to your question on mix, obviously, our synthetic businesses, the margins on our synthetic business are well above the corporate average. And by that -- on top of that, our BioSurgery margins are well above the corporate average. So with mid-teens growth in those and into the 20s for BioSurgery, obviously, that will have a positive impact on our overall margins long term. Relative to ACS, it's interesting. I'm speaking to one of our key leaders in that business this afternoon about the same exact issue. And we have not seen anything that's launching or plans to launch that gives us concern relative to the growth drivers in that business either in the fixation side of things or in the synthetic mesh side of things. We think our Phasix product line and product category has such unique capabilities in terms of providing long-lasting repairs for patients without leaving a mesh behind long term that the benefit to patients is significant and we've not seen anything yet. Although we're always diligent about it, we've not seen anything yet that gives us pause for concern."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics have a place, the Phasix opportunity to offset",137,"Maybe just the one point I'd add there, Mike, I think is underappreciated is the entire portfolio gives us literally a product for every patient. And we're obviously the only one with that. So while biologics have a place, the Phasix opportunity to offset biologics is a terrific win for us and a terrific win for the physician and the hospital in a lot of cases. And we're seeing customers, because of the breadth of the portfolio, literally standardize on Bard's hernia portfolio from basic synthetic to an absorbable synthetic to a biologic. And we're the only one that could even sit down and have that conversation with customers. And there's a lot of advantages, as you can imagine, for them to do that. And that's certainly part of the reason we're driving and capturing share."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, I missed it, if you made some comments just about use of cash during the quarter, but it didn't look like there was activity from a buyback standpoint. It looked like it was pretty minimal. Just can you give us thoughts on -- it seems like you guys",89,"Chris, I missed it, if you made some comments just about use of cash during the quarter, but it didn't look like there was activity from a buyback standpoint. It looked like it was pretty minimal. Just can you give us thoughts on -- it seems like you guys have been largely sitting on your cash in the last couple of quarters, maybe paying down a little bit of your debt. Is there any thought process behind that? And any updated thoughts, Tim, on the environment for business development?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Nothing's changed from our perspective strategically relative to the use of cash. Priorities are still the same. Acquiring technologies of businesses are the first priority. Share buybacks, second, and then dividends, third. So none of that's really",133,"Sure. Nothing's changed from our perspective strategically relative to the use of cash. Priorities are still the same. Acquiring technologies of businesses are the first priority. Share buybacks, second, and then dividends, third. So none of that's really changed. As you know, the business development environment is opportunistic and episodic. But relative to our internal efforts or initiatives, none of that's changed. We're still pedal to the metal in terms of our initiatives globally. Frankly, as we've added business development resources geographically over the last couple of years, they've matured and we're in the space more. So we feel good about the initiative and the momentum. And I would fully expect to continue to see the same kind of cadence going forward that you've seen over the last couple of years with us."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the co",109,"And Mike, just on your question around repurchase activity. We did buy 190,000 shares in the quarter. We absolutely will continue to be active in the coming quarters. We're really not sitting -- we're sitting on very little cash in the U.S., and so the commitment to shareholders to not do that, we're certainly continuing to deliver on that commitment. So to Tim's point, the priority remains to be strategic. We obviously continue to have a lot flexibility with the balance sheet to do both in a reasonable and appropriate way. And it'll ebb and flow quarter-to-quarter, but we'll continue to be an active repurchaser in an ordinary course."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Amit Hazan with Citi.",9,"We have a question from Amit Hazan with Citi."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Let me maybe start with the nonorganic guidance piece. So I think you've raised it a little bit. You're now at 2% to 3% contribution for this year. That's about $85 million at the midpoint. If we think about this, just the components of that, Liberator, y",130,"Let me maybe start with the nonorganic guidance piece. So I think you've raised it a little bit. You're now at 2% to 3% contribution for this year. That's about $85 million at the midpoint. If we think about this, just the components of that, Liberator, you started out, when you acquired it, saying $70 million for the year. Clearly, you're talking about at being more than $70 million. Medicon is another $30 million net for the year, if I'm doing my math right. So we're already at $100 million. We've got a few other small pieces. Seems to me like we're easily over even high end of that. So maybe give me a sense of what I'm missing on the nonorganic side even to get to your new guidance."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related",89,"Yes, obviously, offsetting that within the nonoperational items, Amit, is the sales to Boston Scientific on the EP side. So that's a negative put against those takes there. So in combination with the revenue from the acquisitions, there's a deduct related to that year-over-year decline in revenue. To John's point, the acquisitions are both going well from an immigration standpoint, and we're trending ahead of the model. But when you do the math on all the puts and takes, we're comfortable with the guidance here for the full year."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then let me just ask the second question about PICC. So if would kind of look back, just the trend line, it's been this really nice consistent 10%-plus grower. I don't want to pick on it too much at 9% for the year, so just under that, not a big",165,"Okay. And then let me just ask the second question about PICC. So if would kind of look back, just the trend line, it's been this really nice consistent 10%-plus grower. I don't want to pick on it too much at 9% for the year, so just under that, not a big deal, but just want to make sure we're not missing anything there and you're still very comfortable with how PICC performance is going. And related to that, if we kind of go back to the Analyst Day and we think about your discussion today about the pipeline, one thing I haven't seen you guys talk about or at least highlight is new products coming in Oncology, at least there was, I think, nothing there in the Analyst Day that was really highlighted. And I didn't see -- I just don't think I heard anything today. So just maybe touch on those 2 points, both the PICC and the pipeline inside of the [indiscernible]."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","No, we are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date. So we had a very strong quarter in ports. And PICCs were up 8%,",92,"No, we are very happy with the overall growth rates in Oncology and our growth rates worldwide in ports. We mentioned to you that ports are up 9% for the quarter. They're up 7% year-to-date. So we had a very strong quarter in ports. And PICCs were up 8%, which is very similar to our full year growth year-to-date, which is up 9%. So I think we're very comfortable with our 2 leading product lines in the oncology space and our gross [ph] there. And I'll let John talk about the pipeline."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, PowerGlide Pro, and we've got new versions of those launching early next year. I didn't talk this",168,"Yes. So I did mention today a few items, including our new PROVENA family of power PICCs, to reduce the risk of DVT. We just recently launched Power Midline, PowerGlide Pro, and we've got new versions of those launching early next year. I didn't talk this call about AccuCath, but we've launched a first couple of versions of that. We've got more launches of those coming up early next year. And I also talked about the pediatric Tip Confirmation technology that we launched in Europe last quarter, and we expect to launch around the end of year here in the U.S. that gives us access for both -- for all products, all venous products. So central venous catheters, PICCs and ports in the pediatric case. And then we've got other things like our chemical-resistant PICCs that I've talked about before that I didn't mention today on the call, but are launching here in the near term as well. So I think there's a pretty darn robust pipeline there."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins from Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins from Bank of America."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So one thing I wanted to ask about is the emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a",105,"So one thing I wanted to ask about is the emerging market growth. It's obviously been an enormous source of strength for the company over the course of the last bit of time here. And I know or at least I think, growth propped up to around 30% from maybe a quarter or 2. And then more recently, it's been back at around 20%. And I'm just curious in this particular quarter, did emerging market growth sustain in that 20% growth range? And as we think forward, what's your confidence that we can continue to see growth around 20%, plus or minus, in emerging markets?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we've said many times, we are really developing a lot of tho",250,"Well, if I look at it overall, we actually had a real uptick in our growth in emerging markets for the quarter. And it was across the board. I mean, we had a very strong quarter in China. And as we've said many times, we are really developing a lot of those markets from scratch, in particular, biopsy, PICCs, hernia repair. We continue to see great opportunities for growth there. We've built a whole new BioSurgery sales team that is really just starting to get their traction. And we have some pretty interesting investment opportunities for next year sales force-wise there. Latin America, we saw a nice move in the positive direction, and I think as I mentioned, it was our best quarter in Latin America in the last 5 quarters. And that's always been a pretty solid area of growth for us, with the exception of last quarter. So we rebounded significantly, made up great ground there. and I'd say the other area that we haven't talked about an awful lot, but we've made a number of investments in, what we call rest of Asia or the smaller markets in Asia that we build out sales forces, build out marketing teams and are getting approvals and registrations for our products and launching those. So I'd say we looked at our appetite in emerging markets, it's certainly high. As we -- if we look at our investment profile, that's equally high, and we're very optimistic about what we'll see there."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","So then just maybe to try and pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then I also just wanted to get a quick view, and I apologize if I",115,"So then just maybe to try and pin you down a little bit. It's been such an important contributor to growth for the company. Is something around that 20% level sustainable, do you think? And then I also just wanted to get a quick view, and I apologize if I missed this, on hernia. And from what you're seeing in the marketplace, is there any sign of any competitive offerings that look interesting? Because obviously, J&J has been exiting some portions of the market, and you guys have been launching great products. So just curious on the competitive landscape, what you're seeing on hernia, and if you think something around 20% is sustainable in EM."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me take the first part of EM, and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month, an",253,"So let me take the first part of EM, and I'll turn it over to John Weiland for hernia. So if you recall, Bob, we've shown now several times kind of a pipeline of regulatory filings in various emerging markets and geographies. We track that every month, and that we continue to build and invest in that pipeline. So we feel good about that, if you want to think about that. It's almost like another R&D portfolio. It's just products that have already been de-risked, because they've most likely been launched someplace else already. So it's really a regulatory filing. So that's one component. Second, as John mentioned, we continue to invest and build out sales forces and expand in those geographies, and that will continue with the U.S. World Series beginning tonight to put in kind of a baseball analogy. I don't even think we're into the fifth inning yet in emerging markets. So I'd say it's still in the early innings of the game. And that is further -- is another good metric for us. The enthusiasm level from clinicians to be trained on our products almost overwhelms our capability to keep up with the capacity for the demand. So we just opened up another training center in some of the South Asia markets that John has referred to. And that demand continues to be very, very strong. So all of those things really make us believe that we've got a lot of runway left in emerging markets. You want to...?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We have not seen anything in the marketplace right now that gives us pause for concern. We",97,"The only thing I'd add to that, Bob, is on your comment about new competitive offerings. We've not seen anything, and we were just off of the ACS meeting last week. We have not seen anything in the marketplace right now that gives us pause for concern. We think that our broad portfolio and, in particular, the new technologies that are really early into their introduction phase, and based on that and the pipeline that we have coming, we're very comfortable, although always diligent about what we see coming up in the marketplace from a competitor."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","We wake up a little afraid everyday here.",8,"We wake up a little afraid everyday here."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And we have a question from Larry Biegelsen with Wells Fargo.",11,"And we have a question from Larry Biegelsen with Wells Fargo."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's Lei Huang calling in for Larry. So you raised guidance several times this year, both top line and bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. But can you talk about some of the key factors t",75,"It's Lei Huang calling in for Larry. So you raised guidance several times this year, both top line and bottom line. Part of it, I would assume, is just your level of conservatism building into the guidance. But can you talk about some of the key factors that contributed to the upside in the guidance raise? How much of it was perhaps the overall market strength, utilization trend versus your execution versus other things?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me start with that. So obviously, we put together -- the way we roll up our process. We have budgets. Businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built in to some of the guidanc",124,"So let me start with that. So obviously, we put together -- the way we roll up our process. We have budgets. Businesses tell us what they're going to do. That's not what we tell you they're going to do. So we've got a hedge built in to some of the guidance. The fact of the matter is if everybody performs at the high end of what they told us, we're going to do very well. And that is about execution, both on the new product side, the sales force, marketing, everything. Frankly, that has to do with running a business. And when you execute well, you perform pretty well and that's kind of been the way it's been here the last several quarters."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I'd try to really strongly echo that. We are not building in a significant level of conservatism. I think we're completing a year here where the execution, to Tim's point, has really been outstanding across the board. And when you get that kind of broad-b",188,"I'd try to really strongly echo that. We are not building in a significant level of conservatism. I think we're completing a year here where the execution, to Tim's point, has really been outstanding across the board. And when you get that kind of broad-based outstanding execution, you're in a position to do what we're doing here, again, for the third time, which is raising guidance. So the base businesses and again the balance of it, I think it's critically important where all the businesses are contributing really attractive organic growth. The acquisitions, as we've said, have exceeded our expectations. We're doing better on price. Our operations teams are delivering what they committed to and the mix within the portfolio, frankly, the portfolio -- the growth in surgery is very helpful to mix and to margins, as John highlighted as well. And as those emerging market sales reps become more and more productive, that execution gives us some upside. So it's a lot of little things across a lot of parts of the company that, in combination, really result in really strong top and bottom line performance."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And just one quick follow-up. So Spectranetics will be presenting data for their DCB product at TCT. Do you have any just kind of thoughts on the data and what we should be thinking about versus the data that you presented both trial and registry d",47,"Great. And just one quick follow-up. So Spectranetics will be presenting data for their DCB product at TCT. Do you have any just kind of thoughts on the data and what we should be thinking about versus the data that you presented both trial and registry data?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they present will be in line. If you look at our data, I think consistently",157,"Well, John DeFord here. We anticipate that they're going to put forth good results. They have in their other studies in Europe and so on. So we expect that this 12-month data that they present will be in line. If you look at our data, I think consistently, as we've gotten in real-world use of our technology, we have similar results to what they've shown previously and what Medtronic has shown. So we kind of anticipate all of that, and we think we've got pretty robust data. Obviously, LEVANT 2 was a ""first of a kind"" study, and we learned a lot from that study, and we've seen and talked about, at length, some of the findings on the importance of procedural aspects of that. And so when we've seen it in real-world use where they've followed those procedural learnings that we've had, we've had really great results. So we think we're going to be pretty similar."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come.",32,"I think it validates the category and the benefit of DCBs potentially, and we certainly stand to benefit as that category gets larger and larger and larger in the years to come."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","We do have one more question. We'll go to Dave Turkaly with JMP Securities.",14,"We do have one more question. We'll go to Dave Turkaly with JMP Securities."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a follow-up sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. And we saw your 24-month registry data. There was a lot of speculation prior to launch sort of how people would view this data, what docs w",86,"Just a follow-up sort of on the data comment on the DCBs. Obviously, you guys now have your registry data on label. And we saw your 24-month registry data. There was a lot of speculation prior to launch sort of how people would view this data, what docs would think, I guess. Do you have any commentary on that? Do clinicians -- is that something that's brought up by customers? Or is this something more of a kind of competitive thing in the marketplace today?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me start. So if you look at market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare our pivotal data for their pivotal data and then the registry data that we presented, clearly, we th",177,"Well, let me start. So if you look at market share, we're clearly 50-50 by almost all accounts between us and Medtronic. So to the extent that you compare our pivotal data for their pivotal data and then the registry data that we presented, clearly, we think data does make a difference. We think there's other important features and characteristics beyond the data, things that are now just beginning to be better understood relative to the amount of drug use, how much of a drug stays on, the agent that's used to bind the drug to the balloon, et cetera, et cetera. All those things over time will play out with more usage and more information and data. And that includes things that are going to have to be understood and learned with new entrants to the market. So we generally feel very good about our market position, our growth prospects, our new indications that we've got in the pipeline and the way that the products performed and we've executed since we've launched. John DeFord, anything else?"
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think part of your question was how much of data is sort of a discussion at meetings and with KOLs as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more",135,"Yes. I think part of your question was how much of data is sort of a discussion at meetings and with KOLs as opposed to sort of everyday interactions with customers. And I can say that it's certainly a combination of both, but there's probably a lot more bander at the competitive level from company to company than the clinicians necessarily pay that much attention to. It seems like in my interactions with physicians. And so I think data are important. I think safety is really a key point that I think we have a lot of strength in that particular space. And then our long-term data, as we look at our registries and real-world use in long lesions and calcified lesions and in-stent restenosis and all those pieces are continued validation of this technology."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments.",26,"And this will conclude our Q&A session. And I would like to turn the call back over to Bard's management for closing or additional comments."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Laurie. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call.",41,"Thanks, Laurie. I'll just briefly close by thanking Bard employees around the world for their commitment to excellence and continued great execution through 3 quarters of this year and to thank all of you for joining us today on the call."
254131,403600059,1062334,"CR Bard Inc., Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. Ladies and gentlemen, this will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect.",29,"Thank you. Ladies and gentlemen, this will conclude our teleconference for today. Thank you for your participation and for using AT&T's Executive Teleconference service, and you may now disconnect."
